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Abstract
Marta Sanz Gaitero- Crystallographic structure determination of
bacteriophage-encoded enzymes that specifically target pathogenic
bacteria
Antibiotic resistance is becoming a serious public health concern. Infections that
some decades ago could be treated with antibiotics now sometimes do not respond
to traditional treatment, causing higher mortality and economic losses. An
alternative to the use of antibiotics are bacteria's natural predators,
bacteriophages (or phages), and specifically their lytic enzymes. These proteins are
produced by phages to degrade bacterial peptidoglycan to inject their genetic
material into the bacteria (virion-associated peptidoglycan hydrolases) or to
release their progeny once the infection is finished (endolysins). They can be
applied exogenously to lyse Gram-positive bacteria or be genetically engineered to
lyse Gram-negative bacteria.
Phages also code for proteins that allow them to reach their receptors
(depolymerases) and recognize them (receptor binding proteins or fibres). These
receptor-binding proteins can be used to detect and to identify pathogenic
bacteria.
More knowledge on the structure of these proteins is necessary to understand their
mechanisms of action and to design chimeric or active-site mutant endolysins able
to lyse different pathogenic bacteria.
In this work, the structure of the N-acetylmuramidases from two bacteriophages
(Pseudomonas bacteriophage vB_PaeM_KTN6 and Erwinia jumbo bacteriophage
vB_EamM_Y3) have been determined by X-ray crystallography and catalytic
mechanisms have been proposed. Although both proteins are inverting glycoside
hydrolases with similar catalytic mechanisms, they present large morphological
differences, illustrating the different ways phages solve similar biological problems.
A third structure, the Cysteine-Histidine Aminopeptidase/Hydrolase (CHAP)
domain from the endolysin of staphylococcal bacteriophage K, was determined in
the presence of triglycine, an analogue of its natural substrate, revealing a potential
secondary ligand binding site.
Additional endolysins and fibres targeting both Gram-positive and Gram-negative
bacteria have been purified and crystallized, increasing the knowledge on these
proteins. In the cases where their structure could not be obtained, in-silico models
were generated to explore the mechanism of these enzymes.
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1 Introduction
Antibiotic resistance is becoming an increasingly serious health concern. The
emergence of pathogenic bacteria unaffected by conventional drugs is generating an
increment of the mortality due to infections that some years ago would have been
treated easily (Bragg et oL, 2014). This is a serious problem, especially for
immunocompromized or bed-ridden patients, generating important economic
losses. The challenge to find new methods to treat these infections is becoming a
priority.
One possible alternative to antibiotics is the use of bacteriophages (or phages),
bacteria's natural predators. They are the most abundant biological replicating
entities, are ubiquitous and evolve fast to overcome the escape mechanisms
developed by their host bacteria (what is known as the red queen hypothesis). Phages
havebeen used to develop important molecular biology techniques, but their use as
a treatment for bacterial infections was abandoned in the Western World when
penicillin was discovered. Nowadays, with antibiotics losing their effectivity, phages
are again considered as an effective alternative or additional treatment for these
pathogens.
The use of viral particles presents some advantages. There is a wide variety of
different phages infecting the same kind of bacteria, providing alternatives for
treatment if their host develop resistance to some of them. Phages are nottoxic, they
infect specifically some genera or species, not damaging commensal microbiota.
Moreover, they can reproduce quickly if their host bacteria are present, increasing
their number exponentially.

The use of phages as antimicrobial agents also presents some drawbacks. Their dose
is difficult to control, as they can self-replicate upon infection. Because they are
unknown entities to the host, they may generate immunogenicity problems. Finally,
their genomic material could integrate into the genome of their host bacteria and
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thus may confer some advantage to these pathogens, potentially increasing their
virulence.
A solution that helps avoid the above drawbacks is to use isolated phage proteins:
tail fibres, tail spikes, phage-associated cell-wall modifying enzymes and/or
endolysins. Tailed bacteriophages present structures associated to their tails as fibres
or spikes that allow them to recognize receptors in their host bacteria and to degrade
extracellular polymers that might impair that recognition. Tail fibres can be used to
detect and identify pathogenic bacteria due to their specificity and stability.
Determining their structure can help to generate chimeric fibres changing the host
range of certain phages, to fuse them to fluorophores to detect bacteria or to bind
them to antibodies or drug delivery systems to increase their effectiveness.
Some phages have virion-associated peptidoglycan hydrolases to degrade the
peptidoglycan and facilitate the DNA injection machinery to reach the cell membrane
and deliver the genetic material into the host. Once the phage progeny has been
generated, they need to escape from the bacteria. To be released, phages generate
a protein called endolysin, able to break the peptidoglycan links, causing the bacteria
to burst due to the osmotic pressure. To allow the pass of these endolysins through
the inner membrane, bacteriophages produce pore-generating proteins called holins.
Endolysins are often multi-modular, combining cell wall binding domains and
catalytic domains. Each catalytic domain can cleave a different link present in the
peptidoglycan (muramidases, glycosidases, peptidases or amidases).
These proteins can be applied exogenously to Gram-positive bacteria to lyse them
(lysis from without). In the case of Gram-negative bacteria, the endolysins should be
genetically modified to allow them to pass through the bacterial outer membrane
and reach the peptidoglycan. The clinical perspectives of these enzymes are
considerably high, but more knowledge on them is needed.
Determining their shape, where they bind, how they cleave their target bond and
what amino acids are involved in their stability is important to design tailor-made
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proteins to treat determined pathogenic bacteria. The different domains available
can be combined to change the host or the efficiency of the lysis and some residues
can be modified to increase the protein solubility and stability to different pH and
temperatures.
To do that, their structure must be determined. Determining the structure of an
endolysin domain not only helps to elucidate their mechanism of action and their
important residues, but also allows to predict the structure of closely-related
enzymes and guides the design of mutated or chimeric enzymes.
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2 Literature review
2.1 The diversity of viruses
Viruses are the most abundant biological entities on earth and they infect practically
all living organisms. There are approximately 10^^ viral particles on Earth, most of
them located in the ocean waters (Suttle, 2005; Minot et al., 2013). This number
exceeds the number of host cells by at least one order of magnitude, implying that
virtually every organism is constantly under attack from viruses and that viruses are
responsible for the greatest selection pressure on cellular organisms (Bamford et al.,
2015). Viruses show high levels of diversity, with porcine circovirus type 1 (PCVl) the
smallest with only 17 nm in diameter and a circular ssDNA genome of 1759 bp,
encoding for only two open reading frames (ORFs) (Finsterbusch et al., 2009). The
largest known virus belongs to the Pithovirus genus with dimensions of ~1.5 pm in
length and 500 nm in diameter and 600 kb of circular dsDNA. In terms of genome,
the largest virion is Pandoravirus salinus, containing a 2.8Mb linear dsDNA genome
(Legendre et al., 2014; Abergel et al., 2015).
There are three main hypotheses about the origin of the viruses:
1. Virus-first hypothesis: Viruses originated from pre-cellular life forms.
2. Reduction hypothesis: Viruses are derived by reduction from unicellular
organisms.
3. Escape theory: Viruses originated from fragments of genetic material that
escaped control of the cell.
The virus-first hypothesis has been dismissed because viruses are obligate parasites
and require a living cell for their reproduction. The reduction hypothesis main
inconsistences are that no intermediate form of life between cells and viruses has
been discovered. Virions do not retain characteristics from the cell they originated
from, in contrast to other cell parasites such as Mycoplasma in Bacteria,
Microsporidia in Eukaryotes or Nanoarchaea in Archaea. The fact that viruses can
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integrate cellular genes into their own genomes supports the escape theory.
According to this hypothesis, plasmids can be considered as viral precursors.
However, the main drawback of this theory is the lack of explanations on how a free
nucleic acid could be able to recruit a capsid and to develop the complex mechanisms
required to infect its host cell. Another drawback is that the escape theory predicts
that bacteriophages and eukaryotic viruses originated from bacterial and eukaryotic
genomes respectively. If this hypothesis were true, evolutionary affinities should be
found between viral proteins coded by viruses from one domain and their cellular
homologues in that domain, but this is not always the case. For instance, some
proteins encoded by T4 bacteriophage are more similar to eukaryotic proteins or
viruses than to prokaryotes (Miller et al., 2003) and most of the viral proteins have
no cellular homologues (Prangishvili et al., 2004; Forterre, 2006). Additional virion
structures must be analysed in order to determine whether any of these hypotheses
is correct.

Over the years, viruses have been classified according to two systems: the Baltimore
classification, which divides viruses into seven groups according to the nature of their
genome, and the ICTV classification, carried out by the International Committee on
Taxonomy of Viruses, which classifies every virus according to order, family, genus
and species, indicating the host organism for every virus. Most families have not been
assigned to any order yet (Abrescia et ol., 2012).

In 1979, the first high resolution (2.9 A) virion structure was determined, belonging
to ssRNA tomato bushy stunt virus (Harrison et al., 1978). Two years later, the
structure of Southern bean mosaic virus was determined (Abad-Zapatero et al.,
1980). These viruses showed similarities between them in the capsid arrangement
and in the capsid subunit structures. In 1985, the structures of two picornaviruses,
small ssRNA icosahedral animal viruses, were published (human common cold virus
and poliovirus) (Rossmann et al., 1985; Hogle et al., 1985). As expected, they were
similar to each other but, surprisingly, the coat protein folds were related to those
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seen in plant viruses. In 1999 an insect virus showed structural similarity to these
picornaviruses (Tate et al., 1999). These discoveries showed that viruses infecting
different hosts could have a similar architecture.

In the same year, the structure of the major coat protein from PRDl, a bacteriophage
infecting Gram-negative bacterial hosts, was solved (Benson et al., 1999). Its closest
structural relative was the corresponding protein of adenovirus. This fact, along with
the presence of penton and spike proteins and a similar replication mechanism,
strongly suggested a divergence from a common origin. Some years later, Sulfolobus
turreted icosahedral virus, an archaeal virus, was shown to have a similar fold in its
capsid proteins, suggesting that structurally similar viruses can infect hosts in the
three domains of life (Khayat et al., 2005; Abrescia et al., 2012).

These observations led to the development of a new system of classification into four
lineages of viruses, according to the virion capsid architecture (Abrescia et al., 2012;
Bamford et al., 2005) (Figure 2.1):

•

P/cornowrus-like lineage.

•

HK97-like lineage. Includes dsDNA viruses that infect bacterial hosts, archaeal
hosts and herpesviruses.

•

PRDl/adenovirus lineage. Includes icosahedral dsDNA viruses. The building
block of this lineage capsid is a trimeric molecule, comprised by concatenated
P-barrels arranged to form a pseudohexameric structure.

•

BTV-like lineage. Includes icosahedral dsRNA viruses.
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BTV

ECVl

HK97

PRDl

Figure 2.1: Structure of viral coat proteins from viruses belonging to the four lineages
described. Blue tongue virus (BTV) is represented in green, Echovirus-l (ECVl,

picornavirus) in red, Hong-Kong 97 (HK97) in blue and PRDl in magenta.

2.2 Bacteriophages
Bacteriophages, or "phages", are viruses that infect bacteria. In 1891, bacteriologist
Ernest Hanbury Hankin reported an unidentified, filterable and heat labile
antibacterial agent in the water of Yamuna and Ganga rivers (Hankin, 1896), but it
wasn't until two decades later, when Frederick William Twort (Twort, 1915) and Felix
Hubert d'Herelle (d'Herelle, 1917) independently discovered bacteriophages, that
this unknown antibacterial agent was identified.
In 1915, Twort, while growing Micrococcus cultures, found clear lysis plaques and
concluded they were caused by an "ultramicroscopic virus" that could multiply itself
in the process of killing the bacteria and that was more effective in young multiplying
cells. This virus could be isolated and stored for more than six months, maintaining
its activity. It could infect closely-related bacteria, albeit less effectively, and was
destroyed when exposed to heat (Twort, 1915). In 1917, Felix d'Herelle observed that
bacteria-free filtrates from faecal samples of patients with dysentery could cause lysis
plaques in Shigella cultures grown in solid media and proposed this phenomenon was
caused by a bacterial parasitizing virus that he named as bacteriophage (d'Herelle,
1917).
Phages are a ubiquitous feature of prokaryotic existence (Clokie et ai, 2011). They
are not only abundant but also highly diverse: their genetic material can be dsDNA,
ssDNA, dsRNA or ssRNA; they can be filamentous, tailed, icosahedral or pleomorphic
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and they may have a naked capsid, an outer lipid envelope or even an inner
membrane (Adriaenssens et oL, 2018;

https://talk.ictvonline.org/ictv-reports/

ictv_online_report). They can be found in practically every ecosystem (Sharma et oL,
2017), from environments with extreme salinity, pH, temperature, dryness or
pressure (Le Romancer et ol., 2007), to forest floors and agricultural soil, mammal
gastrointestinal tracts or sea water, where a huge diversity can be found (Figure 2.2).

B

+RNA

+DNA

H
-V-

dsDNA

dsDNA

dsDNA

Figure 2.2: Diversity of phages. Schematic drawing of the levirus MS2 (A), the microvirus
phiX174 (B), the inovirus M13 (C), the cystovirus phi6 (D), the tectivirus PRDl (E), the
corticovirus PM2 (F), the myovirus T4 (G), the siphovirus T5 (H) and the podovirus T7 (I).
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2.3 Order Caudovirales
Thanks to the advances of Electron Microscopy, more than 6300 prokaryote viruses
have been described morphologically since 1959 (Ackermann, 2007; Ackermann et
oL, 2012). Out of these, 96.3 % are tailed and only 3.7 % are polyhedral, filamentous
or pleomorphic.
Tailed viruses, grouped in the order Caudovirales, are basically composed of an
icosahedral head, which might be isometric or prolate, and a tail attached to one of
its twelve vertices. Inside the capsid, a single molecule of linear dsDNA is located.
They belong to the HK97 lineage. Their head is made up of subunits called
capsomeres which present a very similar structural fold between them and with the
Herpesviridae family (Ackermann, 1998; Bamford et ai, 2005; Suhanovsky et al.,
2015). They are relatively large viruses whose head diameters vary between 34 and
160 nm and their genome length ranges between 17 and 725 kb (Ackermann, 1998).
The tail is a helical hollow tube, regularly showing a six-fold symmetry, whose
function is to recognize a suitable host cell and to transfer the viral genome into it. In
many cases, some additional structures such as a plate, fibres or spikes are attached
to the tail. These structures help to recognize receptors on the host cell, including
surface proteins, polysaccharides and lipopolysaccharides (Leiman et al., 2003; Yap
et al., 2014; Chaturongakul et al., 2014; Fokine et al., 2014). Initial reversible
attachment is followed by irreversible adsorption and ejection of the phage genome
into the host cytoplasm, starting the replication cycle (Nobrega et al., 2018).
Caudovirales can be classified into three families according to the morphology of their
tail; Myoviridae, Siphoviridae and Podoviridae (Ackermann, 2007; Xu et al., 2017)
(Figure 2.3).
•

Myoviridae: They present a long contractile outer tail that, during its
contraction, drives an inner tail tube through the outer membrane of the host
cell, allowing the insertion of the dsDNA molecule into the cytoplasm. They
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represent a 24.5% of all studied phages. The most studied members of this
group are phages T4 and Mu.
Siphoviridae: Their tail is long, flexible and non-contractile. Their tail tube is
blocked by a tail tip complex (TTC), that upon interacting with the host
receptor protein, triggers the release of the genetic material. They represent
61% of all known phages. The most well-known members of this family are
phages X, T5 and SPPl.
Podoviridae: They show a short tail. They represent 14% of all known phages.
Proteins located in the inside of the viral capsid are ejected to form a tube in
the periplasmic space allowing the delivery of dsDNA to the cytoplasm. The
most famous members of this family are phages 17, P22 and 4)29.

Myoviridae

Podoviridae

Siphoviridae

100 nm

Figure 2.3: Different families belonging to the genus Caudovirales. Micrograph

and schematic representation of representatives from the families Myoviridae,
Podoviridae and Siphoviridae. Figure from Harper et al., 2014.
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2.4 Jumbo bacteriophages
Giant or jumbo phages are tailed bacteriophages with a genome of more than 200
kbp of DNA. In January 2019, only 134 of this kind of phages had been isolated, mostly
during the last five years. Out of them, the one with the biggest genome discovered
to date is Bacillus phage G, a myovirus with a genome size of 498 kbp (Figure 2.4).

OT8M

Figure 2.4: Electron micrograph of a mixture of Bacillus phage G and Serratia phage
OT8M. The inset shows coliphage lambda to the same scale for size comparison. Figure
adapted from Flendrix, 2009.

They are rarely isolated because their size hinders their diffusion in semisolid
medium, preventing the formation of visible lysis plaques (Serwer et oL, 2007) and
because they are unable to pass through the filters used to remove bacteria during
traditional phage purification methods. These phages have not been systematically
classified (Hendrix, 2009; Yuan et al., 2017). Most jumbo phages belong to the family
Myoviridoe, with only a few siphoviruses infecting Caulobocter sp.
Jumbo phages have most often been isolated from Gram-negative host bacterial
strains belonging to the genera Synechococcus, Pseudomonas, Caulobacter, Vibrio,
Erwinia,

Ralstonia,

Dickeya,

Escherichia,

Yersinia, Acinetobacter, Salmonella,

Agrobacterium, Serratia and Aeromonas. Only six Gram-positive jumbo phages have
been discovered, all of them infecting the genus Bacillus.
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The large genome size allows jumbo phages to contain genes absent in small-sized
genome phages. All jumbo phages have more genes related with replication and
nucleotide metabolism than their regular-size counterparts. In addition to this, they
have more proteins for the lysis of the host cell-wall peptidoglycan, such as
endolysins, glycoside hydrolases and chitinases (Yuan et oL, 2016).

Jumbo phage virions are complex and diverse in morphology. They contain more
structural protein than the smaller phages and present some specific substructures
in their capsids and tails, such as long, wavy, curly tail fibres (Fokine et ai, 2005;
Thomas et oi, 2007; Buttimer et ol., 2017). Some jumbo phages show an internal
proteinaceous structure, encased within genomic DNA, called "the inner body"
(Krylov et oi, 1984; Sokolova et al., 2014).
More knowledge is needed about jumbo phages, especially on the interaction with
their host bacteria and phage propagation. Due to this, their tail fibres and their lytic
proteins must be studied. In this thesis, I will focus on proteins from two different
Jumbo phages: Enterobacteria phage vB_PcaM_CBB and Erwinia amylovora phage
vB_EamM_Y3.
2.4.1 Erwinia amylovora phage vB EamM Y3.

Erwinia amylovora phage vB_EamM_Y3 was isolated in 2008 from soil collected at an
apple orchard with trees displaying fire blight symptoms in Switzerland (Buttimer et
al., 2018). The phage infects a number of strains of E. amylovora, E. persicina and
E. billingiae as well as strains of Pantoea agglomerans and Pantoea vagans.

Erwinia amylovora is a Gram-negative Enterobacteriaceae. It is a facultative
anaerobic rod-shaped bacterium causing fire blight, a disease that affects some
members of the plant family Rosaceae and makes the infected areas of the plant
appear burnt (Khan et al., 2012). Fire blight is a global threat to commercial apple and
pear production. E. amylovora has spread worldwide and has been catalogued as a
quarantine organism in the European Union. Prophylactic application of antibiotics
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during the bloom period is the most effective method for controlling the disease, but
regulatory

restrictions,

public

health

concerns,

and

pathogen

resistance

development make alternative control methods necessary (Pique et al., 2015), such
as the use of lytic bacteriophages or their isolated lytic proteins to treat the infection
(Born et al., 2014). Pontoea agglomerans is a Gram-negative bacterium, it belongs to
the Enterobocteriaceae. It can be found in plants and in the guts of some animals and,
although it has some beneficial effects like producing antibiotics and competing with
certain plant pathogens, it can also cause opportunistic human infections, such as
septic

arthritis,

endophthalmitis,

periostitis,

endocarditis

and

osteomyelitis

(Dutkiewicz et al., 2016). E. persicina is a phytopathogen of the common bean plant
and E. billingiae and Pantoea vagans are used for bioremediation, as they compete
with E. amylovora.

vB_EamM_Y3 is a myovirus with an icosahedral head of 129 nm in diameter and with
a contractile tail with a length of 192 nm. It exhibits hair-like structures along the
surface of its tail (Figure 2.5), a characteristic only observed in a small number of
jumbo phages (Buttimer et al., 2018). Its genome size is 261kbp, coding for 333 ORFs
with putative gene products ranging in size from 39 to 1951 amino acids. One of these
ORFs code for the protein Y3_301,

a

SAR-endolysin

with

an

N-terminal

transmembrane domain (12-34 aa) with a high alanine content and a C-terminal
soluble

lytic

transglycosylase

(SLT)

domain

(111-202

aa),

which

degrades

peptidoglycan by cleavage of the (3-(1^4)-glycosidic bond, resulting in the formation
of a 1,6-anhydro bond in the muramic acid residue.
vB_EamM_Y3 possesses another protein, Y3_197, with a lysozyme-like domain
(IPR023346) and a peptidoglycan binding domain (Buttimer et al., 2018). To date, no
enzymatic activity has been shown for this protein. Therefore, it is important to try
to get structural data on this protein that might shed some light on the function and
catalytic mechanism of this enzyme, which may be used as a possible treatment for
fire blight disease.
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Figure 2.5: Electron micrograph of vB_EamM_Y3. Hair-like structures can be seen around

the tails. The scale bar represents 100 nm. Figure adapted from Buttimer et ai, 2017.

2.4.2 Enterobacteria phage vB PcaM CBB.

Enterobacteria bacteriophage vB_PcaM_CBB was isolated from activated sludge
from a wastewater treatment plant in Ireland. The phage can infect several species
within the family Enterobacteriaceae, including P. carotovorum, Pectobacterium
atrosepticum,

Erwinia mallotivora,

Cronobacter muytjensii,

and

Cronobacter

malonaticus. It can also cause 'lysis from without" on Dickeya dianthicola, Dickey a
solani, Pantoea agglomerans, and Erwinia amylovora (Buttimer et ai, 2017).
CBB phage belongs to the /V/yov/r/c/oe family, displaying a large regular icosahedral
head with a diameter of 128 nm. The tail measures 123 nm in length and 27 nm in
width and it possesses a base plate and a neck structure. It also displays six short tail
fibres. The contractile tail of CBB was found to be highly unusual as it possesses hair
like appendages (whiskers) covering its surface (Figure 2.6). These hairs, 120 nm long,
are highly stable, as they did not dissociate from the phage tails after long storage
periods (Buttimer et ai, 2017).
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"W

Figure 2.6: Phage vB_PcaM_CBB electron micrograph. Morphology of myovirus CBB. A
simple arrow indicates baseplate fibres, a triple arrow hair-like appendages (whiskers)
and a triangle indicates the neck passage structure. Figure adapted from Buttimer et ai,

2017.

The CBB phage genome contains 378 kbp and has 554 predicted ORFs. CBB_187 is
predicted to be the endolysin of CBB. In s/7/co analysis shows that the protein is
modular in structure, possessing three domains, an N-terminal transmembrane
domain, an intermediate domain with a possible cell wall-binding domain and a
C-terminal lysozyme domain. This protein has not been successfully expressed,
suggesting it may be toxic, as induction results in inhibition of E. coli growth (Buttimer
etol., 2017).
Three proteins with a lysozyme domain (CBB_238, 239 and 240), possibly associated
with the baseplate, have been identified. CBB_238 is 129 amino acids in size and it is
related to baseplate protein gp25 of phage T4, with acidic lysozyme activity. CBB_239
has a T4-type lysozyme domain and CBB_240 has an N-terminal gp5 domain (with
oligosaccharide binding fold) and a C-terminal lysozyme. Three ORFs, coding for
putative tail fibres (CBB_226, 260, 261) have been identified (Buttimer et ai, 2017).
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More structural knowledge on these endolysins and tail fibres is necessary to
understand the phage-host interaction in this phage and to design possible
antibacterial agents and detection systems for bacteria.

2.5 The life cycle of tailed bacteriophages
Once the bacteriophage has released its genetic material into the host's cytoplasm,
either a lytic or a lysogenic replication cycle can take place, depending on the type of
phage.
Lytic or virulent bacteriophages "kidnap" the bacterial host's metabolic machinery
and use it to produce new bacteriophage virions. This includes the replication of the
bacteriophage, the synthesis of viral proteins and the assembly of the progeny
virions. Upon the assembly of the new virions, two proteins called holin and endolysin
are synthetized. Holins are small membrane proteins that accumulate in the
membrane until, at a specific time, they form a pore that permeabilizes the host's
inner membrane allowing the endolysin to reach the peptidoglycan and to degrade it
with its muralytic activity (Young et al., 1995, Harada et ol., 2018). This mechanism
causes the burst of the bacteria due to the osmotic pressure and the release of the
viral progeny.
Temperate phages use an alternative life cycle. While a fraction of the infected
bacteria undergoes the lytic cycle, other bacteria survive the infection and the phage
genome becomes integrated within the bacterial genome in a quiescent form, called
a prophage. This prophage protects the bacteria from the infection of other
bacteriophages of the same strain. Cells that harbour a prophage are known as
lysogenic. Certain agents, such as ultraviolet light, stress or cellular damage, can
induce a lysogenic phage to re-enter the lytic-cycle (Campbell, 2003; Weinbauer,
2004) (Figure 2.7).
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Attachment

Integration

Replication

Figure 2.7: Phage replication cycle. After infection, the phage can be integrated in the
host's genome and replicate with it (lysogenic cycle) or generate viral proteins, assemble
new virions and lyse the cell to release them. Figure adapted from Kakasis et ai, 2018.

2.6 The bacterial cell envelope
The bacterial cell envelope (BCE) is a multi-layered structure whose integrity must be
preserved to guarantee the cell survival. The bacterial cell envelope protects bacteria
from their hostile environment, while allowing selective passage of nutrients from
the outside and waste from the inside (Silhavy et al., 2000).
Gram-positive bacteria possess the simplest bacterial cell envelope, composed of a
cytoplasmic membrane (CM) or inner membrane (IM) and a thick cell wall (CW).
Gram-negative bacteria have an additional membrane, the outer membrane (OM)
surrounding a less thick cell wall. In addition to the bacterial cell envelope, some
bacteria are encased by proteinaceous S-layers and polysaccharidic capsules. Some
protein machineries such as pili, flagella and specialized transport systems may be
attached to the bacterial cell envelope (Fernandes et oL, 2018) (Figure 2.8).
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Figure 2.8: Gram-positive and Gram-negative cell envelopes. CAP, covalently attached
protein; IMP, integral membrane protein; LP, lipoprotein; LPS, lipopolysaccharide; LTA,
lipoteichoic acid; OMP, outer membrane protein; WTA, wall teichoic acid. Figure from
Silhavy et al., 2010.

2.6.1 The Gram-negative cell envelope

There are three principal layers in the envelope: the outer membrane (OM), the
peptidoglycan cell wall and the cytoplasmic or inner membrane (IM). The aqueous
cellular compartment delimited by the two membranes is called periplasm.
The outer membrane is a distinguishing trait of Gram-negative bacteria. It is a lipid
bilayer, but only the inner leaflet of this membrane contains phospholipids. Its outer
leaflet is composed of glycolipids, mainly lipopolysaccharide (LPS) (Osborn et al.,
1964; Kamio etai, 1976). Lipopolysaccharides are large molecules consisting of a lipid
and a polysaccharide, with three different parts: the 0-antigen, the core
oligosaccharide and the lipid A. Lipid A, lipopolysaccharide innermost region, is
responsible for the endotoxicity of Gram-negative bacteria (Westphal et ol., 1954;
Takada et al., 1989). There are two kinds of proteins in the outer membrane,
lipoproteins and P-barrel proteins. Lipoproteins are located in the inner leaflet of the
outer membrane and they are not transmembrane proteins. All the integral proteins
of the outer membrane assume a p-barrel conformation and they are known as
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OMPs. Some of these OMPs are used for the diffusion of small molecules through the
outer membrane (Silhavy et ai, 2000).
A peptidoglycan cell wall gives the cell rigidity and resistance to the mechanic stress
and determines its shape. It is formed by linear glycan strands cross-linked by short
peptides. The glycan strands are made of alternating N-acetylglucosamine (GIcNAc)
and N-acetylmuramic acid (MurNAc) residues linked by p-(l->4) bonds. The D-lactoyl
group of each MurNAc residue is substituted by a peptide stem whose composition
is most often L-Ala-y-D-Glu-meso-2,6-diaminopimelic acid-D-Ala-D-Ala. The glycan
strands are generally cross-linked between the carboxyl group of D-Ala at position 4
in the peptide stem and the amino group of the diamino acid at position 3, either
directly or through a short peptide bridge. Some variability between bacteria exists
in the peptide stem, in the glycan strands or in the position or composition of the
interpeptide bridge (Vollmer et ol., 2008). The outer membrane is attached to the
underlying peptidoglycan by Lpp lipoprotein (Braun, 1975).
The periplasm is a space delimited by the inner membrane and the outer membrane.
It is more viscous than the cytoplasm and allows Gram-negative bacteria to
compartmentalize potentially harmful degradative enzymes.
The inner membrane is a phospholipid bilayer where all the membrane-associated
functions, such as energy production, lipid biosynthesis, protein secretion and
transport, are performed (Silhavy et oL, 2000).
2.6.2 The Gram-positive cell envelope
Contrary to Gram-negative bacteria. Gram-positive cell envelope lacks the outer
membrane (OM). As this layer helps to stabilize and protect the cell. Gram-negative
bacteria present a relatively thin peptidoglycan mesh. In the case of Gram-positive
cells, as this membrane is absent, they need much thicker peptidoglycan layers to be
able to stand the turgor pressure from the inside of the cell.
Embedded in these layers of peptidoglycan are the teichoic acids (TAs), long anionic
polymers composed of glycerol phosphate, glucosyl phosphate or ribitol phosphate
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repeats. There are two kinds of TAs: Cell wall teichoic acids (WTAs), linked covalently
to the peptidoglycan; and lipoteichoic acids (LTA), linked covalently to the
cytoplasmic membrane (Xia et al., 2010). These polymers are the major component
of the Gram-positive cell wall, accounting for almost 60% of its mass. In addition to
teichoic acids, Gram-positive bacteria are decorated by multiple proteins. They can
be transmembrane, attached to lipid anchors inserted in the membrane, associated
with peptidoglycan or with teichoic acids (Silhavy et oL, 2000).
The chemical structure of peptidoglycan in Gram-positive and Gram-negative
bacteria is similar. The main differences between them is that Gram-positive
peptidoglycan layer is thicker and the third residue of the peptide stem in Gram
positive is L-Lys instead of y-D-Glu-meso-2,6-diaminopimelic acid (L-Lys-L-Ala-L-LysD-Ala-D-Ala), except in Gram-positive Bacillus sp. and Listeria sp. (Figure 2.9). Among
Gram-positive bacteria, the most notable difference in their peptidoglycan structure
is the composition of the peptide crosslinks between glycan strands (Vollmer et al.,
2008). Stem peptides attached to the glycan strands can be linear or branched,
depending on the organism.
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Figure 2.9: Peptidoglycan structure. A) Peptidoglycan found in Gram-negative bacteria

and Gram-negative bacilli, containing meso-diaminopimelic acid (m-DAP) as the third
amino acid in the peptide linker. B) Gram-positive bacteria (except Bacillus sp. and Listeria
sp.) peptidoglycan, containing L-lysine as the third amino acid in the linker. Adapted from
Dworkin et al., 2010).
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2.7 The glycocalyx
The glycocalyx is a polysaccharide and protein film that surrounds bacterial cells,
outside the bacterial cell envelope. It may be found surrounding individual cells or
colonies and it makes part of bacterial biofilms. There are two kinds of glycocalyx:
capsules and S-layers.
Capsules are well-defined outer layers of uniform diameter located on bacterial
surfaces mainly composed of polysaccharide chains that form a negatively-charged
hydrated gelatinous mass on the cell surface. Their thickness depends on genetic and
environmental factors. They can be found both in Gram-negative and Gram-positive
cells. This structure protects the bacteria against bacteriophages, phagocytosis and
antibodies, while allowing the diffusion of small molecules (Hobot, 2015). In some
strains encapsulation is associated with virulence, as proved in 1928 by Griffiths, who
exposed rough (unencapsulated) avirulent strains of Streptococcus pneumoniae to
heat inactivated smooth (encapsulated) virulent stains, making the first ones develop
a capsule and become virulent thanks to the transfer of what he called "transforming
principle". It was later demonstrated that the transforming principle were capsule
synthesis genes transferred from the encapsulated strains to the unencapsulated
ones (Griffiths, 1928) (Figure 2.10).

100 nm

Figure 2.10: Electron micrograph of bacterial capsules from S. pneumoniae strain ST556.

Figure from Horton, 2015.
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S-layers can be found in Gram-positive organisms, on the outer surface of the
peptidoglycan layer, and in Gram-negative bacteria, located outside the outer
membrane. They are composed of proteins or glycoproteins forming a crystalline
array. The S-layer protects bacteria from their environment, allows the pass of certain
macromolecules while impeding the pass of some others, thanks to the presence of
pores within the protein subunits (Hobot, 2015).

2.8 Strategies for DNA penetration
In Caudoviroles, the phage tail complex is important not only for the search and
adsorption to its receptors in the bacterial cell envelope surface, but also for the
perforation of the bacterial cell envelope and the injection of the viral genome into
the host bacteria (Fokine et al., 2014; Vinga et ai, 2016).

For adsorption, the tail receptor-binding proteins (RBPs) must interact specifically
with one or more bacterial cell envelope receptors. Receptor-binding proteins may
be located in different parts of the tail complex, such as the baseplate, fibres or spikes
(Figure 2.10 and 2.11). They are a major host range determinant (Casjens et ol., 2012;
Davidson et al., 2012; Leiman et al., 2012; Dowah et al., 2018), but the host range
also depends on proteins that play a role in other phage life cycle stages, such as
restriction modification (RM) systems, clustered regularly interspaced short
palindromic repeats (CRISPR), abortive infection (abi), bacteriophage exclusion
(BREX), and defence island systems associated with restriction-modification
(DISARM) (de Jonge et al., 2019). These receptor binding proteins are highly diverse
and usually form trimers (Figure 2.11 and 2.12). Host cell receptors are usually
located in the outer part of the bacterial cell envelope and can be sugars, proteins,
structural polymers like lipopolysaccharides, peptidoglycan, cell wall teichoic acids or
lipoteichoic acids, glycocalyx components such as polysaccharide capsules or slime
layers; or cell structures such as pili or flagella (Bertozzi-Silva et al., 2016). Upon
binding of the receptor-binding protein to its receptor, the virion undergoes some
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Structural changes that allows the DNA to exit the head and to pass through the host's
bacterial cell envelope to be delivered into its cytoplasm (Fernandes et oi, 2018).
Some receptor-binding proteins cleave or modify the bacterial cell receptor they
recognize.

►1

gp9
Tail spike

gp26
Tail needle

Head fibre

Tail fibre/Appendage

Lysozyme-like domain

Endopeptidase-like domain

Figure 2.11: Diversity of receptor binding proteins (RBPs). Up: P22 tail cryoEM
reconstruction with 3D structures for the tail needle (gp26; 2POH) and the tail spike (gp9;
2XC1) fitted. Down: (j)29 phage representation indicating the location of the structures
from p8.5 (head fibre; 3QC7), pl2 (tail appendage; 3GQ7) and pl3 (tail-knob associated
protein, with a N-terminal lysozyme-like domain (left; 3CZS) and a C-terminal
endopeptidase-like domain (right, 3CSQ)). Figure adapted from Garcia-Doval etoi, 2013.
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Figure 2.12: Diversity of receptor binding proteins (RBPs) in T4 phage. T4 phage presents
multiple receptor binding proteins, most of them trimeric. Structures for long tail fibre tip
(gp37; 2XGF), long tail fibre "knee" (gp34; 4UXE), short tail fibre (gpl2; IPDI), whiskers or
fibritin (wac, lAAO) and tail lysozyme or cell puncturing device (gp27 and gp5; IWTH) are
shown.

2.8.1 Phage depolymerases

The tail complex may contain some proteins with enzymatic activity to degrade or
modify parts of the bacterial surface. These proteins can either degrade substances
that prevent the recognition and binding of the receptor-binding proteins to their
receptors, making a tunnel through the capsule, or help the phage trespass barriers
in the bacterial cell envelope.
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The most common of these enzymes are polysaccharide depolymerases. This kind of
depolymerases can degrade the extracellular polysaccharides (EPS) present in
capsules or bacterial biofilms to gain access to the cellular receptor or cleave the
bacterial

cell

envelope

polysaccharides

like

the

lipopolysaccharide

or the

peptidoglycan glycan strands (Figure 2.13).

OM

cytoplasm
Figure 2.13: Actions of phage depolymerases during recognition and penetration of the
bacterial cell envelope. Phage depolymerase degrades the capsule. Then it hydrolyzes
the 0-polysaccharide of lipopolysaccharide to allow the phage to bind to its secondary
receptor and inject the DNA. CM, cytoplasmic membrane; PG, cell wall peptidoglycan;
OM, outer membrane; LPS, lipopolysaccharide; CA, capsule. Figure from Fernandes et oi,
2018.

Some bacteria have polysaccharide capsules to protect themselves from the infection
by phages, hiding phage receptors and preventing phage access to their membrane.
To overcome this barrier, some phages have one or more tail fibres and tailspikes
that can degrade the capsule by cleaving the polymer bonds sequentially. In this way,
the phages can reach their secondary receptors in the bacterial cell envelope and
trigger the DNA-entry process (Leiman et al., 2007; Hsieh et oi, 2017; Pan et ai,
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2017). Some other phages encode extracellular polysaccharide depolymerases to
degrade biofilm matrices (Cornelissen et al., 2011; Gutierrez et oi, 2012).
Phages infecting Gram-negative bacteria frequently hydrolyze the 0-antigen
lipopolysaccharide using their depolymerases. The tailspikes of podoviruses
hydrolyze lipopolysaccharide to allow the phages to reach a secondary receptor in
the outer membrane and trigger the DNA ejection (Letarov et ol., 2017).

Phage depolymerases can be classified as hydrolases or lyases, according to the
mechanism of polysaccharide cleavage. Hydrolases include sialidases that degrade
capsular polysialic acid, rhamnosidases that hydrolase the lipopolysaccharide
0-antigen and depolymerases with phosphoesterase activity towards cell wall
teichoic acids. Lyases include the hyaluronidases that cleave hyaluronate-based
capsules and exopolysaccharides, the pectate,/pectin lyases that degrade biofilm
exopolysaccharides and

the

alginate

lyases that degrade the alginic

acid

exopolysaccharide of host cells (Pires et al., 2016; Latka et al., 2017).

2.8.2 Virion-associated lysins

The only virion-associated depolymerases able to cause host cell lysis are those
targeting the peptidoglycan. Many phages need to eject proteins or protrude some
tail substructures to extend their tails and penetrate the bacterial cell envelope (Xu
et al., 2017). Traversing the cell wall can be challenging and, to make this task easier,
some viral proteins that insert in the bacterial cell envelope have local peptidoglycandegrading activity (Figure 2.14). These enzymes are known as virion-associated lysins
(VALs),

virion-associated

peptidoglycan

hydrolases

(VAPGH),

tail-associated

muralytic enzymes (TAME), tail-associated lysins (TAL), exolysins or structural lysins
(Latka et o/.,2017; Fernandes et al., 2018).

If the multiplicity of infection (MOI) is high, these enzymes can cause extensive
damage to the peptidoglycan layers of the bacteria, causing their host to burst
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immediately due to the phenomenon of "lysis from without" and preventing
productive phage infection (Abedon, 2011).

Hydrolase

Figure 2.14: Mechanism of action of a virion-associated lysin (VAL). The virionassociated lysins degrade the peptidoglycan layer to allow some tail substructures to
reach the cell membrane and inject the DNA. Figure from Rodriguez-Rubio et al., 2013.

Virion-associated lysins promote a local digestion of the peptidoglycan to facilitate
penetration or extension of the tail tube across the cell wall and its fusion to the inner
membrane. They can be located in the tail complex, such as the tape measuring
protein (TMP), fibres or tail tip knobs and puncturing devices, but they can also be
proteins ejected from the virus head (Moak et al., 2004). The virion-associated lysins
catalytic domains (CD) usually show glycosidase or endopeptidase activity. Virionassociated lysins of phages infecting Gram-negative bacteria have a single catalytic
domain, while those of Gram-positive ones can carry two catalytic domains, with
different activities (Latka et o/.,2017; Fernandes et al., 2018).

2.8.3 T7 bacteriophage tail fibre

T7 bacteriophage is a member of the Podoviridae family. It was first characterized in
1945 as a member of T-type phages that replicate in an exclusively lytic way in E. coll
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B strains (Demerec et ol., 1945). It can infect E. coli C and K-12 derivatives
productively. These strains differ in the structure of their lipopolysaccharide (LPS;
Wright et ol., 1980). To summarize, it can infect E. coli strains which do not contain
0-antigen in their lipopolysaccharides.

Bacteriophage T7 has a T=7 icosahedral capsid with a diameter of 60 nm, an internal
core, a head-tail connector, a tail and six fibres. The tail fibres are long kinked
structures formed by gpl7 trimers bound to the phage tail through their N-terminal
domains. The N-terminal domains are followed by the proximal region of the fibre,
an a-helical region 117 amino acids long. The distal, C-terminal region of the fibre is
by residues 268-553. This region is made up of four globular domains (Steven et al.,
1988).

Tail fibres bind to the lipopolysaccharide (LPS) of E. coli and serve as the initial binding
organelle (Molineux, 2001). The N-terminal tail fibre sequences are highly conserved
among T7 group members. However, the sequence divergence at the C-terminal end
suggests that this region corresponds to the lipopolysaccharide-binding region.

The tail fibres are folded against the phage capsid to help the phage diffuse through
the medium. During adsorption, fibres undergo rotation by the N-terminal domain
pivoting on its connection to the tail. During the first stage of absorption, each tail
fibre of the T7 can bind independently to lipopolysaccharide, but binding is weak and
reversible, perhaps to allow the phage to move along the cell (Hu et al., 2013).
Interactions between multiple tail fibres and lipopolysaccharide orient the virion, so
that the tail is positioned against the outer membrane (Molineux, 2001). After these
initial adsorption steps, the cooperative binding of all six fibres or the binding of a
secondary recognition site in the phage tail could lead to an irreversible highly specific
binding (Hu et al., 2013). After these adsorption steps, a signal is transduced to the
phage head to initiate the irreversible steps of the infection (Molineux, 2001).
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A tube-like extension of the tail that penetrates both cell membranes is formed,
probably composed of ejected core proteins. During ejection, the proteins located in
the core partially unfold to pass through a channel located in the connector. The
extended tail allows the phage to traverse the cell membranes and the periplasmic
space and to inject the DNA (Molineux, 2001; Hu et ai, 2013).

Figure 2.15: T7 phage morphology and ejection system. A) T7 proteins and ejection of
the extended tail. Panel modified from Molineux et oi, 2001. B) Micrograph showing T7
fibres. Panel extracted from Steven etoi, 1980. C) Schematic model of T7 infection. After
moving across the cell surface to find the receptor for the tail, all fibres rotate downward
to contact the outer membrane. Internal core proteins are ejected from the virion and
the extended tail (red arrow) forms. Panel from Hu et oL, 2013.

It is known that lipopolysaccharide recognition by the T7 receptor is essential for
phage adsorption to the host, but the exact sugar moiety to which the phage binds is
not known. By a T7 infection assay on several E. coli mutants defective in different
genes responsible for lipopolysaccharide biosynthesis, the first glucose of the
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lipopolysaccharide core was identified as a potential binding site for 17. When one or
more glucose residues are attached to this glucose, the binding site is probably
obscured, and therefore either the penultimate glucose or the terminal heptose of
the K-12 lipopolysaccharide backbone or both become essential for 17 infection
(Qimron et ai, 2006).

Regarding the tail fibre, several mutations have been identified that can modify the
host range of the phage. The mutation V544A impairs the phage binding to K-12
strains, while the mutation D520E impair the phage binding to B strains (Heineman
et al., 2008). 4)A1122 phage infects only Yersinia pestis, however, its tail fibre is 86%

identical to the one of T7. The residues involved in the binding to Y. pestis
lipopolysaccharide are probably located in the 16% of different residues. The
mutation of Leu523 to Ser (corresponding to Ala518 in T7 gpl7), results in a host
range change of c})A1122, reducing the infectivity on Y. pestis and acquiring ability to
infect E. coli. The mutations of Alall8 to Thr and the exchange of the residues 1-190
by the equivalent ones from 17 fibre also modified the host range (Garcia et al.,
2013).

The structure of the C-terminal part (residues 371-553, corresponding to the three Cterminal globular domains) of T7 tail fibre has been elucidated by X-ray
crystallography (Figure 2.16). It shows an N-terminal pyramid domain composed of
three concave nine-stranded mixed (B-sheets stacked over each other, forming a
tapered pyramid with a triangular cross-section. At the top of the pyramid domain
three a-helices are located, one from each protein chain. This domain is connected
to a C-terminal globular tip domain, where each monomer (residues 464-553) forms
a (3-sandwich, through a loop. The residues identified in the host-range modification
(Ala518, Asp520, and Val544) are located in exposed loops within the tip domain
(Garcia-Doval et al., 2012b).
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The residues involved in lipopolysaccharide recognition and which sugar moiety they
specifically recognize must be determined. In this work, a study of the ligand binding
interactions will be attempted.

Figure 2.16: T7 tail fibre (371-553) crystal structure. A) T7 fibre structure showing a C-

terminal tip domain and an N-terminal pyramid domain B) Region of T7 tail fibre (black
rectangle) crystallized and determined. C) Position of the mutations affecting T7 host
range. Figure adapted from Garcia-Doval etai, 2012.

2.9 Strategies for host cell lysis
Once the new virions have been assembled, they must escape from the host cell to
find a new bacterium to infect and start a new cycle. To do this, they need to
overcome the cell wall. They do this by enzymatically degrading the rigid
peptidoglycan layer, leading the bacteria to burst (lyse) and disseminate the phage
progeny. The peptidoglycan-degrading enzymes are produced in the cytoplasm and
need to traverse the inner membrane to reach their target. Tailed phages have
developed different strategies for this.
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2.9.1 Canonical holin-endolysin lysis

Canonical holin-endolysin lysis system uses at least two different proteins to lyse their
host bacteria: a small membrane protein called holin and a muralytic enzyme called
endolysin. The holin accumulates without causing any harm to the bacteria. At a
genetically-controlled moment, triggering occurs and holins assemble forming holes
and permeabilizing the inner membrane. As a result, the endolysin escapes from the
cytoplasm, reaching the peptidoglycan and degrading it (Young, 2013).
2.9.1.1 Endolysins

Endolysins can display one or more of the following peptidoglycan-cleavage activities
(Loessner, 2005; Fenton el ol., 2010b) (Figure 2.17):
•

N-acetylmuramidases (lysozymes or muramidases): hydrolyse the (B-(l->4)
glycosidic bond in the sugar moiety of the cell wall bond in the sugar moiety
of the cell wall between N-acetylglucosamine (GIcNAc) and N-acetylmuramic
acid (MurNAc).

•

N-acetyl-P-D-glucosaminidases
glycosidic

bond

between

(glycosidases):

hydrolyse

N-acetylmuramic

acid

the

p-(l->4)

(MurNAc)

and

N-acetylglucosamine (GIcNAc).
•

N-acetylmuramoyl-L-alanine amidases (amidases): cleave the amide bond
connecting the sugar and peptide moieties of the bacterial cell wall.

•

L-alanoyl-D-glutamate endopeptidases and interpeptide bridge-specific
endopeptidases

(peptidases):

attack

the

peptide

moiety

of

the

peptidoglycan.
Endolysins can be as simple as one globular polypeptide corresponding to a catalytic
domain, showing one of the above-mentioned peptidoglycan degrading activities.
This single-domain kind of endolysins are exclusive to phages infecting Gram
negative bacteria. Most endolysins exhibit a modular configuration with one or
several catalytic domains (CD) connected to a cell wall binding domain (CWBD)
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(Navarre et al., 1999; O'Flaherty et al., 2005a; Rashel et al., 2007; Fernandes et ai,
2018) (Figure 2.18).
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Figure 2.17: Enzymatic activities of peptidoglycan degrading enzymes. Basic structure of
Gram-negative cell wall peptidoglycan, indicating the possible enzymatic activities of
peptidogivcan-degrading enzymes and the bonds they cleave. Figure from Fernandes et
ol., 2018.

The cell wall binding domain is responsible for attaching the enzyme to its specific
substrate, a specific cell wall component, binding non-covalently to carbohydrate
ligands. The cell wall binding domain appears to be necessary for the activity of some
endolysins but not for all of them (Fenton et al., 2010b). The lytic spectrum of
endolysins depends on their cell wall binding domain and on the conservation among
bacteria of the cell wall motif they recognize (Nelson et al., 2012).

The endolysins of phages infecting Gram-positive bacteria usually present a cell wall
binding domain. After lysis, this domain remains attached to the cell wall debris
limiting the diffusion of the protein and the destruction of new potential host cells.
In Gram-negative bacteria, the outer membrane protects the peptidoglycan, so the
cell wall binding domain is not as necessary to preserve the integrity of the neighbour
bacteria (Fernandes et al., 2018).
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Figure 2.18: Modular architecture of several endolysins. CBD: Cell wall binding domain;
ChBD: Choline binding domain; Cpl-7: Cpl-7-like cell wall binding domain; SH3b: Bacterial
Src homology 3 domain. Figure adapted from Schmelcher et ai, 2012.

2.9.1.2 Holins

Holins are small membrane proteins that accumulate in the cell membrane until a
specific time that is coded in the phage genome. At that specific moment, they are
triggered and the cell membrane permeabilizes to allow the passage of the fullyfolded endolysin to the periplasm, ultimately causing the digestion of the
peptidoglycan and host cell lysis. Holins control the duration of the infective cycle in
lytic phages. Due to this reason, they are known as the "protein clocks" of
bacteriophage infections and they are strongly regulated (Wang et al., 2000).
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Most knowledge about holins derives from the study of lambdoid phages, specifically
the study of the S105 holin from phage X (Young et oL, 2013). In phage X, during the
infection, holin 5105 accumulates in the inner membrane as homodimers uniformly
distributed and mobile (Altman et al., 1983). At the same time, R endolysin, with
transglycosylase activity, accumulates in the cytoplasm fully formed and active. At a
specific time, after reaching a critical holin concentration genetically determined
(from 1000 to 3000 copies of the protein in phage A), the holin "triggers" (Chang et
al., 1995). Holin molecules redistribute to form a relatively small number (an average
of 3.3 per cell) of large aggregates in the inner membrane, called "rafts". Each raft is
formed by hundreds of holin molecules (White etoL, 2011). This redistribution causes
a halt in the host cell growth and respiration, a loss of cytoplasmic ions and a sudden
decrease in the proton motive force (PMF) due to the permeabilization of the inner
membrane

(Young

et

al.,

2014).

This

membrane

depolarization

causes

conformational changes that allow the conversion of holin rafts into holes. These
holes are irregular and can have a diameter larger than 1 pim (White et al., 2011;
Young et al., 2014).
2.9.1.3 Antiholins
The strict time-regulation of the hole formation and lysis in cells infected by lambdoid
phages is achieved because they do not only encode a holin but also a holin
antagonist or antiholin. In some phages, the holin gene codes both the lysis and
inhibitor functions through a "dual-start motif". In phage X, the S gene codes not only
for the holin protein 5105 but also for its specific inhibitor or antiholin, 5107. The
protein translation begins at codon 1 in the case of the antiholin 5107 and at codon
3 in the case of the holin 5105 (Blasi et al., 1996). The timing of lysis depends on the
proportion of the two proteins, which is 2:1 in favour of 5105 under regular culture
conditions.
The holin 5105 is a membrane protein with three transmembrane domains (TMDs).
The antiholin 5107 presents two extra amino acids at the N-terminus, Met and Lys.
These extra positive charges prevent the insertion of the first transmembrane
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domain of S107 into the inner membrane. The capacity of the antiholin S107 to
heterodimerize with the holin S105 causes its inhibitory effect. Dissipation of the
proton motive force causes the insertion of the first antiholin transmembrane
domain into the inner membrane, adopting the same topology of S105 and leading
to hole formation and subsequent lysis (Fernandes et ai, 2018).

In some phages, such as T4, PI and P2, holin and antiholin functions are coded by
separate genes (Ziermann et al., 1994; Schmidt et ai, 1996). For other phages, cell
lysis requires the action of two holin-like proteins that may act as a complex (Catalao
et al., 2011; Fernandes et al., 2017). Flolins are very diverse. According to the
Transporter Classification Database (TCDB, www.tcdb.org) there are 60 families of
holin-like proteins (Saier et al., 2016).

2.9.2 SAR-endolysins and pinholins

Some years ago, it was thought that the confinement of endolysins in the cytoplasm
until holin triggering and hole formation was the main strategy used by tailed phages
to avoid premature host cell lysis. In 2000, it was discovered that the endolysin of
Oenococcus oeni phage fOg44, Lys44, is synthesized with a signal peptide (SP) that
allows the protein to be secreted to the cell wall compartment using the Sec system,
a general secretion system conserved in bacteria (Sao-Jose et al., 2000; Crane et al.,
2017). Lys44 is exported to the cell wall in its mature form, without signal peptide,
and it accumulates in the cell wall compartment during the phage cycle. The
endolysin is inactive as long as the host cell proton motive force remains unaltered.
However, although the fOg44 holin is not necessary for the endolysin to reach the
peptidoglycan layer, it is still necessary to trigger the proton motive force dissipation
and, therefore, to act as a "lysis clock" (Nascimento et al., 2008).

After the discovery of Lys44, more endolysins with export signals have been detected,
both for Gram-positive and Gram-negative-infecting phages. Two of these proteins,
Lyz of coliphage PI and R21 of the lambdoid phage 21, have been studied in depth
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and considered as the model of a new class of lytic enzymes, the SAR endolysins (Xu
et al., 2004; Xu et al., 2005; Sun et ai, 2009). These enzymes present an N-terminal
SAR (Signal-Anchor-Release) domain that allows the translocation to the periplasm
through the Sec system, in a holin-independent manner. This SAR domain is not
cleaved by the signal peptidase after the translocation, and the SAR endolysin
remains attached to the membrane in its inactive conformation during phage
maturation thanks to the N-terminal transmembrane domain embedded in the inner
membrane. To become active, the endolysins must be released from the inner
membrane and refolded into the catalytically active form. Dissipation of the proton
motive force causes the transmembrane domain to be released from the cell
membrane. After leaving the bilayer, the protein refolds into a periplasmic active
form (Kuty et al., 2010; Fernandes et al, 2018). The holins facilitate this process by
mediating the collapse of the proton motive force (Xu et al., 2004; Xu et al., 2005;
Sun et al., 2009).

Holins expressed by phages using SAR endolysins are different from those used in the
canonical lysis system. Phage 21 holin (S2168), a 68 residue holin with two
transmembrane domains, forms holes with a lumen up to 2 nm, much smaller than
the micron-scale holes formed by S holin of A phage. In fact, holes formed by S2168
are too small to allow the passage of a canonical endolysin, but they are large enough
to cause the proton motive force dissipation (Park et al., 2007). Due to the small size
of the pores, these proteins were named "pinholins". S2168 pinholin forms
homodimers in which the transmembrane domain 1, which is a SAR domain, and the
transmembrane domain 2 of each monomer are stabilized in the cell membrane. At
some point, the transmembrane domain 1 from each monomer spontaneously exits
the membrane and the pinholin dimer is activated for the raft formation or
"triggered". S21 gene also codes for S2i71, an antiholin with extra positive charge at
the N-terminus that inhibits the escape of transmembrane domain 1 from the bilayer.
$2171 antiholin forms inactive heterodimers with the pinholin S2168, slowing down
the lysis process (Young et al., 2013). After triggering, around 7,000 pinholin
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molecules participate in the formation of 10^ heptameric pinholes of small diameter
(Pang et al., 2009; Pang et oL, 2013). Some phages with endolysins containing an
export signal, as fOg44 and PI, may present canonical holins instead of pinholins
(Sao-Jose et al., 2004; Young et al., 2014).

Figure 2.19: Two pathways for bacterial lysis. Schematic view of canonical (left) and
pinholin-SAR endolysin (right) lysis pathways. Holin or pinholin (blue) accumulate in the
inner membrane (IM). When they reach a critical concentration, holins form a few large
holes (left), while pinholins form many small-sized pinholes (rigth). The active canonical
endolysin (orange pacman, left) passes through the holes reaching the peptidoglycan and
cleaving it. The opening of the pinholes causes dissipation of the proton motive force
(PMF), promoting the inactive membrane-attached SAR endolysin (red pacman, right) to
be released from the membrane and to activate, reaching the peptidoglycan and
degrading it. Figure from Young et al., 2013.
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2.9.3 Spanins

After the destruction of the peptidoglycan, lysis of Gram-negative bacteria requires
the action of an extra protein, a spanin, to disrupt the outer membrane (OM) (Berry
et ol., 2012). There are two kinds of spanins: two-component spanins and
unimolecular spanins (Summer et al., 2007).

Studies performed in the phage X have shown that it codes for two extra proteins, Rz
and Rzl; whose genes are located immediately downstream the holin (S) and
endolysin (R) genes, being Rzl totally embedded in Rz gene, with a +1 frame shift.
These four genes form the complete phage A lysis cassette (Young et al., 2014). Rz
codes for an integral inner membrane protein and Rzl codes for an outer membrane
lipoprotein (Hanych et al., 1993; Kedzierska et al., 1996). In the absence of Rz or Rzl
proteins, the lysis process terminates in spherical cells lacking the cell wall and
surounded by the outer membrane (OM) (Berry et al., 2012).

In 2007, during a genome database survey, it was shown that most Gram-negativeinfecting phages code for Rz and Rzl equivalents. These genes could be embedded,
overlapped or separated, depending on the bacteria (Summer et al., 2007). Some
phages, such as Tl, code for a single protein sharing the features of both proteins,
able to anchor to the inner and outer membranes. This fact was a clue indicating that
probably Rz and Rzl could interact to bridge the inner membrane and the outer
membrane.

Rz and Rzl proved to be subunits of a complex that spans the entire periplasm,
connecting the inner and outer membranes, and thus designated as a spanin (Berry
et al., 2008). Rz is a 153 amino acids integral membrane protein, or i-spanin. It
contains an N-terminal transmembrane domain and a periplasmic domain. Rzl is a
40 amino acids proline-rich outer membrane lipoprotein, or o-spanin. Rz and Rzl
form covalent homodimers that associate via C-terminal interaction to assemble the
Rz-Rzl heterotetrameric complex (Berry et al., 2013).
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For the two-component spanins, the Rz-Rzl heterotetrameric complexes connecting
the inner and outer membranes accumulate in the periplasm during phage infection,
trapped in the gaps formed by the peptidoglycan cross-linking. When the endolysin
reaches the peptidoglycan and cleaves its links, spanin complexes can diffuse laterally
and form aggregates providing the free energy for a conformational change that
brings the surfaces of the outer membrane and the inner membrane together and
cause membrane fusion (Young et oL, 2013).

In some cases, a single protein is needed for the membranes to fuse. It is called
unimolecular spanin or u-spanin and its prototype protein is gpll from phage Tl. This
protein is an outer membrane lipoprotein, but it also presents a C-terminal
transmembrane domain inserted in the inner membrane. Gpll monomers diffuse
laterally once the peptidoglycan is cleaved by the endolysin, oligomerizing and
getting the free energy necessary to undergo a conformational change that allows
membrane fusion (Young et al., 2013) (Figure 2.20).

O-spanin

I-spanin

U-spanin

Figure 2.20: Mechanism of action of spanins. Schematic view of model for the function
the two-components (top panel) and unimolecular (bottom panel) spanins. Spanins
accumulate connecting the inner membrane and the outer membrane. Once the
peptidoglycan is cleaved, they can diffuse, form aggregates and bring both membranes
together, causing them to fuse. Figure adapted from Kongari et al., 2018.
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2.10 The applications of bacteriophages
Historically, some of the most fundamental discoveries of modern molecular biology
were revealed studying phage-infected cells (Rohwer et oL, 2015). In the early 1900s,
most phage scientists were interested in using viruses as antibacterial agents, but the
interest decreased with the discovery of antibiotics in 1928. Nowadays, as antibiotic
resistance is becoming a concern, "phage therapy" is resurging.

In 1952, Hershey and Chase showed that DNA and not protein was the genetic
material used by the bacteriophage T2 (Hershey et oi, 1952). By using T4
bacteriophage. Crick et al. discovered that codons are degenerate and code for single
amino acids (Crick et al., 1961). Brenner and colleagues discovered that mRNA acts
as the messenger in relaying the information from DNA to ribosomes, by using
bacteriophage T2 (Brenner et al., 1961).

In 1968, the semiconservative mechanism of DNA replication was demonstrated
using phage \ (Taylor et al., 1968). The discovery of phage-encoded, DNAmanipulating enzymes such as DNA and RNA polymerases, ligases and endo- and
exonucleases allowed important discoveries in the field of molecular biology.
Restriction enzymes, used by bacteria to protect themselves from phage infection,
are a key for molecular biologists. Nowadays, the CRISPR-Cas system, another
bacterial defence system against phages, is being widely used for genome edition
(Strich et al., 2018). The mechanism of action of heat shock genes encoding for
molecular chaperones were discovered in X phage-infected Escherichia coll
(Georgopoulos, 2006). In 1977, Sanger sequenced the first complete genome, that of
phage 0X174 (Sanger et al., 1978; Asija et al., 2018).

One of the most useful techniques involving bacteriophages is the phage display
system, the use of bacteriophage particles to display exogenous peptides or proteins.
It has numerous applications, including epitope identification, antigen delivery, drug
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discovery, vaccine design, targeting of eukaryotic cells, bioimaging and biosensing,
enzyme display or design of nanomaterials (Henry et oi, 2012; Harada et al., 2018).

Phages have also been used for the development of vaccines, both displaying
antigenic epitopes (phage display vaccines) or transferring antigen genes into
mammalian cells (bacteriophage DNA vaccines). Bacteriophages have also been used
as gene-delivery vehicles, food biopreservation tools, bacterial biosensing devices,
surface disinfectants and nanomaterials (Harada et al., 2018). A special mention must
be made of phage therapy, which was the first practical application of phages, was
then largely forgotten and is now starting to make a deserved comeback.

2.10.1 Phage therapy

After the discovery of bacteriophages, the idea of phage therapy was contemplated,
and it was implemented in many cases. After the discovery of antibiotics in 1928 and
their successful use during the Second World War, this approach was abandoned in
the Western World. However, the research in phage therapy and its use to treat
bacterial infections continued in Eastern Europe and the Soviet Union until the fall of
the Iron Curtain (Alisky et al., 1998; Abedon et al., 2011).
Currently, the world is facing the serious problem of antibiotic resistance. In 1947, the
first antibiotic-resistant bacteria were found, penicillin-resistant Staphylococcus
aureus. By the 1960s, antibiotic resistance had become widespread and clinically
significant. In 1996, the first bacteria resistant to third generation antibiotics, such as
vancomycin and cephalosporin, were reported. Since then, bacteria resistant against
multiple antibiotics have been discovered. Humanity may be approaching a "post
antibiotic" era, when antibiotics will no longer be effective to treat bacterial
infections, posing a serious threat to human and animal health (Bragg et al., 2014). In
2017, the WHO published a list of bacteria for which new antibiotics are urgently
needed

(https://www.who.int/en/news-room/detail/27-02-2017-who-publishes-

list-of-bacteria-for-which-new-antibiotics-are-urgently-needed), bemg Acinetobacter
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baumannii Pseudomonas aeruginosa and Enterobacteriaceae the most critical
concerns; and Enterococcus faecium, Staphylococcus aureus, Helicobacter pylori,
Campylobacter spp., Salmonellae and Neisseria gonorrhoeae highly-important
concerns. Most of these bacteria are included in the group of "ESKAPE" (E. faecium,
5. aureus, K. pneumoniae, A. baumannii, P. aeruginosa and Enterobacter spp.), that
represents the most common cause of nosocomial diseases, especially in
immunosuppressed and chronically ill patients. Due to this, alternatives to antibiotics
are urgently needed.
The use of bacteriophages to treat bacterial infections has several advantages (Bragg
et ai, 2014):
1. Bacteriophages evolve fast. If a bacterium develops resistance to a phage, the
phage can adapt through mutations to be able to infect the bacterium again.
The Red Queen hypothesis proposes that coevolution of interacting species
drives molecular evolution through continual natural selection for adaptation
and counter-adaptation. In the case of phages, it has been shown that
Pseudomonas fluorescens phage 4)2 mutation rate is higher when it coevolves
with its host than when it evolves against a constant host genotype (Paterson
etal., 2010).
2. Bacteria may be susceptible to many different phages. If the bacterium
develops resistance to a specific kind of phage, there is a high possibility that
other phages can still infect it. In the case of antibiotics, there is a limited
number and it is difficult to find an alternative in case of the development of
resistance. For instance, to date, more than 10,400 phages infecting
Mycobacterium

smegmatis

mc^l55

have

been

identified

(http://phagesdb.org).
3. When

administered

intravenously,

intranasally

or

intraperitoneally,

bacteriophages can be found in nearly all organs (Dabrowska et ai, 2005). An
example of this is the efficacy of a Klebsiella pneumoniae phage in the
treatment of Klebsiella infections. When the phage was administered on day
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two after the infection, it could be detected in the blood and internal organs
of the animals within 24 hours, irrespective of the route of its administration.
(Bogovazova et al.,1991).
4. Bacteriophages reproduce quickly during the cell cycle, growing exponentially
in number. This fact makes them effective for the treatment of bacterial
infections, even if the administered dosage is low. The higher the bacterial
population, the more viral particles will be produced (Carlton, 1999).
5. They are non-toxic and there is a low occurrence of allergic reactions. Major
life-threatening immune reactions, such as anaphylaxis, have not been
reported in phage therapy (Speck et al., 2016), but immune response can
decrease phage efficacy. Naturally occurring bacteriophages are able to
induce humoral immunity: phage-neutralizing antibodies not stimulated by
phage treatment have been detected in the sera of different species (Smith
et al., 1987). The immunogenic effect of bacteriophages has been observed
in patients subjected to oral phage therapy (Kucharewicz-Krukowska et oi,
1987). Furthermore, phages, such as (J)X174, are able to induce in vivo
humoral responses (Fogelman et ol., 2000). The reaction of bacteriophages
and antibodies can cause the neutralization of bacteriophages in a time and
dose

dependent

way

(Stent,

1963).

Besides

humoral

immunity,

bacteriophages interact with the innate immune system as well. In
nonimmune, germ-free mice, bacteriophages were cleared by the spleen,
liver and other filtering organs of the reticulo-endothelial system (Geier et ol.,
1973). Bacteriophages can be phagocytized by the liver Kupffer cells or
inactivated by splenic macrophages (Inchley, 1969; Dabrowska et al., 2004).
6.

Bacteriophages are usually specific for a specific genus or species and do not
damage the commensal microbiota (Abatangelo et ol., 2017)

The major factors contributing to the failure of phage therapy have been
inappropriate phage selection, preparation and storage (Gill et al., 2010). The most
important criteria for selecting a suitable bacteriophage for therapeutic phage
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preparation are specificity, efficacy and lack of adverse effects. The selected
bacteriophage should efficiently absorb and lyse the bacterial host (WeberD^browska et ai, 2016). To ensure the desirable host range, mixtures containing two
or more bacteriophages, called '"phage cocktails", have been developed (Chan et ol.,
2013). Phage preparations should be stored correctly, as they are vulnerable to high
temperature, extreme pH, organic substances and mechanical stresses. Several
techniques, including encapsulation, have been developed to improve phage storage
(Malik et ai, 2017). For phage therapy to be effective, bacteriophages must be
delivered to the target site and maintain therapeutic levels (at least 10 virions per
bacterial cell) for enough time. Phage administration can be enteral, topical, inhaled
or injected (Abedon et al., 2010).

The safety concerns of phage therapy include the possible impact of bacteriophages
on body tissues and non-target microbiota. Bacteriophages can modify their bacterial
targets by expressing virulence genes or by transducing DNA between bacteria (this
risk can be reduced by avoiding the use of temperate phages), and bacteriophages
may induce both adaptive or innate immunological reactions. Phage formulation may
contain harmful products, such as endotoxins, due to incorrect purification
processes.

Moreover,

the

pharmacological

dose

cannot

be

calculated,

as

bacteriophages are able to auto-replicate (Kakasis et al., 2018).

2.11 Endolysins as antimicrobial agents
The phage-encoded peptidoglycan hydrolases or endolysins used by the phage to
release its progeny can be purified and used to treat bacterial infections instead of
the full viral particle. The use of these protein represents a solid alternative to the
use of antibiotics. The first report of an activity of a recombinant endolysin dates back
to 1959 (Freimer et al., 1959). Since then, small amounts of certain endolysins have
proved to be efficient in eliminating bacterial suspensions in vitro, for example
against MRSA (endolysin LysK, O'Flaherty et al., 2005a) or vancomycin-resistant E.
faecalis (endolysin PlyV12, Yoong et al., 2004). Endolysins can also been used in
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cocktails or in combination with antibiotics to eliminate pathogenic bacteria: Cpl-1
and Pal endolysins, with different catalytic activities, have been used succesfully to
lyse antibiotic-resistant S. pneumoniae strains (Jado et a!., 2003). Cpl-1 endolysin has
also shown synergistic effect when applied together with penicillin or gentamicin
against S. pneumoniae strains (Djurkovic et oL, 2005).

The Gram-positive phage endolysins generally contain at least one catalytic domain
(CD) and a cell wall binding domain (CWBD). As the peptidoglycan layer of the
bacteria is typically exposed, they can lyse the bacteria when applied exogenously.
This phenomenon is called "lysis from without" (Abedon, 2011). The catalytic
capacities and host range of the endolysin can be modified by the generation of
chimeric endolysins by fusing different catalytic domains to alternative cell wall
binding domains.

In the case of Gram-negative bacteria, the outer membrane blocks the access of
exogenously added endolysins to the peptidoglycan. To facilitate outer membrane
penetration, genetically engineered constructs, fusing polycationic peptides to the
Gram-negative endolysin, have been designed. These molecules are called artilysins
(O'Sullivan et al., 2016).

2.11.1 Properties of endolysins as potential therapeutic agents

To evaluate the potential of natural or genetically engineered endolysins as
antibacterial agents, it is necessary to evaluate some of their properties such as drug
toxicity, immunogenicity, efficacy, resistance or synergy (Fenton et al., 2010b).
•

Toxicity: Endolysins should not be toxic to humans and animals, as phages do
not infect mammalian cells. No signs of toxicity or side-effects have been seen
in preclinical trials for the use of endolysins in mouse models (Nelson et al.,
2001; Jado et al., 2003; McCuller et al, 2007; Fenton et al., 2010a).

•

Immunogenicity: As proteins, endolysins can stimulate an immune response
that could decrease their activity. Experiments have showed that immune
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response could slow down but not block lytic activity (Loeffer et oi, 2003).
Lysin treatment can induce an inflammatory response that could be reduced
by using smaller doses of enzyme (Entenza et al., 2005). Immunogenicity of
lysins is reduced by PEGylation (Walsh et al., 2003).
•

Resistance: Occurrence of lysin-resistant bacteria is not likely because lysins
have evolved to target specific molecules in its host peptidoglycan that are
essential for its viability (Fischetti, 2008). This event is even less likely in lysins
with two or more catalytic domains. Several experiments showed that after
several cycles of endolysin exposure to their host bacteria, they did not
develop any kind of resistance towards it (Loeffler et al., 2001; Schuch et al.,
2002). Capsules present in some bacteria also did not block endolysins' lytic
activity. (Loeffler et al., 2001).

•

Synergy: Studies have demonstrated that some lysins can work in synergy
with others or with certain antibiotics both in vitro and in vivo (Fenton et al.,
2010a, Jado et al., 2003; Loeffler et al., 2003; Becker et al., 2008). One
example is the synergic effect of the staphylococcal endolysin LysK and
lysostaphin (Becker ef al., 2008).

2.11.2 Endolysin Domains

As shown in section 2.9.1.1, most endolysins exhibit a modular configuration with
one or several catalytic domains (CD) connected to one or several cell wall binding
domains (CWBD). To date, different kinds of catalytic domains have been found,
showing either amidase, enteropeptidase, carboxypeptidase,

muramidase or

glucosaminidase activity. These domains can be combined between, both in naturally
occurring or genetically engineered endolysins:
•

CHAP: Cysteine, histidine-dependent amidohydrolase/peptidase.

•

Amidase.

•

Amidase 2.

•

Amidase 3.

71

Crystallographic structure determination of bacteriophage-encoded enzymes that specifically
target pathogenic bacteria

Amidase 5.
Peptidase.
PGRP: Peptidoglycan recognition proteins homologous to bacteriophage T3
lysozyme. It shows amidase activity.
Glucosaminidase.
Muramidase.
SLT and SLT2: Transglycosylases.
Peptidase M23: Gly-Gly endopeptidases.
Peptidase C30: Cysteine peptidase.
These domains can be combined with one or more repeats of the following cell wall
binding domains (CWBD):
LysM: anchors to extracellular polysaccharides such as peptidoglycan and
chitin.
PG_binding_l: Peptidoglycan binding domain.
SH3: Found in many membrane-associated proteins.
CW_binding_l or ChBr: Choline binding domain.
CW_7: Cell wall binding domain found in Cp-7 phage.
GBS Bsp-like: Found in Streptococcus proteins that control cell morphology.
SLH: S-layer homology domain.
NlpC/P60: Domain found in many lipoproteins.
Tachylectin: Binds NAG.
Cadherin-like: Putative carbohydrate-binding domain.
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Such a big diversity of domains that can be combined to form an endolysin gives an
idea of the great versatility of this kind of proteins. The structures of some of these
domains have been determined, showing big structural differences between them.
Elucidating the structure of more endolysin domains will allow us to increase the
knowledge about their catalytic mechanism and to design

more effective

antibacterial agents (Broendum et oi, 2018).
In some cases, the full endolysin with all its domains can be crystallized and its
structure determined by X-ray crystallography. In some other cases, it is necessary to
isolate and crystallize each domain independently, because the links between
domains induce flexibility that impairs crystallization.
2.11.3 Endolysins against Gram-positive bacteria

In Gram-positive bacteria, the peptidoglycan can be easily accessed by an endolysin
applied exogenously, cleaving the peptidoglycan and causing the bacteria to burst
due to osmotic pressure ( "lysis from without"). Endolysins have been used to treat
successfully infections of Gram-positive bacteria: Cpl-1 from Cp-1 phage and PAL
from DP-1 phage for Streptococcus pneumoniae,

PlyC from Cl phage for

Streptococcus pyogenes, PlyGBS from NCTC 11361 phage for Bacillus agalactiae, PlyG
from y phage and PlyPH for Bacillus anthracis and MV-Lfrom phage Mil, CHAPk from
phage K, LysGHlS from phage GH15 and ClysS for Staphylococcus aureus (Nelson et
ai, 2012)
These proteins have also been used as disinfectants, bacteria-detection systems and
in food safety applications (Bai et ai, 2016; Schmelcher et ai, 2016) due to their lack
of toxicity.
2.11.3.1 Staphylococcus aureus
Staphylococcus aureus are Gram-positive bacteria causing disease in both humans
and animals. It is the most common cause of nosocomial cases of pneumonia and
surgical-wound infections and the second most common cause of nosocomial
bloodstream infections, specially affecting immunosuppressed patients. It can cause
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skin, soft tissue, respiratory, bone, joint, and endovascular disorders such as
endocarditis, bacteraemia, metastatic infections, sepsis or toxic shock syndrome
(Lowi, 1998).
Five decades ago, methicillin-resistant Sfop/?y/ococcL/s aureus {MRSA) was first
described. Nowadays it has spread worldwide and remains a major global cause of
health-care-associated infections, becoming a serious health concern (Holden et ol.,
2013). In addition to its resistance to most antibiotics, 5. aureus is able to form
biofilms, a characteristic that can cause an up to 1000-fold increase in bacterial
antibiotic resistance (Olson et al., 2002). An alternative to treat these serious
infections are bacteriophages. It is known that phages, such as the myovirus
bacteriophage K (Rees et al., 1981; O'Flaherty et al., 2005a), siphovirus phages DW2
and CS (O'Flaherty et al., 2005b) or 4)11 (Das et al., 2019) and their endolysins are
highly effective at lysing Staphylococcus aureus, including methicillin-resistant strains
(MRSA; Ralston et al., 1955; Sonstein et al., 1971; O'Flaherty et al., 2005a; Fenton et
al., 2011).

These endolysins target 5. aureus peptidoglycan, that is composed of strands of
GInNAc and MurNAc bound to a tetrapeptide stem formed by L-Ala-D-iso-GIn-L-LysD-Ala. The L-Lys from one pentapeptide stem is bound to the D-Ala of the next one
through a pentaglycine bridge (Figure 2.21).

74

Crystallographic structure determination of bacteriophage-encoded enzymes that specifically
target pathogenic bacteria

-------- ( CIcNAc

GIcNAc ^^—

.l-A*, a
L-AIa

__________

[)-Glu

t-Lys

i.-Lys

i)-Glu

—

(Gly)5

—

in
o-Ala

D-Ala

Figure 2.21: Scheme of the S. aureus peptidoglycan structure. Figure adapted from SanzGaitero et al., 2013.

2.11.3.1.1 Bacteriophage K and its endolysin, LysK.

Bacteriophage K is a virulent myovirus (Figure 2.22A) that infects a wide range of
staphylococci (Rees et al., 1981; O'Flaherty et al., 2004). It encodes the endolysin LysK
to allow its progeny to escape from the cell once the virions have been assembled.
This 495-residue enzyme can cause exolysis or "lysis from without" when applied
exogenously (Ralston et al., 1964). LysK kills a wide range of staphylococci, including
multi-drug-resistant Staphylococcus aureus (MRSA) (O'Flaherty et al., 2005a).

LysK is a multidomain endolysin containing an N-terminal cysteine-histidine
dependent amido-hydrolase/peptidase (CHAP) domain, a central amidase-2 domain
and a C-terminal SH3b cell wall-binding domain (Figure 2.22B). The amidase domain
cleaves the peptidoglycan between N-acetylmuramic acid and L-alanine of the stem
peptide, while the CHAP domain hydrolyses it between the D-alanine of the tetrapeptide stem and the first glycine of the penta-glycine cross-bridge (Becker et al.,
2009) (Figure 2.22C).
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Figure 2.22: Bacteriophage K morphology, LysK domains and CHAPk peptidoglycan
cleaving site. A) Bacteriophage K micrograph. Panel adapted from Rees et ol., 1981, B)
LysK domains. Panel adapted from Becker et al., 2008. C) CHAPk and amidase-2
peptidoglycan cleavage sites. Panel adapted from Fenton et al., 2011.

A truncated enzyme called CHAPk, containing only the first 165 amino acids of LysK
(i.e. the CHAP domain), shows exolytic activity and can lyse several staphyloccocal
species, independently from their origin, their antibiotic resistance profile and their
ability to produce exopolysaccharides or biofilms (Horgan et al., 2009; Fenton et al.,
2010a; Fenton et al., 2013). It is also effective against other related genera, such as
Micrococcus or Streptococcus (O'Flaherty et al., 2005a). CHAPk showed a lytic activity
two-fold higher than the native protein (Horgan et al., 2009). The reason for this may
be that the SH3b domain is inhibitory when not bound to the cell wall, so removing
it may activate the enzyme (Low et al., 2005). CHAPk can act in vivo, eliminating 5.
aureus in the nares of mice (Fenton et al., 2010a) and it has also been demonstrated
to act against staphylococcal biofilms in vitro (Fenton et al., 2013). In addition to this,
it can act synergistically with lysostaphin to kill MRSA (Becker et al., 2008; Hathaway
eta!., 2017).
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The structure of CHAPk was determined by X-ray crystallography (Sanz-Gaitero et ai,
2013; Sanz-Gaitero et al., 2014). This structure shows a monomeric protein with a
deep negatively-charged group where a catalytic triad formed by Cys54, Hisll? and
Glul34 is located. It contains a coordinated calcium ion whose removal resulted in
the complete abolishment of the staphylolytic activity of the enzyme (see section
7.5). To further analyse what part of the peptidoglycan CHAPk recognizes, how it
binds to it and the catalytic mechanism of CHAPk, it is necessary to crystallize it with
its natural ligand or a structural analogue. During this thesis, the crystallization with
several components of 5. aureus peptidoglycan of both wild-type and C54A, a mutant
for one of the catalytic residues, will be tried.

2.11.3.1.2 Bacteriophage DW2

Bacteriophage DW2 was isolated from a farmyard slurry sample. It is a siphovirus with
a long flexible tail measuring 120 nm in length and an isometric head measuring 40
nm in diameter (Figure 2.23A). It can lyse several S. aureus strains that cause bovine
mastitis. It also shows weak lytic activity on S. aureus strains causing human
infections, some of them methicillin-resistant (O'Flaherty et al., 2015b).
This phage codes for a modular endolysin, LysDW2, with 481 residues, a molecular
weight of 53.9 kDa and a predicted pi of 8.48. It contains a SH3b cell wall binding
domain (residues 398-466) and two peptidoglycan hydrolysing (PGH) domains. One
of the peptidoglycan hydrolysing domains is a N-acetylmuramoyl-L-alanine amidase
(amidase 2, residues 188-338), cleaving the peptidoglycan bond between the
N-acetylmuramoyl residues and L-amino acid residues in the peptide stem. The other
one is a N-terminal cysteine, histidine-dependent amidohydrolase/peptidase (CHAP)
domain (residues 13-148). A truncated version of this protein, containing the 153
N-terminal amino acids (CHAPi-153) showed lytic activity in vitro (Keary et al., 2014).
DW2 phage also codes for a tail hydrolase (THDW2) 564 residues long with a
calculated molecular weight of 63.8 kDa and predicted pi of 9.5. It has a C-terminal
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lysozyme 2 (Lyz_2) domain (residues 413-559), that cleaves the bond between the
glycan backbone of the peptidoglycan and the L-alanine of the stem peptide and a
truncated N-terminal CHAP domain (residues 2-86) (Keary et ai, 2014, Figure 2.23B).
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Figure 2.23: Bacteriophage DW2 and its peptidoglycan hydrolases. A) Phage DW2
micrograph. The scale bar represents 50 nm. Panel modified from O'Flaherty et ol., 2015b.
B) Multidomain structure of the lysin (LysDW2) and the tail hydrolase (THDW2) of DW2
and representation of the constructs made of their CHAP domains. Panel modified from
Keary et ai, 2014. C) CHAP, amidase and lysozyme domains peptidoglycan cleavage sites.
Panel adapted from Fenton et ai, 2011.

2.11.3.2 Listeria monocytogenes
Listeria monocytogenes is a Gram-positive foodborne human pathogen that can
cause Listeriosis. It mainly affects immunocompromised individuals, old and very
young population and pregnant women, causing up to 30% mortality rates. This
organism can stand hypersaline and cold environments and is able to form biofilms.
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representing a serious challenge for food producers. To date, more than
500 Listeria phages have been isolated and characterized (Klumpp et ai, 2013).
Bacteriophages and their proteins can be used as biosensors (fibres) and lysis systems
(endolysins) for Listeria (Hagens et ai, 2014). One of these phages is vB_LmoS_293,
a siphovirus infecting L. monocytogenes serotypes 4b and 4e that was isolated from
mushroom compost in Ireland, its lysogenic nature excludes its use as a biocontroi
agent, but its proteins can be used as antimicrobial or detection systems.

2.11.4 Endolysins against Gram-negative bacteria

The presence of an outer membrane in Gram-negative bacteria in principle makes
them insensitive to exogenously applied endolysins due to the impossibility to reach
the

peptidoglycan

layer.

There

are

some

exceptions

to

this.

Bacillus

amyloliquefaciens phage lAM 1521 endolysin (Lysl521) is able to pass through the
outer membrane and cause "lysis from without", thanks to the basic residues present
in two aliphatic helices. These residues displace the divalent cations that stabilize the
lipopolysaccharide layer, causing local disruption of the outer membrane and
allowing passage of the endolysin into the periplasm (Orito et aL, 2004). Another
example is LysAB2 from Acinetobacter baumannii phage cpAB2, which is able to lyse
both Gram-negative and Gram-positive bacteria when applied exogenously (Lai et aL,

2011).

The main approaches to use endolysins to treat Gram-negative pathogens are
focused on the combined use of endolysins and outer membrane permeabilizing
chemicals, the synergy with physical treatments that damage the outer membrane
and protein modification of these enzymes. Among the physical methods to
permeabilize the outer membrane is the transient permeabilization of the outer
membrane when high hydrostatic pressure (HHP) is applied. Several chemical
compounds may that permeabilize the outer membrane: The polycationic
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compounds (polymyxin, lysine polymers and aminoglycosides) displace the divalent
cations that connect adjacent anionic lipopolysaccharide molecules; the chelating
agents (EDTA and citric acid) sequester those same divalent cations (Briers et oL,
2015).

An alternative successful approach has been the development of Artilysins, proteinengineered endolysins able to pass through the outer membrane (Briers et al., 2015).
Artilysins fuse an outer membrane permeabilizing peptide and an endolysin. The
peptide, with polycationic, hydrophobic or amphipathic properties, promotes the
uptake of the endolysin across the outer membrane through local distortion of the
lipopolysaccharide layer, and then the cell is killed by extensive peptidoglycan
degradation (Briers et al., 2015; Gerstmans et oL, 2016).

2.11.4.1 Pseudomonas aeruginosa

P. aeruginosa is an aerobic Gram-negative bacterium. It is an opportunistic human
pathogen, causing infections of burnt wounds and urinary or respiratory tracts
(Kobayashi et al., 2009). It infects especially immunocompromised patients and
patients suffering cystic fibrosis (Murray et al., 2007). These bacteria cause tissue
damage and interfere with the immune system. Some strains are able to form
biofilms that provides resistance to many antibiotics (Essoh et al., 2013).
P.aeruginosa can change its phenotype in response to environmental signals by gene
expression regulation, protecting the bacteria in hostile environments (Bragonzi et
al., 2009). In 2017, the WHO included P. aeruginosa in the list of bacteria for which
new antibiotics are urgently needed as a critical concern (WHO, 2017).
An alternative treatment could be the use of phages or phage-encoded proteins. One
of these phages is KTN6. Pseudomonas phage vB_PaeM_KTN6 is a myovirus
belonging to the Pbllikevirus genus. It was isolated in a wastewater treatment plant
in Poland. It shows an isometric icosahedral head measuring 72 nm in diameter and
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a contractile tail with a length of 123 nM in extended state (Figure 2.24) (DanisWlodarczyk et al., 2015).

■

c»

Figure 2.24: Electron micrograph of Pseudomonas phage vB_PaeM_KTN6. The scale bar

represents 100 nm. Figure adapted from Danis-Wlodarczyk et al., 2015.

Phage KTN6 is stable at temperatures under 70 °C and in a broad pH range, from 3 to
12, not being affected by treatments with chloroform. Its efficiency has been tested
in 58 P. aeruginosa strains, lysing 67% of them. The bacterial receptor for this phage
is lipopolysaccharide, with phage propagation inhibited by the absence of 0-antigen.
This phage is unable to degrade biofilm completely, but it is able to kill 70-90% of the
bacterial cells hidden inside the biofilm structure. Nevertheless, surviving cells can
develop resistance to the phage, becoming insensitive to it (Danis-Wlodarczyk et al.,
2015).

The phage KTN6 genome presents an ORF coding for a 220 amino acids endolysin.
This protein might be important for the treatment of Pseudomonas infections. To
develop new antibacterial drugs that might prevent the phage resistance, such as
Artilysins or combined treatments, its structure must be determined and analysed.
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2.11.5 Genetically engineered endolysins
Different techniques can be used to create more active or resistant chimeric or
mutated endolysins, as well as to change their host range or to use them as
biomarkers (Yang et al., 2014; Gerstmans et al., 2018):
•

Mutagenesis and protein truncation are commonly used to modify the
properties of a protein. Both techniques have successfully been used to
modify the lytic and antibacterial activity,

cell-wall

binding domain

dependence, specificity, half-life and thermostability of endolysins.
•

Synthetic domain recombination or domain swapping to create endolysins
with altered properties (chimeolysins), such as activity against a certain type
of bacteria or increased solubility.

•

Use of cell wall binding (CWBD) domains for bacteria detection, fusing them
to fluorescent proteins or to antibodies.

•

Development of Artilysins targeting Gram-negative bacteria.

2.12 Conclusion
Antibiotic-resistant bacteria are becoming a serious concern and new approaches
need to be found to treat these pathogens. One alternative is the use of
bacteriophages, their natural enemy, which evolve rapidly to overcome any possible
bacterial mutation to prevent infection and lysis.
The use of phages has several drawbacks related to preparation, storage and delivery,
possible toxicity or immunogenicity and the impossibility to calculate the exact
pharmacological dose. To avoid these problems, instead of using the entire virions,
their endolysins can be used.
Endolysins are peptidoglycan-degrading proteins used by the phages during the last
steps of infection to release their progeny. Endolysins are modular proteins
combining one of several catalytic domains with one of several cell wall domains.
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In the case of Gram-positive bacteria, they can lyse their host when applied
exogenously, and in the case of Gram-negative bacteria they can be genetically
engineered to add an outer-membrane-permeabilizing peptide that will allow them
to pass through the outer membrane and lyse their host.
Endolysins are a very promising alternative to antibiotics. Further information about
their mechanism of action and structure is needed to understand how they work and
to design tailor-made endolysins addressed to fight pathogenic bacteria more
effectively.
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3 Objectives
The main objective of this doctoral thesis was to obtain increased structural
knowledge on the structure of bacteriophage-encoded enzymes that specifically
target pathogenic bacteria. According to this purpose, the following specific
objectives were pursued:
1- Crystallization and

structure determination

of endolysin

gp46 from

Pseudomonas aeruginosa phage vB_PaeM_KTN6.

2- Structural analysis of endolysin gp46 from Pseudomonas aeruginosa phage
vB_PaeM_KTN6 and comparison with other endolysins.
3- Purification, crystallization and structure determination of endolysin gpl97
from Erwinia amylovora phage vB_EamM_Y3.
4- Structural analysis of endolysin gpl97 from Erwinia amylovora phage
vB_EamM_Y3 and comparison with other endolysins.
5- Crystallization of CHAPk endolysin from Staphylococcus aureus bacteriophage
K and its mutant version C54A together with an analogue of its natural ligand.
6- Purification and crystallization of the CHAP domains of the tail hydrolase and
the endolysin of Staphylococcus aureus bacteriophage DW2.
7- Purification and crystallization of endolysin gp239 from Enterobacteria phage
vB_PcaM_CBB.
8- Cloning, expression and crystallization of the endolysin and tail fibre of Listeria
monocytogenes phage vB_LmoS_293.

9- Determination of the lipopolysaccharide region recognized by T7 phage fibre
and identification of the amino acids involved in substrate recognition.
10- Building of a trimeric T7 chimeric fibre that allows to swap its head domain by
other phage tail fibres' heads.
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ll-MATERIALS AND METHODS
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4 Material and Methods
The first step to determine the structure of a protein through protein crystallography
is to obtain a protein sample with enough quality to be crystallized. This sample
should be highly pure (at least 90-95%), stable, homogeneous, reproducible and
abundant to be able to perform crystallization experiments (Bergfors, 2009).
To get a high-quality sample, protein production protocols should be carefully
selected for each specific protein. Fragment and vector selection, cloning, expression,
protein purification and concentration should be considered as highly important
steps for the crystallization process, each needing optimization for them to succeed
(Figure 4.1).

TARGET GENE

SOLUBLE
PROTEIN

CRYSTAL

PHASING

DRUG
LEAD

Figure 4.1: Steps of structural determination of a protein by X-ray crystallography.

Figure from Rupp, 2009.
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4.1 Material
4.1.1 Cell strains

The following bacterial strains were used for cloning and expression (Table 4.1):
Table 4.1: Cell strains used during this work
Cell strain

BL21(DE3)

LEM021(DE3)

XLl-Blue

Rossetta2(DE3)pLysS

XL-Gold:

Purpose

Genotype

Provider

E. coli B

Protein
expression

F", ompJ, hsdSBire,
me), dcm, gal, Ion,
X(DE3)

Promega

E. coli B

Protein
expression

fhuA2, ompT,
/tsc/SsirB mB‘), dcm.
Ion, gal, X(DE3),
pLemo (Cam'^)

New England
Biolabs

Cloning

recAl, endAl,
gyrASe, thi-1,
hsdRll, supE44,
re/Al, lac [F' proAB
/ocIqZAMlSTnlO
(Tetr)]

Stratagene

Protein
expression

F-, ompT, /tsdSB(rBmB-), gal, dcm, Ion,
\(DE3),
pLysSRARE2
(CamR)

Novagen

Cloning

endAl glnV44
recAl thi-1 gyrA96
relAl lac Hte
A(mcrA)183
(mcrCB-hsdSMRmrr)173
tetR F'lproAB
lacIqZAMlS
TnlO(TetR Amy
CmR)]

Agilent

Origin

E. coli K-12

E. coli B

E. coli K-12
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Cell strain

BLR(DE3)

TOPIO

DH5a

Origin

E. coli B

E. coli K-12

E. coli K-12

Purpose

Genotype

Provider

Protein
expression,
infection
assays

F-, ompT, /?sdSB(rBmB-), gal, lac, ile
dcm A(srlrecA)306:;Tnl0
(tetR)(DE3)

Novagen

Cloning,
infection
assays

F- mcrA A(mrrhsdRMS-mcrBC)
4)80lacZAM15
AlacX74 nupG
recAl araD139
A(ara-leu)7697
galElSgalKie
rpsL(StrR) endAl X

Invitrogen

Cloning

- endAl glnV44 thi1 recAl relAl
gyrA96 deoR nupG
CD80d/ocZAM15
t^(lacZYA-argF)
U169,
hsdR17(rK- mK+),
X-

Invitrogen

For protein expression, strains that contain X(DE3) lysogen were used, including the
lactose operon inhibitor gene (/ocl) and T7 RNA polymerase gene under the control
of /ocUVS

promoter.

Lac\

represses /ocUVS,

impairing T7

RNA polymerase

transcription. Upon induction, IPTG (isopropyl-(3-D-l-thiogalactopyranoside) blocks
the repressor and the promoter can transcribe T7 RNA polymerase. Recombinant
proteins are usually under the control of T7 promoter and they can be transcribed,
expressing the protein of interest.
E. coli B derived strains are defective in Ion and ompT proteases, that could degrade
the recombinant proteins. HsdS allows efficient transformation of unmethylated
DNA, preventing its degradation by restriction enzymes. Gal impairs the use of
galactose as carbon source. FhuA2 makes the cells resistant to phage T1 infection.
The pLemo plasmid produces LysY, a variant of T7 lysozyme lacking amidase activity
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yet retaining the ability to inhibit T7 RNA polymerase. Its expression can be regulated
with L-rhamnose, regulating the production amounts of T7 RNA polymerase, and
therefore, the recombinant protein expression levels. XLl-Blue is usually a cloning
strain, but as it produces lad, it can be used to express proteins under the control of
the T5 promoter, such as the ones cloned in pQE60 plasmid. Rosetta2 (DE3) pLysS, in
addition to LysS, a plasmid that codes for T7 lysozyme to avoid leaky expression,
contains a plasmid expressing tRNA non-common in E. coli such as codons AUA, AGG,
AGA, CUA, CCC, GGA and CGG. BLR (DE3) is a recA- derivative of BL21 (DE3), it reduces
the risk of non-homologous recombination.

4.1.2 Plasmids
Plasmid choice is a key step to get enough expression of properly folded protein. The
factors to consider in choosing an adequate vector are the length of the DNA insert,
the number of copies of the vector, the compatibility with the cell strain and with
other plasmids, the number and location of the restriction sites and whether these
are compatible with the insert, the selection marker, the number of cloning sites, the
tags it codifies for and the expression system it uses. During this work, the following
vectors were used (See table 4.2):

Table 4.2: Plasmids used during this work
Vector

Provider

pET28a-(-

Novagen

pET30a-(-

Novagen

pEXP5-CT/TOPO

Invitrogen

pQE60

Qiagen

pCri-8a

Xavier Gomis-Ruth
Novagen

pETDuet-1
pRK793

David Waugh

pJetl.2

Thermo fisher

Vectors belonging to the pET system present a pBR322 origin of replication,
producing 20-60 copies of the plasmid per cell. They provide a strict control of protein
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expression. They carry the T7/oc promoter upstream the multicloning site (MCS).
They also carry the natural promoter and coding sequence for the lac repressor (lad).
In absence of IPTG, lac repressor acts simultaneously in both cellular /cfcUVS,
impairing the production of T7 RNA polymerase, and in vector T7/oc, avoiding the
production of recombinant protein even if there is T7 RNA polymerase leaky
expression.

The plasmid pET28a+ contains a kanamycin-resistance gene for selection and a single
MCS that allows to clone the insert with a histidine tag (i.e. six consecutive histidine
residues) in its N-terminal or C-terminal end for purification purposes. N-terminal Histag can be cleaved with thrombin. It also contains a N-terminal T7 tag. pET30a+ is
very similar to pET28a+ but it contains a S-tag instead of a T7 tag.

The expression vector pETDuet-1 contains an ampicillin-resistance gene and has two
different multicloning sites, allowing to express two proteins at the same time. One
of them can be expressed with a N-terminal histidine-tag to facilitate its purification.

The plasmid pEXP5-CT/TOPO allows to clone directly undigested PCR products thanks
to the TA topoisomerase cloning system. A C-terminal histidine tag can be added to
the protein for purification. It has an ampicillin-resistance gene.

The pQE60 plasmid has an ampicillin resistance gene. The protein of interest can be
expressed with a C-terminal hexahistidine tag. The inserted gene is under the control
of T5 promoter (recognized by the E. coll RNA polymerase, so DE3 lysogen is not
necessary) and can be expressed in any strain containing lad by adding IPTG.

The plasmid pCri-8a is specially designed for crystallography. It was a gift from Xavier
Gomis-Ruth (Addgene plasmid 61317, Goulas et al., 2014). It contains a kanamycin
resistance gene. The protein can be cloned with a N-terminal histidine tag that can
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be cleaved with TEV protease. The protein can also be cloned with a N-terminal GFP
protein or with a C-terminal histidine tag.

The plasmid pRK793 is used for production of the catalytic domain of tobacco etch
virus (TEV) protease in the form of an MBP fusion protein that cleaves itself in vivo to
yield a TEV protease catalytic domain with an N-terminal His-tag and a C-terminal
polyarginine tag. It contains an ampicillin resistance gene.

The cloning vector pJetl.2 contains a lethal gene that is interrupted when a DNA
fragment is inserted. All the colonies grown using this plasmid contain a vector with
an inserted gene.
4.1.3 Culture media

The choice of culture media depends strongly on the characteristics of the organism
grown and the purposes of the growth and it affects the yield of bacterial expression.
Culture media can have a defined composition or be complex if they are prepared
from digested organism extracts. Complex media exact composition cannot be
determined, but they contain all the necessary ingredients for bacterial growth. The
media can be supplemented with components such as cofactors, alcohols, sugars or
amino acids in order to increase protein solubility. During this work, the following
media were used:
•

LB (Luria-Bertani): 10 g/L tryptone, 5 g/L yeast extract, 10 g/L sodium
chloride.

•

LB-agar: 10 g/L tryptone, 5 g/L yeast extract, 10 g/L sodium chloride, 15 g/L
bacto-agar.

•

LB-top agar or LB-soft agar: 10 g/L tryptone, 5 g/L yeast extract, 10 g/L sodium
chloride, 7.5 g/L bacto-agar.

•

TSS: LB supplemented with 12% (w/v) PEG 8000, 5% (v/v) DMSO, 25 mM
magnesium chloride and 1% (v/v) glycerol (Chung et ai, 1989).

91

Crystallographic structure determination of bacteriophage-encoded enzymes that specifically
target pathogenic bacteria

•

SOC: 20 g/L tryptone, 5 g/L yeast extract, 0.5 g/L sodium chloride, 20 mM
glucose.

LB medium is the liquid medium of choice for the grown of bacteria. For culture of
bacteria on petri dishes, the same medium supplemented with 1,5% (w/v) bacto-agar
is used. If the bacteria or the cell to grow carry an antibiotic resistance gene for
selection, LB medium is supplemented with the following amounts of antibiotic:
•

Ampicillin: 100 pg/mL.

•

Chloramphenicol: 34 pg/mL.

•

Kanamycin: 50 pg/mL.

•

Streptomycin : 50 pg/mL.

•

Tetracycline: 10 pg/mL.

TSS medium is used to make and store chemically competent cells. PEG and
magnesium chloride are necessary to induce chemical competency, DMSO enhances
the transformation efficiency and glycerol is used to cryoprotect the cells for storage
at -80 °C. SOC medium is a rich media used in the recovery step off. coli cell
transformations, maximizing its efficiency.

4.1.4 Buffers and reagents

The following buffers and reagents were used during this work:
•

TAE buffer: 40 mM Tris-HCI pH 8.3, 20 mM acetic acid 1 mM EDTA.

•

DNA loading buffer (6X): 0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene
cyanol FF, 30% (v/v) glycerol.

•

SDS-PAGE electrophoresis running buffer: 25 mM Tris-HCI pH 8.3, 192 mM
glycine, 0.1% (w/v) SDS.

•

Laemmli protein loading buffer {6X): 375 mM Tris-HCI pH 6.8,12% (w/v) SDS,
18% DTT, 0.06% bromophenol blue, 60% glycerol.

•

Coomassie brilliant blue staining buffer: 0.25% (w/v) Coomassie brilliant blue
R-250, 33%(v/v) ethanol and 10% (v/v) glacial acetic acid.
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•

Destaining buffer: 33% (v/v) ethanol and 10% (v/v) glacial acetic acid.

•

Lysis buffer Y: 50 mM Tris-HCI pH 8.5, 300 mM NaCI, 10% (v/v) glycerol.

•

CHAPk lysis buffer: 40 mM Tris-HCI pH 7.5, 400 mM NaCI, 10% (v/v) glycerol.

•

Lysis buffer S: 50 mM Tris-HCI pH 8,5, 600 mM NaCI, 30% (v/v) glycerol,
20 mM imidazole.

•

Lysis buffer Hyd: 50 mM MES-NaOH pH 6, 300 mM NaCI, 10% (v/v) glycerol.

•

TMS buffer: 60 mM NaCI, 10 mM MgCH, 50 mM Tris-HCI, pH 7.5.

4.2 General Methods
4.2.1 Bacterial cells
4.2.1.1 Chemically-competent cells
To obtain chemically-competent cells, an isolated colony was grown overnight in LB
medium supplemented with the adequate antibiotic to maintain any plasmid the cells
may carry (like chloramphenicol for pLysS and pLemo) at 37 °C.

Fresh LB medium was inoculated with 1:100 of the preculture and the cells were
grown at 37 °C with shaking until they reached an ODeoo of 0.3. They were centrifuged
at 3,000 X g for 10 min at 4°C and resuspended in a volume 1:10 of the volume of the
cell culture (typically 10 mL for 100 mL cell cultures) in ice-cold TSS medium. 200 pL
aliquots were prepared, flash-frozen in liquid nitrogen and stored at -80 °C until their
use.

4.2.1.2 Chemical tronsformotion of bacteria
Competent cells were thawed in ice and 50 pL of bacteria were mixed with 50-200 ng
of plasmid DNA. The tubes were incubated for 30 min on ice. A heat shock at 42 °C
for 45 s was performed. The cells were immediately put on ice for 2 min. After that,
200 pL of LB medium were added and the bacteria were incubated with shaking for
Ih at 37 °C. The bacteria were plated on LB-agar plates supplemented with the
selection antibiotic for each plasmid and grown at 37 °C overnight.
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4.2.1.3 Electrocompetent cells

To obtain electrocompetent cells, used for difficult transformations, an isolated
colony was grown overnight in LB medium supplemented with the adequate
antibiotic at 37 °C. 1 L of fresh LB medium was inoculated with 1:100 of the preculture
(10 mL) and the cells were grown at 37 °C with shaking until they reached an ODeooof
0.5-1. The flask was chilled on ice for 20 min, then the cells were centrifuged in a cold
rotor at 4,000 x g for 15 minutes. The pellet was resuspended in 1 L of sterile cold
milli-Q water and then centrifuged again with the same parameters. The pellet was
again resuspended in 0.5 L of sterile cold water and centrifuged. Then, the pellet was
resuspended in 20 mL of cold sterile 10% glycerol and centrifuged. Finally, the cells
were resuspended in 3 mL of cold, sterile 10% glycerol, divided in 120 pL aliquots,
flash- frozen in liquid nitrogen and stored at 80 °C until their use (protocol adapted
from

the

one

designed

by

Krantz

lab

in

Berkeley

university,

http://mcb.berkeley.edu/labs/krantz/protocols/electrocomp_cells.pdf).

4.2.1.4 Bacterial electroporation

Before the electroporation procedure, DNA samples must be desalted through a drop
dialysis versus milli-Q water using Type-VS membrane (MF type, VS filter, mean pore
size = 0.025 pm) (Millipore). 20-100 pL of desalted DNA were mixed with 40 pL of
cells thawed on ice and transferred to chilled electroporation vials. The vials were
placed in the electroporator chamber and electroporated (2.5 kV voltage, 25 pF
capacitor and 25 Q pulse controller). 1 mL of chilled SOC medium was added to each
chamber. The samples were transferred to microfuge tubes and incubated at 37 °C
for 30 minutes. The bacteria were concentrated using centrifugation, and 50-150 pL
were spread on LB-agar plates supplemented with antibiotic and incubated overnight
at 37 °C.
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4.2.2 Nucleic acids

4.2.2.1 DNA visualization
DNA was visualized and sized using agarose gel electrophoresis. Gels were casted
using 1% (w/v) agarose and 0.5 pig/mL ethidium bromide in TAE buffer. 5 pL of DNA
samples were mixed with 1 pL of DNA loading buffer, loaded in the gel and run in TAE
buffer at 75 V. A1 kb DNA ladder (Gene Ruler, Thermo Scientific) was loaded together
with the protein samples to determine their molecular size. Gels were visualized
using UV-light.
4.2.2.2 Purification of plasmid DNA
Plasmid DNA was purified from 20 ml of saturated bacterial culture obtained from a
single colony using the GeneJET plasmid miniprep kit (Thermo Scientific) according to
the protocol indicated by the manufacturer.
4.2.2.3 Nucleic acid amplification
Taq DNA Polymerase (New England Biolabs) was used to perform the amplification
reactions. For each 50 pL reaction 0.2 pM of each oligonucleotide, 0.2 mM dNTPs,
500-2000 ng of DNA, 0.25 pL (1.25 units) of Taq polymerase and 5 pL of lOX reaction
buffer were added. The final Mg^^ concentration was 1.5 mM. A PCR was performed
on each sample, including an initial denaturalization during 4 minutes at 94 °C,
36 cycles of 30 s denaturalization (94 °C), 1 min hybridation (temperature according
to the oligonucleotides Tm and 1 min/kbp amplification (72 °C).
Amplified products were purified using the GeneJET PCR purification kit (Thermo
Scientific).
4.2.2.4 Enzymatic dipestion
Digestion of the vectors and the PCR products was performed using restriction
enzymes according to the provider instructions (Thermo Fisher or New England
Biolabs) at 37 °C.
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Digested DNA fragments were visualized using 1% agarose gel electrophoresis. DNA
bands of interest were cut using a blade and purified using GeneJET gel Extraction kit
(Thermo Fisher).
4.2.2.5 DNA liaation
Ligation reactions were performed using T4 DNA ligase (Promega) according to the
manufacturer instructions, using 50-100 ng of vector and a proportion insert: vector
3:1 at room temperature for 30 min, at 16 °C for 4 h or at 4 °C for 16 h.
Bacterial cells were transformed with the ligation reaction and the success of the
ligations was checked

performing a

PCR on the colonies obtained

using

oligonucleotides that hybridize at both sides of the vector multi-cloning site. The
plasmidic DNA was purified and digested with the restriction enzymes used for the
cloning to confirm the results. To analyse the absence of mutations and to check that
the insert is in the correct reading frame, the samples were sent for sequencing.
4.2.3 Proteins production and analysis

For an overview of protein expression, cell lysis and protein purification methods, see
appendix A.
4.2.3.1 SDS-PAGE analysis
Laemmli protocol was followed to analyse the presence of proteins by SDS-PAGE
(Laemmli, 1970). The resolving gel had a 12.5% (w/v) concentration of polyacrylamide
and the stacking gel a 4% (w/v). 15 pL of protein sample were mixed with 3 pL of 6X
loading buffer. In cases where there is a suspicion that the protein might be
multimeric, as trimeric phage fibres, two samples are loaded in the gel, one heated
at 95 °C for 5 minutes to observe the monomer and another non-heated, to visualize
the protein as a multimer. Not seeing the protein as a multimer in the non-heated
sample does not mean that they do not multimerize, it might just mean that the
multimer is not resistant enough to stand the denaturing action of SDS and
temperature reached during electrophoresis.
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4.23.2 Thermal shift assay
The Thermal Shift Assay (TSA) is a technique used to determine the melting
temperature (Tm) of a protein in determined conditions. It may be used to find an
adequate crystallization temperature, to choose buffers and additives that might
stabilize a protein or to determine if a protein mutant is more stable than other
(Huynh et oL, 2015). It is based on the capacity of the fluorescence dye SYPRO Orange
to bind non-specifically to hydrophobic surfaces. Water quenches its fluorescence.
When a protein unfolds, hydrophobic surfaces get exposed and bind the dye,
increasing the fluorescence of the sample. This assay can be performed using a qPCR
machine that creates a temperature gradient and is able to detect and to excite it at
the right wavelength (\ex 300 or 470 nm) and analyse the fluorescence emitted by the
dye (Aem 570 nm). For each sample to be analysed 1.6 pL of protein at 15 mg/ mL,
12.2

pL of additive solution, 4 pL of buffer 5x and 1.6 pL of Sypro Orange 50x were

mixed. The additive can be substituted by water in cases where the assay is not aimed
to find additives. The protein amount can be increased if the signal obtained is low.
The samples are placed in a qPCR machine (Abi Prism 7900 HT, Applied Biosystems)
and slowly heated on a linear ramp from 4 °C to 95 °C, while being excited with light
at a wavelength of 470 nm. The light emitted by the dye is collected and quantified,
obtaining a raw dissociation curve. By calculating the derivative curve, the melting
temperature (Tm) for each protein sample can be obtained.
4.2.3.3 TEV protease purification
TEV is the protease from tobacco etch virus. It recognizes the amino acid sequence
ENLYFQG with high efficiency and cleaves between Q and G. This sequence can be
coded in some plasmids between the protein and a tag, to be able to remove the tag
after purification. The TEV protease used was expressed using the plasmid pRK793,
with an N-terminal histidine-tag for purification. This plasmid shows an ampicillin
resistance selection gene. The protein was expressed in Rosetta2(DE3) pLysS grown
in LB medium supplemented with 100 pg/mL of ampicillin and 34 pg/mL of
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chloramphenicol. It was purified following the protocol described by Tropea et al.
(Tropea et al., 2009).
To perform the proteolysis the protein buffer was supplemented with DTT at a
concentration of 1 mM and EDTA to a concentration of 0.5 mM. The proportion
protein/TEV used was 10/1 to 100/1. The protein and the protease were incubated
together at 30 °C for 16 h and the digestion was assessed by SDS-PAGE.
4.2.4 Crystallographic methods

An overview of crystallographic methods is included in appendix B.

4.3 Methods for the structural determination of endolysin gp46 from
Pseudomonas aeruginosa phage vB_PaeM_KTN6
The methods shown below have been applied to obtain the results described in
chapter 5.
4.3.1 Characterization of gp46

Blastp (Basic Local Alignment Search Tool, Altschul et al., 2010) was used to perform
a homology search against the non-redundant protein sequences database to search
sequence-related proteins. Blastp was also used to perform a homology search
against the protein data bank (PDB) to search for homologous proteins whose
structure had already been determined that could be used as a model for molecular
replacement phasing.
An analysis of the conserved domains was performed using the conserved domains
database (CDD, Marchler-Bauer et al., 2011). Secondary structure prediction was
performed with Phyre2 (Kelley et al., 2015).
4.3.2 Gp46 protein purification

Gp46 was cloned, expressed and partially purified by Dr. Katarzyna Danis-Wlodarczyk
(Prof. Rob Lavigne group. Laboratory of Gene Technology, KU Leuven, Belgium). It
was expressed in BL21(DE3)pLysS using the expression vector pEXP5-CT/TOPO, with
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a C-terminal 6x His-tag. A large-scale purification was performed using a HisTrapTM
HP 1 ml column. To improve the stability, the protein was kept at a concentration of
1.5 mg/mL (61 pM) in 5 mM HEPES-NaOH buffer and frozen.
Upon arrival of gp46 to our lab, the protein was thawed, and its integrity and purity
checked by SDS-PAGE. The sample was diluted with 20 mM HEPES pH 7.0 until a
volume of 10 ml was reached and then purified by cation exchange chromatography
using an AKTA purifier (GE Healthcare) and a Resource S-6 (GE Healthcare) column.
The column was equilibrated with 20 mM HEPES pH 7.0. The protein was eluted using
a linear gradient of sodium chloride between 0 M and 1 M in the same buffer.
The

absorption

peaks

obtained

were

analysed

by

SDS-PAGE

and

pooled

independently. The protein fractions were desalted and concentrated using an
Amicon centrifuge filter device with a molecular weight cut-off of 10,000 Da
(Millipore, Billerica MA, USA).
4.3.3 Crystallization of gp46

Crystallization assays were performed using manual sitting drop vapour diffusion
techniques. Swissci 96-well 2-drop MRC crystallization plates (Molecular Dimensions)
were used. The reservoir was filled with 50 pL of different crystallization conditions
containing a variety of salts, precipitants and buffers. Drops contained a mixture of
0.4 pL of gp46 at a concentration of 4.9 mg/mL (0.2 mM) and 0.4 pL of the
crystallization solution contained in the reservoir. More than 400 crystallization
conditions were tried.
The crystals were cryoprotected by sequential soaking into the same solution in
which they were crystallized with increasing concentrations of glycerol (5%, 10% and
20%), then collected in cryo-loops and flash-cooled by immersion in liquid nitrogen.
4.3.4 Structure determination of Rp46

The frozen crystals were analysed at the BL13-XALOC beamline of the ALBA
synchrotron (Juanhuix et oi, 2014).
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The different diffraction patterns obtained from the crystals measured were indexed,
integrated and scaled using the programs XDS (Kabsch, 2010b) and Aimless (Evans et
oL, 2013), from CCP4 suite (Dodson et al., 1994). Matthews coefficient was measured
using CCP4 suite.
The phase determination was performed by molecular replacement using the
program Molrep (Vagin et al., 2010) and the endolysin from Salmonella typhimurium
phage SPNIS (PDB code 40K7) as a model. After that, RefmacS (Murshudov et al.,
2011) rigid body refinement was used to obtain a preliminary density map. The initial
model was modified using the automatic building program ARP/wARP (Langer et al.,
2008) and by manual rebuilding with Coot (Emsiey et al., 2004), imposing the
expected protein sequence of gp46.

The solution obtained was refined using RefmacS. 20 cycles of restrained refinement
were performed, followed by manual optimization of the model using Coot. The
RefmacS refinement and Coot optimization steps were repeated until convergence
of refinement R factors, assessing in parallel the quality of the geometry with
MolProbity (Chen et al., 2010).
4.3.5 Structure analysis of gp46

The atomic coordinate files (PDB) were visualized and the figures generated using
PyMOL (Delano, 2002). TopDraw (Bond, 2003), from CCP4 suite (Dodson et al., 1994)
was used to generate the topological representations.
The degree of conservation of every residue in gp46 was determined using ConSurf
(Ashkenazy et al., 2016), a bioinformatics tool for estimating the evolutionary
conservation of amino acid positions in a protein molecule based on the phylogenetic
relations between homologous sequences.
Dali server was used to search for structurally related proteins and to superpose
protein structures (Holm et al., 2016).
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Clustal Omega with default parameters was used to generate a sequence alignment
with the endolysin from 5. typhimurium phage SPNIS. The alignment was used as
input to generate a figure of the alignment including secondary structure elements
with ESPript3 (Robert et al., 2014).

4.4 Methods for the structure determination of endolysin gpl97 from
Erwinia amylovora phage vB_EamM_Y3
The methods shown below have been applied to obtain the results described in
chapter 6.
4.4.1 Characterization of Y3 197

Blastp (Basic Local Alignment Search Tool, Altschul et al., 2010) was used to perform
a homology search against the non-redundant protein sequences database to search
sequence-related proteins. Blastp was also used to perform a homology search
against the protein data bank (PDB) to search for homologous proteins whose
structure had already been determined that could be used as a model for molecular
replacement phasing.
An analysis of the conserved domains was performed using the conserved domains
database (CDD, Marchler-Bauer et al., 2011). Secondary structure prediction was
performed with Phyre2 (Kelley et al., 2015).
The presence of transmembrane domains and disordered regions was assessed using
XtalPred server (Slabinski et al., 2007).
4.4.2 Expression and purification of Y3 197

The expression vector for Y3_197 was constructed by Colin Buttimer (Aidan Coffey's
lab, Department of Biological Sciences, Cork Institute of Technology, Ireland). The full
length ORE was introduced between the Ncol and Xhol restriction sites of plasmid
pET28a-r.
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The protein was expressed using E. coli Lemo21 (DE3) cells transformed with the
plasmid. Bacteria were grown at 37 °C in LB medium supplemented with 50 pg/mL of
kanamycin and 34 pg/mL of chloramphenicol until they reached ODeoo = 0.6. The
expression was induced with ImM IPTG.
An expression test at 37 °C was performed. Culture samples were collected before
induction and at 1 h, 2 h and 3 h post-induction. The samples were sonicated and
centrifuged at 10,000 x g during 20 min to separate pellet and supernatant. An SDSPAGE was performed on the supernatants heated to 95 °C for 5 min.
Four cultures of 1 L were grown under the same conditions for 3 h. The cultures were
centrifuged for 10 min at 5,000 x g and the pellet was resuspended in 40 mL of buffer
Y. The resuspended bacteria were sonicated to lyse the cells. An additional
centrifugation step for 40 min at 14,000 x g was used to separate the soluble protein
(supernatant) from the bacterial debris (pellet).
Metal ion affinity chromatography (IMAC) was performed on the supernatant. The
supernatant was incubated for 30 min with the Ni-NTA resin. After that, a column
was used to pack the resin. The column was equilibrated with buffer Y and the protein
eluted with increasing concentrations (0 M to 1 M) of imidazole in that same buffer.
The presence of Y3_197 in the samples eluted from 50-500 mM imidazole was
checked by SDS-PAGE.
A 16 h dialysis at 4 °C from fractions 50-500 against 10 mM MES-NaOH pH 6.1 was
performed. After dialysis the protein was centrifuged at 14,000 x g and filtered to
remove any precipitated protein that might harm the chromatography equipment.
A cation exchange chromatography was performed using an AKTA purifier (GE
Healthcare) and a Resource S-6 (GE Healthcare) column. The column was equilibrated
with 10 mM MES-NaOH pH 6.1 buffer. After that, the protein sample was loaded and
eluted with a gradient of 0 to 1 M of NaCI in the same buffer. The presence of the
protein in the eluted samples was checked by SDS-PAGE . The fractions containing
protein were pulled together, desalted and concentrated using an Amicon centrifuge
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filter device with a molecular weight cut-off of 10,000 Da (Millipore, Billerica MA,
USA) and filtered.
4.4.3 Crystallization of Y3 197

Crystallization assays were performed using sitting drop vapour diffusion techniques.
The reservoirs were filled manually with 50 pL of different crystallization conditions
containing a variety of salts, precipitants and buffers. Drops containing a mixture of
0.4 pL of 14.43 mg/mL (0.64 mM) Y3_197 and 0.4 pL of the crystallization solution
were set up in Swissci 96-well 2-drop MRC crystallization plates (Molecular
Dimensions), by manual and automated techniques (Genesis RSP 150 workstation,
Tecan Trading AG). More than 400 crystallization conditions were tested.
Some of the crystals were soaked in methylmercury chloride for different times, from
5 min to 1 h. The crystals were cryoprotected by sequential soaking into the same
solution in which they were crystallized with increasing concentrations of glycerol
(5%, 10% and 20%), then collected in cryo-loops and flash-cooled by immersion in
liquid nitrogen.
4.4.4 Structure determination of Y3 197

Crystallographic data was measured at the ID30A-1 / MASSIF-1 beamline of the ESRF
synchrotron, Grenoble, France (Bowler et al., 2015; Svensson et al. 2015) and
collected at a wavelength of 0.9660

A.

Diffraction patterns obtained from Y3_197 crystals were indexed, integrated and
scaled using the programs XDS (Kabsch, 2010b) and Aimless (Evans et al., 2013), from
CCP4 suite (Dodson et al., 1994). Matthews coefficient was calculated using CCP4
suite.
The data was processed by single anomalous dispersion techniques (SAD), using the
Crank2 pipeline (Skubak et al., 2013) from the CCP4 suite. SHELXC (Sheldrick, 2008)
was used for the estimation of the structure factors and SHELXD (Schneider et al.,
2002) for the detection of the heavy atoms' substructure. RefmacS (Murshudov et
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al., 2011); was used for substructure phasing and refinement. To determine the hand,
Solomon (Abrahams et al., 2016) was used for density modification and Multicomb
(Skubak et oL, 2010) for phase combination. After that, 25 cycles of density
modification were performed using Parrot (Cowtan, 2010) and the phases were
combined using RefmacS. Finally, an initial model was built using Buccaneer (Cowtan,
2006) and refined with RefmacS.
Coot (Emsiey et oL, 2004) was used for manual model modification. Several cycles of
refinement with RefmacS (Murshudov et al., 2011) and model building with Coot
were performed until convergence of refinement R factors. The quality of the
geometry was checked by MolProbity (Chen et al., 2010) and PDB-SUM (Laskowski et
al., 2017).
4.4.5 Structure analysis of Y3 197

The atomic coordinate files (PDB) were visualized and the figures generated using
PyMOL (DeLano, 2002). TopDraw (Bond, 2003), from CCP4 suite (Dodson et al., 1994)
was used to generate the topological representations.
The PISA server (Krissinel et al., 2007) was used to analyse the contact surface
between the two protein monomers present in the asymmetric unit to determine if
they were independent.
The degree of conservation of every residue in gp46 was determined using ConSurf
(Ashkenazy et al., 2016), a bioinformatics tool for estimating the evolutionary
conservation of amino acid positions in a protein molecule based on the phylogenetic
relations between homologous sequences.
Dali server was used to search for structurally related proteins and to superpose
protein structures (Holm et al., 2016).
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4.5 Methods for the crystallization of CHAPk endolysin from
staphylococcal phage K and its mutant C54A with a ligand
The methods shown below have been applied to obtain the results described in
chapter 7.
4.5.1 Expression and purification of CHAPk C54A mutant

CHAPk was cloned in pQE60 vector between the restriction sites Ncol and Bglll by
Marianne Morgan (Dr. Olivia McAuliffe's group, Teagasc, Moorepark Food Research
Centre, Fermoy, Ireland). The protein was expressed with a C-terminal hexahistidine
tag. Dr. Ruth Keary mutated Cys54 to Ala using the QuikChange il Site-Directed
Mutagenesis Kit from Agilent as per the manufacturer's instructions.
CHAPk (C54A) was expressed in XLl-Blue cells. A preculture was grown from a single
colony in LB medium supplemented with ampicillin (100 pg/mL) and tetracycline
(10 |ig/mL). The next day, a culture was grown in LB medium supplemented with
ampicillin (100 pg/mL) and tetracycline (10 pg/mL) inoculated with 1:100 (v/v) of the
preculture. Cells were grown to an ODeoo of 0.6, cooled in ice and then induced with
1 mM IPTG. The protein was expressed at 16 °C for 16 h and at 37 °C for 3 h. Cells
were harvested and centrifuged at 5,000 x g for 20 min, lysed by sonication and
centrifuged at 15,000 x g for 40 min to separate the soluble proteins (supernatant)
from the cell debris (pellet). Pellet and supernatant fractions were analysed by SDSPAGE.
Four 1 L cultures were grown in the same condition as the expression trial, at 37 °C
for 3 h. Cells were harvested and centrifuged for 20 min at 5,000 x g. After that, they
were resuspended in a volume 1:100 of the culture volume of CHAPk lysis buffer and
stored at -20 °C. For purification, cells were thawed and lysed by sonication. The cell
debris (pellet) and the soluble protein

(supernatant) were separated

by

centrifugation (40 min, 15,000 x g). After that, an affinity purification was performed.
The supernatant was incubated with Ni-NTA resin (1 mL per 4 L of cell culture) on ice
for 30 min. It was loaded in a column and the unbound proteins were washed with
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CHAPK lysis buffer supplemented with 20 mM imidazole. The protein was eluted with
a step gradient of imidazole in the same buffer, using imidazole concentrations from
50 mM to IM. The fractions were analysed by SDS-PAGE to assess the presence of
protein. Fractions eluted between 50 mM and 350 mM imidazole were pooled
together.
The protein was dialyzed overnight at 4 °C versus 20 mM MES pH 6.1 and filtered.
Cation exchange chromatography was performed using an AKTA purifier (GE
Healthcare) and a Resource S-6 (GE Healthcare) column. The column was equilibrated
with 20 mM MES pH 6.1. After that, the protein sample was loaded and eluted with
a gradient of 0 to 1 M of NaCI in the same buffer. The fractions were analysed by SDSPAGE to assess the presence of protein of CHAPk(C54A). The protein was desalted
and concentrated to 16 mg/mL (0.9 mM) using an Amicon centrifuge filter device
with a molecular weight cut-off of 10 kDa (Millipore). Its purity was checked by SDS
page. Crystallization experiments were performed without delay.
4.5.2 Crystallization CHAPk with ligands

Crystallization experiments using both wild type and CHAPk (C54A) mutant, obtained
in different purifications, were performed in Swissci MRC Maxi plates (Molecular
Dimensions) with 50 pL of reservoir condition and drops with 1 pL of protein sample
and 1 pL of reservoir condition. The protein concentration was 20 mg/ ml for the WT
protein and 16 mg/mL for the mutant. The experiment was set up at 20 °C and, in
addition to the gradient of 14-24% PEG 8,000 in 0.1 M buffer pH 6.5-10.5, conditions
containing 16-24% PEG 2000 in 0.1 M Tris-HCI buffer pH 6.8 and conditions
containing 22% PEG 8,000, 0.1 M HEPES-NaOH pH 7.5 or 20% PEG 8,000, 0.1 M MES
pH 6.5 and a gradient from 0 to 20% glycerol were tried.
The crystals obtained in the condition with 20% PEG 8,000 in 0.1 MES pH 6.5 were
soaked with 5x-Gly. 0.5 pL of 5x-Gly at a 2.74 mM concentration were added to the
2 pL drop (final 5x-Gly concentration 0.55 mM) and incubated for different times
(5-30 min). The crystals obtained in the condition with 20% PEG 8,000 and 5% glycerol
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in 0.1 M MES pH 6.5 were soaked with 3x-Gly. 0.5 pL of 3x-Gly at a 352 mM
concentration were added to the 2 pL drop (final 3x-Gly concentration 70 mM) and
incubated for different times (5-30 min).
The crystals were collected in liquid nitrogen and frozen.
The crystallization process of this protein is a substantial part of the results of this
project, therefore more details can be found in section 7.3.
4.5.3 Structure determination of CHAPk with triglycine

The frozen crystals were taken to BL13-XALOC (ALBA synchrotron, Cerdanyola del
Valles, Spain; Juanhuix et oL, 2014) and collected at a wavelength of 0.97918

A.

The different diffraction patterns obtained from wild type CHAPk crystals were
indexed, integrated and scaled using the programs XDS (Kabsch, 2010b) and Aimless
(Evans et al., 2013), from CCP4 suite (Dodson et al., 1994). Matthews coefficient was
calculated using CCP4 suite.
The phases of the new dataset were determined by molecular replacement using the
old native structure as model (PDB code 4CSH), using Phaser (McCoy et ol. 2007).
Several rounds of data refinement with RefmacS (Murshudov et al. 2011) and manual
model building in Coot (Emsiey et al. 2010) were performed until the Rworkand Rfree
converged. The geometry of the model was assessed using MolProbity (Chen et al.

2010).
4.5.5 Structure analysis of CHAPk with triglycine

The atomic coordinate files (PDB) were visualized and the figures generated using
PyMOL (DeLano, 2002). TopDraw (Bond, 2003), from CCP4 suite (Dodson etal., 1994)
was used to generate the topological representations.
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4.6 Methods for the crystallization of lytic proteins from staphylococcal
phage DW2
The methods shown below have been applied to obtain the results described in
chapter 8.

4,6.1 Characterization of THDW2 and CHAPthdwz
Blastp (Basic Local Alignment Search Tool, Altschul et al., 2010) was used to perform
a homology search against the non-redundant protein sequences database to search
sequence-related proteins. Blastp was also used to perform a homology search
against the protein data bank (PDB) to search for homologous proteins whose
structure had already been determined that could be used as a model for molecular
replacement phasing.
An analysis of the conserved domains was performed using the conserved domains
database (CDD, Marchler-Bauer et al., 2011). Secondary structure prediction was
performed with Phyre2 (Kelley et al., 2015).
A Needleman-Wunsch global sequence alignment of CHAPiHDwzand CHAPk proteins

was done with EMBOSS needle (Madeira et al., 2019). The matrix used was
BLOSSUM62, the gap opening penalty was 10, the gap extension penalty was 0.5. No
gap ending penalties were used.

4.6.2 Purification of THDW2 and CHAP THDW2
Two different sequences were cloned into the plasmid pQE60 by Dr. Ruth Keary (Prof.
Aidan Coffey's laboratory, department of Biological Sciences, Cork Institute of
Technology, Ireland). The full length THDW2 without the insert was cloned between
Ncol and Bglll restriction sites without His-tag. The amino acids corresponding to the
CHAP domain without the insert were cloned between Ncol and Bglll restriction sites
with a C-terminal His-tag.
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Both plasmids were transformed into XLl-blue cells. A preculture was grown
overnight at 37 °C. The following day, the preculture was diluted in a proportion 100:1
of LB supplemented with ampicillin (100 pg/mL) and tetracycline (10 pg/mL). The cells
were grown to an ODeoo of 0.6, cooled in ice and then induced with 1 mM IPTG. The
protein was expressed at 16 °C for 20 h and at 37 °C for 3 h. The cells were harvested
and centrifuged at 5,000 x g for 20 min, lysed by sonication and centrifuged at 15,000
X g for 40 min to separate the soluble proteins (supernatant) from the cell debris
(pellet).

For large-scale expression of CHAPthdwz, four 1 L volume expressions in the same
conditions during 20 h at 16 °C were performed. The cells were harvested and
resuspended in 40 mL of Hyd lysis buffer (50 mM MES pH 6.0, 300 mM NaCI, 10%
(v/v) glycerol) and frozen. The following day the cells were thawed, lysed using a bead
beater and centrifuged at 15,000 x g to separate the soluble protein from the cell
debris. The presence of the protein in the supernatant was assessed by SDS-PAGE,
before and after heating at 95 °C for 5 min.
The supernatant was incubated for 30 min on ice with Ni-NTA resin. The unbound
protein was washed using 50 mM MES pH 6.1 and 180 mM NaCI. The protein was
eluted with a step gradient of imidazole in the same buffer, using the imidazole
concentrations from 50 mM to IM. The fractions 50-1,000 mM imidazole, containing
protein, were dialyzed against 20 mM MES-NaOH pH 6.1.
A cation exchange chromatography was performed using an AKTA purifier (GE
Healthcare) and a Resource S-6 (GE Healthcare) column. The column was equilibrated
with 20 mM MES-NaOH pH 6.1. The protein was eluted with a gradient 0-1 M NaCI in
the same buffer. The presence of protein in each elution peak was assessed by SDSPAGE. The fractions corresponding to each elution peak were pulled and
concentrated independently versus 20 mM MES-NaOH pH 6.1 using an Amicon
centrifuge filter device with a molecular weight cut-off of 10,000 Da (Millipore,
Billerica MA, USA). Crystallization experiments were set up immediately.
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4.6.3 Crystallization of CHAPthdwz

Using sitting drop vapour diffusion techniques, crystallization assays were set up at
20 °C. The reservoirs of Swissci 96-well 2-drop MRC crystallization plates (Molecular
Dimensions), were filled manually with 50 pL of different crystallization conditions.
Drops containing a mixture of 0.5 pL of 3 mg/mL (0.15 mM) or 6 mg/mL (0.29 mM)
CHAPthdwz

and 0.5 pL of the crystallization solution were set by automated

techniques (Genesis RSP 150 workstation, Tecan Trading AG). More than 600
different precipitant conditions were tried. This process was repeated using fresh
protein at 8 mg/mL (0.39 mM), 13 mg/mL (0.63 mM) and 6 mg/mL (0.29 mM).
4.6.4 CHAPthdwz structure predictions

An in silica 3D model of the protein was generated using RaptorX (Kallberg et ai,
2014), a template-based protein structure modelling server.
The atomic coordinate files (PDB) were visualized and the figures generated using
PyMOL(DeLano, 2002).
Dali server was used to search for structurally related proteins and to superpose
protein structures (Holm et al., 2016).
4.6.5 Characterization of LysDW2 and CHAPei-isb

Blastp (Basic Local Alignment Search Tool, Altschul et al., 2010) was used to perform
a homology search against the non-redundant protein sequences database to search
sequence-related proteins. Blastp was also used to perform a homology search
against the protein data bank (PDB) to search for homologous proteins whose
structure had already been determined that could be used as a model for molecular
replacement phasing or homology modelling.
An analysis of the conserved domains was performed using the conserved domains
database (CDD, Marchler-Bauer et al., 2011). A secondary structure prediction was
performed with Phyre2 (Kelley et al., 2015).
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4.6.6 Purification CHAPei-isb
The 153 N-terminal residues that correspond to the CHAP domain of LysDW2 were
cloned between the restriction sites Ncol and Bglll in pQE60 vector without His-tag
by Dr. Ruth Keary (Prof. Aidan Coffey's laboratory, Department of Biological Sciences,
Cork Institute of Technology, Ireland).
The plasmid was transformed into XLl-blue cells to perform an expression test. A
preculture was grown overnight at 37 °C. The following day, the preculture was
diluted in a proportion 100:1 of LB supplemented with ampicillin (100 pg/mL) and
tetracycline (10 pg/mL). The cells were grown to an ODeoo of 0.6, cooled in ice and
the induced with 1 mM IPTG. The protein was expressed at 16 °C for 16 h and at 37 °C
for 3 h. The cells were harvested and centrifuged at 5,000 x g for 20 min, lysed by
sonication and centrifuged at 15,000 x g for 40 min to separate the soluble proteins
(supernatant) from the cell debris (pellet).

Four 1 L cultures of XLl-B cells transformed with the plasmid were grown at 16 °C in
LB supplemented with ampicillin (100 pg/mL) and tetracycline (10 pg/mL) to an ODeoo
of 0.6, cooled down on ice and induced with 1 mM IPTG. The protein expression was
performed at 16 °C during 16 h. The cells were harvested and centrifuged at 5,000 x
g for 20 min. The pellet was resuspended in Y lysis buffer (50 mM Tris-HCI pH 8.5,
300 mM NaCI, 10% (v/v) glycerol) and lysed by sonication. The cell debris was
separated from the soluble protein using a centrifugation at 15,000 x g for 40 min.
A small fraction of the supernatant was incubated with solutions of ammonium
sulphate with a saturation of 0-90% at room temperature for half an hour. The pellet
and the supernatant were separated by centrifugation at 5,000 x g for 10 min. The
soluble proteins present in the supernatant were analysed by SDS-PAGE.
Saturated ammonium sulphate solution was added to the rest of the supernatant to
a concentration of 25%. After 30 mins of incubation, the pellet and the supernatant
were separated by centrifugation at 5,000 x g for 10 min. The supernatant was
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transferred to a fresh tube. Then, the concentration of ammonium sulphate was
increased to 40%. After 30 mins of incubation, the pellet and the supernatant were
separated by centrifugation at 5,000 x g for 10 min. The pellets were resuspended.
The resuspended pellets and the supernatant of every precipitation fraction were
analysed by SDS-PAGE.
The fraction that precipitated from 25-40% ammonium sulphate was resolubilized in
20 mM Tris pH 8.5, 1.5 M (NH4)2S04and a hydrophobic interaction chromatography
was performed using an AKTA purifier (GE Healthcare) and a Phenyl FF high sub (GE
Healthcare) column. The column was equilibrated with the same buffer used to
resolubilize the protein. The protein was eluted with a gradient from 1.5-0 M
(NH4)2S04 in the same buffer.
The protein was dialyzed against 20 mM bicine-NaOH pH 9.0 at 4 °C overnight to
perform an anion exchange chromatography using an AKTA purifier (GE Healthcare)
and a Resource Q-6 (GE Healthcare) column. The column was equilibrated with
20 mM bicine-NaOH pH 9.0 and the protein was eluted with a gradient of 0-1 M NaCI
in the same buffer. A single wide peak was obtained at a concentration of 150 mM
NaCI. The eluted samples were analysed by SDS-PAGE.
Fractions 22 to 26 were pulled together, desalted and concentrated to 11.5 mg/mL
(0.65 mM) in 20 mM bicine-NaOH pH 9.0). Crystallization experiments were set up
immediately.
4.6.7 Crystallization of CHAPei

153

Crystallization assays were performed using sitting drop vapour diffusion techniques
at 20 °C. The reservoirs of Swissci 96-well 2-drop MRC crystallization plates
(Molecular Dimensions), were filled manually with 50 |iL of different crystallization
conditions containing a different salts, precipitants and buffers. Drops containing a
mixture of 0.5 pL of 12.4 mg/mL (0.71 mM) CHAPemsb and 0.5 pLof the crystallization
solution were set in by automated techniques (Genesis RSP 150 workstation, Tecan
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Trading AG). Plates containing the same conditions but at a protein concentration of
6.15 mg/mL (0.36 mM) were also tested.
The crystallization process of this protein is a substantial part of the results of this
project, therefore more details can be found in section 8.7.
4.6.8 CHAPei-153 structure predictions

An in silico 3D model of the protein was generated using RaptorX (Kallberg et oi,
2014), a template-based protein structure modelling server.
The atomic coordinate files (PDB) were visualized and the figures generated using
PyMOL (Delano, 2002).
Dali server (Holm et a!., 2016) was used to search for structurally related proteins and
to superpose CHAPemss model to CHAPk protein structure.

4.7 Methods for the purification and crystallization of gp239 tail
associated endolysin from Enterobacteria phage vB_PcaM_CBB
The methods shown below have been applied to obtain the results described in
chapter 9.
4.7.1 Characterization of CBB 239

Blastp (Basic Local Alignment Search Tool, Altschul et oi, 2010) was used to perform
a homology search against the non-redundant protein sequences database to search
sequence-related proteins. Blastp was also used to perform a homology search
against the protein data bank (PDB) to search for homologous proteins whose
structure had already been determined that could be used as a model for molecular
replacement phasing.
An analysis of the conserved domains was performed using the conserved domains
database (CDD, Marchler-Bauer et oi, 2011). Secondary structure prediction was
performed with Phyre2 (Kelley et ai, 2015).
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4.7.2 Purification of CBB 239

The expression vector for CBB_239 was constructed by Colin Buttimer (Prof. Aidan
Coffey's laboratory, Department of Biological Sciences, Cork Institute of Technology,
Ireland). The full length ORF was introduced between the Ncol and Xhol restriction
sites of plasmid pET28a+. This plasmid encodes for a 6x His-tag that is added at the
C-terminus of the protein upon translation.
The plasmid was transformed into E. coli BL21(DE3) cells. An expression test at 37 °C
was performed. A preculture was grown from a single colony in LB medium
supplemented with kanamycin (50 pg/mL). The next day, a culture was grown in LB
medium supplemented with 50 pg/mL kanamycin, inoculated with 1:100 (v/v) of the
preculture. Cells were grown to an ODeoo of 0.6, cooled in ice and then induced with
1 mM IPTG. The protein was expressed at 37 °C for 3 h. Samples of the culture were
collected every hour, then sonicated and centrifuged at 15,000 x g for 30 min. The
supernatants were mixed with loading buffer, heated at 95 °C and analysed by SDSPAGE.
Four 1 L cultures were grown using the same parameters determined in the
expression test (3 h at 37 °C, 50 pg/mL kanamycin, 1 mM IPTG). Cells were harvested,
centrifuged at 5,000 x g for 20 min, resuspended in Y lysis buffer and frozen. The
following day, the cells were thawed, lysed by sonication and centrifuged at 15,000 x
g for 40 min to separate the soluble fraction from the cell debris.
An IMAC was performed. The supernatant was incubated with Ni-NTA resin. The
unbound sample was washed with Y lysis buffer. The protein was eluted with a step
gradient of imidazole in the same buffer, using concentrations from 50 mM to IM of
imidazole. The pellet, flow-through, wash and elution fractions were analysed by SDSPAGE. The flow-through and the wash fractions, they were incubated with the resin
a second time to repeat the affinity chromatography step.
Fractions from the affinity chromatography eluted at 50-500 mM imidazole
concentrations were pulled together and dialyzed at 4 °C against 20 mM MES-NaOH
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pH 6.0. A cation exchange chromatography was performed using an AKTA purifier (GE
Healthcare) and a Resource S-6 (GE Healthcare) column. The column was equilibrated
with 20 mM MES-NaOH pH 6.0 and the protein was eluted using a gradient of 0-1 M
NaCI in the same buffer. The protein contents of every elution fraction were analysed
by SDS-PAGE.
The fractions 19-21, and 23-24, eluted from the cation exchange chromatography,
were desalted and concentrated in 20 mM MES-NaOH pH 6.0 independently using an
Amicon centrifuge filter device with a molecular weight cut-off of 10,000 Da
(Millipore,

Billerica

MA,

USA).

Crystallization

experiments

were

performed

immediately.
4.7.3 Cry.^^ization of CBB 239
Crystallization trials were performed at 20 °C using sitting drop vapour diffusion
techniques. The reservoirs of Swissci 96-well 2-drop MRC crystallization plates
(Molecular Dimensions, Suffolk, UK), were filled manually with 50 pL of different
crystallization conditions. Drops containing a mixture of 0.5 pL of 9 mg/mL (0.46 mM)
or 13.5 mg/mL (0.66 mM) of CBB_239 and 0.5 pL of the crystallization solution were
set up in by automated techniques (Genesis RSP 150 workstation, Tecan Trading AG).
The crystallization screens initially tried were JBScreen Classic 1-10, Pi-Minimal (Jena
Biosciences, Germany), JBS PEG/Salt 1 and 2, Sigma Cryo and Sigma Extension (SigmaAldrich, USA).
The crystals obtained were flash frozen and saved to transport them to the
synchrotron for measurement.
The crystallization process of this protein is a substantial part of the results of this
project, hence more details can be found in section 9.3.
4.7.4 CBB 239 structure determination attempts
Crystals were transported to ALBA and ESRF synchrotrons. The different diffraction
patterns obtained were indexed, integrated and scaled using the programs XDS
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(Kabsch, 2010b) and Aimless (Evans et oi, 2013), from CCP4 suite (Dodson et al.,
1994). Matthews coefficient was calculated using CCP4 suite.
Molrep (Vagin et al., 2010) and Phaser (McCoy et al. 2007) were used to try to
elucidate the crystal phases.
In silica protein models were generated using QUARK (Xu etol., 2012), ROBETTA (Kim
et al., 2004), Galaxy (Ko et al., 2012), intFOLD4 (McGuffin et al., 2017), RaptorX
(Kallberg et al., 2014), HHPred (Meier et al., 2015), Modeller (Webb et al., 2016) and
iTasser (Yang et al., 2015) and Phyre2 (Kelley et al., 2015). Each model was used to
try to get the phases of the dataset using Molrep (Vagin et al., 2010) and Phaser
(McCoy et al. 2007).The loops of each model were optimized using GalaxyRefine (Ko
et al., 2012). The outputs were used again as models for molecular replacement.
The atomic coordinate files (PDB) were visualized and the figures generated using
PyMOL (Delano, 2002).
Dali server was used to search for structurally related proteins and to superpose
protein structures (Holm et al., 2016).
4.7.5 Additional proteins from CBB phage

A homology search against non-redundant protein sequences, using standard genetic
code, was performed on CBB phage genome using Blastx (Altschul et al., 2010). The
objective was to identify putative tail fibres.
The Xtalpred server (Slabinski et al., 2007) was used to try to determine the difficulty
to crystallize each protein and the presence of disordered regions.
Serial Cloner was used for the visualization of DNA and amino acid sequences and to
perform an in silica cloning to check that the designed primers were correct before
ordering them.
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4.8 Methods for the cloning, purification and crystallization of proteins
from Listeria monocytogenes phage vB_LmoS_293
The methods shown below have been applied to obtain the results described in
chapter 10.
4.8.1 Cloning of vB LmoS 293 tail fibre and endolysin

An analysis of the conserved domains in vB_LmoS_293 endolysin was performed
using the conserved domains database (CDD, Marchler-Bauer et al., 2011). A
secondary structure prediction was performed with Phyre2 (Kelley et ol., 2015).
Blastp (Basic Local Alignment Search Tool, Altschul et al., 2010) was used to perform
a homology search against the protein data bank (PDB) to search for homologous
proteins whose structure had already been determined that could be used as a guide
to design the fragments to clone.
Four different fragments of the endolysin were designed to be cloned between the
Ncol and Hindlll restriction sites of pCri-8a plasmid. Serial Cloner was used for the
visualization of DNA and amino acid sequences and to and to design primers.
The designed fragments were amplified by nucleic acid amplification using as a
template vB_LmoS_293 phage genome (Section 4.2.2.3). The oligonucleotides used
for each fragment are detailed in table 4.3.
The PCR products were assessed by 1% agarose gel and cleaned by GeneJET PCR
purification kit (Thermo Scientific). After that, the fragments and the plasmid were
digested with Ncol and Hindlll restriction enzymes (Section 4.2.2.4) and run in a 1%
agarose gel. The digested bands were extracted from the gel using GeneJET Gel
Extraction kit (Thermo Fisher) and ligated with T4 DNA ligase (Section 4.2.2.5).
The ligation products were transformed in chemically competent (Section 4.2.1.2)
and electrocompetent (Section 4.2.1.4) TOPIO and DH5a cells. The resulting colonies
were checked by PCR using the vector sequencing primers (Table 4.4). The plasmids
from the positive colonies were extracted using the GeneJET plasmid miniprep kit

117

Crystallographic structure determination of bactericphage-encoded enzymes that specifically
target pathogenic bacteria

(Thermo Scientific) and digested with Ncol and Hindlll restriction enzymes to check if
they contained the insert in the vector. The positive colonies were sequenced

in

Secugen using the vector sequencing oligonucleotides.

Table 4.3: Oligonucleotides used to amplify vB_LmoS_293 endolysin
Name

Fragment

Oligonucleotides

Fw/Rv

Restriction
site

Endol

1-316

gp25endoFwNcol

Fw

Ncol

CGCG ccatgg CC
ATG TCA GTA CTA
CAA TAT AAT TAT
ATC AAT AAA AAT
CAATTT

gp25endoRvHindlll

Rv

Hindlll

GCGC aagctt TAT
TTC AAG AAG TAG
TTT GCT GTG TAA
TA

gp25endoFwNcol

Fw

Ncol

gp25endoAA178RvHindlll

Rv

Hindlll

CGCG ccatgg CC
ATG TCA GTA CTA
CAA TAT AAT TAT
ATC AAT AAA AAT
CAATTT
CGCGC aagctt gca
cct ttc a at ttt gca

gp25endoAA20FwNcol

Fw

Ncol

gp25endoAA178RvHindlll

Rv

Hindlll

gp25endoAA178FwNcol

Fw

Ncol

Endo2

Endo3

1-178

20-178

Sequence

ttg
CGCG ccatgg CC
TTG CTT AGA GTA
AGT AAG ATT GTT
ATG
CGCGC aagctt gca
cct ttc aat ttt gca
ttg

Endo4

178-316

CGCG ccatgg CC
GCA TCA CAA AAT
AAA AAC AGA CAT
GAT

gp25endoRvHindlll
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Table 4.4: pCri-8a and pET system vectors sequencing oligonucleotides

Oligonucleotides

Fw/Rv

Sequence

T7promFw:

Fw

GTTATGCTAGTTATTGCTCAGCGG

T7termRv

Rv

GAAATTAATACGACTCACTATAGG

An analysis of the conserved domains in vB_LmoS_293 fibre was performed using the
conserved domains database (CDD, Marchler-Bauer et oi, 2011). Secondary structure
prediction was performed with Phyre2 (Kelley etal., 2015).
Blastp (Basic Local Alignment Search Tool, Altschul et aL, 2010) was used to perform
a homology search against the protein data bank (PDB) to search for homologous
proteins whose structure had already been determined that could be used as a guide
to design the fragments to clone.
HHpred (Soding et al., 2005) search was performed to search for sequence
homologous proteins based on the pairwise comparison of profile hidden Markov
models.
A Needleman-Wunsch global sequence alignment of vB_LmoS_293 tail fibre and
TP901-1 baseplate tripod protein (PDB code 3U6X was done with EMBOSS needle
(Madeira et al., 2019). The matrix used was BLOSSUM62, the gap opening penalty
was 10, the gap extension penalty was 0.5. No gap ending penalties were used.
Another alignment using the same parameters was performed between the
sequence of vB_LmoS_293 tail fibre and gpl7 371-551 (4A0T).
Four different fragments of the tail fibre were designed to be cloned between the
Ncol and Hindlll restriction sites of pCri-8a plasmid. Serial Cloner was used for the
visualization of DNA and amino acid sequences and to and to design primers.
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The designed fragments were amplified by nucleic acid amplification using as a
template vB_LmoS_293 phage genome (Section 4.2.2.3). The oligonucleotides used
for each fragment are detailed in table 4.5.
The PCR products were assessed by 1% agarose gel and cleaned by GeneJET PCR
purification kit (Thermo Scientific). After that, the fragments and the plasmid were
digested with Ncol and Hindlll restriction enzymes (Section 4.2.2.4) and run in a 1%
agarose gel. The digested bands were extracted from the gel using GeneJET Gel
Extraction kit (Thermo Fisher) and ligated with T4 DNA ligase (Section 4.2.2.5).
Table 4.5: Oligonucleotides used to amplify vB_LmoS_293 tail fibre

Name

Fragment

Oligonucleotides

Fw/Rv

Restriction
site

Taill

1-355

gp20liMosFwNcol

Fw

Ncol

Sequence
CGCG ccatgg CC
ATG ACT GAA AAC
GTT ATT CAT AAA
AAT GGT

gp20liMosRvHindlll

Rv

Hindlll

CGCGC aagctt TCA
TGT TGT CAC CTC
TTT AGT TAA ATA

Tail2

67-355

gp20liMos67FwNcol

Fw

Ncol

CGCG ccatgg CC
TAC CTT GTA AAA
CCG AAA GTT GTT

gp20liMosRvHindlll

Rv

Hindlll

CGCGC aagctt TCA
TGT TGT CAC CTC
TTT AGT TAA ATA

Tails

137-355

gp20liMosl37FwNcol

Fw

Ncol

CGCG ccatgg CC
TTC CCG GTA AAA
GAA TAC TAT GTT
GAA

gp20liMosRvFlindlll

Rv

Hindlll

CGCGC aagctt TCA
TGT TGT CAC CTC
TTT AGT TAA ATA

Tail4

153-355

gp20liMosl52FwNco

Fw

Ncol

CGCG ccatgg CC
AAA ATA TTC GAC
GAA TCG TTC GAG

gp20liMosRvFlindlll

Rv

Hindlll

CGCGC aagctt TCA
TGT TGT CAC CTC
TTT AGT TAA ATA
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The ligation products were transformed in chemically competent (Section 4.2.1.2)
and electrocompetent (Section 4.2.1.4) TOPIO and DHSa cells. The resulting colonies
were checked by PCR using the vector sequencing primers (Table 4.4). The plasmids
from the positive colonies were extracted using the GeneJET plasmid miniprep kit
(Thermo Scientific) and digested with Ncol and Hindlll restriction enzymes to check if
they contained the insert in the vector. The positive colonies were sequenced in
Secugen using the vector sequencing oligonucleotides.
4.8.2 Purification of vB LmoS 293 endolysin

The versions Endol and Endo2 of the protein were expressed in BL21 (DE3) cells. LB
supplemented with 50 pg/mL of kanamycin was inoculated with 1:100 (v/v) of cell
culture grown overnight. The cells grew until the ODeoo was 0.6. Then, they were
cooled down on ice and induced with 1 mM IPTG. The expression was performed at
16 °C for 16 h. The cells were harvested and centrifuged at 5,000 x g for 20 min. They
were resuspended on 50 mM Tris-HCI pH 8.5, 500 mM NaCI and 10% glycerol lysis
buffer, lysed by sonication and centrifuged again to separate the soluble protein from
the cell debris.
A Ni-NTA affinity chromatography was performed on both proteins. They were
incubated with the resin for 20 min, the unbound sample was washed with lysis
buffer. The target protein was eluted in a gradient from 50 to 1,000 mM of imidazole
in the same buffer. The presence of protein was checked by SDS-PAGE.
4.8.3 Purification of vB LmoS 293 tail fibre

Both Tail3 and Taill versions of the tail fibre were expressed in BL21 (DE3) at 16 °C,
centrifuged and resuspended in Y3 buffer, lysed by French press and centrifuged to
separate the cell debris from the soluble protein in the same way as the endolysins
(Section 4.8.2).
A Ni-NTA affinity chromatography was performed for both proteins with the same
protocol used for the endolysin fragments (Section 4.8.2).
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Taill elution fractions were dialysed versus 20 mM bicine pH 9.3 and used to perform
an anion exchange chromatography. The column was equilibrated with 20 mM bicine
pH 9.3.
Tail3 elution fractions were dialyzed against 10 mM Tris-HCI pH 8.5 at 4 °C for 16 h.
The following day, an anion exchange chromatography with an AKTA purifier (GE
Healthcare) and a Resource Q-6 (GE Healthcare) column equilibrated with 10 mM
Tris-HCI pH 8.5 was performed. The protein was eluted with a gradient from 0 to 1 M
NaCI in the same buffer. The elution fractions were analysed by SDS-PAGE before and
after heating to 95 °C. The protein was concentrated in 20 mM Tris-HCI pH 8.5 and
desalted using an Amicon centrifuge filter device with a molecular weight cut-off of
10 kDa (Millipore). Crystallization experiments were performed immediately.
To facilitate crystallization, a batch of protein was produced without His-tag. After
the Ni-NTA affinity chromatography, the His-tag was cleaved using TEV protease. The
digestion reaction was performed in 50 mM Tris-HCI pH 8.5, ImM DTT, 0.5 mM EDTA
at different temperatures (4 °C, 16 °C, 20 °C, 30 °C and 37 °C) for 24 h (Section 4.2.3.3).
After the digestion, a dialysis to remove the EDTA and the DTT and another Ni-NTA
chromatography were performed on the protein. The Flow-Through obtained was
dialyzed against 10 mM Tris pH 8.5 at 4 °C for 16 h to perform an anion exchange
chromatography the following day. The protein was concentrated in 20 mM Tris-HCI
pH 8.5 and desalted. Crystallization experiments were set up immediately.
4.8.4 Crystallization of vB LmoS 293 tail fibre (Fragment 3)

Crystallization assays were set using sitting drop vapour diffusion techniques at 20 °C.
The reservoirs of Swissci 96-well 2-drop MRC crystallization plates (Molecular
Dimensions, Suffolk, UK), were filled manually with 50 pL of 500 different
crystallization conditions containing a different salts, precipitants and buffers. Drops
containing a mixture of 0.5 pL at 34 mg/mL (1.2 mM) or 15 mg/mL (0.7 mM) of
undigested protein or 3.8 mg/mL (0.15 mM) of digested protein and 0.5 pL of the
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crystallization solution were set in by automated techniques (Genesis RSP 150
workstation, Tecan Trading AG).
Crystals obtained were cryoprotected with 20% glycerol and taken to the synchrotron
for data collection.
The crystallization process of this protein is a substantial part of the results of this
project, therefore more details can be found in section 10.4.

4.9 Methods for site-directed mutation study of T7 tail fibre (gpl7)
residues involved in host recognition
The methods shown below have been applied to obtain the results described in
chapter 11.
4.9.1 Generation of gpl7 mutants and preliminary assays

Twenty-six different point mutants were generated of the full-length gpl7 protein
cloned between the restriction sites Ncol and Hindlll MCSI of pETDuet-1. The same
mutants were generated in the truncated (371-553) version of gpl7 cloned between
the restriction sites Ncol and Hindlll MCSI of pET30a+, with an N-terminal His-tag. The
directed mutagenesis was performed using QuikChange II Site-Directed Mutagenesis
Kit (Agilent), according to the instructions supplied with the kit (including a PCR,
digestion with Dpnl of non-mutated DNA and transformation into XL-Gold cells). A
list of the oligonucleotides used is included in table 4.6.
The presence of the mutation was assessed by sequencing using the oligonucleotides
gpl7.370Fw and T7termRV (Table 4.7).
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Table 4.6: Oligonucleotides used to generate point mutations in gpl7

Mutation

Fw/Rv

Sequence

V482A

Fw

TCT GGT AGT GCT GGC GGT GGG GCA AGT GTG ACT GTT TCA
CAG GAT

Rv

ATC CTG TGA AAC AGT CAC ACT TGC CCC ACC GCC AGC ACT ACC
AGA

S483A

Fw

GGT AGT GCT GGC GGT GGG GTA GCT GTG ACT GTT TCA CAG
GAT CTC

Rv

GAG ATC CTG TGA AAC AGT CAC AGC TAC CCC ACC GCC AGC
ACT ACC

V484A

Fw

AGT GCT GGC GGT GGG GTA AGT GCG ACT GTT TCA CAG GAT
CTC CGC

Rv

GAG ATC CTG TGA AAC AGT CAC AGC TAC CCC ACC GCC AGC
ACT ACC

N501A

Fw

ATC TGG ATT AAG TGT GCC GCC AAC TCT TGG AAC TTC TTC CGT
ACT

Rv

AGT ACG GAA GAA GTT CCA AGA GTT GGC GGC ACA CTT AAT
CCA GAT

N502A

Fw

ATC TGG ATT AAG TGT GCC AAC GCC TCT TGG AAC TTC TTC CGT
ACT

Rv

AGT ACG GAA GAA GTT CCA AGA GGC GTT GGC ACA CTT AAT
CCA GAT

S503A

Fw

TGG ATT AAG TGT GCC AAC AAC GCT TGG AAC TTC TTC CGT ACT
GGC

Rv

GCC AGT ACG GAA GAA GTT CCA AGC GTT GTT GGC ACA CTT
AAT CCA

W504A

Fw

ATT AAG TGT GCC AAC AAC TCT GCG AAC TTC TTC CGT ACT GGC
CCC

Rv

GGG GCC AGT ACG GAA GAA GTT CGC AGA GTT GTT GGC ACA
CTT AAT
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W515A

Fw

CGT ACT GGC CCC GAT GGA ATC GCC TTC ATA GCC TCT GAT
GGTGGA

Rv

TCC ACC ATC AGA GGC TAT GAA GGC GAT TCC ATC GGG GCC
AGT ACG

F516A

Fw

ACT GGC CCC GAT GGA ATC TAC GCC ATA GCC TCT GAT GGT
GGATGG

Rv

CCA TCC ACC ATC AGA GGC TAT GGC GTA GAT TCC ATC GGG
GCC AGT

I517A

Fw

GGC CCC GAT GGA ATC TAC TTC GCA GCC TCT GAT GGT GGA
TGGTTA

Rv

TAA CCA TCC ACC ATC AGA GGC TGC GAA GTA GAT TCC ATC
GGG GCC

D520A

Fw

GGA ATC TAC TTC ATA GCC TCT GCT GGT GGA TGG TTA CGA
TTC CAA

Rv

TTG GAA TCG TAA CCA TCC ACC AGC AGA GGC TAT GAA GTA
GAT TCC

W523A

Fw

TTC ATA GCC TCT GAT GGT GGA GCG TTA CGA TTC CAA ATA
CAC TCC

Rv

GGA GTG TAT TTG GAA TCG TAA CGC TCC ACC ATC AGA GGC
TAT GAA

N537A

Fw

TCC AAC GGT CTC GGA TTC AAG GCT ATT GCA GAC AGT CGT
TCA GTA

Rv

TAC TGA ACG ACT GTC TGC AAT AGC CTT GAA TCC GAG ACC
GTTGGA

I538A

Fw

AAC GGT CTC GGA TTC AAG AAT GCT GCA GAC AGT CGT TCA
GTA CCT

Rv

AGG TAC TGA ACG ACT GTC TGC AGC ATT CTT GAA TCC GAG
ACC GTT

D540A

Fw

CTC GGA TTC AAG AAT ATT GCA GCC AGT CGT TCA GTA CCT AAT
GCA

Rv

TGC ATT AGG TAC TGA ACG ACT GGC TGC AAT ATT CTT GAA TCC
GAG
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S541A

Fw

CTC GGA TTC AAG AAT ATT GCA GAC GGT CGT TCA GTA CCT
A AT GCA

Rv

TGC ATT AGG TAC TGA ACG ACC GTC TGC AAT ATT CTT GAA TCC
GAG

R542A

Fw

GGA TTC AAG AAT ATT GCA GAC AGT GCT TCA GTA CCT AAT
GCA ATC

Rv

GAT TGC ATT AGG TAC TGA AGC ACT GTC TGC AAT ATT CTT GAA
TCC

S543A

Fw

AAG AAT ATT GCA GAC AGT CGT GCA GTA CCT AAT GCA ATC
ATG GTG

Rv

CAC CAT GAT TGC ATT AGG TAC TGC ACG ACT GTC TGC AAT ATT
CTT

V544A

Fw

AAT ATT GCA GAC AGT CGT TCA GCA CCT AAT GCA ATC ATG
GTG GAG

Rv

CTC CAC CAT GAT TGC ATT AGG TGC TGA ACG ACT GTC TGC AAT
ATT

A518L

Fw

CCC GAT GGA ATC TAC TTC ATA CTC TCT GAT GGT GGA TGG TTA
CGA

Rv

TCG TAA CCA TCC ACC ATC AGA GAG TAT GAA GTA GAT TCC
ATC GGG

Table 4.7: Oligonucleotides used to sequence gpl7 site-directed mutants
Name
gpl7.370Fw
T7termRV

Sequence
CCGGCCATGGGGCATGTTCTTCAATTAGAGTC
GAAATTAATACGACTCACTATAGG

4.9.2 T7 amber mutant purification
Amber suppressor strain Sull was grown in 1 L LB at 37 °C until it reached
an ODgoo of 0.3. At that point, it was inoculated with a MOI of 0.025 of T7 amber
mutant (Q12) and grown until the OD stopped dropping.
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10 ml of chloroform were added and incubated for 15 min at 20 °C. DNase I and
RNase A to a final concentration of 1 |ig/mL were added to the culture and incubated
for 2 h at 20 °C. The culture was centrifuged at 12,000 x g for 15 min at 4 °C. The
supernatant was transferred to a clear tube and filtered through a 0.45 pm filter.
1 M NaCI and 10% (w/v) PEG 8,000 were added to the lysate, stirred until dissolved
and then stirred on ice for 30 min. The lysate was incubated at 4 °C overnight. The
next morning, it was centrifuged at 10,000 x g for 30 min at 4 °C. The pellet was
resuspended in 5 mL of TMS buffer, titrated and stored at 4 °C.
4.9.3 T7 amber mutant titration

100 mL of Sull suppressor cells and 100 mL of Top 10 non-suppressor cells were
grown to an

ODeoo

of 0.6. Phage dilutions from 10'^ to 10'^ in TMS buffer were

prepared. 250 pL of cells were mixed with 100 pL of the phage dilutions and
incubated for 20 mins. After that, they were mixed with 10 mL of top agar pre-heated
to 50 °C and plated on top of culture plates containing 10 mL of LB-agar.
The plates were incubated upside down at 20 °C overnight. The next morning lysis
plaques were counted. The plates with a number of plaques from 20 to 100 were
used for quantification to determine the concentration of infectious phage in the
sample in plaque forming units (PFU) per mL.
PFU = 10

X

dilution

x

number of plaques

4.9.4 T7 fibre complementation assays

For the complementation assay, BLR(DE3) and TOPIO cell strains were transformed
with pETDuet-1 plasmid containing the wild type gpl7 (positive control) and the
mutants. They were also transformed with pJETl.2 containing gpl7 in an incorrect
reading frame as a recombination control and with empty pETDuet-1 as a negative
control.
The transformed cells were grown to an

ODeoo

of 0.6. Amber mutant T7 phage

dilutions from 10'^ to 10'^ in TMS buffer were prepared. 250 pL of transformed cells
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were mixed with 100 [xl of the phage dilutions and incubated for 20 min. After that,
they were mixed with 10 ml of top agar pre-heated to 50 °C and plated on top of
culture plates containing 10 ml of LB-agar.
If the fibres are able to recognize new bacteria and infect them, a lysis plaque will be
formed. If, on the contrary, the fibres are useless, no plaques will be observed.
The plates were incubated upside down at 20 °C overnight. The next morning the lysis
plaques were counted. The plates with a number of plaques from 20 to 100 were
used for quantification to determine the plaque forming units (PFU) of each of the
mutants.
The PFU per ml of each mutant were compared with the ones of the wild type fibre
to determine if the infectivity on any of the cell strains had been decreased. They
were also compared with the negative control and with the recombination control.
4.9.5 T7 fibre solubility and thermal stability assays

To determine the solubility of each mutant the truncated His-tagged 371-553 version
of the fibre for each mutant was expressed and purified as indicated in Garcia-Doval
et oi, 2012a. The ionic exchange chromatography step was avoided. The solubility of
each mutant was checked by SDS-PAGE.
The melting behaviour of each mutant was determined (in tetraplicate) by a thermal
shift assay (see section 4.2.3.2).
4.9.6 T7 liquid medium phage infection assays

The method used is adapted from Storms et ai, 2015. BLR(DE3) and TOPIO cells were
transformed with pETDuet-1, containing wild-type full length gpl7 tail fibre or
without insert. The cells were grown to an ODeoo of 0.6. 0.6 pL of cells were mixed
with MOI 1 to 10'^ of T7 amber mutant phage Q12, unable to produce tail fibres, and
with LB medium to reach a final volume of 200 pL in a microtiter plate, with a final
ODeoo of 0.05. Tetraplicates of every experiment were performed.
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The ODeoo of every sample at different times was measured using a SpectraMax ID3
(Molecular Devices) and plotted in a graph. The area under the curve of this graph
rt = 7

{ I

^ OD

f=0

600

dt) for each cell at different MOIs was calculated. The average of this

area between the tetraplicates for the same kind of cells and MOIs was calculated
and plotted. The result was a graph where the lower the values, the more phage
infectivity. To correct this and to obtain positive values, the following formula was
applied, were Imoi is the phage infectivity for each MOI:

. 2 - f ■'<>£.
MOI
600

The values of Imoi were plotted against the log of the MOI. To evaluate the effects of
the tail fibres, the values obtained for the cells transformed with the empty vector
were subtracted from the ones of the cells transformed with the vector containing
the tail fibre. The results were also plotted.
4.9.7 Crystallization of

rp17

371-553 with kojibiose

Gpl7(371-553) fragment was purified as indicated in Garcia-Doval et al., 2012a.
Vapour diffusion crystallization experiments at 20 °C in sitting-drop CrysChem plates
(Hampton Research) with 0.5 ml reservoirs and drops consisting of 2 pL proteinligand solution mixed with an equal volume of reservoir solution were set up. The
precipitant conditions contained 0.2 M TMAO in a gradient from 0 to 25% of PEG
2000 MME and 0.1 M buffer from pH 7.5 to 9.0.
A flower multi-crystal, obtained in 15% PEG 2,000 MME, 0.1 M Tris-HCI pH 8.5, 0.2 M
trimethylamine N-oxide (TMAO) with protein at 6 mg/mL was incubated with 300
mM kojibiose for 24 h, cryoprotected with 20% glycerol and transported to the
synchrotron.
4.9.8 Structure determination of gpl7(371-553) bound to kojibiose

X-ray diffraction was collected at the XALOC beamline of the ALBA synchrotron
(Juanhuix et al., 2014). The different diffraction patterns obtained from gpl7(371-
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553) crystals were indexed, integrated and scaled using the programs XDS (Kabsch,
2010b) and Aimless (Evans et al., 2013), from CCP4 suite (Dodson et al., 1994).

A rigid body refinement using 4A0T as a model was performed using Refmac5
(Murshudov et al., 2011). Several rounds of model building with Coot (Emsiey et oL,
2004) and restrained refinement with Refmac5 (Murshudov et al., 2011) were
performed until refinement R factors converged. The quality of the geometry was
checked by MolProbity (Chen et al., 2010) and PDB-SUM (Laskowski etal., 2017).

4.9.9 Kojibiose binding sites

The atomic coordinate files (PDB) were visualized and the figures generated using
PyMOL (Delano, 2002).

4.9.10 Generation of new mutants

New mutants were generated for the residues involved in the interaction with
kojibiose: W454A and D442A and for residues involved in the expansion of T7 host
range: N501H, R542H, double mutants N501H-R542H, N501H-V544A and R542H\/544A and the triple mutant N501H-R542H-V544A. These mutants were generated
using the method described in section 4.9.2. The new oligonucleotides used are listed
in table 4.8. Mutants N501H-R542H, N501H-V544A and N501H-R542H-V544A were
generated by performing a site directed mutagenesis using the oligonucleotides for
R542H, V544A and R542H-V544A, respectively, over a N501H gpl7 point mutant
previously generated .
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Table 4.8: Oligonucleotides used to generate point mutations in gpl7 (2)

Mutation

Fw/Rv

D442A

Fw

GGC CGT TGT GGC CAC TGC TGG TAA TAT TCA AGG

Rv

CCT TGA ATA TTA CCA GCA GTG GCC ACA ACG GCC

Fw

TCAAGGTACTAAGTGGGG AGGTAAAGCGCTGGATGCTTA

Rv

GGT AAG CAT CCA GCG CTT TAC CTC CCC ACT TAG TAC CTT GA

Fw

ATATCTGGATTAAGTGTGCCCACAACTCTTGGAACTTCTTC

Rv

GAA GAA GTT CCA AGA GTT GTG GGC ACA CTT AAT CCA GAT

W454A

Sequence

CC

N501H

AT
R542H

Fw

TTCAAG AATATTGCAGACAGTCATTCAGTACCTAATGCA
ATC ATG

Rv

CAT GAT TGC ATT AGG TAC TGA ATG ACT GTC TGC AAT ATT
CTT GAA

R542H_V544A

Fw

CAA GAA TAT TGC AGA CAG TCA TTC AGC ACC TAA TGC AAT
CAT GGT GG

Rv

CCA CCA TGA TTG CAT TAG GTG CTG AAT GAC TGT CTG CAA
TAT TCT TG

4.9.11 T7 chimeric fibre

A synthetic gene containing an N-terminal histidine tag, amino acids 371 to 467 from
T7 gpl7 (corresponding to the shaft domain), a short GS linker and T4 fibritine cloned
in pEt30a+, was ordered from Genscript®.
The plasmid was expressed in BL21(DE3) induced with 1 mM IPTG at 16 °C for 16 h.
The cells were lysed centrifuged at 15,000 x g for 30 min. Samples of the pellet and
the supernatant before and after heating to 95 °C were analysed by SDS-PAGE.
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5 Structure determination of endolysin
gp46 from Pseudomonas aeruginosa
phage vB PaeM KTN6
5.1 Characterization of gp46
Pseudomonas aeruginosa is a Gram-negative bacterium. It is an opportunistic human

pathogen able to form biofilms and it infects especially immunocompromised
patients. vB_PaeM_KTN6 is a myovirus belonging to the Pbllikevirus genus that
infects P. aeruginosa. The bacterial receptor for this phage is lipopolysaccharide. The
phage is stable in a wide range of pH and temperatures. KTN6 genome codes for a
220-residue endolysin, gp46, with a molecular weight of 24 kDa and a theoretical pi
of 8.76. This enzyme could have potential as an antimicrobial agent. Due to this, this
protein crystallization and structure determination was performed in this thesis.
A homology search showed that gp46 sequence presents high identity with some
endolysins from Pseudomonas-mfect\r\g phages and with enzymes belonging to the
glycoside hydrolase family 19. An analysis of the conserved domains confirms that
gp46 belongs to the glycoside hydrolase family 19 and shows the presence of a
lysozyme-like domain (from residue 22 to 217), a glycoside hydrolase family 19
chitinase domain (from residue 39 to 219) and a chitinase class I domain (from
residue 121 to 173) (Figure 5.1A). Secondary structure prediction showed no
disordered regions that might hinder the crystallization process (Figure 5.IB). The
protein does not show any transmembrane domain or signal peptide that might
indicate it is a SAR-endolysin.
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Figure 5.1: Conserved domains and secondary structure of gp46. A) Conserved domains
prediction of gp46 obtained using using the conserved domains database (CDD, MarchlerBauer et ai, 2011). B) Secondary structure representation of gp46 performed with ESPriptS
(Robert et al., 2014). The relative accesibility of each residue (acc) is indicated in blue
(accesible), cyan (intermediate) or white (buried).

5.2 Purification of gp46
Gp46 was cloned, expressed and partially purified by Dr. Katarzyna Danis-Wlodarczyk
(Prof. Rob Lavigne group, Laboratory of Gene Technology, KU Leuven, Belgium).
Upon arrival of gp46 its integrity and purity were checked by SDS-PAGE. The protein
was further purified by cation exchange chromatography, obtaining two absorption
peaks, a large one that eluted at a NaCI concentration of 0.57 M (fractions 21 and 22)
and a smaller one that eluted at 0.63 M of NaCI (fraction 24) (Figure 5.2). As analysed
by SDS-PAGE, both peaks contained gp46, but there was some difference between
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them causing a different protein net charge at pH 7.0. Since samples aimed for
crystallography must be highly pure and uniform, both peaks were pooled
independently.
The large peak (fractions 21 and 22) was desalted and concentrated to obtain 300 pL
of pure gp46 at a concentration of 4.9 mg/mL (0.2 mM). Crystallization experiments
were set up immediately.

B
kQa

116

BL21 22 24

-

66 45

#

35

^

25
18 f

Figure 5.2: Chromatogram obtained after running a cation exchange chromatography on
gp46. The contents of the protein sample before running the chromatography (BL) and of
each elution fraction (21, 22 and 24) were analyzed by SDS-PAGE (B) showing that the two
peaks contained a single protein band of molecular weight around 25 kDa, compatible with
gp46.

5.3 Crystallization of gp46
Crystallization assays were performed using manual sitting drop vapour diffusion
techniques.
More than 400 crystallization conditions were tried. The first crystals appeared after
one week at 20 °C. Crystals of different shapes were obtained in several conditions
(Figure 5.3A-D). The most promising crystals were grown in conditions B2 from JBS
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Classic kit 4 (16% w/v polyethylene glycol 6,000, 10 mM tri-sodium citrate) (Figure
5.3D) and 29 from Pi-Minimal kit (25.7% w/v polyethylene glycol monomethyl ether
5,000, 150 mM MBS pH 6.0, 6% v/v 1,2-propanediol) (Figure 5.3C) at a protein
concentration of 4.9 mg/mL (0.2 mM). These crystals were cryoprotected and saved
for measurement at the synchrotron.

Figure 5.3: Gp46 crystals grown in different conditions and diffraction pattern. A) Weak
multicrystals requiring further optimization. B) Poorly diffractive multicrystals. C-D)
Monocrystals showing an interpretable diffraction pattern. The crystal in D, obtained in
16 % (w/v) polyethylene glycol 6,000 and 10 mM tri-sodium citrate, was used to determine
the final structure of gp46. E) Diffraction pattern at 1.4 A, obtained during data collection
in BL13-XALOC (ALBA, Spain).
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5.4 Structure determination of gp46
The frozen crystals were analysed at the BL13-XALOC beamline of the ALBA
synchrotron (Juanhuix et al., 2014) and a diffraction pattern (Figure 5.3E) was
obtained with enough quality to determine the protein structure at atomic level.
Table 5.1: Gp46 diffraction statistics.
Parameter

gp46

Space group
a, b, c

a=

P2i2i2i

(A)

40.8, 43.3, 126.3

(3 = Y (°)

Wavelength

90.0, 90.0, 90.0

(A)

0.9793
BL13 (ALBA)

Beamline
Temperature (K)

100

Resolution (A)
No. of reflections

43.2-1.39 (1.47-1.39)

Total

297,441 (42,865)

Unique

46,757 (6,679)

Mn(l/ol)

15.8 (1.8)
0.026 (0.425)

f^pim

Completeness (%)

99.9 (99.7)

Multiplicity

6.4 (6.4)

*The values in brackets belong to the highest resolution shell.

The different diffraction patterns obtained from the crystals measured were indexed,
integrated and scaled. The best crystal diffracted to a resolution of 1.4 A, belonging
to the space group P2i2i2i with unit cell parameters a = 40.8 A, b = 43.3 A,
c = 126.2 A. Table 5.1 shows the data collection statistics. The estimated Matthews
coefficient was 2.3 AVDa, suggesting the presence of a single monomer in the
asymmetric unit and 47% of solvent percentage.

During a search for sequence identity in the Protein Data Bank (PDB), a protein
structure with a 38% identity and 83% query coverage was identified. This protein is
the endolysin from Salmonello typhimurium phage SPNIS (PDB code 40K7) (Park et
al., 2014). This structure was used as a model to perform a molecular replacement as
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phasing method. After that, a preliminary density map was obtained. The initial
model was modified, and the solution was refined.

The final refinement R factors were Rwork= 0.19 and Rfree= 0.22. Table 5.2 shows the
statistics of gp46 refinement phase.

Table 5.2: Gp46 data refinement statistics.
Parameter

gp46

Resolution (A)

43.2 - 1.39
0.190 /0.220

Rwork /Rfree

No. atoms (not H)
Protein (not H)

1685

Di(hydroxyethyl)ether

14

Glycerol

12

1,2 ethanediol

4

HEPES

30

Waters

198

Wilson B factor (A^)
Average B, all atoms (A^)

17.6
27.0

Bond RMSD
Distances (A)

0.0127

Angles (°)

1.8650

Ramachandran (%)
Favoured

99.7

Outliers

0

Rotamers (%)
Favoured

99.1

Bad

0

Distances and bond RMSD values, as well as the percentage of favoured rotamers
and Ramachandran residues indicate very good geometry. The general B factors show
a good correlation with the theoretical values expected for the resolution of the
collected diffraction data.
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5.5 Structure analysis of gp46
The quality of the diffraction data and the electron density maps allowed the building
the structure of gp46 from Lys2 to Glyll9. Density for Metl, the last residue (Ser220)
and the His-Tag used for purification were not observed, probably because of their
high flexibility. Two HEPES molecules, three molecules of di(hydroxyethyl)ether, two
glycerol molecules, one molecule of 1,2-ethanediol and 198 water molecules from
the crystallization condition could be also fitted in the electron density map.
Gp46 is a helical monomer with a Pac-man-like shape, measuring 60 by 38 by 32 A
(Figure 5.4A). A total of thirteen a-helices and two 3io-helices form two differentiated
domains: a large one comprising the N-terminal and C-terminal regions of the protein
(from Lys2 to Ser52 and from Lysl35 to Gly219) and a smaller one comprising the
central part of the protein (from Ala66 to Tyrl24) (Figures 5.4B and C). The large
domain is formed by a total of eight a-helices, three of them from the N-terminal
region of the protein (al to a3) and the other five helices from the C-terminal area
(a9 to al3). Helix a3 is located in the central part of the domain, surrounded by
helices al, a2 and al0-al3. Helix 3iol connects this bundle to helix a9. The small
domain is formed by the five central a-helices (a4-a8) and the second 3io-helix.
Helices a4, a6 and a7 form an antiparallel three-helix bundle whose axis is
perpendicular to the one of the bundles formed by the helices in the large domain.
In the linking region between both domains, two interesting loops are observed: loop
A, connecting helices a3 and a4 (from residue GluSl to Ala66) and loop B, connecting
helices a8 and a9 (from residue Tyrl24 to Lysl35). Loop A is quite straight, but loop
B forms a longer hairpin-like or U-shaped structure (Figures 5.4B and C).
As a result, a deep wide groove (26 A high, 15 A wide and 19 A deep) is formed
between both domains, completing the Pac-man-like shape (Figure 5.4A). Loops A
and B conform the central exposed deep surface and one side, being the opposite
side formed by residues from helix a3 and the loop connecting helices al2 and al3
(Figure 5.4B).
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The two HEPES molecules found in the structure are located along this groove, while
the other compounds present in the solvent and observed in the electron density
map are distributed along exposed regions around the whole structure (Figure 5.4A).

38 A

32 A

60 A

60 A

B

al3

Large domain

Figure 5.4: Gp46 overall shape and topology. A) Surface representation of gp46, showing
a Pac-man-like shape with a deep groove. The non-protein molecules present in the
structure are shown in sticks: HEPES in light pink, di(hydroxyethyl)ether in yellow, glycerol
in magenta and 1,2-ethanodiol in orange. Image generated with PyMOL (DeLano,
2002). B) Cartoon representation with a-helices in red and 3io-helices in magenta. The
orientations do not correspond to the ones in panel A, to facilitate the visualization of
every structural feature. Panel generated in PyMOL (DeLano, 2002). C) Topological
representation. Both domains are surrounded by a dashed line, green for the large
domain and blue for the small one. Catalytic residues are represented in yellow. Image
generated with TopDraw (Bond, 2003), from CCP4 suite.
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Based on sequence similarity, gp46 is probably a member of the glycoside hydrolase
family 19, mostly containing proteins showing chitinase activity. Chitinases break the
links between (3-(1^4) linked N-acetyl-D-glucosamine that make up chitin. As it was
described in Section 2.6, bacterial peptidoglycan glycan strands consist of N-acetylglucosamine (GIcNAc) and N-acetylmuramic acid (MurNAc), with MurNAc a variant of
GIcNAc with a D-lactate attached to the C3 by an ether bond. Due to this similarity,
gp46 could either recognize and cleave the links between MurNAc and GIcNAc
(muramidase) or between GIcNAc and MurNAc (glucosaminidase) (Figure 5.5).
CH,OH
CHjOH

N- Acetylglucosaxnine

Figure 5.5: Structural differences between GIcNAc and MurNAc. The extra D-lactate
present in MurNAc, only difference between them, is circled in red.
The degree of conservation of every residue in gp46 was determined. The most
conserved residues are those located in the base of the groove, indicating that this
region may be important for protein function (Fig 5.6A and B). This fact leads to
hypothesize that the catalytic residues, expected to be conserved, could be found
somewhere in the groove. As previously described, two HEPES molecules are located
in this area (Figure 5.6A and Figures 5.6A and B), possibly mimicking the enzyme's
natural ligand (Sanz-Go/tero et ai, 2014). In addition to the conservation, the
electrostatic surface representation unveils the presence of negatively charged
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residues along the surface of the catalytic groove, while the side belonging to the
small domain contains positively charged residues (Figure 5.6C).
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Figure 5.6: Conservation and electrostatic potential of gp46. A-B) Degree of residue
conservation. The protein is shown in surface (A) and cartoon (B) representation. The
most conserved residues, located mainly in the groove, are represented in purple.
Solvent molecules that co-crystallized with the protein are shown in green. C) Protein
electrostatic potential surface. Negative charges are coloured in red and positive in blue.
Figure generated with PyMOL (Delano, 2002).

After performing a search to compare gp46 against the proteins deposited in the PDB,
it was determined that the endolysin of bacteriophage SPNIS from Solmonella
typhimurium (PDB 40K7, rmsd = 1.6, sequence identity 38%) (Park et al., 2014), a
family 19 Chitinase from Streptomyces coelicolor (PDB 2CJL, rmsd = 2.8, sequence
identity 26%) (Hoell et al., 2006), a family 19 chitinase from Cryptomeria joponica
pollen

(PDB

5H7T,

rmsd = 2.7,

sequence

identity

24%)

(Takashima

et al.,

unpublished), the chitinase C from Streptomyces griseus (PDB code 2DBT, rmsd = 2.9,
sequence identity 26%) (Kezuka et al., 2006) and a class IV chitinase from Picea able
(PDB code 3HBE, rmsd = 2.7, sequence identity 25%) (Ubhayasekera et al., 2009)
were its closest structural relatives. The closest structural relatives crystallized with
their ligand were a family 19 chitinase from Bryum coronatum in complex with
(GlcNAc)4 (PDB code 4IJ4, rmsd = 3.0, sequence identity 26%) (Ohnuma et al., 2014)
and a family 19 chitinase from Secale cereale (rye) seeds in complex with (GlcNAc)4
(PDB code 4DYG, rmsd = 2.6, sequence identity 24%) (Ohnuma et al., 2012).
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By performing a structural alignment between gp46 and its closest structural relatives
crystallized with their ligand, it is observed that the ligand is located in the region
corresponding to the gp46 deep groove, providing further evidence that this cleft is
the region responsible for substrate recognition and catalysis. (Figure 5.7).

Figure 5.7: Structural alignment between gp46 and two chitinases co-crystallized with
their ligands. Gp46 (in green) is structurally aligned with PDB 4IJ4 (chitinase from Bryum
coronatum in complex with (GlcNAc)4 -in yellow) and PDB 4DYG (chitinase from Secale
cereale in complex with (GlcNAc)4 -in magenta). Their ligands are located in the area
corresponding to gp46 groove. HEPES molecules in the gp46 structure, shown as green
sticks, are not coincident with the area where the ligand is located in the chitinases.
Figure generated with PyMOL (Delano, 2002).

Most of the structural information from family 19 chitinases was obtained from the
study of barley {Hordeum vulgore) chitinase (PDB code 2BBA). This enzyme is an
inverting glycoside hydrolase. The catalytic residues from family 19 chitinases are two
glutamates. A glutamate located at the end of the third a-helix (Glu67 in the H.
vulgore enzyme) acts as the catalytic general acid, whereas another glutamate
located in a more variable loop-like structure (Glu89 in the H. vulgore chitinase) acts
as the catalytic general base (Hart et oL, 1993; Hoell et oL, 2006; Huet et oL, 2008;
Hoell et oL, 2010). It has been shown that at least two more conserved charged
residues are crucial for catalysis. These residues, Glu203 and Arg215 in H. vulgore
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chitinase, interact with the catalytic acid Glu67 to facilitate the catalysis (Ohnishi et
oi, 2005).
By performing a structural alignment of gp46 with the molecules with PDB codes
40K7 (endolysin of phage SPNIS), 2CJL (chitinase from 5. coelicolor), IWVU (chitinase
from 5. griseus), 5H7T (chitinase from Cryptomeria joponica), 3HBE chitinase from
Picea abie), 4IJ4 (chitinase from Bryum coronatum), 4DYG (chitinase from Secale
cereale) and 2BBA (chitinase from Hordeum vulgare) (Hart et al., 1995) it can be seen
that the catalytic residues are highly conserved among the structures, corresponding
in gp46 to Glu51 and Glu60 (Table 5.3). Moreover, the residues interacting with the
catalytic acid Glu67 in H. vulgare enzyme (Glu203 and Arg215), correspond to the
residues Asnl92 and Arg205 in gp46, interacting with Glu51 (Figure 5.9). According
to Brameld and collaborators (Brameld et aL, 1998), Serl20 of H. vulgare could also
be involved, together with Glu89, in coordinating a water molecule required for the
nucleophilic attack to the chitin. In gp46, this residue corresponds to Thrl33, a highly
conserved residue. To summarize, the catalysis general acid is conserved in 0.89% of
the sequences structurally aligned (8/9), the catalysis general base is conserved in
every sequence analysed and the water positioning residue is a threonine is 22% (2/9)
of the sequences analysed and a serine in the 78% (7/9) of the sequences (Figure 5.8).

Table 5.3: Catalytic residues in proteins structurally-related to gp46.
Protein or PDB code

Catalytic general acid

Catalytic general base

gp46
40K7
4DYB
2CJL
4IJ4
3HBE
5H7T
2 BAA
IWVU

GluSl
Glu49
Glu67
Glu68
Gln60
Glull3
Glu66
Glu67
Glul47

Glu60
Glu58
Glu89
Glu77
Glu70
Glul22
Glu75
Glu89
Glul56
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Figure 5.8: Structural alignment between gp46 and structurally related proteins. The

alignment was generated using DALI server (Holm et al., 2016). The position of the
catalysis general acid is marked with a blue star, the catalysis general base is marked with
a red star and the water positioning residue is marked with an orange star.

In the crystal structure of gp46, several molecules present in the protein buffer can
be observed. These molecules must interact with the protein in a fixed position to
generate significant peaks in the electron density map. Out of these, only two HEPES
molecules are located in the putative catalytic cleft. These molecules interact with
residues Glu60, Asn61, Leu62, Asn63, Tyr64 (located in the loop A), Asn71, Thr72,
Trp73 (located in helix a4), Tyrl07 (helix a7) and Glnl31 (loop B). Five of these
residues are highly conserved among homologous proteins (Glu60, Asn63, Tyr64,
Tyrl07 and Glnl31), being Glu60 the catalytic general base. These results lead us to
think that those five may be involved in peptidoglycan binding and/or catalysis
(Figure 5.10).
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Figure 5.9: Proposed catalytic site of gp46. A) Hydrolysis of P-(1^4)-glycosidic linkage in
gp46 (panel adapted from Ohnuma et ai, 2014). B) Residues involved in the catalysis of
the p-(l->4)-glycosidic bond. Catalytic residues (Glu60 and Glu51) are sho\A/n in green.
Residues assisting in catalysis are shown in yellow (Asnl92 and Arg205 interact with GluSl
and Thr233 coordinates a water molecule - red sphere - with GluGO, that will perform a
nucleophilic attack). Conserved aliphatic residues and conserved aromatic residues that
may play a role in catalysis or substrate binding are shown in purple and orange,
respectively. Panel generated with PyMOL (Delano, 2002).
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The thermal factors of gp46 protein are quite low in the small domain, but they
increase significantly in the large domain (Figure 5.11A). This asymmetrical
distribution of the thermal factors could be due to the crystal packing. To check this,
symmetrically-related molecules were generated, showing that the low thermal
agitation regions of the protein and the high agitation ones are equally exposed to
the solvent and both are interacting with neighbouring molecules (Figure 5.11B).
Therefore, the differences in B-factors are probably not due to the crystal packing.
This high thermal agitation in the large domain could mean that the protein has
certain flexibility due to a hinge or torsion component centred on the catalytic
groove, corresponding with loops A and B. This hypothetical hinge movement would
generate open and closed conformations for gp46, allowing the deep groove to
accommodate and stabilize the peptidoglycan glycan strand.

Asn71

Asn63

Figure 5.10: Interactions between HEPES and gp46. HEPES (black) interacts with the residues

shown in stick representation. Out of these, the residues shown in purple are highly
conserved among homologous species (Asn63, Tyr64, Tyrl07 and GlnlSl) and the green
residue is the catalytic base (Glu60). Figure generated with PyMOL (Delano, 2002).
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B

Figure 5.11: Gp46 thermal agitation. A) B-factor representation of gp46, showing that
the large domain has higher thermal agitation than the small one. B) Crystal packing
representation, showing regions with high and low temperature factors are equally
exposed to the solvent and interacting with symmetry mates. Figure generated with
PyMOL (Delano, 2002).

To summarize, the proposed catalytic mechanism for gp46 is as follows (Figure 5.9):
gp46 catalyses the cleavage of the 3-(l->4)-glycosidic bond between GInNAc and
MurNAc or between MurNAc and GInNAc that form the peptidoglycan glycan strands.
The protein is composed by two domains, large and small, connected between them
by two long loops, A and B. Between both domains there is a deep catalytic groove
with certain flexibility thanks to loops A and B, facilitating the binding and catalysis of
the ligand. GluSl, located in the helix a3, establishes electrostatic interactions with
the conserved residues Asnl92 and Arg205 (located in helices al2 and al3,
respectively) and acts as the catalytic general acid. Glu60, located in the loop A is the
catalytic base residue. Thrl33, in the loop B, helps to position one water molecule
between the ligand anomeric carbon and Glu60 carboxylic group. This water,
activated by Glu60 carboxylic group, acts as the catalytic nucleophile.
The surface of the catalytic cleft contains several conserved residues, such as Asn63
Tyr64, Tyrl07, Tyrl38, Leul56 and Glnl31, that could be involved in the binding
and/or cleavage of the substrate. To fully understand and to confirm the mechanism
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of action hereby proposed for gp46, a co-crystallization in presence of a polymer of
(3-(1^4) linked MurNAc and GInNAc, or a structural analogue will be required.
The structural similarity between gp46 and its closest structural relative, the
endolysin of phage SPNIS (40K7), is remarkable. The only difference between them
is that the loop connecting helices a5 and a6 is much longer in gp46, while the loop
connecting helices a6 and al is longer in 40K7. In addition, gp46 contains an extra
3io-helix between helices al and a8. As 40K7 is the endolysin of a phage infecting
Salmonella typhimurium and gp46 is the endolysin of a phage infecting Pseudomonas
aeruginosa, it can be expected that both bacteria might have differences in the
composition of their cell walls. This fact, together with the low sequence
conservation in the loop connecting helices a5 and a6, make us suggests that this
loop may be the region of the protein responsible for cell wall recognition and binding
(Figure 5.12).
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Figure 5.12: Structural alignment of gp46 and 40K7. With a rmsd of 1.6, endolysins
from 5. typhimurium phage SPNIS (magenta) and from P. aeruginosa phage KTN6
(gp46 - green) show a notable difference: the presence of a long loop connecting
helices a5 and a6 in gp46 and a6 and a7 in 40K7. These could be the cell wall binding
sites for each protein. A) Cartoon representation generated with PyMOL
(DeLano, 2002). B) Surface representation showing the location of the cell wall
binding domains of gp46 and 40K7. Panel generated in PyMOL (DeLano, 2002).
C) Sequence alignment between gp46 and 40K7 generated with Clustal
Omega (Sievers et al., 2011) with default parameters showing secondary
structure elements. An insertion can be observed between helices aS and a6
in gp46 and a6 and al in 40K7, corresponding to putative cell wall binding
sites. Figure generated with ESPriptS (Robert et ol., 2014).
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6 Structure determination of endolysin
gpl97 from Erwinia amylovora phage
vB EamM Y3
6.1 Characterization of Y3_197
Erwinia amylovora is a Gram-negative bacterium causing fire blight, a disease that
affects some members of the family Rosaceae, causing important economic losses to
the apple and pear production industry. Phage vB_EamM_Y3 is a jumbo myovirus
able to infect several Erwinia species and related genera. It codes for a 189-residue
endolysin, gpl97 (Y3_197), with a molecular weight of 21 kDa and a theoretical pi of
8.6. To date, no enzymatic activity has been shown for this protein. In this section,
the crystallization and structure determination of this endolysin was performed to
elucidate its function and catalytic mechanism will be described.

A homology search shows that the sequence of Y3_197 presents a high identity with
some putative glycosyl hydrolases from Erwinia sp. and Dickeya sp. phages and with
some hypothetical proteins from Aeromonas sp. and Halomonas sp. An analysis of
the conserved domains predicts that Y3_197 has a lysozyme domain (COG3926) from
residue 8 to 182, a family glycosyl hydrolase 108 domain (pfam05038) from residue
11 to 96 and a peptidoglycan-binding domain 3 (IPR018537) from residue 100 to 180.
The glycosyl hydrolase family 108 contains several N-acetylmuramidases used by
bacteria to break and rearrange the peptidoglycan for the secretion of large proteins.
Some phage proteins show this domain. Secondary structure prediction of Y3_197
shows no disordered regions that might prevent crystallization. Additional analysis
do not predict any transmembrane domain or signal peptide that might indicate it is
a SAR-endolysin (Figure 6.1).

151

Crystallographic structure determination of bacteriophage-encoded enzymes that specifically
target pathogenic bacteria

BHJ.IffJi!JJ MPA L’FRKNAI AEVI DREGGSKYTNRAADRGGPTRWGViEKNARAYGYKGDMQNLPYEI A
Secondary
iUUUUUMUMUUUUUUA
mUUUkAAKKAAA
structure

YAI YSANFWDFCKCDEI AKYSQELALWMFDYAVNSGPPAAI AELQDOLNI LNQRGKLYPD
Secondary

iUUUUUUUIA A4

JUUUUUUUUUMMIA

JUUUUUUUUUIAA

SS
confidence
Disorder
Disorder
confidence

B.-fJiH'fJiVJ F-. PAANI GPKI LAALAAYCKVRDI KVL

JUUUMUUUUIAA

^Itruclure

Y>FNGCRI AKLKNI AKADE : OEDNI YGWYQRV

JUUUUMUUUUMUAiUUUUUIAA

lUUUUUUUUUUkA

SS
confidence
Disorder
Disorder
confidence

i
Secondary
structure
SS
confidence
Disorder
Disorder
confidence

m

tkov

vlehhhhhh

JUUUMMUUUUMUUUM^

Confidence Key
High(9) lllllllll Low (0)
?

Disordered ( 8%)
Alpha helix ( 66%)
Beta strand ( 0%)

Figure 6.1: Secondary structure prediction for Y3_197. Performed with Phyre2, Kelley et
ai, 2015.

Nmbl012 from Neisseria meningitides (PDB 2IS5; Chang et oL, to be published) is the
protein with the highest sequence identity to Y3_197 for which a structure is available
(37% sequence identity, 47% query coverage). This is a bacterial protein, not a viral
one designed for bacterial lysis, so there are likely important differences in their
properties.
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6.2 Purification of Y3_197
The expression vector for Y3_197 was constructed by Colin Buttimer (Aidan Coffey's
lab, department of biological sciences, Cork Institute of Technology, Ireland). The full
length ORF was introduced between the Ncol and Xhol restriction sites of plasmid
pET28a+. This plasmid codifies for a 6x His-tag at the C-terminus of the protein (Figure
6.2). The predicted MW and predicted pi of the His-tagged protein are 22.2 kDa and
8.25, respectively.

Ncol

Figure 6.2: Cloning vector pET-28a+ with Y3_197. Y3_197 ORF is inserted between the

restriction sites Ncol and Xhol.

The protein was expressed in

E. coli Lemo21 (DE3) cells transformed with the

plasmid. An expression test at 37 °C was performed to determine if the protein
expression levels were acceptable and the best expression time. Supernatants of
culture samples collected before induction and at 1 h, 2 h and 3 h post-induction and
heated to 95 °C for 5 min were analysed by SDS-PAGE. It was determined that the
protein expression levels at 37 °C were good, that the protein was soluble and that
the best expression time was 3 h (Figure 6.3).

153

Crystallographic structure determination of bacteriophage-encoded enzymes that specifically
target pathogenic bacteria

Hours post-induction
0 12 3

22 KDa

Figure 6.3: Expression test of Y3_197 in E. coli Lemo21 (DE3) at 37 °C. Expression of

Y3_197 before induction and 1 h, 2 h and 3 h after induction. The higher expression
levels are achieved at 3 h post-induction.

Four cultures of 1 L were grown under the same conditions for 3 h. A metal ion affinity
chromatography (IMAC) was performed on the supernatant. The presence of Y3_197
in the samples eluted from 50-500 mM imidazole was checked by SDS-PAGE (Figure
6.4).
As the predicted pi of the protein was 8.25, the best option to further purify the
protein was judged to be by cation exchange chromatography. To remove sodium
chloride and imidazole, that might prevent the binding of the protein to the cation
chromatography column, and to exchange the buffer by another suitable for the
cation exchange chromatography, a dialysis was performed.
A cation exchange chromatography was performed. A large single absorption peak
was obtained eluted at a 600 mM concentration of NaCI and corresponded to the
collected fractions 21, 22 and 23. The presence of the protein was checked by SDSPAGE (Figure 6.5). These fractions were pulled together, desalted, concentrated and
filtered to obtain 150 pL of pure Y3_197 at a concentration of 14.4 mg/mL (0.65 mM).
Crystallization experiments were performed immediately.
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Figure 6.4: IMAC purification of Y3_197. SDS-PAGE gel with pellet (P), flow-through
(FT), wash (W) and elution with 50-1000 mM imidazole loaded. Large amounts of
protein with a size compatible with Y3_197 without contaminants can be observed in
fractions 50- 500 mM imidazole.
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Figure 6.5: Y3_197 cation exchange chromatography. Chromatogram obtained after
performing

a

cation

exchange

chromatography

on

Y3_197.

Fractions

21-23,

corresponding to the absorption peak were analyzed by SDS-PAGE, observing a band at a
size of 22 kDa (framed in black), compatible with Y3_197. The molecular weight ladder
and the protein samples belong to the same polyacrylamide gel.
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6.3 Crystallization of Y3_197
Crystallization assays were performed using sitting drop vapour diffusion techniques.
More than 400 crystallization conditions were tested.
The first crystals grew in one day. Crystals of different shapes were obtained in many
different conditions including different concentrations of PEG lOK, PEG 8K, PEG 6K,
PEG 4K, PEG MME 2K and ammonium sulphate (Figure 6.6A-P). The crystal that
allowed structure solution was obtained at 14.43 mg/mL (0.64 mM) protein
concentration in 2.2 M ammonium sulphate, 20% glycerol (Figure 6.60).
Some of the crystals were soaked in methylmercury chloride for different times, from
5 min to 1 h. Mercury was chosen as heavy atom over other options because it could
potentially bind covalently to the 4 cysteines in Y3_197.
The crystals grown in conditions with low amounts of glycerol were cryoprotected,
stored and transported to ESRF synchrotron for data collection.
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Figure 6.6: Different crystals obtained during Y3_197 crystallization experiments. A)

Pseudocrystals. B-E) Small crystals. F-l) Multicrystals. Crystals in A-J need optimization.
K-P) Monocrystals suitable for X-ray diffraction experiments. The crystals in 0 allowed

to determine the protein structure.

6.4 Structure determination of Y3_197
Crystallographic data was measured at the ID30A-1 / MASSIF-1 beamline of the ESRF
synchrotron, Grenoble, France (Bowler et al., 2015; Svensson et al. 2015) and
collected at a wavelength of 0.9660 A, very close to the Hg L-lll absorption edge. This
would allow us to solve the phase problem through single-wavelength anomalous
dispersion (SAD) techniques.
The best diffraction data was obtained from a crystal grown in 2.2 M ammonium
sulphate and 20% glycerol and soaked in CHaCIHg for 5 min (Figure 6.7B). The best
quality data does not necessarily mean the maximum resolution but the best
integration statistics and the most anomalous signal. So, although the best resolution
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obtained was 1.3

A,

a dataset at 1.85

A

was used to determine the structure of

Y3_197 (Figure 6.7C). From the diffraction images it can be seen that the
cryoprotectant did not work properly, as ice rings can be observed. This was not a
problem for structural determination, as the ice rings were weak enough to be
ignored during data processing.
Diffraction patterns obtained from Y3_197 crystals were indexed, integrated and
scaled. The best crystal diffracted to a resolution of 1.85
group P4i22 with unit cell parameters a = 56.7

A,

A,

b = 56.7

belonging to the space

A,

c = 237.9

A.

Table 6.1

shows the data collection statistics. Matthews coefficient obtained was 2.16 AVDa,
showing the presence of two monomers per asymmetric unit and 42.97% of solvent
percentage with a probability of 99%.

The data was processed by single anomalous dispersion techniques (SAD). Four
mercury atoms with occupancy higher than 0.7 were found. An initial model was built
and refined. The phasing statistics are shown in Table 6.2.
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Table 6.1: Y3 193 diffraction statistics.
Parameter

gp46

Space group

P4i22

(A)
ct = [3 = vn

56.7, 56.7, 237.9

a, b, c

90.0, 90.0, 90.0

Wavelength

(A)

0.9600
ID30A-1 (ESRF)

Beamline
Temperature (K)
Resolution

100
237.85-1.85 (1.891.85)

(A)

No. of reflections
Total

657,003 (9427)

Unique

33,839 (1,743)

Mn(l/ol)

23.0 (1.1)
0.018 (0.614)

Completeness (%)

98.5 (83.5)

Multiplicity

19.4 (5.4)

Anomalous completeness (%)
Anomalous multiplicity

97.3 (74.2)
10.3 (3.0)

*The values in brackets belong to the highest resolution shell.
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Anomalous Scattenng coefficients for Hg
X-ray wavelength m A
123A

1 isA

1 12A

1.07A

103A

0 99A

0 95A

0 9iA

X-ray energy in eV

Figure 6.7: Data collection of Y3_197 in presence of mercury. A) Anomalous scattering
for mercury. The red line indicates the wavelength (0.966 A) at which the datasets were
collected. B) Crystal during data collection at ID30A (ESRF, Grenoble, France). C)
Diffraction pattern of Y3_197.
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Table 6.2: Y3_197 data phasing statistics.
Parameter

Y3_197

Wavelength (A)

0.96000

Anomalous resolution (A)*

2.85

No. of reflexions (acentric / centric)

28,268/5,571
0.706

CCanom
CCall / CCweak

0.44/0.27
8.7

PATFOM
CFOM
CC (Average / Overall)

69.9
0.1309/0.5695
4

No. of Hg^"' atoms*
Ffand determination
CCmap

0.854/0.563

(original /inverse)

Overall mean FOM (original / inverse)

0.785/0.566

Density modification^
Overall MEAN FOM

0.6085

Model building
Overall MEAN FOM

0.9249

Model refinement
Final

0.2291/0.2519

Rwork / Rfree

•Anomalous signal to noise limit is determined by (d”/sig)> 1.3
tOnly heavy atoms with occupancy higher than 0.7 considered

^25 density modification cycles

The Y3_197 structure obtained after phasing was used as a model to try to solve
additional datasets at higher resolution by molecular replacement. The programs
Phaser (McCoy et ai, 2007) and Molrep (Vagin et al., 2010) were used to try to find a
solution and

RefmacS was used to calculate the electron density maps.

Unfortunately, although the resolution was good (the best dataset diffracted to
1.3 A), there was no clear density in some flexible regions of the protein and the
complete polypeptide chain could not be built, so the decision to continue with the
refinement of the dataset used for SAD was made.

The structure obtained by automatic model building had some amino acids missing
in several loops that were added manually. Several cycles of refinement and model
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building were performed. The final refinement R factors were Rwork = 0.18 and Rfree
= 0.22. The statistics of Y3 197 refinement is shown in Table 6.3.

Table 6.3: Y3 197 refinement statistics.
Parameter
Resolution

Y3_197
59.46- 1.85
0.182/0.219

(A)

Rwork/Rfree

No. atoms (not H)
Protein (not H)

2947

Methyl mercury ion

8

MES

36

Glycerol

24

Sulphate ion

40

Waters

147

Wilson B factor (A^)
Average B, all atoms
Bond RMSD
Distances

31.9
(A^)

39.0
0.0094

(A)

Angles (°)

1.482

Ramachandran (%)
Favoured

97

Outliers

0.5

Rotamers (%)
Favoured

96

Bad

1

The percentage of favoured rotamers and Ramachandran residues, together with the
RMSD values of the bond distances and angles indicate that the model built has an
overall good geometry, although some flexible regions could not be built due to the
lack of electron density.

6.5 Structure analysis of Y3_197
Two different molecules of Y3_197 are present in the asymmetric unit. The electron
density maps allowed to build molecule A from Metl to Glnl69 and from Glyl75 to
the last residue (Leul90). There was no appreciable electron density for residues
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Glul70 to Tyrl74 nor for the C-ternninal histidine-tag. In molecule B, residues from
Metl to Proll9, from Alal25 to Aspl66 and from Asnl72 to the final amino acid
(Leul90) could be built. Residues from Aspl20 to Alal24, from Glul67 to Aspl71 and
the C-terminal His-tag are absent in the structure. Taking the two molecules into
consideration, the only residues that could not be built in any of them were Glul70
and Aspl71. The impossibility to trace these regions of the protein could be due to
the high flexibility of these segments that might be related to the function of the
protein. Four methylmercury ions used for the experimental phasing could be found
bound to Cysl39 and Cysl54 from both molecules. The other two cysteine residues
present in the protein, Cys72 and Cys74, are located in a buried region of the protein,
within an a-helical bundle. Three MBS molecules, four glycerol molecules, eight
sulphate ions and 147 water molecules from the crystallization condition could be
also determined from the electron density map.
The crystal is very compact, with molecule A in close contact with molecule B and
with their symmetry mates (Figure 6.8). To determine whether Y3_197 is a monomer
or interacts with another chain from the same asymmetric unit or with a symmetryrelated molecule to form a dimer of multimer, an analysis of protein interface
between Y3_197 and its symmetry-related molecules was performed. Molecule A has
an exposed surface of 9953

and B has a surface of 9960 A^. Both molecules interact

but the surface of the interface is just 285 A^. The solvation free energy gain upon
formation of the interface (A‘G) is just -0.1 kcai/mol. The CSS (Complexation
Significance Score), which indicates how significant for assembly formation an
interface is, is 0, so molecules A and B from the same asymmetric unit do not interact
with each other. Table 6.4 shows the interactions with the symmetry related
molecules. The complexation significance score is low in all cases, indicating that
Y3_197 is likely a monomer in solution.
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Figure 6.8: Crystal packing of Y3_197. Representation of molecule A (yellow) and B (red)
of Y3_197 and their symmetry related molecules (green and cyan). The molecules are very
closely packed, showing few solvent channels between them.

Table 6.4: Analysis of protein interface between Y3_197 and its symmetry-related
molecules.
Molecule

Interacting

Symmetry

Interface

AiG

Molecule

operator

surface

(kcal/mol)

CSS

(A^)
B

A

x,y,z

285.4

-0.1

0.000

B

B

-x,y,-z

167.6

-3.3

0.012

B

B

y,x,-z-l/4

222.9

-1.0

0.005

B

A

-x,y,-z

542.5

0.8

0.000

B

A

-x+l,y,-z

641.7

-6.8

0.064

A

B

-x-Hl,y-l,-z

617.1

-4.7

0.000

A

B

-y+l,x,z+l/4

983.4

-15.9

0.117

A

A

-x+l,y,-z

456.8

-5.5

0.000

Y3_197 is a mainly a-helical globular protein, measuring 50 x 36 x 32 A (Figure 6.9A).
A total of nine a-helices, three p-strands and three 3io-helices conform two
differentiated domains: a large one called the a-domain, comprising the first Nterminal a-helix and the C-terminal regions of the protein (from Metl to Glyl8 and
from Ile59 to Leul90), and a smaller domain called p-domain, comprising the central
part of the protein (from Glyl9 to Glu58) (Figures 5.9B and C). The a-domain is
formed by a total of eight a-helices, including the N-terminal (al) and the seven C-
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terminal ones (a3-a9), and by the third 3io helix . The helices in this domain form a
seven-helix bundle with a5 in the centre, surrounded by the others. Between helices
a6 and a7 there is a large loop, called loop C.
The f3-domain is formed by the three p-strands, one a-helix and two 3io-helices
located in the central part of the peptide. The core of this domain are three 3-strands
forming an antiparallel 3-sheet. Connecting strands 31 and 32 there is a loop
containing the 3io-helix 1, named loop A. Helix a2 is located just after the third
3-strand and its axis is perpendicular to the one of the helices belonging to the
a-domain. Connecting both domains there is a loop containing the 3io-helix 2, named
loop B.
A narrow and closed groove is formed in the interface between both domains, with
a base formed by helices al, a5 and a9 from the a-domain, one of the side walls
formed by helix a8 from the a-domain and the opposite side formed by the
antiparallel 3-sheet from the 3-domain. This cleft is covered by loop A, containing the
3io-helix 1, that connects the first and second 3-strands. Another small narrow
channel is formed by loop C located in the a-domain. A glycerol molecule and a
sulphate ion occupy this channel in molecule A. In molecule B, only the sulphate ion
can be observed, but the cavity itself cannot be properly determined, since five
residues from loop C (Aspl20-Alal24) could not be built. Based on sequence
similarity, Y3_197 belongs to the glycosyl hydrolase family 108 and it likely has
muramidase activity, cleaving the 3-(l“^4)-glycosidic bond between MurNAc and
GIcNAc.
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Groove

39 A
36 A

50 A

B

Loop C

Loop C

Figure 6.9: Y3_197 overall shape and topology. A) Surface representation of Y3_197,
showing a globular shape with a narrow closed groove. Panel generated in PyMOL
(DeLano, 2002). B) Cartoon representation with a-helices in red, 3io-helices in magenta
and P-strands in green. The orientations do not correspond to the ones in panel A, to
facilitate the visualization of every structural feature. Panel generated in PyMOL
(DeLano, 2002). C) Topological representation. The P-domain is surrounded by a yellow
dashed line, the rest of the protein belongs to the a-domain. Panel generated in with
TopDraw (Bond, 2003), from CCP4 suite.
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By determining the degree of conservation of every residue, it can be observed that
the residues located in the bottom of the groove and in the side corresponding to the
(3-sheet from the (3-domain are highly conserved (Figure 6.10A and B). The amino
acids located in helix a6 are also quite conserved. The groove is strongly negativelycharged while the interface between helices a6 and a? is strongly positively-charged
(Figure 6.IOC). This could mean that the groove could be the catalytic site of the
enzyme and the interface between helices a6 and a? could be somehow involved in
the binding or recognition of the substrate. To further confirm where the catalytic
site of Y3_197 is, a search for its closest structurally-related proteins was performed.
The main results obtained are shown in table 6.5.

Table 6.5: Proteins structurally similar to Y3_197
PDB

Protein

Organism

RMSD

Identity

Ligand

(%)
21KB

Hypothetical protein

Neisseria

3.0

26

No

3.0

28

No

meningitidis
Secretion activation

Porphiromonas

protein

gingivalis

4QWP

Chitosanase

Pseudomonas sp.

3.0

17

Yes

ICHK

Chitosanase

Steptomyces sp.

3.4

13

No

4CFP

Transglycosylase MltC

E. coli

3.2

7

Yes

5HWA

Chitosanase

Bacillus circulans

3.1

11

Yes

40YV

MItF

P. aeruginosa

3.2

10

Yes

6ET6

Muramidase

A. baumannii

3.3

13

No

2NR7

prophage
4ZPU

Endolysin

E. coli prophage

3.6

9

No

3HDE

Muramidase

Phage P21

3.4

12

No

2LZIVI

Lysozyme

T4 phage

3.4

9

No

167

Crystallographic structure determination of bacteriophage-encoded enzymes that specifically
target pathogenic bacteria

KfaT/e^
3

Variabl*

4

5

6

Averag*

(8]

7

Conaarvad

Figure 6.10: Conservation and electrostatic potential of Y3_197. A-B) Degree of residue

conservation. The protein is shown in surface (A) and cartoon (B) representations. Most
conserved residues, located mainly in the groove, are represented in purple. Solvent
molecules that co-crystallized with the protein but are not located in the putative catalytic
groove, are shown in green. Sulphate ions are shown in yellow. C) Protein electrostatic
potential surface. Negative charges are coloured in red and positive in blue. Figure
generated in PyMOL (Delano, 2002).

It must be noted that although these proteins are structurally similar, they have low
sequence identities, meaning that proteins use different residues to obtain a similar
folding and function. Among all the related structures, 4QWP {Pseudomonas sp.
chitosanase, Lyu et al., 2015), 4CFP {E. coli transglycosylase MitC, Artola-Recolons et
oi, 2014), 5HWA (chitosanase from Bacillus circulans, Suzuki et al., unpublished) and
40YV (MItF from P. aeruginosa, Reddem et al., unpublished) have been crystallized
together with their ligand. Structure superpositions of Y3_197 with these molecules
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show that the ligands are located in the region corresponding to Y3_197 groove,
supporting that the catalytic site may be in this cavity.

Large domain

Small domain

Figure 6.11: Structural alignment between Y3_197 and structurally-related proteins co
crystallized with ligand. Alignment of 4QWP {Pseudomonos sp. chitosanase, crystallized
with NAG4, shown in yellow., 4CFP (E. coli transglycosylase MItC crystallized with NAGNAM-NAG-NAM, shown in blue) and 5HWA (chitosanase from Bacillus circufans,

crystallized with NAG4, shown in pink) with Y3_197 shown as green cartoon and cyan
surface. The ligands fit in the hypothetical catalytic groove of Y3_197. Figure generated
in PyMOL (Delano, 2002).

One of the molecules which Y3_197 was superposed to was T4 lysozyme (2LZM,
Weaver et al., 1987). T4 lysozyme has been studied in depth during years and
exhaustive mutational analyses have been performed to infer the function of every
residue (Rennell et ol., 1991). This enzyme is an inverting glycoside hydrolase. A
nucleophilic water, activated by the general base Asp20 attacks the p-(1^4) linked
anomeric Cl carbon of the peptidic NAM, while the general acid Glull donates a
proton to the leaving aglycone, NAG. Mediated by hydrogen bonds, Thr26 assists on
the positioning of the water that will perform the nucleophilic attack near Asp20
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(Kuroki et oi, 1995). Y3_197 shows the same residues in the same position,
coincident with all the structurally-related molecules superposed to it. Table 6.6
shows the residues involved in catalysis in these enzymes, proving that they are very
conserved and important for the function of these enzymes. In Y3_197, the general
acid is GlulS located in helix al, the catalytic base is Asp29 from loop A and the
residue helping to position the nucleophilic water is Thr34 from strand (32.
Table 6.6; Residues involved in catalysis in several glycosyl hydrolases
PDB

Catalytic acid

Catalytic base

Water positioning
residue

Y3_197

Glul8

Asp29

Thr34

2LZM

Glull

Asp20

Thr26

2NR7

GlulS

Asp24

Thr29

4QWP

Glu25

Asp40

Thr48

5HWA

Gln37

Asp55

Thr60

6ET6

Glu64

Asp73

Thr79

4ZPU

Glu35

Asp44

ThrSO

3HDE

Glu35

Asp44

ThrSO

21KB

Glul6

Asp25

Thr30

ICHK

Glu22

Asp37

Thr45

An analysis of the B-factors of Y3_197 shows the thermal agitation of different parts
of the protein (Figure 6.12). In molecule A, loop A has high temperature factors. The
same happens with the C-terminal part of helix a8 and the loop connecting helices
a8 and a9. In molecule B, these regions do not show a significant mobility, because
they are stabilized by crystallographic interactions with symmetrically-related
molecules. These specific regions are probably the parts of the protein closing or
capping the catalytic groove. It is possible that they might ''open'' to allow the
entrance of the substrate in the groove and then they must "close" it to allow the
approaching of Asp29, located in the loop A, to Glul8, positioned in helix al, hence
hydrolysing the (3-(1^4)-glycosidic bond between the MurNAc and the GInNAc.
Structural alignments with related molecules support this hypothesis. From the
molecules shown in Table 6.5, all but one showed the catalytic residues in the same
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conformation and approximately the same distances. I will call this state "closed
conformation". But, contrary to the rest, the secretion activation protein from
Porphiromonas gingivalis

(2NR7, Tan

et aL,

unpublished) shows an

open

conformation (Figure 6.13A). In this protein, the p-strand 3, the a-helix 2 and the
3io-helix 2 are totally unfolded, forming a disordered loop. This means that the
(3-hairpin composed by strands (31 and P2 connected by the loop A moves away from
the catalytic groove. As a result, the groove is free for the substrate to enter, but the
catalytic residues are too far from each other, with the catalytic acid GlulS and the
catalytic base Asp24 almost 30 A apart and unable to perform any catalysis. Even the
loop connecting helices a8 and a9 moves apart from the catalytic groove.

Loop C

Molecule B
20

Molecule A

120

Figure 6.12: Y3_197 thermal agitation. Helix a9, loop A and loop B show the largest

thermal agitation of Y3_197. Figure generated with PyMOL (Delano, 2002).

On the contrary, the rest of the enzymes analysed, including Y3_197, show a closed
conformation, with the distances from the catalytic acid to the catalytic base varying
between 7 and 17 A. My hypothesis for this fact is that this kind of enzymes shows
two different conformations. In the open conformation, the (3-hairpin formed by (3strands 1 and 2 together with the loop A moves away from the catalytic groove. The
loop connecting a-helices 8 and 9 also moves away to facilitate the entry of the ligand
to the catalytic pocket. Once the substrate is bound, this loop moves back closer to
the catalytic groove and the (3-hairpin formed by strands (31 and (32 and the loop A
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moves closer to the groove, interacting with P-strand 3 to form a p-sheet that fixes
the residues in the proper place. This conformational change promotes the correct
geometry and distances between the catalytic residues to perform the hydrolysis of
the peptidoglycan (Figure 6.13B).

B

lul5

Figure 6.13: Open and closed conformation of Y3_197 structurally related proteins. A)

Open conformation observed in secretion activation protein from Porphiromonas
gingivolis (2NR7, cyan). The distances and geometry between the catalytic residues do
not allow catalysis. B-C) Structural comparison between Y3_197 loop A (yellow, closed
conformation) and 2NRY (cyan, open conformation). Figure generated with PyMOL
(Delano, 2002).

Another area with high temperature in both molecules, is loop C. This loop is absent
in most Y3_197 structurally-related proteins. Only the secretion activation protein
from Porphiromonas gingivalis (2NR7) and a hypothetical protein from Neisseria
meningitidis (21KB) have a similar but much shorter loop. This loop is located in the
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predicted peptidoglycan-binding domain 3 (IPR018537). This fact, together with the
high flexibility of this region, might indicate that this loop is the cell wall binding
region of the protein, used to recognize the peptidoglycan. The loop forms a small
slightly positively-charged tunnel where a PEG molecule and a sulphate ion are
located, maybe mimicking the natural ligand of this pocket. Inner residues involved
in the shape of this cavity are conserved (Figure 6.14).

Figure 6.14: Properties of loop C and the channel it forms. A-B) Degree of conservation
of the residues forming the loop, with the most conserved in purple and the most variable
in cyan. C) Inner view of the channel, with a glycerol molecule (green) and a sulphate ion
(yellow) represented in sticks. D) Electrostatic potential surface. Residues coloured in red
are negatively charged an those in blue positively charged. Figure generated with PyMOL
(DeLano, 2002).
Regarding the rest of the ligands crystallized with the protein, since the molecules are so
close to their symmetry-related molecules, establishing interfaces with them, the interaction
of Y3_193 with its ligands and those from neighbour symmetric molecules were analysed,
not finding any ligand that could interact with the catalytic residues (Figure 6.15).
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Molecule B

Molecule A

4

Figure 6.15: Ligands and solvent molecules found in Y3_197 structure. Ligands from the

asymettric unit (green) and from the symmetrically-related ones (white) where analized.
With the exception of a glycerol molecule and a sulphate ion located in the cavity formed
by loop C, any of the remaining ligands is located in a known catalytic site (purple sticks).
Figure generated with PyMOL (DeLano, 2002).

To

summarize,

Y3_197

is

probably

a

muramidase

that

hydrolyses

the

(3-(l->4)-glycosidic bond between the MurNAc and the GInNAc. It is formed by two
domains, a big a-domain and a small P-domain. In between these domains, a narrow
closed catalytic groove is formed. To allow the entry of the substrate, the p-domain
partially unfolds and moves away from the site where the groove is located (Figure
6.16A and B). During this stage, catalysis is not possible because the catalytic residues
are not at the required distances and their geometry and orientation is not suitable
for it. Once the substrate enters into the cavity, the p-domain refolds back and moves
towards the groove, reconstituting the catalytic site (Figure 6.16C and D). This site is
formed by GlulS, Asp29 and Thr34. A water molecule activated by the catalytic base
Asp29 and held in place by interactions with Thr34, performs a nucleophilic attack on
the P-(1^4)-linked anomeric Cl carbon of the MurNAc. The catalytic acid GlulS
donates a proton to GInNAc, the leaving aglycone (Figure 6.17). Then, the p-domain
unfolds to allow the exit of the cleaved peptidoglycan (Figure 6.16E) and to be ready
for the entry of a new substrate.
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A

B
D29

D29

T34

T34

Figure 6.16: Putative conformational changes in Y3_197. A) Y3_197 open conformation.
The 3-domain (blue) partially unfolds and moves away from the groove to allow the entry
of the substrate (a polymer of GInNAc and MurNAc, in white). B) The substrate enters in
the groove and the 3-domain refolds back to its original location. C) Y3_197 closed
conformation. D) Y3_197 closed conformation. The catalytic residues are located at a
distance that allows the cleavage of the link between MurNAc and GInNAc. E) After
catalysis, the 3-domain (blue) unfolds again and Y3_197 adopts an open conformation,
allowing the exit of the cleaved peptidoglycan and the entry of a new substrate to repeat
the process. Figure generated with PyMOL (DeLano, 2002).
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Figure 6.17: Catalytic site of Y3_ 197 inside the groove. The catalytic general acid (Glul8)
and general base (Asp29) are shown in green. Thr34 (yellow) helps to position a water
molecule that will perform a nucleophilic attack on the 3-(1^4)-glycosidic bond upon
activation by the Asp29. Conserved residues are shown in purple. Figure generated with
PyMOL (Delano, 2002).
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7 Crystallization of CHAPk endolysin from
staphylococcal phage K and its mutant
C54A with a ligand
7.1 Characterization of CHAPk
Bacteriophage K is a virulent phage that infects a wide range of staphylococci,
including multi-drug-resistant Staphylococcus aureus (MRSA). It codes for the
endolysin LysK to allow its progeny to escape from the cell once the virions have been
assembled. The structure of CHAPk, the Cysteine-Histidine dependent Amido
Peptidase/Hydrolase of LysK has been elucidated (Sanz-Gaitero et ai, 2013; SanzGaitero et al 2014; Keary et ai, 2016). Although the amino-acids participating in the
active centre were identified (Cys54, Hisll7 and Glul34) and solvent molecules were
found which may mimic the peptidoglycan, it was necessary to determine the amino
acids involved in the recognition and binding of the substrate, the location of the
substrate in the catalytic groove and the distances with the catalytic residues, in order
to understand the catalytic mechanism.

To solve these questions, the protein should be crystallized with a peptidoglycan
analogue. CHAPk cleaves the link between the pentaglycine bridge and the D-Ala from
the peptide bridge of 5. aureus peptidoglycan. Due to this, it was decided to crystallize
the protein with triglycine (3x-Gly), pentaglycine (5x-Gly) and Gly-D-Ala. The inactive
mutant C54A should also be crystallized with these ligands to detect any differences
in the binding and/or cleavage of the peptidoglycan. The protein molecular weight is
19.3 kDa, including the histidine tag, and 18.5 kDa without it. The predicted pi of the
protein is 9.3.

7.2 Purification of CHAPk C54A mutant
Wild type protein with a C-terminal hexahistidine tag was cloned in pQE60 vector by
Marianne Horgan (Dr. Olivia McAuliffe's group, Teagasc, Moorepark Food Research

177

Crystallographic structure determination of bacteriophage-encoded enzymes that specifically
target pathogenic bacteria

Centre, Fermoy, Ireland) and purified by Dr. Ruth Keary (Prof. Aidan Coffey's
laboratory. Department of Biological Sciences, Cork Institute of Technology, Ireland).
CHAPk (C54A) mutant for the catalytic residue , containing a C-terminal hexahistidine
tag, was expressed at 16 °C and at 37 °C in XLl-Blue cells. Pellet and supernatant
fractions were analysed by SDS-PAGE determining that CHAPK (C54A) was soluble
and expressed equally at both temperatures, so it was decided to express it at 37 °C
for convenience. However, two bands were observed. This might be due to partial
proteolysis of the unstable C-terminal His-tag (Figure 7.1).

19 kDa
18 kDa

Figure 7.1: CHAPk(C54A) expression trial. CHAPk SDS-PAGE showing expression levels of
the protein at 16 °C (left) and 37 °C (right). Both pellet (P) and supernatant (Sn) show two
bands with molecular weights compatible with the ones of CHAPk with and without Histag, meaning that at least part of the protein is soluble, but the His-tag is not very stable.
The molecular weight ladder and the protein samples belong to the same polyacrylamide
gel.

Four 1 L cultures of XLl-blue cells expressing CHAPk (C54A) were grown at 37 °C. Cells
were lysed, and an affinity chromatography was performed on the supernatant.
Relatively pure protein was obtained in fractions eluted with 50-350 mM imidazole.
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Some protein was lost in the flow-through, probably the one that had lost its His-tag
before running the IMAC (Figure 7.2).
W

kDa

FT

50
MW

150
100

250

200

350

300

500

400

P

1000

[mM Imidazole]

116
66

45
35
25

18.5 kDa
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Figure 7.2: CHAPk{C54A) IMAC purification. CHAPk SDS-PAGE showing flow-through (FT),

wash (W), molecular weight marker (MW), elution fractions 50-1000 mM imidazole and
pellet (P). A protein band compatible with the size of the protein is observed. Some
unbound protein can be observed in the FT fraction.

Fractions containing the protein (50 and 350 mM imidazole) were pooled together.
Based on the protein predicted high pi, it was decided to purify the protein further
by cation exchange chromatography. The protein was dialyzed to remove the
imidazole and change the buffer, no aggregation was observed.
A cation exchange chromatography was performed, obtaining a single peak at a
concentration of 0.58 M NaCI (Figure 7.3A). The peak contained protein with a
molecular weight compatible with the one of CHAPk(C54A). Two bands were again
observed, probably with and without the histidine tag. (Figure 7.3B) The protein was
desalted and concentrated to 16 mg/mL (0.9 mM). Its purity was checked by SDS
page, showing a single protein band at 18 kDa compatible with CHAPk without
histidine tag (Figure 7.3C). Crystallization experiments were performed without
delay.
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Figure 7.3: CHAPk{C54A) cation exchange chromatography. A)CHAPk C54A cation
exchange chromatogram showing a single peak eluted at 0.58 M NaCI, corresponding to
fractions 30 and 31. B) SDS-PAGE of fractions 30 and 31, showing that both fractions
contain two protein bands, whose sizes correspond with the molecular weight of CHAPk
C54A with (19.3 kDa) and without His-tag (18.5 kDa). The molecular weight ladder and
the protein samples belong to the same polyacrylamide gel. C) SDS-PAGE showing CHAPk
C54A after concentration. A single band, compatible in size with the non-tagged protein
is obtained, indicating that the protein has fully auto-cleaved its His-tag. The molecular
weight ladder and the protein samples belong to the same polyacrylamide gel.
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7.3 Crystallization of CHAPk with ligands
CHAPKhad been already crystallized in the conditions 20% (vv/v) PEG 8000,0.1 M MES
pH 6.5 for the native structure and 22% (w/v) PEG 8000, 0.1 M HEPES-NaOH pH 7.5
for the methylmercury derivative structure (Sanz-Gaitero et a!., 2013), both with a
protein of 33 mg/mL (1.7 mM). During these first crystallization assays, CHAPk
showed some tendency to form multi-crystals, composed of several layers. As a first
approach, co-crystallization was attempted. As the protein cleaves the link between
the pentaglycine bridge, three different protein/ligand samples were prepared:

•

CHAPK/G!y-DL-Ala: 1:5 ratio. 0.4 mM CHAPk and 2 mM Gly-DL-Ala.

•

CHAPK/3x-Gly: 1:5 ratio. 0.4 mM CHAPKand 2 mM 3x-Gly.

•

CHAPK/5x-Gly: 1:1 ratio. 0.4 mM CHApKand 0.4 mM 5x-Gly.

Crystallization experiments at 20 °C were performed using CombiClover plates
(Molecular Dimensions), a volume of 150 pL of precipitant solution in the reservoir
and drops containing 2 pL of the mix protein/ligand previously prepared and 2 pL of
the reservoir conditions. The conditions used were exactly the same from the
optimization screening used to crystallize the protein without the ligand in SanzGaitero et al. 2013 (14-24% PEG 8000 and 0.1 M of different pH buffers ranging from
6.5 to 10.5). Because no crystals were obtained, the same crystallization conditions
were assayed but without the ligands, to try to obtain only protein crystals to soak in
different ligands afterwards. The plate used was a Cryschem plate (Hampton
Research) and the concentration of protein used was 0.4 mM (11.5 mg/mL).
However, no crystals were obtained.
The reason for this could be the low protein concentration. The first time the protein
was crystallized, the protein concentration was 33 mg/mL, being this time
11.5 mg/mL. To check if this was the case, the same conditions were assayed in a
CombiClover plate (Molecular Dimensions), using a protein concentration of
41 mg/mL (2.2 mM). In this case, the protein forms sea urchin-shaped crystals,
instead of single crystals.
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Therefore, the behaviour of the crystal growth strongly depended on the
concentration of the protein. Under the same conditions (14-24% PEG 8000 in 0,1 M
of buffers at pH 6.5-10.5, 20 °C, 150 pL of reservoir volume and 2 pL protein + 2 pL
precipitant drops), at a protein concentration of 11.5 mg/mL crystallization does not
occur, at 33 mg/mL large plate-shaped multi-crystals are formed and at 41 mg/mL
sea-urchin shaped multi-crystals grow. To try to optimize the protein concentration,
an additional crystallization experiment was set up using the same conditions but at
a protein concentration of 20 mg/mL. No crystals were obtained. Crystallization
experiments with the protein at high concentration (20 and 41 mg/mL) in the same
conditions but at 4 °C were set up to try to slow down the crystallization and to get
single crystals instead of stacked plates. However, no improvement was observed.
Seeding was also tried, crushing multi-crystals grown in high protein concentrations
(41 mg/mL) and transferring them to the plates with lower protein concentrations
(11 mg/mL), with the aim of acting as nuclei to induce the crystallization. No crystals
were obtained by this method.
At this point, CHAPk sample from a different purification was used as a control to
check if the protein behaved differently due to degradation during storage or thawing
or any other variable. Crystallization experiments using both wild type and CHAPk
(C54A) mutant, obtained in different purifications, were performed in Swissci MRC
Maxi plates (Molecular Dimensions) with 50 pL of reservoir condition and drops with
1 |iL of protein sample and 1 pL of reservoir condition. The protein concentration was
20 mg/ mL for the WT protein and 16 mg/mL for the mutant. The experiment was set
up at 20 °C and, in addition to the gradient of 14-24% PEG 8000 in 0.1 M buffer
pH 6.5-10.5, conditions containing 16-24% PEG 2000 in 0.1 M Tris-HCI buffer pH 6.8
and conditions containing 22% PEG 8000, 0.1 M HEPES-NaOH pH 7.5 or 20% PEG
8000, 0.1 M MES pH 6.5 and a gradient from 0 to 20% glycerol were tried.
Sea urchin-shaped crystals were obtained after one day, but only for the WT protein.
This may mean that the protein crystallization is strongly dependent on the protein
concentration WT was concentrated to 20 mg/mL and mutant C54A to 16 mg/mL),
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that the small differences in purification affect the crystallization or simply that the
mutation affects the packing of the protein.
The best crystal of wild type CHAPk was obtained in a condition containing 20% PEG
8000 and 0.1 M MES pH 6.5. Optimization was tried using an additive screen to
improve the crystal shape. A plate with reservoir containing 50 pL of 20% PEG 8000
and 0.1 M MES pH 6.5 supplemented with 100 pL of different additives was set up
(Table 7.1), with 0.5 + 0.5 pL protein drops at a concentration of 20 mg/mL and
10 mg/mL.

Table 7.1: Additive kit used to optimize CHAPk crystals
Additive

Concentration

Barium Chloride

0.1 M

Cadmium Chloride

0.1 M

Calcium Chloride

0.1 M

Copper Chloride

0.1 M

Cobalt Chloride

0.1 M

Magnesium Chloride

0.1 M

Manganese Chloride
Strontium Chloride

0.1 M
0.1 M

Barium Chloride

0.1 M

Zinc Chloride

0.1 M

Ferric Chloride

0.1 M

Nickel Chloride

0.1 M

Ammonium Sulphate

1 M

Potassium Chloride

1M

Lithium Chloride

1M

Sodium Chloride

1M

Sodium Fluoride
Sodium Iodide

0.5 M
0.5 M

Sodium Tartrate

2M

Sodium Citrate

1M

Caesium Chloride

1M

DMSO

30%

Glycine

1M

Spermine

0.1 M

Betaine

0.1 M
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Crystallization from scratch, using the crystallization kits JBScreen Classic 1-10, PiMinimal and JBS PEG/Salt 1 and 2 (Jena Biosciences, Germany) with both the mutant
and the wild type protein was also assayed.
After few weeks, large plate-shaped crystals grew in conditions containing 20% PEG
8000 in 0.1 M MES pH 6.5 and 0 (Figure 7.4A) or 5% glycerol (Figure 7.4B), being the
protein concentration 20 mg/mL. Since this crystallization condition was quite similar
to the one in which the protein was crystallized for the first time, the reasons for the
previous unsuccessful attempts to reproduce the crystals might have been small
differences during the purification, undetectable differences in the protein quality,
differences on protein or buffer concentration or, since nucleation is a stochastic
process, more drops should have been set to increase the probability of obtaining a
hit.
The crystals obtained in the condition with 20% PEG 8000 in 0.1 MES pH 6.5 were
soaked with 5x-Gly. 0.5 pL of 5x-Gly at a 2.74 mM concentration were added to the
2 pL drop (final 5x-Gly concentration 0.55 mM) and incubated for different times
(5-30 min). The crystals obtained in the condition with 20% PEG 8000 and 5% glycerol
in 0.1 M MES pH 6.5 were soaked with 3x-Gly. 0.5 pL of 3x-Gly at a 352 mM
concentration were added to the 2 pL drop (final 3x-Gly concentration 70 mM) and
incubated for different times (5-30 min). There were no crystals available to incubate
with Gly-DL-Ala.
The crystals were collected in liquid nitrogen and frozen, but no cryoprotectant was
used, with the exception of the 5% glycerol present in the crystallization condition
used in 3x-Gly soaking. The reason not to cryoprotect was that with soaking, the inner
structure of the crystal suffers, as it happens with cryoprotection. Since there were
only two drops with crystals, I decided not to add any cryoprotectant that might
damage the crystals, despite the increased probability of obtaining ice rings in the
diffraction pattern during X-ray diffraction.
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Figure 7.4: Wild type CHAPk crystals. A) CHAPk plate-shaped crystals grown in 20% PEG
8000 and 0.1 M MES-NaOH pH 6.5, used for soaking with pentaglycine. B) CHAPk plate
shaped crystals grown in 20% PEG 8000, 0.1 M MES-NaOH pH 6.5 and 5% glycerol used
for soaking with triglycine. C-l) Typical multicrystals obtained during CHAPk purification.

7.4 Structure determination of CHAPk with triglycine.
These frozen crystals were taken to BL13-XALOC (ALBA synchrotron, Cerdanyola del
Valles, Spain; Juanhuix et oL, 2014). Some of them diffracted, but only one obtained
in 20% PEG 8000, 0.1 M MES pH 6.5 and 5% glycerol, soaked for 5 min in 3x-Gly
(Figure 7.5), generated a pattern useful for structure determination. The rest of the

185

Crystallographic structure determination of bacteriophage-encoded enzymes that specifically
target pathogenic bacteria

crystals taken to the synchrotron showed ice damage and low diffraction probably
caused by internal crystal damage during the soaking. In few cases, multiple
overlapped diffraction patterns were obtained, due to the difficulty in separating
stacked plates into single crystals.

B

Figure 7.5: Data collection of CHAPk soaked with triglycine. A) Crystal grown in 20% PEG
8000, 0.1 M MES-NaOH pH 6.5 and 5% glycerol, soaked for 5 min in 3x-Gly, ready for data
collection. B) Diffraction pattern of the crystal in panel A.

The different diffraction patterns obtained from wild type CHAPk crystals were
indexed, integrated and scaled. The best crystal diffracted at a resolution of 1.66 A,
belonging to the space group P2i with unit cell parameters a = 39.4

A,

b = 61.6 A,

c = 73.78 A, a = y = 90°, (B= 98.2°. These parameters are very similar to the ones of
the native crystal used to determine CHAPk structure back in 2013 (Sanz-Gaitero et
oi, 2013), being the main difference that the space group is P2i for the new data for
the molecule soaked with triglycine, instead of the PI in the old native crystal.
Therefore, the symmetry of the new crystal is higher. Table 7.2 shows the data
collection statistics of both the original native data and the crystal soaked with
triglycine. Matthews coefficient was 2.4AVDa, suggesting the presence of two
monomers per asymmetric unit and 48 % of solvent. The number of molecules per
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asymmetric unit in the native crystal that allowed to solve the structure was four,
which makes sense considering the absence of the two-fold screw axis.
Table 7.2: CHAPk diffraction statistics.
Parameter
Space group
0,

CHAPk Native

CHAPk + Triglycine

(Sanz-Gaitero et al, 2013)
PI

P2i

b, c (A)

39.2, 61.5, 73.2

39.4, 61.6, 73.8

a, P, Y (°)
Wavelength

91.5, 98.7, 90.1

90.0, 98.2, 90.0

0.87290

0.97918

ESRF, ID23-2

BL13 (ALBA)

Temperature (K)

100

100

Resolution (A)
No. of reflections

36.53-1.79 (1.88-1.79)

73.00-1.66 (1.75-1.66)

116,355 (5,607)

243,671 (25,415)

60,396 (3,112)

39,747 (5,189)

(A)

Beamline

Total
Unique
Mn(l/ol)
i^pim

Completeness (%)
Multiplicity

6.3 (2.9)

14.4 (3.8)

0.082 (0.391)

0.058 (0.422)

97.2 (94.3)

96.7 (86.8)

2.0 (1.9)

6.1 (4.9)

*The values in brackets belong to the highest resolution shell.

Although the cell parameters were very similar, it was not possible to use the old
native structure to perform a direct refinement on the new dataset due to the
differences in the space group. Therefore, the phases of the new dataset were
determined by molecular replacement using the old native structure as model (PDB
code4CSH).

Several rounds of data refinement and manual model building were performed until
the Rworkand Rfree converged. The final refinement R factors were Rwork= 0.18 and Rfree
= 0.22. Table 7.3 shows the statistics of CHAPk refinement stage. The percentage of
favoured rotamers and Ramachandran residues, as well as the distances and bond
RMSD values and temperature factors, are all reasonable.
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Table 7.3; CHAPk with triglycine refinement statistics.
Parameter

CHAPk

Resolution (A)

73.00- 1.66
0.175/0.215

Rwork/Rfree

No. atoms (not H)
Protein (not H)
3x-Gly
Tris
Glycerol
Calcium ion
Ethanediol
Waters
Wilson B factor (A^)
Average B, all atoms (A^)
Bond RMSD
Distances (A)
Angles (°)
Ramachandran (%)
Favoured
Outliers
Rotamers (%)
Favoured
Bad

2658
26
16
18
2
8
469
11.7
11.5
0.010
1.625
98.46
0
97.15
0.7

7.5 Structure analysis.
The CHAPk protein consists of a single globular domain showing a papain-like fold,
that contains two a-helices, two 3io-helices and six (3-strands (Sanz-Gaitero et al.,
2014; Figure 7.6B and C). The N-terminal part of the protein consists of the two
a-helices interconnected by a long loop that borders a groove in the protein, at the
bottom of which the catalytic site is located (Sanz-Gaitero et al., 2014). The CHAPk
protein has a relatively long and deep hydrophobic groove, where MES and HEPES
molecules were co-crystallized, perhaps mimicking the peptidoglycan substrate of
the protein (Figure 7.6D). The protein contains a calcium ion bound to an "EF-handlike" motif located in the N-terminal part of the protein, involving residues from the
long loop connecting the first and second a-helices and Asp56 in the second a-helix.
It is bound in a monodentate way to the side chain of residues Asp45 and Asp47 and
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in a bidentate way to both oxygen atoms of the Asp56 side chain. It is also bound to
the main chain oxygen atoms of Tyr49 and HisSl and a structural water molecule
(Figure 7.6E).

The catalytic triad of CHAPk is formed by Cys54, located in the second a-helix, Hisll7
in the third (3-strand and Glul34 in the fourth (3-strand (Figure 7.6F). Mutating Cys54
or Flisll7 to Ala results in a total elimination of staphylolytic activity, while mutating
Glul34 strongly reduces the catalytic activity. A mutation to alanine of those residues
whose side chain is involved in calcium coordination (Asp45, Asp47 and Asp56)
resulted in the complete abolishment of the staphylolytic activity of the enzyme
(Sanz-Gaitero et ai, 2014).

Groove

Figure 7.6: Structure analysis of native CHAPk. A) CFIAPk plate-shaped crystals. B) CHAPk
overall structure. C) Topology scheme showing a-helices in blue, 3io-helices in red and
(3-strands in yellow. D) Protein surface view, showing the catalytic groove and a MES
molecule in it. E) Residues coordinating calcium binding. F) Catalytic triad (Cys54, Hisll7
and Glul34). Figure adapted from Sanz-Gaitero et oL, 2014.
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In the new crystal form, there are two protein molecules (A and B) in the asymmetric
unit. Two triglycine, two Tris, three glycerol, one ethanediol, 469 water molecules
and two calcium ions were also found (Figure 7.7A). The overall structure of CHAPk
crystallized with triglycine does not show strong variations compared with the
previous structures obtained in the past (native, 4CSH, and methylmercury
derivative, 4CT3). As in the native structure (Sanz-Gaitero et al., 2014), a calcium ion
is found in the N-terminal part of the protein, involving residues from the long loop
connecting the two a-helices and Asp56 in the second a-helix.
The CHAPk protein contains a long and deep hydrophobic groove. In the previously
solved structures of CHAPk, a MBS (PDB code 4CSH) or HEPES (PDB code 4CT3)
molecule was found inside this groove, perhaps mimicking the peptidoglycan
substrate of the protein. Before starting the crystallization experiments of CHAPk in
presence of ligands, these were expected to bind to the aforementioned groove.
Surprisingly, we did not find any triglycine or MES molecule in this area. However, we
did find a glycerol molecule located in the groove in both A and B molecules and an
ethanediol molecule in chain B (Figure 7.8A).

B

A

Molecule B
Figure 7.7: Overall structure of CHAPk soaked with triglycine. A) Contents of the
asymmetric unit. The two protein molecules are represented as cartoon and surface.
Triglycine, Tris, ethanediol and glycerol molecules are represented as sticks, being the
Ca^^ shown as black spheres. B) Monomer of CHAPk with ligands shown as sticks, a-helices
and 3io-helices are coloured in blue and red respectively. (3-strands are coloured in yellow.
Figure generated with PyMOL (DeLano, 2002).
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The glycerol molecule interacts through hydrogen bonds with the sulphur atom of
Cys54, the oxygen from the side chain of Asn75 and the nitrogen atoms from the
main chains of Ala76 and Gln55. The ethanediol molecule interacts with the oxygen
in the side chain of Gln53. TrpllS may establish some contacts with the ligands
through hydrophobic interactions (Figure 7.8B-D). In addition, all these molecules
interact with Cys54, one of the residues from the catalytic triad (Cys54, Hisll7, Glu
134), hence this glycerol and this ethanediol could be the mimicking the substrate
(Figure 7.8E and F).
The absence of binding of the triglycine molecules to the catalytic groove can mean
that even though CHAPk cleaves the link between the last glycine from the
pentaglycine link and the D-Ala from the stem peptide of the peptidoglycan (Figure
2.22), the pentaglycine bridge is not recognized and bound by the catalytic groove. It
is possible that the peptidoglycan part recognized by the groove is the stem peptide
(L-Lys-L-Ala-L-Lys-D-Ala) or simply that the link between Gly and D-Ala is necessary
for the molecule recognition and binding. To confirm these hypotheses, it is
necessary to crystallize the protein with Gly-D-Ala and with an analogue of the stem
peptide. Another possibility could be that the glycerol and the ethanediol are
competing with the triglycine for the binding to the active site, and the presence of
hydroxyl groups in these compounds makes the competition more favourable for
them.
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r

,

Figure 7.8: CHAPk catalytic groove. A) Superposition of CHAPk ligands crystallized in the
groove from different crystals. The native crystal (4CSH) contains a MBS molecule
(magenta sticks) and a Zn^'' atom (magenta sphere) in the groove. The methylmercury
derivative (4CT3) shows a HEPES molecule (yellow sticks) and a Cl ion (Yellow sphere).
The crystal soaked with triglycine contains a glycerol and an ethanediol molecule (green
sticks). B) Residues interacting with the glycerol (GOL) and ethanediol (EDO) located in
the catalytic groove and stabilized by hydrogen bonds (yellow) and hydrophobic
interactions (magenta). C-D) Schematic visualization of ethanediol (EDO) and glycerol
(GOL) binding sites. These panels were created with Ligplot+ (Laskowski et al., 2011). E)
CHAPk catalytic triad. F) Location of glycerol (yellow) and ethanediol (green) relative to

the catalytic triad (magenta). Panels A, B, E and F were generated with PyMOL (DeLano,
2002).
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The triglycine molecule was found in a different and unexpected part of the CHAPk
protein. It was located in the region comprised between the loop connecting
(3-strands 1 and 2, the loop connecting (3-strands 3 and 4 and the loop connecting
(3-strands 5 and 6. Since the triglycine was found far from the catalytic groove,
additional tests were performed to assess the presence of the molecule at that
specific location, discarding bias induced by over-refinement. Some facts indicate
that the triglycine molecule is present in that location.
1. A positive density with a shape compatible with triglycine can be observed in
the difference map

(Fobs-Fcai)

just after molecular replacement, before even

building the 3x-Gly. This density remained invariant for several refinement
cycles in absence of the ligand (Figure 7.9A).
2. The density was found in both crystallographically independent protein
molecules in the same area and with equivalent interactions.
3. After building the triglycine molecule and refining the structure, the B-factors
of those triglycine atoms close to the protein were about 10 A^, similar to the
ones of the protein residues.
4.

If the ligand molecule is removed from the model and an omit map is
generated, density in the

2Fobs-Fcai

map is observed at that location (Figure

7.9B).
The triglycine molecule interacts through hydrogen bonds with the oxygen in the
main chain of Lys94 and Thr97 from the loop connecting (3-strands 1 and 2, with the
oxygen of the carbonyl group in the main chain of Thrl27, located in the loop
connecting (3-strands 3 and 4, and with the oxygen and the nitrogen atoms in the side
chain of Asn93, located in the loop connecting (3-strands 1 and 2. Pro95 from the loop
connecting p-strands 1 and 2 and Tyrl52 from the loop connecting p-strands 5 and 6
could be also interacting with the ligand through hydrophobic interactions (Figure
7.9Cand D) .
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Thrl27

()

N

Lys94

GGG

d

Figure 7.9: CHAPk triglycine binding site. A) Difference map (Fobs-Fcai) generated just after
molecular replacement shows a positive density area (green), compatible with the shape
of triglycine. Panel generated with Coot (Emsiey et al., 2004). B) Omit map

(2Fobs-Fcai)

around the triglycine molecule. Panel generated with PyMOL (DeLano, 2002). C) Amino
acids involved in triglycine binding (yellow) through hydrogen bonds (green) and
hydrophobic interactions (magenta). Panel generated with PyMOL (DeLano, 2002). D)
Diagram showing triglycine (GGG) binding site. Generated using Ligplot-i- (Laskowski et al.,
2011).

The triglycine molecule is located near a highly conserved area of the protein (Figure
7.10A). From the residues interacting with the ligand directly, only Asn93 and Tyrl52
are strongly conserved. This correlates with the fact that these residues are the only
ones interacting with the triglycine through their side chains, while the rest of them
interact with their main chains (Figure 7.11B).
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Catalytic groove

Secondary groove

Figure 7.10: CHAPk triglycine binding site conservation. A) 3x-Gly (yellow) is located in a
highly conserved (purple and pink) area far from the catalytic groove. B) The residues
interacting with triglycine (yellow) through hydrogen bonds, as well as the hydrophobic
residues, are strongly conserved (purple and pink). Figure generated using PyMOL
(DeLano, 2002)

The highly conserved pocket where the triglycine ligand was crystallized, far from the
catalytic groove, suggests that this pocket acts as a secondary ligand receptor.
Peptidoglycan is a very complex structure. While the catalytic groove recognizes
some part of the peptidoglycan (probably the stem peptide) and cleaves the Gly-DAla bond, this secondary site could be recognizing another peptidoglycan bridge,
attaching the protein at the optimum region to act. To prove this hypothesis the
protein should be crystallized with both a stem peptide (L-Lys-L-Ala-L-Lys-D-Ala)
analogue or Gly-D-Ala and with pentaglycine. These structures would allow to
determine the binding sites for every peptidoglycan moiety. If any of these ligands
bind to the catalytic groove, then the crystallization of the C54A mutant in the same
conditions should be assayed to check whether the absence of the catalytic cysteine
impairs the recognition and binding of the peptidoglycan substrate.
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Finally, a Tris molecule was found in an exposed and non-conserved area near Argil.
Due to the lack of conservation of the residues in this area, this binding might be
simply a crystallographic artifact, not mimicking any natural ligand of CHAPk.
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8 Crystallization of lytic proteins from
staphylococcal phage DW2
Bacteriophage DW2 is a siphovirus that lyses several 5. aureus strains that cause
bovine mastitis. It also shows weak lytic activity on 5. aureus strains causing human
infections, some of them methicillin-resistant. DW2 phage codes for two different
peptidoglycan hydrolases, a multidomain endolysin named LysDW2 and a tail
hydrolase called THDW2.

8.1 Characterization of THDW2 and CHAPthdwz
DW2 phage tail hydrolase (THDW2) is a 564-residue protein. According to the
Conserved Domains Database (CDD; Marchler-Bauer etal., 2011) it has two domains:
a C-terminal lysozyme 2 (Lyz_2) domain (residues 413-559) and a truncated
N-terminal CHAP (residues 2-86) domain.
THDW2 is coded by ORF60 and ORF61. According to their sequence, these ORF should
only code for a 36 residues protein, because they present a stop codon after the
nucleotide 108. By doing a sequence alignment with its closest protein homolog,
gp61 from S. aureus phage cpMRll with 94.8% amino acid sequence identity, it was
clear that THDW2 had a 349 bp insertion, changing the reading frame and disrupting
the protein (Figure 8.1). It was decided to clone the gene avoiding the insertion, to
be able to produce a functional tail hydrolase protein (Keary et al., 2014).
ORF61 (l,875bp)
LysozYme 2 (l,417-l,857bp)

CHAP (61-438bp)

(t>MRll

DW2
349bp
ORF60(lllbp)

ORF61 (l,695bp)
THDW2 (l,776bp)

Figure 8.1: Comparison of ORF61 from cpMRll and ORF60/61 from DW2. A 349 bp
insertion can be observed in the N-terminal part of THDW2 sequence. Figure from Keary
etai, 2014.
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Doing a search for the closest-related proteins, it can be noticed that a gene with a
94% homology and 100% query coverage (including the insert) is present in the
chromosome of several S. aureus strains (MOK042, Ch21, Ch22, TUM9463, TUM9458,
FORC_062, FORC_027, NCCP14558, BN75). In the chromosomes of several other 5.
aureus strains and in several other phages, the sequence can be found without the
insertion. This could be a horizontal transference case, where the bacteria may have
acquired the tail hydrolase gene from an infecting bacteriophage, modified for
inactivation and passed to bacteriophage DW2. As a consequence, I believe that this
phage might be or might have been temperate at its origins.

Performing a search against the Protein Data Bank, we can only find structures similar
to one of the THDW2 domains, but not to the whole protein. 5. aureus autolysin (PDB
code 4PIJ) shows a 39% identity with the lysozyme 2 domain, C. perfringens autolysin
(PDB code 5WQW) has a 37% identity with the lysozyme 2 domain, and streptococcal
peptidoglycan hydrolase LytB (PDB code 4Q2W) shows a 32% identity with the same
domain. Regarding the CFIAP domain, it is similar to the 5. pyogenus phage cell-wall
hydrolase PlyPy (5UDM, 26% identity, 86% query coverage) and to the CHAP domains
of staphylococcal phages K and GH15 (PDB codes 40LK and 4CSH, 34% identity, 68%
query coverage). Tail hydrolases are often trimeric, but no sequence-related known
protein seems to be trimeric. One of the sequence related protein whose structure
had been determined was CHAPk, the CHAP domain of endolysin LysK from 5. aureus
bacteriophage K, crystallized by our group back in 2013 (Sanz-Gaitero et ai, 2013;
Sanz-Gaitero et a!., 2014). Due to the experience crystallizing this domain, a clone
was designed containing the nucleotides coding for the CHAP domain after removing
the 349 bp insertion that disrupted the protein, changing the reading frame
(CHAPthdwz).

Sequence alignment of CHAPjHDwzand CHAPKshowed that although the sequences of
these proteins are quite different, the positions for the catalytic residues are
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conserved. Cys54, HisllG and Glul34 from CHAPk correspond to Cys38, HislOO and
Aspll7 in CHAPthdwz,

so

the catalytic mechanism of both proteins could be similar

(Figure 8.2A). A secondary structure search using Phyre2 server (Kelley et oi, 2015)
predicts a protein with 4 a-helices and 8 (3-strands. Residues 1-12 and 151-169 are
predicted to be disordered, so it might be necessary to cleave them for the protein
to crystallize (Figure 8.2B).
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Figure

8.2 CHAPthdwz

sequence analysis.

A)

Secondary structure and disordered regions prediction generated using Phyre2 (Kelley et
al., 2015), showing a disordered region at the C-terminus.
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8.2 Purification of THDW2 and CHAPthdwz
Two different sequences were cloned into the plasmid pQE60 by Dr. Ruth Keary (Prof.
Aidan Coffey's laboratory, department of Biological Sciences, Cork Institute of
Technology, Ireland). The full length THDW2 without the insert was cloned between
Ncol and Bglll restriction sites without His-tag. The amino acids corresponding to the
CHAP domain without the insert were cloned between Ncol and Bglll restriction sites
with a C-terminal His-tag for purification reasons. The predicted pi and molecular
weight for the complete protein were 9.5 and 72 kDa and for the truncated CHAP
domain, 9.7 and 19 kDa.

Both plasmids were transformed into XLl-blue cells. The proteins were expressed at
16 °C for 20 h and at 37 °C for 3 h. The full-length hydrolase was totally insoluble at
both 16 and 37 °C. A refolding technique or a fusion protein, to make it more soluble,
should be tested. The CHAP domain (CHAPthdwz), however, expressed in good
amounts and it was partially soluble, being the expression higher at 16 °C than at
37 °C (Figure 8.3). The presence CHAPthdwz in the pellet of might be due not to folding
problems, but to the fact that the protein could bind somehow to E. coli
peptidoglycan and precipitated together with the cell debris. Due to this, it was
decided to continue with the purification of the CHAP domain instead of the fulllength protein.
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THDW2
Sn

p

THDW2

CHAPthdwj
Sn

Sn

P

CHAP,

P

Sn p

16 °C

37 “C

Figure 8.3: Expression test of THDW2 and CHAPthdwz at 37 °C and 16 “C. The expression
of both proteins is optimal, but THDW2 is totally insoluble at both temperatures (a protein
band appears at 72 kDa in the pellet

(P),

soluble (band at 19 kDa in both pellet

(P)

but not in the supernatant (Sn)).

CHAPthdwz

is

and supernatant (Sn)), but the expression levels

are higher at 16 °C, The molecular weight ladder and the protein samples belong to the
same polyacrylamide gel.

For large-scale expression of CHAPthdwz, four 1 L volume expressions in the same
conditions at 16 °C were performed. After lysis, the presence of the protein in the
supernatant was assessed by SDS-PAGE, before and after heating at 95 °C for 5 min,
to check it behaved as a monomer (some tail hydrolases are trimeric). There was no
difference in size between the heated and non-heated samples, checking that the
protein either was monomeric or formed trimers non-resistant to the denaturing
action on SDS.
An IMAC was performed on the supernatant, and the protein was eluted using the
imidazole concentrations shown in Figure 8.4A. Protein was obtained in the fractions
containing 50-1000 mM imidazole. These fractions were dialysed to remove the
imidazole and to change the buffer. No aggregation was observed.
A cation exchange chromatography was performed. The protein bound to the column
eluted in two different peaks, at 55% and 63% NaCI, respectively (Figure 8.4B). The
fractions

corresponding

to

those

peaks

were

pulled

and

concentrated

independently). The peak 1 (fractions 33-37) was concentrated to 13 mg/mL (0.63
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mM) and the peak 2 (fractions 39 and 40) was concentrated to 5.4 mg/mL (0.26 mM).
Crystallization experiments were set up immediately.
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Figure

8.4: CHAPthdwz

purification.

A)

SDS-PAGE run after Ni-NTA IMAC showing pellet

(P), flow-through (FT), wash (W) and fractions eluted from 50 to 1000 mM imidazole B)
Cation exchange chromatography at pH 6.1. The chromatogram shows two peaks. Both
flow through, peak 1 (fractions 33-37) and peak 2 (fractions 39 and 40) contain protein
with a size compatible with

CHAPthdwz-
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8.3 Crystallization of CHAPthdw2
Using sitting drop vapour diffusion techniques, crystallization assays were set up at
20 °C. The reservoirs of Swissci 96-well 2-drop MRC crystallization plates (Molecular
Dimensions), were filled manually with 50 pL of different crystallization conditions.
Drops containing a mixture of 0.5 pL of 3 mg/mL (0.15 mM) or 6 mg/mL (0.29 mM)
CHAPthdw2

and 0.5 pL of the crystallization solution were set by automated

techniques . More than 600 different precipitant conditions were tried. As no crystals
were obtained, this process was repeated using fresh protein at 8 mg/mL (0.39 mM),
13 mg/mL (0.63 mM) and 6 mg/mL (0.29 mM). No protein crystals were obtained.
A thermal shift assay was attempted to try to determine which additive could stabilise
the protein allowing the crystallization, but very low fluorescence signal was
obtained. Using different crystallization conditions to look for at least a preliminary
hit could have been useful, but it is possible that the protein did not crystallize due
to the disorder in both N-terminal and C-terminal region of the protein. Designing a
new clone avoiding these sequences could be the best solution to try to crystallize
this protein. Another option is a limited proteolysis using trypsin or chymotrypsin, to
try to remove the flexible loops.

8.4 CHAPthdwz structure predictions
Given the impossibility to crystallize the protein, an in silico model of the protein was
generated using RaptorX (Kallberg et oi, 2014) that provides a homology-based
three-dimensional model (Figure 8.5A).

This server has a high success rate at

predicting 3D structures for protein sequences without close homologs in the Protein
Data Bank (PDB). Given an input sequence, RaptorX predicts its secondary and
tertiary structures, contacts, solvent accessibility, disordered regions and binding
sites. Although the sequence identity with CHAPk (4CSH) was not very high (24%), the
model generated showed resemblance to it, so their structures were superposed
(rmsd 1.5). In general, the protein topology is similar to the one of CHAPk. The only
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difference is the absence of the first a-helix and the presence of an extra disordered
region in the C-terminus of CHAPthdwz (Figure
The

CHAPk

8.5B).

calcium ion binding EF-hand appears to be conserved in

and Asp47, that bind calcium in a monodentate way in
and Asp31 in

main chains in

CHAPk,

CHAPthdwz.

Asp45

correspond to Asn29

Asp56, that binds to calcium in a bidentate way in

CHAPthdwz.

corresponds to Asp40 in

CHAPk,

CHAPthdwz.

CHAPk,

Tyr49 and HisSl, binding calcium through their

correspond to Tyr33 and Gly35 in

residues are not conserved compared to the ones in

CHAPthdwz.

CHAPk,

In this case, the

but the position of the

oxygens of the main chain is. The calcium binding site of CHAPk is perfectly conserved
in the generated models, hypothesising that

CHAPthdwz

contains a calcium binding

site (Figure 8.5F). This could be determined by chelating the calcium with EDTA and
checking if the hydrolase activity decreases and then supplementing the protein with
different ions and observing if the enzymatic activity is recovered.
The catalytic triad is also conserved in the model, finding a clear correspondence
between Cys54, Hisll7 and Glul34 with Cys38, HislOO and Aspll7, respectively
(Figure 8.5E). Thus, the catalytic mechanism should be very similar to the one of the
CHAP domain of the endolysin from phage K (Sanz-Gaitero et al., 2014).
The catalytic groove is strongly negatively-charged (Figure 8.5D). The absence of the
first a-helix in

CHAPthdwz

generates a groove in the protein that might have some

function, but the C-terminal disordered region of the protein is located quite close to
this groove, possibly being located inside it in vivo (Figure 8.5C).
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Helix only
present in CHAPk

Disordered region only
present in CHAPthdw2

Groove
Catalytic groove

Disordered region

F

Asp40

Gly35

His33

Figure 8.5:
between

CHAPthdwz

(green) and

CHAPthdwz

in CHAPk but not in

model structure. A) Overall structure. B) Structural alignment

CHAPthdwz

CHAPk

(4CSH, magenta). The N-terminal a-helix present

is circled in red. The C-terminal disordered region present

only in CHAPiHDwzis circled in black. C) Groove created in
of a-helix present in

CHAPk

CHAPthdwz

due to the absence

and location of the C-terminal disordered region, that could

be located inside that groove. D) Negatively charged catalytic groove. E) Putative catalytic
site. F) Putative cation binding site. In magenta is represented the calcium ion present in
a structurally-aligned aligned

CHAPk

molecule. Figure generated using PyMOL (Delano,

2002)
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8.5 Characterization of LysDW2 and CHAPemss
LysDW2 is a multidomain endolysin containing 481 residues, with a molecular weight
of 53.9 kDa and a predicted pi of 8.48. It presents a SH3b cell wall binding domain
(residues 398-466), an amidase 2 domain (residues 188-338) and a histidinedependent amidohydrolase/peptidase (CHAP) domain (residues 13-148). It is
encoded by DW2 phage ORF64. A protein 99% identical to this is coded by S. aureus
chromosome, supporting once more the possible temperate origin of phage DW2.
A search against the protein database (PDB) does not identify a similar protein for the
complete sequence, but it identifies structurally-determined proteins with identity to
one of the three protein domains. Not finding a protein whose structure has been
determined with identity to the complete sequence of LysDW2 is logical, due to the
high inter-domain flexibility of multi-domain proteins, which seriously hinders the
crystallization of these proteins.
A truncated version of this protein, containing the 153 N-terminal amino acids
(CHAPi-153) showed lytic activity when tested in vitro, although it was weaker than
the full endolysin (Keary et oL, 2014). CHAPi-153 has a molecular weight of 17.4 kDa
and a theoretical pi 5.06. This CHAP domain sequence is not similar to the one of
CHAPk, the structurally determined protein with higher identity to CHAPi-153 is
envelope-protein E from dengue virus (PDB 3J27), with a 37% query coverage and
31% sequence identity.
Secondary structure and disordered regions prediction shows that CHAPm53 has
three a-helices and nine (3-strands and contains a disordered region from residue 117
to 130 (Figure 8.6).
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Figure 8.6: CHAP1.153 secondary structure prediction generated using Phyre2 (Kelley et

oL, 2015), showing a disordered region from residue 117 to 130.

8.6 Purification of CHAPemss
The 153 N-terminal residues that correspond to the CHAP domain of LysDW2 were
cloned between the restriction sites Ncol and Bglll in pQE60 vector without His-tag
by Dr. Ruth Keary (Prof. Aidan Coffey's laboratory, Department of Biological Sciences,
Cork Institute of Technology, Ireland). An expression test was performed in XLl-blue
cells at 16 °C for 16 h and at 37 °C for 3 h. The protein levels in the pellet and the
supernatant of every culture were assessed by SDS-PAGE (Figure 8.7). CHAPemss was
soluble and the expression levels were higher at 16 °C.
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17 KDa

16 °C

37 °C

Figure 8.7: CHAPei-iss expression test. Protein of a size compatible with CHAPei-i53 can be

found in both pellet (P) and supernatant (Sn) fractions at 37 °C and 16 °C.

The protein was expressed in XLl-B cells 16 °C during 16 h. CHAPemss does not have
a histidine tag to make possible a purification by affinity chromatography, so it was
decided to perform an ammonium sulphate precipitation as first purification step.
After lysis, a solubility test using concentrations from 0-90% of ammonium sulphate
was performed. The soluble proteins were analysed by SDS-PAGE, determining that
CHAPei-153 is soluble at 30% ammonium sulphate, but not at 40% (Figure 8.8).
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Figure 8.8: CHAPei

isb

ammonium sulphate precipitation test. Soluble protein analyzed

by SDS-PAGE after adding different percentages (0-90%) of saturated ammonium
sulphate solution to the protein sample. CHAPemss precipitates between 30 and 40%
(NH4)2S04. The presence of the salt impairs the sample running uniformly through the gel.

Based on this result, a purification protocol was designed. Saturated ammonium
sulphate solution was added to the supernatant to a concentration of 25% (instead
of 30%, to give the protein some margin because the ammonium sulphate
concentration varies depending on the temperature). The proteins with lower
solubility than CHAPemss should precipitate, while the protein of interest together
with the high solubility proteins should remain soluble. Then, the concentration of
ammonium sulphate was increased to 40%, value at which CHAPemss should
precipitate, while the proteins with higher solubility should remain in the
supernatant. The protein pellets were resuspended and loaded into a gel. The higher
amount of CHAPemss was obtained in the fraction precipitated between 25-40%
ammonium sulphate. Some protein was obtained in the fraction precipitated to 0-
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25% (NH4)2S04 and no protein was obtained in the fraction that precipitates from 40
to 100% (NH4)2S04(Figure 9.8A),
The fraction that precipitated from 25-40% ammonium sulphate was resolubilized
and a hydrophobic interaction chromatography was performed. A single peak was
obtained at 0 M, containing CHAPemss and a small amount of visible contaminants
(Figure 8.9B).
The protein was dialyzed and an anion exchange chromatography (theoretical pi of
the protein is 5.06) was performed. A single wide peak was obtained at a
concentration of 150 mM NaCI. The eluted samples were analysed by SDS-PAGE,
checking that they contained pure CHAPemss. Only fractions 22 to 26 contained no
contaminant bands, so these fractions were pulled together, desalted and
concentrated to 11.5 mg/mL (0.65 mM) in 20 mM bicine-NaOH pH 9.0 (Figure 8.10).
Crystallization experiments were set up immediately.
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Figure 8.9: CHAPei-iss ammonium sulphate precipitation and hydrophobic interaction
chromatography (HIC). A) SDS-PAGE of proteins that precipitate between 0-25%, 25-40%
and 40-100%. Large amounts of CHAPemsb can be observed in fraction 25-40% (NH4)2S04.
The molecular weight ladder and the protein samples belong to the same polyacrylamide
gel. B) Chromatogram obtained during the HIC of the sample precipitated in 25-40%
(NH4)2S04 resuspended in 20 mM Tris-HCI pH 8.5 and 1.5 M (NH4)2S04. A single peak is
obtained at 0 M (NH4)2S04. Upon analysis by SDS-PAGE (right), the peak contained a
protein with a size compatible with CHAPEi issand some contaminant proteins.
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Figure 8.10: CHAPei-iss anion exchange chromatography. A) Chromatogram. A single
wide peak was obtained at 150 mM NaCI. B) SDS-PAGE showing CHAPEi isain fractions
22-30. Only fractions 22-26 were pure.
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8.7 Crystallization of CHAPemss
Crystallization assays were performed using sitting drop vapour diffusion techniques
at 20 °C. The reservoirs of Swissci 96-well 2-drop MRC crystallization plates
(Molecular Dimensions), were filled manually with 50 pL of different crystallization
conditions containing a different salts, precipitants and buffers. Drops containing a
mixture of 0.5 pLof 12.4 mg/mL (0.71 mM) CHAPemsb and 0.5 pLof the crystallization
solution were set in by automated techniques. Plates containing the same conditions
but at a protein concentration of 6.15 mg/mL (0.36 mM) were also tested.
Some small crystals grew in conditions with 20-30% PEG 4000, 100 mM Tris-HCI
pH 8.5 and CaCb/MgCb, including conditions containing ammonium sulphate. An
optimization screening was designed using a 18-25% PEG 4000, pH 7.0-8.5 and
calcium chloride. Another screening was designed using 25% PEG 4000, 100 mM
Tris-HCI pH 8.5 and different chloride salts at 0.2 M. Swissci MRC Maxi plates
reservoirs were filled manually with 150 pLofthese conditions. Drops containing2 pL
ofCHAPE 1-153 at 12.35 mg/mL (0.71 mM) and 2 pL of precipitant were set up. The plate
was incubated at 20 °C. Some crystals from the original screening and the
optimization screening were cryoprotected with 20% glycerol, flash frozen and taken
to the synchrotron, but they did not diffract X-rays.
In the initial screening several bad-looking crystals were obtained in conditions
containing 0.8-3 M ammonium sulphate in different buffers, so a screening was
designed containing 0.5-3 M (NH4)2S04, buffers at 0.1 M pH 5-8.5 and 5% PEG 400.
The plates, volumes, concentrations and incubation temperatures were the same
used in the previous optimization plate. After two weeks, sea urchin-shaped crystals
appeared in conditions containing 1.7 M (NH4)2S04, pH 5-6.5 and 5% PEG 400.
New initial screening plates using the same kits and conditions were used. This time,
the protein was concentrated to 11.5 mg/mL (0.65 mM) and the protein sample was
purer than in the first attempt, so it was worthy to check if the crystallization
improved. After two weeks, crystals grew in a condition containing 30% PEG 8000
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and 200 mM (NH4)2S04. More plates were set in the same conditions with protein
from different batches and concentrations (5 mg/mL, 13.5 mg/mL and 27 rng/mL).
Some plates were set up using frozen and thawed protein or protein left for days at
4 °C to induce some variability and induce partial degradation.
A new optimization kit was designed with conditions containing 15-40% PEG 8000
and 100-400 mM (NH4)2S04. Crystallization plates were set up with 150 pL of
precipitant in the reservoir and drops containing 2 pL of protein at 11.5 mg/mL and
2 pL of precipitant. To determine the optimum protein concentration for
crystallization, an assay based on PCT pre-crystallization test (Hampton, Aliso Viejo,
USA) was performed, deciding that the optimal protein concentration was closer to
5 mg/mL than to 13 mg/mL.
The best crystal obtained during the crystallization assays was obtained using protein
sample at 10 mg/mL and in a condition containing 0.2 M (NH4)3P04, 0.1 M Tris-HCI
pH 8.5 and 50% 2-methyl-2,4-pentanediol This crystal was cryoprotected and its
diffraction was analysed at the synchrotron, but it did not show an optimal diffraction
pattern (Figure 8.11D).

Figure 8.11: Different CHAPei-iss pseudocrystals and crystals.
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To identify an additive that might stabilize the protein, a thermal shift assay trying 78
different compounds was performed. It can be observed that the Tm of the protein is
about 42

but no sharp derivative peak was obtained from the dissociation curves,

so the differences in the Tm produced by different additives could not be analysed
reliably.

8.8 CHAPei -153 structure prediction
Because a diffracting protein crystal could not be obtained, an in silico model of the
protein was generated using RaptorX (Kallberg et oi, 2014). The overall structure of
the protein is very similar to CHAPk, although a homology search using BLASTp does
not even consider this protein to have a significant sequence identity with CHAPemss
(the identity between the sequences of both proteins is 19%; Figure 8.12A). A
structural alignment between CHAPk and CHAPemss reveals that their overall
structure is quite similar (Sanz-Gaitero et ol., 2014). The main difference is that
CHAPei -153

presents a much longer loop than CHAPk connecting (B-sheets 4 and 5

(Figure 8.12B). This loop is located in a groove formed by the loop connecting the two
N-terminal a-helices of the protein in CHAPk, and given its location, it could act as a
flexible region regulating the access to the catalytic groove (Figure 8.12C). In addition,
CHAPei-153

is lackingthe first N-terminal a-helix present in CHAPk. The lack of this helix

generates a non-charged groove on the protein surface.
The CHAPKcalcium ion binding EF-hand appears to be conserved in CHAPei-i53. Asp45,
Asp47 and Asp56, residues coordinating the calcium ion through their side chains in
CHAPk,

correspond to Asn23, Asp25 and Asp34 in CHAP Ei-153, respectively. Tyr49 and

HisSl, that bind calcium through their main chains in CHAPk,correspond toTrp27 and
Gly35 in CHAPthdwz,

so

it is quite probable that this enzyme will also bind a cation.

(Figure 8.12E). The catalytic triad is also conserved, corresponding Cys54, Hisll7 and
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Glul34 from CHAPk with Cys32, His95 and Glulll in CHAP Ei-153. Therefore, the
catalytic mechanisms of both proteins are likely similar (Figure 8.12D).

Catalytic groove

Glulll^
His95

E

Catalytic groove

Gly29

Asn34

Hr*

Asp40

Asp25

Tyr27

Figure 8.12: CHAPemss structure prediction using RaptorX. A) Overall structure. B)
Structural alignment between CHAPemss (pale green) and CHAPk (4CSH, pink). The Nterminal a-helix present in CHAPk but not in CHAPEi issis coloured in magenta. The long
loop connecting p-sheets 4 and 5 in CHAPemss is coloured in bright green. C) Catalytic
groove. A simulation of the movement of the loop connecting 3-sheets 4 and 5 (right)
allows to see that this loop might move to cover the catalytic groove. Residues belonging
to the groove are represented in bright green. D) Putative catalytic site. F) Putative cation
binding site. The calcium ion located in a structurally-aligned aligned CHAPk molecule is
represented in magenta. Figure generated using PyMOL (DeLano, 2002),
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9 Purification and crystallization of gp239
tail associated endolysin from
Enterobacteria phage vB PcaM CBB
9.1 Characterization of CBB_239
Enterobacteria bacteriophage vB_PcaM_CBB is a Jumbo phage that infect several
species

\/\/ithin

the family

Enterobacteriaceae.

CBB

phage

belongs to the

/V/yov/r/c/oe family, displaying a large regular icosahedral head a contractile tail and
six short tail fibres. The tail of CBB possesses hair-like appendages covering its
surface.
Gp239 (CBB_239) is a putative tail associated endolysin from Enterobacteria phage
vB_PcaM_CBB. It contains 165 amino acids and has a molecular weight of 19.6 kDa
and a predicted pi of 9.11. The protein has a high sequence identity with baseplate
hub subunits and the tail lysozyme of Gram-negative targeting phages such as
Cronobocter phage vB_CsaM_GAP32, Serratio phage BF, Yersinia phage fHe-Yen9-04
or Escherichia phage vB_Eco_slurp01. A search against the Protein Data Bank shows
that CBB_239 presents a sequence identity of 33% over a 70% query coverage with
the deeply studied T4 lysozyme (ILYI). This identity could be high enough to
determine the structure of CBB_239 by molecular replacement methods. An analysis
of the conserved domains using the CDD (Marchler-Bauer et al., 2011) confirms that
CBB_239 contains a lysozyme-like domain (IPR001165) from residue 41 to 161.
Secondary structure prediction using Phyre2 (Kelley et al., 2015) shows the presence
of disordered regions in the N-terminus of the protein, probably because is the part
through which the tail endolysin is attached to the tail complex, that could complicate
the crystallization (Figure 9.1).
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Figure 9.1: CBB_239 secondary structure prediction. Generated using Phyre2 (Kelley et

ol., 2015). The N-terminus is disordered, probably because is the part through
which the tail endolysin is attached to the tail complex.

9.2 Purification of CBB_239
The expression vector for CBB_239 was constructed by Colin Buttirner (Prof. Aidan
Coffey's laboratory, Department of Biological Sciences, Cork Institute of Technology,
Ireland). The full length ORF was introduced between the Ncol and Xhol restriction
sites of plasmid pET28a+. This plasmid encodes for a 6x His-tag that is added at the
C-terminus of the protein upon translation.
An expression test at 37 °C in E. coli BL21(DE3) cells was performed. Protein levels
before induction and 1-3 h post induction were analysed by SDS, determining that the
expression levels of the protein after 3 h were acceptable and that the protein was
soluble (Figure 9.2)
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0 1 2 3 h post-induction
kDa

CBB 239
Figure 9.2: CBB_239 expression test at 37 °C in BL21(DE3) cells. Protein levels analyzed
before induction with 1 mM IPTG and 1-3 h post induction, showing the highest
expression levels 3 h post-induction. The molecular weight ladder and the protein
samples belong to the same polyacrylamide gel.

Four 1 L cultures were grown using the same parameters determined in the
expression test. The cells were lysed and an IMAC was performed on the
supernatants. The pellet, flow-through, wash and elution fractions were analysed by
SDS, finding protein of a size compatible with CBB_239 in fractions 50-500 mM. Large
amounts of protein were found in the flow-through and the wash fractions, probably
because of overloading of the volume of resin used. Therefore, they were incubated
with the resin a second time to repeat the affinity chromatography step (Figure 9.3A).

As the predicted pi of the protein with histidine tag is 9.1, a cation-exchange
chromatography was chosen as second purification step. Fractions from the affinity
chromatography eluted at 50-500 mM imidazole concentrations were pulled
together and dialyzed to remove the imidazole and to change the buffer. No
precipitation was observed.

A cation exchange chromatography was performed. The chromatogram obtained
showed two sharp peaks, eluted at 0.54 and 0.61 M NaCI, respectively. Upon
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examining the protein contents of every elution fraction by SDS-PAGE, it was shown
that both peaks contained pure CBB_239 (Figure 9.3B). Every of the five times the
protein was purified, a similar two-peaked chromatogram was obtained, probably
due to two different ionization states of the enzyme.

Fractions 19-21, belonging to the first peak, and 23-24, belonging to the second peak,
were desalted and concentrated in 20 mM MES-NaOH pF^ 6.0 independently using an
Amicon centrifuge filter device with a molecular weight cut-off of 10,000 Da
(Millipore, Billerica MA, USA). Depending on the purification, pure protein with
concentrations ranging from 14 mg/mL (0.7 mM) to 40 mg/mL (2 mM) was obtained.
Crystallization experiments were performed immediately.
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Figure 9,3: CBB_239 purification. A) SDS-PAGE run after Ni-NTA affinity purification
showing molecular weight marker (MW), flow-through (FT), wash (W), and eluted
fractions at 0.05-1 M imidazole. Protein with size compatible with CBB_239 can be
observed in the FT, W and 50-500 mM imidazole fractions. B) Cation exchange
chromatogram showing two peaks, both of them containing CBB_239, as analyzed by SDSPAGE.
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9.3 Crystallization of CBB_239
Crystallization trials were performed at 20 °C using sitting drop vapour diffusion
techniques. The reservoirs of Swissci 96-well 2-drop MRC crystallization plates
(Molecular Dimensions, Suffolk, UK), were filled manually with 50 pL of different
crystallization conditions. Drops containing a mixture of 0.5 pL of 9 mg/mL (0.46 mM)
or 13.5 mg/mL (0.66 mM) of CBB_239 and 0.5 pL of the crystallization solution were
set up in by automated techniques (Genesis RSP 150 workstation, Tecan Trading AG).
The crystallization screens initially tried were JBScreen Classic 1-10, Pi-Minimal (Jena
Biosciences, Germany), JBS PEG/Salt 1 and 2, Sigma Cryo and Sigma Extension (SigmaAldrich, USA).
Different-shaped crystal were obtained in several conditions (Figure 9.4), containing
PEG 5000 MME, methyl pentanediol, PEG 8000, PEG 6000 or ammonium sulphate at
high concentrations in pH ranging from 6.5 to 9.5, all of them supplemented with
sodium, potassium or magnesium salts. Diffracting crystals were obtained in 30%
methyl pentanediol, 0.1 M MES-NaOH pH 6.5 and 200 mM magnesium acetate
(Figure 4D). These crystals were very fragile. During the freezing process to transport
them to the synchrotron, they broke easily. Due to that, it was decided not to
cryoprotect them or soak them in heavy atoms to do experimental phasing.
The best diffraction pattern was obtained from a crystal grown in 34% PEG MME
5000,150 mM AMPD-Tris pH 9 and 100 mM potassium/sodium tartrate (Figure 9.4E).
They were composed by several stacked layers and were very fragile, so they were
frozen without cryoprotectant agent to prevent crystal damage.
A thermal shift assay was performed to try to determine the additives that could help
stabilize the crystals. The protein Tm is 55 °C. The only additives that seems to increase
the protein stability are potassium dihydrogen phosphate, ammonium dihydrogen
phosphate, sodium dihydrogen phosphate, sodium formiate, magnesium acetate and
sodium acetate, increasing the Tm to 60 °C. These results coincide with the conditions
where crystals were obtained.
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Figure 9.4: CBB_239 crystals obtained. Crystals in D and E were taken to the synchrotron

for data collection.

9.4 Structure determination attempts
Both crystals were transported to ALBA and ESRF synchrotrons. The different
diffraction patterns obtained were indexed, integrated and scaled. The best crystal
diffracted at a resolution of 2.7 A, belonging to the space group P222i with unit cell
parameters a = 83.8 A, b = 28.7 A, c = 56.3
also obtained at a 3.4
parameters a =136.8

A

A,

A, a =

(3 = y = 90°. A complete dataset was

resolution, with apparent space group P6322 with unit cell
b = 136.8

A,

c = 172.0 A, a = P = 90°, y = 120 °. Table 9.1

shows the data collection statistics for both crystals.
The Matthews coefficient was 2.42 AVDa for the P63 2 2 crystal, showing the presence
of five monomers per asymmetric unit and 49.11% of solvent content with a
probability of 52%. The Matthews coefficient for the P222i crystal is likely to be
1.8 AVDa, assuming 1 molecule per asymmetric unit and 29% solvent content.
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Table 9.1: CBB_239 diffraction statistics.
Parameter
Space group
0, b, c (A)
a, P, V (°)
Wavelength (A)
Beamline
Temperature (K)
Resolution (A)
No. of reflections
Total
Unique
Mn(l/ol)
f^pim

Completeness (%)
Multiplicity

CBB_239 P6322

CBB_239 P222i

P 6322
136.77, 136.77, 171.97
90.00, 90.00, 120.00

P 222i
83.77, 28.670, 56.25
90.0, 90.0, 90.0

0.97920
BL13 (ALBA)
100
97.55-3.40 (3.67-3.40)

0.96600
ID30A-1 (Massif-1)
100
46.70-2.70(2.75-2.70)

257,672 (55,472)
13,676 (2,744)
12.5(3.2)
0.094 (0.756)
100 (100)
18.8 (20.2)

22178 (1,044)
4,040 (194)
6.3 (2.2)
0.138 (0.614)
99.2 (100)
5.5 (5.4)

*The values in brackets belong to the highest resolution shell.

The resolution of the data was not very high, probably due to the fragility of the
crystals. During crystal harvesting and freezing, crystals contacts might have been
distorted, altering the crystal order and decreasing the resolution. As there was a
model available (T4 lysozyme (ILYI), with 33% sequence identity and a 70% query
coverage), molecular replacement was used to determine the phases of the crystal
with the programs Molrep (Vagin et aL, 2010) and Phaser (McCoy et al. 2007). As no
results were obtained, the model was improved by cleaving the loops and the regions
with low identity with CBB_239, without positive results. The datasets were
reprocessed in different space groups to try to improve the data, but the structure
could not be determined.
Due to the lack of success using T4 lysozyme as molecular replacement model, an in
silico model was generated. According to Critical Assessment of Protein Structure
Prediction (CASP12- Kryshtafovych et al., 2018), the best evaluated free servers to
generate in silico models were QUARK (Xu et al., 2012), ROBETTA (Kim et oL, 2004),
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Galaxy (Ko et oL, 2012), intFOLD4 (McGuffin et ai, 2017), RaptorX (Kallberg et ai,
2014), HHPred (Meier et al., 2015), Modeller (Webb et gL, 2016) and iTasser (Yang et
ai, 2015). Models were generated with each of these programs and with Phyre2
(Kelley etai, 2015).
Modeller, intFOLD4, RaptorX and Galaxy are used for homology or template-based
modelling of protein three-dimensional structures. I-TASSER identifies structural
templates from the PDB by multiple threading approach, with full-length atomic
models constructed by iterative template-based fragment assembly simulations.
QUARK is a computer algorithm for ab initio protein structure prediction and protein
peptide folding, which aims to construct the correct protein 3D model from amino
acid sequence only. QUARK models are built from small fragments (1-20 residues
long) by replica-exchange Monte Carlo simulation. Robetta

creates 3D protein

models domains either by homology modelling or by ab initio modelling.
Each model was used to try to get the phases of the dataset. The loops of each model
were optimized using GalaxyRefine (Ko et ai, 2012). The outputs were used again as
models for molecular replacement, with no better results. The loops were removed,
and the phasing tried again without success.
Every model was superposed between them and with ILYI (T4 lysozyme) (Figure 9.5A
left). All models share a basic core composed of eight a-helices (Leull-Glu20, Glu67Ile87, Glu99-Metlll, Lysll3-Lysll8, Lysl20-Argl28, Tyrl31-Asnl40, Alal42-Glnl46
and Thrl46-Thrl60) and a p-hairpin (Tyr40-lle49) (Figure 9.5A right). A truncated
model containing only these conserved regions was used to perform a molecular
replacement, unsuccessfully.
As seen in section 6.5, T4 lysozyme is a glycoside hydrolase where a nucleophilic
water, activated by the general base Asp20 attacks the p (l->4) linked Cl carbon of
the peptidic NAM, while the general acid Glull donates a proton to NAG. Thr26
assists on the positioning of the water (Kuroki et ai, 1995). These three residues
correspond to Glu20, Asp42 and Thr48 in CBB_239. In every model generated, Asp42
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and Thr48 are located in the same positions and distances than Asp20 and Thr26 in
T4 lysozyme, but only in the models generated by Modeller and RaptorX the Glu20 is
located in the same position than Glull in T4 lysozyme (Figure 9.5C).
This fact led me to believe that the models generated by Modeller and RaptorX are
the most accurate ones and that the protein is a muramidase following the same
catalytic mechanism as T4 lysozyme. The main difference between these protein
models and T4 lysozyme is that CBB_239 contains an extra a-helix just after the (3hairpin while T4 lysozyme contains an extra a-helix just before the (3-hairpin (Figure
9.5B).
As the general shape in every model coincide (in both homology and de novo models),
it should not be very different from the actual structure of the protein. As why the
protein could not be solved using these models, considering their accuracy, it could
be due to diffraction data not strong enough for this kind of approach.
To try to solve the protein structure, more crystals of the native protein must be
grown, then soaked into different heavy atoms, aiming for an experimental phasing.
Crystals of the protein where the methionine have been substituted by
selenomethionine (by expressing in a methionine auxotroph cell strain, like
B834(DE3)) can also be grown to avoid soaking them in heavy atoms, preventing
additional crystal damage. If none of these methods is possible, since the protein is
mainly a-helical, a high-resolution crystal could potentially be phased by ab initio
methods (ARCIMBOLDO; Rodriguez-Martinez et oL, 2009). This might help not only
to characterize CBB_239 catalytic mechanism, but also its attachment to the phage
baseplate and its oligomeric state.
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Glu20

Asp42

Figure 9.5: CBB_239 in silico models. A) Structural alignment of 23 different in silico
models generated for CBB_239 with QUARK, ROBETTA, Galaxy, intFOLD, RaptorX,
HHPred, Modeller and iTasser servers, showing their similarity (left). After removing the
loops, their core structure coincides almost perfectly (left). B) Alignment of T4 lysozyme
(ILYI-green solid cartoon) with different CBB_239 models generated with Modeller and
RaptorX (magenta, blue, red and yellow, transparent). These models present an extra ahelix just after the [3-hairpin (red arrows) while T4 lysozyme contains an extra a-helix just
before the 3-hairpin (black arrows). C) Putative catalytic residues from a CBB_239 model
generated with modeller (magenta) and compared with T4 lysozyme catalytic residues
(green). Figure generated generated with PyMOL (Delano, 2002).
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9.5 Additional proteins from CBB phage
The CBB phage codes for two potentially interesting proteins, namely the hair-like
fibres surrounding the tail and the regular tail fibres. A homology search on CBB
phage genome using Blastx (Altschul et al., 2010) identifies the long fibre as the
product of CBB_226 gene (Figure 9.6A), while the tail fibres are encoded by gene
CBB_260. This program was used because, contrary to Blastp, the complete DNA
sequence of phage CBB could be translated and used as an input to search in protein
databases to try to find potential tail fibres. These fibres are usually trimeric. In many
cases, they require one or several chaperones to assist in the folding (Bartual et al.,
2010; Granell et oi, 2017). In the case of CBB, the fibre chaperone could be coded by
CBB_261 (Figure 9.6B).
CBB_226 is a large protein, with 1553 residues per monomer. A search in the Xtalpred
server (Slabinski et al., 2007) identifies this protein as very hard to crystallize. Crystal
fibres are usually hard to crystallize because they have flexible regions that hinder
the crystallization, so truncated versions of the protein must be generated. This
process is not so simple: the C-terminus of the fibre must not be cleaved because this
is usually the region where the trimerization starts (Hyman et al., 2017), a His-tag
must not be included in that region and the truncation must not interrupt any
secondary structure elements or regions that are intertwined because this could
prevent the trimerization of the protein, leading to aggregation.
CBB_260 is a 559 residues per monomer protein. It shows a disordered region from
residue 153 to 179. This region is probably interacting with the other monomers that
comprise the trimers. Therefore, the same precautions taken with cloning of
CBB_226 must be followed now.
The structure of these proteins is hard to predict. Programs used to generate in silica
models of proteins still fail to predict tail fibres, where each monomer is usually
strongly intertwined with the other two to form a long and compact trimer. The
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protein chaperone CBB_261 must be co-expressed with these tail fibres to assist with
the folding.
Based on these premises, the following clones for these proteins were designed:
•

Full length, 223-1553, 341-1553, 539-1553, 739-1553, 960-1553, 1051-1553,
1216-1553, 1333-1553, 1426-1553 and 1466-1553 fragments of CBB_226
(long fibre) to be cloned between the Ncol and Hindlll restriction sites of pCri8a were designed. pCri-8a codes for a C-terminal histidine tag that can be
cleaved using TEV protease. The vector contains a kanamycin resistance gene.

•

Full length, 183-559, 254-553 and 443-553 fragments of CBB_260 (short fibre)
were designed to be cloned between the Ncol and Hindlll restriction sites with
a cleavable N-terminal tag in pCri-8a.

•

The chaperone CBB_261 was designed to be cloned between the restriction
sites Ncol and Hindlll in the MCSI of pETDuet-1 vector without histidine tag.
The vector contains an ampicillin resistance gene to be compatible with pCri8a and be expressed together.

A list of the designed oligonucleotides can be seen below (Table 9.2, 9.3 and 9.4):

Table 9.2: Oligonucleotides to clone CBB_226 between the Ncol and Hindlll restriction sites
of pCri-8a.
Name

Fw/Rv

Restriction
site

Sequence

Cbb226pcriFwNcol

Fw

Ncol

CGCG ccatgg cc ATG TAT TCT
ATA AAA ACT GAT CTT GGC

Cbb226_233pcriFwNcol

Fw

Ncol

CGCG ccatgg cc AAC TTA GTT
GGT GAT TTA AAT GTA ACT
G
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Name

Fw/Rv

Restriction
site

Sequence

Cbb226_341pcriFwNcol

Fw

Ncol

CGCG ccatgg cc CGT CCT TTA
gat

Cbb226_539pcriFwNcol

Fw

Ncol

CGCG ccatgg cc CGC CCA TTA
gat

Cbb226_739pcriFwNcol

Fw

Ncol

ATT AAA TCT GCA ATT

ATT AAA TCT GC

CGCG ccatgg cc AAT GAA
GTT ATC GTT AGT GGT ATT
AGT

Cbb226_960pcriFwNcol

Fw

Ncol

CGCG ccatgg cc ACA ACT
GTA GCA ATT GCA AAA AGT
AC

Cbb226_1059pcriFwNcol

Fw

Ncol

CGCG ccatgg cc CCA AAA
GTA TCT GGT ACA CTA AAC

Cbb226_1216pcriFwNcol

Fw

Ncol

CGCG ccatgg cc AAT ACA
ACA ATC ACT GGT GAC CTA

Cbb226_1333pcriFwNcol

Fw

Ncol

CGCG ccatgg cc ACA TTA GCT
GCT GTT TCA GCA AC

Cbb226_1426pcriFwNcol

Fw

Ncol

CGCG ccatgg cc ATT ACT GTT
ACT GGT ACA TTG AAT GTT

Cbb226_1469pcriFwNcol

Fw

Ncol

CGCG ccatgg cc ACT TCT AAC
GTT TAT AAC GTT ACT GTT

Cbb226pcriRvHindlll

Rv

Hindlll

GCGC aagctt TTA TGG GCG
TTG TGC AAT GAA T
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Table 9.3: Oligonucleotides to clone CBB_260 between the Ncol and Hindlll restriction sites
of pCri-8a.

Name

Fw/Rv

Restriction
site

Cbb260pcriFwNcol

Fw

Ncol

Sequence

CGCG ccatgg cc ATG AGT
ATA AGA TTT AAT CAT GCT
TCC

Cbb260_183pcriFwNcol

Fw

Ncol

CGCG ccatgg cc TAT GTT ACT
AAA ACT GGT TGG TGT TTT

Cbb260_254pcriFwNcoI

Fw

Ncol

CGCG ccatgg cc GTT GGT
AGC ATG TTG GGG TTA A

Cbb260_433pcriFwNcol

Fw

Ncol

CGCG ccatgg cc TTA GTA
GTA TCT TCA CAA AGT GCA
A

Cbb260pcriRvHindlll

Rv

Hindlll

GCGC aagctt TTA AAC ATC
AGA AAT TGT TCT CCA TG

Table 9.4: Oligonucleotides to clone CBB_261 between the Ncol and Hindlll in the MCSI of
pETDuet-1.

Name

Fw/Rv

Restriction
site

CBB261DuetFwNcol

Fw

Ncol

Sequence
CGCG ccatgg gc ATG TTT
AAA AGA TAT GAA AAA CCT
GGC

CBB261DuetRvHindlll

Rv

Hindlll

CGCG aagctt TTA TTT CGA
AAG TTT TTG TAG AAG CAA
TTC
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The cloning of these fibre fragments should be attempted in the future to detect
if any of them is soluble and can be crystallized to determine the structure of
these fibres.

a ip2eVVP.3aM»*M» 1 DNA#««vm«

Figure 9.6: Genome map of CBB phage regions where the putative fibres are located.
A) Genome region where CBB_226, a putative long fibre, is located. B) Genome region

where CBB_260, a putative tail fibre, and CBB_261, its chaperone, are located.
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10 Cloning, purification and
crystallization of proteins from Listeria
monocytogenes phage vB_LmoS_293
vB_LmoS_293 is a siphovirus infecting L. monocytogenes serotypes 4b and 4e. Its
lysogenic nature excludes its use as a biocontrol agent, but its proteins can be used
as antimicrobial or detection systems.

10.1 Cloning of vB_LmoS_293 tail fibre and endolysin
vB_LmoS_293 ORF25 codes for a putative endolysin of 316 residues. A search in the
Conserved Domain Database identifies the full protein as an A/-acetylmuramoyl-Lalanine amidase CwlA (COG5632) family member, with an amidase-2 domain
(pfamOlSlO) from residue 2 to 157. The protein contains a putative Zn^^ binding site,
so it is important to avoid chelating agents during the protein purification.
A homology search shows that residues 178-311 have a sequence identity of 78%
with the Listeria endolysin PlyPsa, structure that has already been determined (PDB
code IXOV).
Four different fragments were designed to be cloned in pCri-8a plasmid, between the
Ncol and Hindlll restriction sites. The proteins expressed include an amino-terminal
histidine tag, cleavable by TEV protease. The fragment 1 contained the full-length
protein (Endol; 1-316), the fragment 2 included from the beginning of the protein to
the end of the amidase domain (Endo2; 1-178), the fragment 3 belonged to the
amidase domain (Endo3; 20-178) and the fragment 4 was the sequence showing high
identity with PlyPsa (Endo4; 178-316) (Table 10.1).
These fragments were amplified by PCR, using as a template vB_LmoS_293 phage
genome and the oligonucleotides described in section 4.8.1, digested with Ncol and
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Hindlll, ligated into pCri-8a plasmid restriction enzymes and transformed in TOPIO
and DH5a cells.
Table 10.1: vB_LmoS_293 endolysin cloning
Name

Endol

Endo2

Endo3

Endo4

Fragment

1-316

1-178

20-178

178-316

Oligonucleotides

Length
after
translation

Predicted

gp25endoFwNcol

1141 bp

9.83

39.11 kDa

gp25endoRvHindlll

339 aa

gp25endoFwNcol

727 bp

9.28

25.17 kDa

gp25endoAA178RvHindlll

225 aa

gp25endoAA20FwNcol

667 bp

8.71

22.75 kDa

gp25endoAA178RvHindlll

205 aa

gp25endoAA178endoFwNcol

607 bp

10.02

19.00 kDa

gp25endoRvHindlll

161 aa

MW

pi

Fragments 1 (FL) and 2 (1-178) were cloned successfully. Their expression was
checked before continuing with the cloning, because these fragments could be stable
and soluble, and therefore, the use of fragments 3 and 4 would be unnecessary.
vB_LmoS_293 ORF20 codes for a putative 316 residues long tail fibre. This fibre may
show hydrolytic activity or a novel fold, thus the interest on its cloning and
characterization. As a tail fibre, this protein vyill probably be trimeric and the
trimerization starts at the C-terminus of the protein. Therefore, it is necessary to
design different truncation clones that maintain intact the C-terminal part of the
protein intact, while truncating the N-terminus regions at locations which do not
impair the proper multimerization of the protein. Some fibres need one or several
chaperones to assist with their folding. After a sequence analysis, no potential
chaperones have been identified, so the strategy to follow was cloning the different
fibre fragments and express them to check their solubility. If none of the fragments
were soluble, a deeper search would be performed on the phage genome to try to
identify some chaperone and co- express it with the fibre.
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A homology search against the Protein Data Bank (PDB) did not show any significant
identity with any knovA/n structures, so a HHpred (Soding et ai, 2005) search was
performed, finding that the closest related structure deposited on the PDB was
Loctococcus phage TP901-1 baseplate tripod protein (PDB code 3U6X). HHpred is a
method for sequence database searching based on the pairwise comparison of
profile hidden Markov models. It is more sensitive in finding remote homologs than
a regular homology search. A quick view of the general structure allowed to find a
correspondence with the tail fibre from T7 phage (gpl7), previously studied in our
group (Garcia-Doval et oL, 2012b). Its most stable fragment is the one containing the
amino-acids 371-553 (PDB code 4A0T) (Figure 10.1).

A

r

Figure 10.1: Structural comparison of Loctococcus phage TP901-1 baseplate tripod
protein (3U6X, A) and T7 phage tail fibre protein (4A0T, B). Figure generated generated

with PyMOL (Delano, 2002).

An alignment was performed between the sequence of vB_LmoS_293 tail fibre and
TP901-1 baseplate tripod protein (PDB code 3U6X), identifying the fragment between
residues 137-296 of vB_LmoS_293 tail fibre as similar to the ones in the Lactococcus
phage fibre. A secondary structure prediction confirmed that amino acid 137 was not
located in any helix or strand.
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Another alignment was performed between the sequence of vB_LmoS_293 tail fibre
and gpl7 371-551 (4A0T) using EMBOSS Needle. Amino acids 153-355 of
vB_LmoS_293 tail fibre were identified as homologues to the T7 tail fibre. A
secondary structure prediction determined that amino acid 153 was located in the
middle of a long a-helix, but to avoid it, more than 10 amino acids should have been
removed or added with respect to gpl7 protein.
Based on this, four different fragments were designed to be cloned between Ncol
and Hindlll of pCri-8a plasmid, to be expressed with a N-terminal histidine tag
cleavable by TEV protease. These fragments corresponded to the full-length protein
(Taill, 1-355), the protein without the first four p-helices (Tail2, 63-355), a fragment
equivalent to 3U6X (Tail3, 137-155) and a fragment equivalent to 4A0T (Tail4, 153355) (Table 10.2).
Table 10.2: vB_LmoS_293 tail fibre cloning

Name

Fragment

Oligonucleotides

Length
after
translation

Predicted pi

MW

Taill

1-355

gp20liMosFwNcol

1259 bp

5.40

41.33 kDa

gp20liMosRvHindlll

377 aa

gp20liMos67FwNcol

1037 bp

6.23

32.98 kDa

gp20liMosRvHindlll

301 aa

gp20liMosl37FwNcol

851 bp

6.07

25.98 kDa

gp20liMosRvHindlll

239 aa

gp20liMosl52FwNco

806 bp

6.72

23.96 kDa

gp20liMosRvFlindlll

224 aa

Tail2

Tails

Tail4

67-355

137-355

153-355

The cloning was performed following the same protocol as with the endolysin. Two
clones were successful, namely, Taill and Tail3. These clones were purified in first
place, leaving the rest of the fragments as a secondary approach in case the solubility
was low.
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10.2 Purification of vB_LmoS_293 endolysin
The versions Endol and Endo2 of the protein were expressed in BL21 (DE3) cells. LB
supplemented with 50 pg/mL of kanamycin was inoculated with 1:100 (v/v) of cell
culture grown overnight. The cells grew until the ODeoo was 0.6. Then, they were
cooled down on ice and induced with 1 mM IPTG. The expression was performed at
16 °C for 16 h. The cells were harvested and centrifuged at 5000 x g for 20 min. They
were resuspended on 50 mM Tris-HCI pH 8.5, 500 mM NaCI and 10% glycerol lysis
buffer, lysed by sonication and centrifuged again to separate the soluble protein from
the cell debris.
Endol

and

Endo2

soluble

expression

was

adequate.

A

Ni-NTA

affinity

chromatography was performed on both proteins. They were incubated with the
resin for 20 min, the unbound sample was washed with lysis buffer. The target
protein was eluted in a gradient from 50 to 1000 mM of imidazole in the same buffer.
In the case of Endo2, the protein was obtained in fractions of 50-200 mM imidazole
with a molecular weight compatible with the protein (25 kDa). In the case of Endol,
the protein with a size compatible with the MW of Endol was eluted in fractions of
50-300 mM imidazole (Figure 10.2). The antilisterial activity of these proteins was
assessed by Vincenzo Pennone (Dr. Olivia McAuliffe laboratory, TEAGASC, Fermoy,
Cork, Ireland) by Minimum Inhibitory Concentration (MIC) assays, showing that both
of them are effective at lysing Listeria cells. These proteins will be tried to be
crystallized in the future.
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Figure 10.2: Ni-NTA affinity chromatography of Endo2 and Endol. A) Endo2 Ni-NTA
affinity chromatography showing molecular weight marker, fractions eluting from 50 to
1000 mM imidazole, Flow-Through (FT), Wash (W) and Pellet (P). A protein band with a
size compatible with Endo2 was obtained in fractions eluted from 50 to 200 mM
imidazole. B) Endol Ni-NTA affinity chromatography showing molecular weight marker,
fractions eluting from 50 to 1000 mM imidazole, Flow-Through (FT), Wash (W) and Pellet
(P). A protein band with a size compatible with Endol was obtained in fractions eluted
from 50 to 300 mM imidazole.

10.3 Purification of vB_LmoS_293 tail fibre
Both Tails and Taill versions of the tail fibre were expressed in BL21 (DEB) at 16 °C.
A Ni-NTA affinity purification was performed for both proteins.
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Taill was eluted in fractions 50-150 mM imidazole at low concentration. It was
dialysed to perform an anion exchange chromatography. After chromatography, a
single peak was obtained, but it did not show any band with a molecular weight
corresponding with Taill when analysed by SDS-PAGE.
Tails was eluted at high concentration in fractions containing 50-250 mM imidazole.
The presence of protein was checked by SDS-PAGE. Although all the samples were
heated at 95 °C before loading the gel, two bands could be observed, one belonging
to the monomeric protein (26 kDa) and other belonging to the trimer (molecular
weight should be 75 kDa but, as they are compact, the band appears at 60-70 kDa)
(Figure 10.3A). Fractions eluting from 50 to 250 mM of imidazole were dialyzed to
remove the imidazole and to change the buffer, with no significant aggregation
observed. An anionic exchange chromatography was performed. A single peak eluted
at 0.3 M NaCI (Figure 10.3B). Fractions 21-23, corresponding to the peak, were
analysed by SDS-PAGE before and after heating to 95 °C, observing that the protein
is pure and trimeric (trimers can be observed in the non-heated samples) (Figure
10.3C). The protein was concentrated in 20 mM Tris-FICI pH 8.5 and desalted.
Crystallization experiments were performed immediately.
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Figure 10.3: Tails purification. A) SDS-PAGE run after Ni-NTA affinity chromatography
showing weight marker, fractions eluting from 50 to 1000 mM imidazole, Flow-Through
(FT), Wash (W) and Pellet (P), all of them heated at 95 °C for 5 min. Two protein bands
with sizes with Tail3 monomer and trimer were obtained. B) Anionic exchange
chromatography, showing a single protein peak eluted at 300 mM sodium chloride. C)
SDS-PAGE of elution fractions 21-23, corresponding to the peak, heated 95 °C for 5 min
(Boiled, B) and non-boiled. Boiled fractions show a band of a size compatible with the
monomer, while non-boiled ones show a band of a size compatible with the trimer. The
molecular weight ladder and the protein samples belong to the same polyacrylamide gel.
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To facilitate crystallization, a batch of protein was produced without His-tag. After
the Ni-NTA affinity chromatography, the His-tag was cleaved using TEV protease. The
digestion reaction was performed in at different temperatures (4°C, 16 °C, 20 °C,
30 °C and 37 °C) for 24 h , determining that the best digestion is obtained at 30 °C.
After the digestion, the protein was dialysed and another Ni-NTA chromatography
were performed on it. This time the TEV, the uncut protein and the histidine tags
bound to the resin, while the protein without histidine tag eluted in the Flow-Through
(Figure 10.4). The Flow-Through obtained was dialyzed to perform an anion exchange
chromatography the following day. The results were the same as the obtained with
the undigested protein. The protein was concentrated in 20 mM Tris-HCI pH 8.5 and
desalted. Crystallization experiments were set up immediately.

kDa

MW

12

3

4

200

Trimer
onomer

Figure 10.4: Tail3 TEV digestion. 1) Undigested Tail3. 2) TEV. 3) Tail3 and TEV before
digestion. 4) Tail3 and TEV after digestion for 24 h at 30 °C. 5) Flow-Through of Ni-NTA
affinity chromatography after digestion (digested protein). 6) Wash of Ni-NTA (undigested
protein, TEV). 7) Elution with 500 mM imidazole (undigested protein, TEV). 8) Elution with
1 M imidazole (undigested protein, TEV). All the samples were heated at 95 °C for 5 min
before loading the gel.
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10.4 Crystallization of vB_LmoS_293 tail fibre (Fragment 3)
Crystallization assays were set using sitting drop vapour diffusion techniques at 20 °C.
The reservoirs of Swissci 96-well 2-drop MRC crystallization plates (Molecular
Dimensions, Suffolk, UK), were filled manually with 50 pL of 500 different
crystallization conditions containing a different salts, precipitants and buffers. Drops
containing a mixture of 0.5 pL at 34 mg/mL (1.2 mM) or 15 mg/mL (0.7 mM) of
undigested protein or 3.8 mg/mL (0.15 mM) of digested protein and 0.5 pL of the
crystallization solution were set in by automated techniques.
Crystals were obtained for the undigested protein in several conditions containing
PEG or ethanol. Crystals grown in conditions containing 20% PEG 3350 and 200 mM
potassium formiate; 20% ethanol or 50% 2-methyl-2-4-pentanediol, 15% ethanol and
10 mM sodium acetate, were cryoprotected with 20% glycerol and taken to the
synchrotron for data collection. The crystal grown in PEG 3350 and 200 mM
potassium formiate diffracted weakly, to 8 A, but the crystal obtained in 50%
2-methyl-2-4-pentanediol, 15% ethanol and 10 mM sodium acetate diffracted to
2.4 A, belonging to a P2 space group. Unfortunately, the data obtained was of low
quality, due to a strong overlapping of multiple diffraction patterns. In addition, no
molecular replacement model was found.
Optimization screenings were designed for these three crystallization conditions, but
no crystals were obtained. Consequently, initial screen plates were set up, getting
several crystals for both digested and undigested Tail3. The best crystals, grown in
conditions 10 % w/v PEG 8,000,100 mM sodium acetate, 50 mM magnesium acetate;
or 10 % PEG 20,000, 0.1 M MES-NaOH pH 6.5 or 14 % ethanol, 5 % glycerol ,100 mM
Tris-HCI pH 8.5, were cryoprotected and transported to the synchrotron for data
collection. Some of these crystals were soaked in methylmercury chloride to allow an
experimental phasing in case they diffracted, but none of them generated a suitable
diffraction pattern.
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Figure 10.5: Different Tail3 crystals obtained.

More optimization plates should be set to try to improve these hits and to determine
the protein structure. While this happens, a protein model has been created using
Galaxy Homomer (Ko et al., 2012). Although in silico models are not good at
predicting multimeric proteins, they have improved a lot, as it can be observed in the
CASP13 webpage, improving their accuracy on time (http://predictioncenter.org/
caspl3/index.cgi). vB_LmoS_293 tail fibre is predicted to be a trimer with a Cterminal head domain and an N-terminal pyramid domain, similar to 17 tail fibre
(Garcia-Doval et oL, 2012b). Although the structure prediction of the N-terminal
region from residue 1 to 165 is almost certainly incorrect, possibly adopting a triple
coiled coil fold in the actual protein, this model gives us a rough idea about the overall
expected structure of this protein. The expected N-terminal region of the protein
(from Metl to AsplSO) is an a-helical triple coiled coil. Following, a neck structure,
where the diameter of the protein increases (from AlalSl to Pro249). Each monomer
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of the protein fornns short a-helices interacting between them (from AlalSl to
Thr217), followed by a region of intertwined loops (from Ala218 to Pro249). Finally,
the C-terminal head domain, formed by three independent (3-sandwiches made up of
8 antiparallel p-strands, is located (from Lys250 to Thr355). The C-terminal head
domain presents long loops connecting the p-strands through which the fibre would
probably bind to its host cell receptor (Figure 10.6).

Figure 10.6: vB_LmoS_293 tail fibre homology model created with Galaxy Homomer.
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11 A site-directed mutation study of T7
tail fibre (gpl7) residues involved in host
recognition
11.1 Generation of gpl7 mutants and preliminary assays.
The C-terminal region of the T7 tail fibre protein gpl7 (residues 373-553) had been
previously crystallized (Garcia-Doval et oL, 2012a) and its structure determined
(Garcia-Doval et oL, 2012b). A sequence alignment with the fibre of phage 4)A1122,
that only infects Yersinia pestis but 86% identical to the one of T7 was performed.
The residues potentially involved in the recognition of E. coli lipopolysaccharide are
the ones that are different between both fibres and are located in the C-terminal
region of T7 fibre. Twenty-six mutants were designed based on this alignment and on
the crystal structure (residues located in exposed loops, Figure 11.lA).
Full-length gpl7 was cloned in between the Ncol and Hindlll restriction sites of
pETDuet-1 vector multicloning site 1, without Flis-tag, by Dr. Carmela Garcia-Doval
(Dr. Mark J. van Raaij group, National Centre for Biotechnology, CSIC, Madrid, Spain).
The truncated (371-553) version of gpl7 was also cloned between the restriction sites
Ncol and Hindlll MCSI of pET30a+, with an N-terminal His-tag. As a continuation of
that work, we generated 26 different point mutants of the full-length protein and of
the truncated gpl7 version containing residues 371-553: S475A, S477A, V482A,
S483A, V484A, K498A, C499A, N501A, N502A, S503A, W504A, Y515A, F516A, I517A,
A518L, S519A, D520A, W523A, N537A, I538A, D540A, R542A, S543A, V544A, P545A
and N546A (see Materials and Methods, Section 4.9.1). These residues were chosen
because they were not identical between the fibre of phage 4)A1122 (infecting Y.
pestis), and the one of T7 (gpl7, infecting E. coli), being potentially involved in host
recognition. They were located in loop regions close to the C-terminal part of T7 tail
fibre (gpl7). This region is the part of the fibre through which the phage interacts
with the bacterial receptor. Only loop residues were mutated because the mutation
of residues located in secondary structure elements such as a-helices or p-strands
could result in an incorrect protein folding.
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The first method to determine whether the mutant protein fibre could bind to
different kinds of lipopolysaccharide vyas to mix T7 tails (purified by Dr. Ana Cuervo,
Jose Marfa Carrascosa Laboratory, National Centre for Biotechnology, CSIC, Madrid,
Spain) with the supernatant of cells expressing the full-length mutant fibres. The
fibres would attach to the tail and then, the binding to different kinds of
lipopolysaccharide would be assessed by electron microscopy. Although the first trial
with lipopolysaccharide EH-100 and the mutant V544A was successful, the binding of
the rest of the mutants could not be assessed due to problems with the purification
of T7 tails (Figure 11.2).
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Figure ll.lrPairwise sequence alignment of phiA1122 and T7 tail fibres. The alignment
was generated using EMBOSS needle using BLOSUM62 weighting matrix. The mutants
generated are marked with a red star.
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Figure 11.2: T7 tail and mutant V544A fibres bound to EH-100 lipopolysaccharide. Image

taken with Jeol JEM 1011 transmission electron microscope at the National Centre for
Biotechnology (Madrid, Spain).

11.2 T7 complementation assay
At this point it was decided to perform a phage infection assay on two different cell
strains, TOPIO and BLR(DE3). These two cell strains are used as an example of a K-12
derived and B derived E. coli strains. They have the mutation RecAl, meaning that
their unspecific recombination is reduced.
A T7 phage amber mutant on gpl7 (containing a nonsense mutation that makes it
unable to produce fibres in a regular cell strain, but able to produce them in an amber
suppressor strain) is grown in the amber suppressor strain Sull. This strain contains a
tRNA coding for glutamine for the amber codon TAG, instead of being interpreted as
a stop codon. Phages produced in these conditions are able to produce tail fibres,
thus, are infective (see Materials and Methods, Sections 4.9.2 and 4.9.3).
These phages are used to infect BLR(DE3) and TOPIO non-suppressor cell strains
transformed with the vector pETDuet-1 containing the mutant fibre. Once the cells
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are infected, the T7 RNA polymerase coded by the phage will induce the expression
of the mutant fibres coded by the vector. A complete phage will be produced with
mutant fibres {RecA mutant cell strains are used to avoid unspecific recombination
between the phage genome and the plasmid fibre that could revert the amber
mutation and produce phages with wild-type fibres). These phages with mutated
fibres will infect new hosts if they are able to recognize them and will produce new
infection, leading to the production of lysis plaques that can be quantified (Figure
11.3). An empty pETDuet-1 vector is used as a negative control, a pETDuet-1 vector
containing the wild-type fibre is used as a positive control and a pJetl.2 plasmid
containing WT gpl7 in the wrong reading frame is used as a recombination control
(the tail fibre cannot be produced from the plasmid, but recombination may revert
the amber mutation) (see Materials and Methods, Section 4.9.4).
The construction of the T7 Q12 amber mutant phage and a part of the
complementation assays were performed by Dr. Laura Cordoba (Dr. Mark J. van Raaij
group. National Centre for Biotechnology, CSIC, Madrid, Spain). These experiments
were performed a single time or in duplicate. They need to be performed in triplicate
or tetraplicate to confirm the results.
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Figure 11.3: T7 amber phage fibre complementation assay. T7 amber mutant, unable to
produce tail fibres, infects non-suppressor cell strains transformed with a plasmid coding
for mutant fibres. The phage progeny contains the mutant fibre. If this fibre is able to
recognise its host, lysis plaques are formed.

The results obtained are shown in Table 11.1. The mutants shown in green, maintain
their infectivity in both TOPIO and BLR(DE3), so the mutated amino acids are not
essential for infectivity. The mutants shown in red totally abolish the infection in both
TOPIO and BLR(DE3), being probably important for infectivity in K-12 and B-derived
cell strains. The mutants shown in yellow are unable to infect TOPIO (and probably
other K-12 derived strains), but they can still infect BLR(DE3) (and possibly other B
derived strains), being probably important for K-12 lipopolysaccharide recognition.
The location of these mutations is represented in Figure 11.4.
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Table 11.1: Effects on infection of different gpl7 mutants in BLR and TOPIO cell strains
Genotype

TOPIO

WT

-H + +

S475A

-I-J-+

-h-f-i-

S477A

-

-f-t-i-

BLR(DE3)

-i-i-i-

V482A
S483A

-

-n-

V484A

-

+

K498A

-

+++

C499A

-

N501A

-

i
-t-i-

N502A
S503A

-t-l-l-

W504A

-

Y515A

-

-

F516A

-

-

I517A

-

-

A518L

-

-

S519A

-

D520A

-

W523A

-

-

N537A

-

-

I538A

-

-

D540A

—

+++

S543A

-

+++

V544A

-

P545A

-

+++
1

1

R542A

N546A
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Figure 11.4; Location and effect of the point mutations generated on T7 tail fibre. The
mutations not affecting infectivity are shown as green spheres, the ones suppresing
infectivity in only one of the K-12 or B strains are shown as yellow spheres and the ones
suppressing infectivity on both strains are shown as red spheres. A) Topological view of
the C- terminal tip domain of gpl7 with the location of the mutations represented. B-E)
Three-dimensional representation of gpl7 tip domain showing the location of every
mutation (B), the mutations not affecting infectivity (C), the mutations affecting the
infectivity in one cell strain (D) and the ones affecting the infectivity in both cell strains
(E).

The mutations not affecting the infectivity are located in the outer region of each
monomer. The mutations affecting the infectivity in just one cell strain are distributed
in all the surface of the tip domain, but not in the central regions where the
monomers contact with each other. The mutations suppressing the infectivity on
both cell strains are distributed throughout all the surface of the tip domain, including
the central region. This might mean that some of the mutants might be affecting the
trimer stability instead of the substrate recognition.
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11.3 T7 fibre solubility and thermal stability assays
The lack of infectivity of the mutants that completely abolished infectivity on both B
and K-12 strains could be due to mutations involved in lipopolysaccharide recognition
or, on the contrary, mutations affecting the tail fibre folding and stability, making the
fibre useless.
To determine if this was the case, the truncated His-tagged 371-553 version of the
fibre for each mutant was expressed and purified. The solubility of each mutant was
checked by SDS-PAGE. All the mutant fibres but Y515A were soluble, indicating that
this mutation affected the solubility of the protein.
The melting behaviour of each mutant was determined (in tetraplicate) by a thermal
shift assay (Table 11.2). Most of the mutants exhibit a complex unfolding pattern with
two apparent melting transitions, probably corresponding to the dissociations of the
pyramid domain and the tip domain (Figure 11.5). The Tm was not reduced
significantly in any of the mutants generated, suggesting that the mutations
introduced did not significantly affect protein stability, except for the mutant Y515A,
that was completely insoluble.
2,00

100

°C

Figure 11.5: Typical gpl7 thermal dissociation curve. The thermal dissociation curve is
represented in blue and the derivative curve in red. Gpl7 shows a two-step dissociation,
probably corresponding to the tip domain and the pyramid domain.
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Table 11.2: Solubility, thermal stability and infectivity of different gpl7 mutants

Infectivity

Genotype

Solubility 371-553

Tm

WT

YES

57.5, 65.1

S475A

YES

57.5, 63.0

S477A

YES

57.1, 67.5

-

+++
+++

TOPIO

BLR(DE3)

+++

+-1-1+++

V482A

YES

57.1, 68.4

++-(-

S483A

YES

56.6, 65.0

-

++

V484A

YES

56.2

-

+

K498A

YES

57.3

-

+++

YES
YES

56.5,64.7

-

:

57.0, 66.0, 76.7

-

'1

YES

59.5

+++

++
+++

C499A
N501A
N502A

^

S503A

YES

57.9

+++

W504A

YES

54.8, 78.3

-

-

Y515A

NO

-

-

F516A

YES

57.0, 65.1

-

-

I517A

YES

57.0, 67.0

-

-

A518L

YES

-

-

S519A

YES

56 .0

-

-

D520A

YES

55.0

-

+++

W523A

YES

56.9, 65.2

-

-

N537A

YES

52.2, 56.1, 62.3

-

I538A

YES

59.1, 66.8

-

D540A

YES

56.7, 63.1

+++

R542A

YES

57.5

+++

S543A

YES

58.4

-

+++

V544A

YES

56.6, 65.5

-

+++

P545A

YES

56.6, 65.5

-

N546A

YES

56.9, 64.0

+-(-+

'

+++

i
+++

11.4 T7 liquid medium phage infection assays
The complementation assays in top agar are a tedious process, requiring large
amounts of time and material. As an alternative, liquid infection assays in microtiter
plates were performed to quantify the infectivity of each mutant. Before proceeding
to analyse the mutants, the method was tested, since the phage tail fibres could not
be as necessary in liquid medium as they are in solid medium. To determine the effect
of the tail fibres, BLR(DE3) and TOPIO were transformed with pETDuet-1 containing
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wild-type gpl7 or empty. The cells were infected with T7 Q12 amber mutant, unable
to produce tail fibres, at different dilutions. In the case of the cells transformed with
the vector coding for gpl7, the progeny of phages contained fibres coded by the
vector, but in the case of cells transformed with the empty vector, fibreless phages
were obtained.
The evolution of the ODeoo after the infection was measured for each type of cell and
phage dilution. From this data, an infectivity index (indicative of how fast the phage
is able to lyse its host bacteria) was calculated for each cell type and MOI. The
differences in the infectivity index between cell strains expressing gpl7 and not
expressing it allowed the effect of the fibre for the infection in different types of cells
to be determined (see Materials and Methods, Section 4.9.6). Figure 11.6 shows the
effects of the tail fibres on infectivity. The conclusions are the following:
•

BLR(DE3) is infected more effectively than TOPIO. In presence of tail fibres,
T7 is three to four orders or magnitude more infective in BLR(DE3) than in
TOPIO.

•

In TOPIO cells, the fibres only increase the phage infectivity in liquid medium
at MOIs close to 10'^. If the multiplicities of infection are lower, the fibre has
no effect, probably because the limiting step in this case is to find bacteria to
infect. At higher MOIs, the fibres do not cause any effect, probably because
the number of phages is so high that random finding of the secondary
receptor is produced. This means that in liquid medium, tail fibres represent
an advantage for the infection of TOPIO cells only under very specific
circumstances.

•

In the case of BLR (DE3), the presence of tail fibres represents an increment
on infectivity of four orders of magnitude. The fibres do not suppose an
advantage at very high (1) or very low (10‘^) multiplicities of infection.
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•

At MOIs higher that 0.1, fibres are not necessary for infection in liquid
medium for BLR (DEB) and TOPIO cells.

Infectivity of T7 amber mutant in several cell strains
1,8

1.6

T

4

3

;

1

0

I og (MOI)
-Etitpiv Top 10

■GpI7ToplO

------- Empty BLR(D£ St

---------Gp 1/8LR(L)E3!

Effect of tail fibres on infectivity
0,8

0,;

•Effect of fibres In ToplO

• Effect of fibres on BLR(DE 3)

Figure 11.6: Effect of tail fibres on infectivity on BLR(DE3) and TOPIO cells (see

Materials and Methods, Section 4.3.5). A) Infectivity of T7 Q12 amber mutant in
different BLR(DE3) and TOPIO strains expressing or not expressing tail fibres at different
MOIs. B) Effect of the fibre in infectivity of TOPIO and BLR(DE3) cells at different MOIs.
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Considering the structure of peptidoglycan, K-12 derived strains are Ra mutants,
containing a complete core oligosaccharide, but no 0-antigen (Figure 11.7). The B
derived strains are Rb mutants, also lacking the last glucose and heptose of the core
oligosaccharide (Washizaki et oL, 2016; Figure 11.7). According to Quimron et al., the
first glucose of the lipopolysaccharide core is a binding site for T7. When one or more
glucose residues are attached to this glucose, the binding site is probably hindered,
and therefore either the penultimate glucose or the terminal heptose of the K-12
lipopolysaccharide backbone, or both, become essential for T7 infection (Quimron et
al., 2016). In our case, in liquid medium, it becomes clear that T7 tail fibres do not
recognize the last heptose and glucose present in K-12 strains or do it very weakly, as
the effect of the fibres presence in this strain is very low, probably because these
residues are blocking the access to their real ligand.

The fact that the presence of fibres affects the infection of B-derived strains
(BLR(DE3)) more, might mean that these fibres indeed recognize the first glucose of
the lipopolysaccharide or even the second one, present in E. coli B strains. At high
multiplicity of infection, fibres are not needed for a successful infection. This fact
might mean thatthe hypothesis of the presence of a secondary phage receptor in the
tail site that causes an irreversible highly specific binding and leads to the signal
transduction (Hu et al., 2013) is correct, superseding the hypothesis that the
cooperative binding of the six tail fibres leads to the irreversible binding and signal
transduction. In solid medium, the presence of fibres in K-12 strains (TOPIO) is more
important, hence maybe in liquid medium the phage can diffuse freely, and can find
its secondary receptor more easily, but in the case of solid medium, the phage uses
the fibres to "walk" through the peptidoglycan to find its secondary receptor.
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Figure 11.7: Structure of lipopolysaccharide of a K-12 derived (Ra) strain and a B derived
strain (Rb). Figure modified from Clifton etai, 2013.

11.5 Identification of the sugar moiety of lipopolysaccharide recognized
by gpl7
To identify the sugar moiety that T7 tail fibres recognize, a glycan array was
performed by Dr. Van Liu (Prof. Ten Feizi Laboratory, Imperial College, London, UK).
The

binding of 371-553

His-tagged truncated version of gpl7 to several

lipopolysaccharide-related glycan arrays was analysed. The bound protein was
detected using anti-His antibodies. The results indicated that gpl7(371-553) had a
strong interaction with pullulan and a weaker interaction with kojibiose (Figure
11.8A). Pullulan is a polysaccharide polymer consisting of maltotriose units. Three
glucose units in maltotriose are connected by an a-(104)-glycosidic bond, whereas
consecutive maltotriose units are connected to each other by an a-(l->6)-glycosidic
bond (Figure 11.8B). Kojibiose is a disaccharide formed by two glucoses bound
through an a-(104)-glycosidic bond (Figure 11.8C). The common part between these
two ligands was the two glucoses bound through an a-(l->4)-glycosidic bond
(kojibiose), so the interaction gpl7-kojibiose was analysed. This result was coherent,
because in the lipopolysaccharide two possible diglucoses are present.
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Figure 11.8: Gpl7 ligands detected by glycan array. A) Glycan array signal for different

saccharides. B) Pullulan maltotriose unit. C) Kojibiose structure.

Saturation transfer difference (STD-NMR) experiments performed by Dr. Alvaro
Berbis (Prof. Jesus Jimenez Barbero laboratory, Centre for Biological Investigations,
CSIC, Madrid, Spain) were used to confirm the binding of gpl7 (fragment 371-553) to
kojibiose. STD-NMR is based on the transfer of magnetization between the protein,
which is selectively irradiated by radiofrequency pulses, and any binding ligands
(Meyer et ai, 2003). The atoms located close to the protein surface receive a higher
amount of magnetization, providing information on the ligand binding epitope
(Mayer et al., 1999). STD experiments performed on kojibiose in the presence of the
gpl7(371-553) originated peaks in the STD spectrum, indicating that the disaccharide
binds to the protein (Figure 11.9A), thus confirming the results obtained by
microarray. Inspection of the STD spectrum revealed differences in the degree of
saturation between the two glucose residues, as well as between the two different
species of kojibiose that coexist due to the a/p anomeric configurations of the
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reducing glucose. Several protons of the reducing glucose showed smaller STD
responses than their counterparts of the non-reducing unit, suggesting that binding
of kojibiose to the gpl7 371-553 fragment occurs mainly at the level of the non
reducing glucose. Glucose was used as a control, showing very low signal in
comparison with kojibiose. These findings suggest that the recognition of the
a-(l->2) linked disaccharide is specific.

Once the interaction of gpl7 with kojibiose was confirmed, isothermal titration
calorimetry (ITC) was performed in an attempt to determine the binding affinity (Dr.
Margarita Menendez (Institute of Physical Chemistry Rocasolano, CSIC, Madrid,
Spain). Unfortunately, it was not possible to determine the Kd of the affinity between
the protein and the ligand because it was very low. Even if the binding affinity of every
gpl7 monomer to kojibiose is low, the binding of three monomers per fibre and six
fibres per phage can lead to an efficient retention of the phage on a bacterium.
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Figure 11.9: STD-NMR experiments performed on gpl7 371-553 with kojibiose. A) STD
experiments performed on kojibiose and glucose in the presence of the gpl7 371-553
fragment. Top spectrum: Reference spectrum of kojibiose, with labels indicating the
assignment for representative signals. Middle spectrum: STD spectrum of kojibiose
Bottom spectrum: STD spectrum of glucose. B) Epitope mapping obtained with the STD
data for kojibiose. The relative intensity of the signal is represented by yellow (<60%),
orange (60-80%) or red (80-100%) circles.
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11.6 Crystallization of gpl7 371-553 with kojibiose
Crystallization of native gpl7 371-553 fragment had been already performed in 2012
by Dr. Carmela Garcia-Doval (Dr. Mark van Raaij group, National Centre of
Biotechnology, CSIC, Madrid, Spain) by sitting drop vapour diffusion techniques in
conditions containing a solution of 0.1 M Tris-HCI pH 8.5, 0.2 M trimethylamine Noxide (TMAO) and between 20 and 25% (w/v) polyethylene glycol monomethyl ether
2000 (Garcia-Doval et ai, 2012a). Every crystal was obtained from the same protein
purification experiment and later attempts to replicate these crystals had failed.

Continuing this work, we tried to co-crystallize gpl7(371-553) fragment, purified as
indicated in Garcia-Doval et al., 2012a, with kojibiose. Gpl7(371-553) at 6.5 mg/mL
(0.26 mM) was incubated with kojibiose at 1.7 mg/mL (5 mM) for 4 h at 20 °C. Vapour
diffusion crystallization experiments at 20°C in sitting-drop CrysChem plates
(Hampton Research) with 0.5 mL reservoirs and drops consisting of 2 pL proteinligand solution mixed with an equal volume of reservoir solution were set up. The
precipitant conditions contained 0.2 M TMAO in a gradient from 0 to 25% of PEG
2000 MME and 0.1 M buffer from pH 7.5 to 9.0. No crystals were obtained. The same
conditions were tried using the protein without ligand, with similar results. To
overcome this problem, it was decided to screen a wide range of precipitants and
crystallization

conditions.

Different

drop

volumes,

crystallization

plates,

temperatures and protein concentrations were also tried. In total, more than 3000
different conditions were tried.

A flower shaped multi-crystal, with independent lobes radiating from a single
nucleation point, was obtained in 15% PEG 2000 MME, 0.1 M Tris-HCI pH 8.5, 0.2 M
trimethylamine N-oxide (TMAO) with protein at 6 mg/mL (Figure ll.lOA). A screen
to optimize it containing 13-18% PEG 2000, 0.2 M TMAO, 0.1 M Tris-HCI pH 8.2-8.8
was designed. Crystallization assays were set up at 20°C in sitting-drop CrysChem
plates (Hampton Research) with 0.5 mL reservoirs and drops consisting of 2 pL
protein solution mixed with an equal volume of reservoir solution. Five different
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concentrations of gpl7(371-553) were used (25 mg/mL, 20 mg/mL, 15 mg/mL,
10 mg/mL and 5 mg/mL). In addition to this, co-crystallization was assayed with
25 mg/mL of gpl7 371-553 and 10 mg/mL of kojibiose.

Crystals grew in conditions containing 17% PEG 2000 MME, 0.1 M Tris-HCI pH 8.6,
0.2 M TMAO (Figure ll.lOB). They were incubated with 300 mM kojibiose for 24 h,
cryoprotected with 20% glycerol and transported to the synchrotron (Figure lO.lOB).
The crystals obtained in 15% PEG 2000 MME, 0.1 M Tris-HCI pH 8.5, 0.2 M TMAO
were incubated for 5 min to 24 h with 300 mM kojibiose, cryoprotected with 20%
glycerol and transported to the synchrotron. These crystals were the ones that
allowed the determination of the structure of gpl7(371-553) in complex with
kojibiose.

B

Figure 11.10: Gpl7 371-553 crystals. A) Crystals obtained in 15% PEG 2000 MME, 0.1 M
Tris-HCI pH 8.5 and 0.2 M TMAO that allowed to determine the structure of the proteinligand complex. B) Crystals obtained in 17% PEG 2000 MME, 0.1 M Tris-HCI pH 8.6 and
0.2 M TMAO.

11.7 Structure determination of gpl7(371-553) bound to kojibiose
X-ray diffraction was collected at the XALOC beamline of the ALBA synchrotron
(Juanhuix et ol., 2014) and a diffraction pattern was obtained with enough quality to
determine the protein structure at atomic level. The different diffraction patterns
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obtained from gpl7{371-553) crystals were indexed, integrated and scaled. The best
crystal diffracted to a resolution of 1.75 A, belonging to the space group P2i2i2i with
unit cell parameters a = 61.9 A, b = 85.4 A, c = 119.0 A, a = (3 = y = 90°. Table 11.3
shows the data collection statistics.

Table 11.3: Diffraction statistics of gpl7 371-553 with kojibiose.

gpl7 371-553 native
Parameter

(Garcia-Doval et al., 2012a)

gpl7 371-553 soaked
with kojibiose

PDB code 4A0T
Space group

P 2i2i2i

P 2i2i2i

(A)
3; V (°)

61.2, 86.0, 118.4

61.87, 85.43, 119.04

90.00, 90.00, 90.00

90.00, 90.00, 90.00

0.97920

0.96600

BM14 (ESRF)

BL13-XALOC (ALBA))

a, b, c

Wavelength

(A)

Beamline
Temperature (K)
Resolution

(A)

100

100

20.0-1.9 (2.00-1.90)

85.4-1.75 (1.78-1.75)

No. of reflections
Total

50,056 (7,224)

Unique

142,630 (7,092)
50,907 (2,652)

Mn/'//a/)
merge

Completeness (%)
Multiplicity

6.3 (2.5)

7.7 (2.6)

0.093 (0.292)

0.07 (0.332)

99.9 (100.0)

79.7 (76.4)

3.7 (3.7)

2.8 (2.7)

"The values in brackets belong to the highest resolution shell.

As the crystal parameters were close to the ones of the native crystal with PDB code
4A0T (Table 11.3) a

direct rigid body refinement with 4A0T as a model was

performed. Several rounds of model building and restrained refinement were
performed until refinement
Rwork=

0.158 and

Rfree=

R

factors converged. The final refinement

R

factors were

0.197. The statistics of gpl7(371-553) with kojibiose

refinement are shown in Table 11.4.
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Table 11.4: Refinement statistics of gpl7 371-553 with kojibiose.
Parameter
Resolution

gpl7 371-553

(A)

85.4-1.75 (1.78-1.75)
0.158/0.197

Rwork/Rfree

No. atoms (not H)
Protein (not FI)

4,331

Kojibiose

138

TMAO

15

Tris

8

Pentaethylene glycol

12

Glycerol

24

Waters

468

Wilson B factor (A^)

17.7

Average B, all atoms (A^)

18.53

Bond RMSD
Distances (A)

0.0106

Angles (°)

1.7095

Ramachandran (%)
Favoured

97.05

Outliers

0.28

Rotamers (%)
Favoured

96.5
0

Bad

11.8 Kojibiose biding sites
Apart from the protein (one trimer of gpl7 371-553), electron density for six kojibiose
molecules, three trimethylamine N-oxide (TMAO) molecules, a Tris molecule, a
pentaethylene glycol molecule, three glycerol molecules and 468 water molecules
were observed in the asymmetric unit (Figure 11.11).

A kojibiose molecule was found near the tip domain of each of the three chains of
the trimer (site 1). The possible residues interacting with the non-reducing end of the
kojibiose (as predicted by STD-NMR) are Gly480, Arg540, Arg542 and Val544 (Figure
11.12A-B). The complementation assay performed before crystallizing the protein
had already identified two of these residues as important for infectivity, being the
mutant D540A and V544A able to infect B derived strains but not K-12 derived ones
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(see section 11.2).These results agree with the ones obtained by Heineman et al.,
who determined that mutation V544A impairs the phage binding to K-12 strains
(Heineman et al., 2008). Surprisingly, a second binding site for kojibiose was found in
the pyramid domain (site 2). The non-reducing glucose of kojibiose interacts with
His431, Ala440, Asp442, Asn444, Trp454 and Asp456 (Figure 11.12C-D). No mutations
had been previously generated for these residues because this was not an expected
binding site for the ligand.

4. -I

.."V

Figure 11.11: Structure of gpl7 371-553 trimer soaked with kojibiose. Kojibiose is
represented as dark orange sticks. Some molecules from the crystallization buffer (PEG,
TMAO, Tris and glycerol) are shown in stick representation. Water molecules are
omitted.Figure generated with PyMOL (Delano, 2002).
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Kojibiose

la440'
Asn444

Asp442

His431

Figure 11.12: Kojibiose binding sites. A) Electron density for kojibiose in binding site 1. B)
Residues involved in the interaction with kojibiose in binding site 1. C) Electron density
for kojibiose in binding site 2. D) Residues involved in the interaction with kojibiose in
binding site 2. Panels A and C were generated using Coot (Emsiey et ai, 2004). Panels
B and D were generated using PyMOL (Delano, 2002).

Three glycerol molecules are bound to the interface between two monomers in the
tip domain. Each glycerol molecule interacts with AlaSlS, Ser519, Asp520 and AsnSOl
from one monomer and with PheSlG, Trp523 and Arg525 from its neighbour (Figure
11.13). It is possible that the glycerol molecules also mimick a ligand binding site.
Complementation assays showed that mutations AlaSlS, Ser519, Phe516, Trp523 or
AsnSOl to Ala drastically decreased the infectivity of T7 in both TOPIO and BLR(DE3).
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Substitution D520 with alanine impaired the infectivity of gpl7 in B derived, but not
in K-12 strains. Arg525 was not mutated (see section 11.2).
A trimethylamine N-oxide (TMAO) molecule was crystallized in the pyramid domain
region of every monomer. This molecule is located in a region rich in
tyrosines/serines. Its presence could have biological significance and mimick some
substrate or just be a crystallization artifact (Figure 11.13B).

B
Ser519
Ala 518

Glycerol
Phe516
Tyr387

AsnSOl
Trp523

Ser402
Arg525

Figure 11.13: Secondary ligand binding sites. A) Binding site for glycerol (grey). The
interacting residues from one monomer are represented in green, while the ones
belonging to the other monomer are represented in magenta. B) Binding site for TMAO.
Figure generated with PyMOL (Delano, 2002).

11.9 Generation of new mutants
As a second binding site for kojibiose was detected on the pyramid domain of
gpl7(371-553), new mutants were generated for the residues involved in the
interaction with kojibiose: W454A and D442A. It was determined that both mutants
reduced the infectivity of T7 phage in both TOPIO and BLR(DE3) strains, confirming
the importance of the binding site 2 (Table 11.5). This site might help the phage to
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weakly recognize the lipopolysaccharide when the fibres are still attached to the
capsid of the phage (Hu et ai, 2013).

In 2006, Quimron et ai, aside from postulating that the first glucose and the terminal
glucose/heptose of lipopolysaccharide may play a significant role in receptor
recognition, generated T7 phage mutants with expanded host range. T7-Re mutant
can infect a host with the Re lipopolysaccharide and can still retain its infectivity on
wild-type E. coli with high efficiency. T7-ReRb can infect all the hosts that T7-Re is
able to infect, plus those containing Rb lipopolysaccharide. T7-ReRd2Rb can also
infect hosts containing Rd2 lipopolysaccharide. Sequencing of these mutant phages
identified that T7-Re contained the substitution gpl7-N501H, T7-ReRb contained the
mutations

gpl7-N501H

and

gpl7-R542H,

and

T7-ReRd2Rb

contained

the

substitutions gpl7-N501H, gpl7-R542H and gpl7-V544A, among other mutations in
different proteins of the phage (Quimron et ai, 2006). The structure of the different
lipopolysaccharide mutant strains can be seen in Figure 11.14.
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Figure 11.14: Structure of different lipopolysaccharide mutant strains. Extracted from

Qimron et ai, 2006.

These three residues had already been mutated to alanine and analysed by
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complementation assays, resulting in the mutant N501A not being able to infect K12 nor B strains. V544A could only infect B derived cells and R542A could infect both
strains (see section 11.2). In addition to this, the crystal structure of the protein with
kojibiose had allowed us to identify Val544 and Arg542 as the amino acids interacting
with kojibiose on binding site 1 (see section 11.9). Interestingly, AsnSOl is one of the
amino acids located in the glycerol binding site, supporting the hypothesis that
glycerol might be mimicking a secondary binding site for other residues of the
lipopolisaccharide. Given the fact that the mutation N501H allows the infection of Re
lipopolysaccharide mutants (Quimron et al., 2006), it is possible that this binding site
recognizes KDO or KDO-KDO present in the Re lipopolysaccharide and the
substitution of asparagine by histidine increases the affinity for this ligand.

Mutants N501H and R542H (V544A had already been tried), double mutants N501HR542H, N501H-V544A and R542H-V544A and the triple mutant N501H-R542H-V544A
were generated by site directed mutagenesis. A preliminary complementation assay
on TOPIO was performed on these mutants. While V544A, R542H and the double
mutant R542H-V544A decreased the infectivity of T7 in TOPIO; N501H, the double
mutants N501H-\/544A and N501H-R544H, and the triple mutant maintained the
same infectivity in TOPIO as the wild type phage. This suggests that the mutation
N501H can revert the effect of the other mutants. The hypothesis for this is that the
mutations R542H and V544A modify the primary ligand binding site of the tail fibre
and prevents the recognition of K12 strains, starting the recognition of Rd2/Rb strains
instead. The mutation N501H modifies a secondary ligand binding site able to
recognize both KDO or KDO-KDO when they are exposed (Re mutants) and the last
glucose/heptose present in K-12 strains. An STD-NMR of the N501H mutant with
KDO-KDO and with glucose/heptose and a co-crystallization, in case of obtaining
signal for the ligands, could be used to prove this hypothesis. Testing the different
mutants in cell strains showing different types of lipopolysaccharide to determine
their effect on infectivity could also be used to study the effect of every mutation on
infectivity.
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Table 11.5: Effects on infection of different gpl7 mutants in BLR and TOPIO cell strains (2)

Genotype

TOPIO

WT
S454A
D442A
V544A
N501H
R542H
N501H-R542H
N501H-V544A
R542H-V544A
N501H-R542H-V544A

-t-t-f-

BLR(DE3)

-

-

-

-

-

+++

+
-

+
+
-

+

An article by Ando et al. published in 2015, describes that phage T3, which infects E.
coli B and Yersinia phage R, show 99.5% of identity between their fibres, presenting
only three amino acid substitutions in the C-terminal region. Substituting these
residues in T3 tail by their equivalent ones in phage R (S478G, S523L and A544S)
increased host range of phage T3, making it able to infect different Yersinia
pseudotuberculosis strains (Ando et al., 2015). In T7, these amino acids correspond
to Ser475, Ala518 and Aia539. A change of the host range of T7 could be tried by
making the substitutions S475G, A518L and A539S, expecting to obtain a T7 phage
able to infect Yersinia strains. The substitution A518L had been already tried in our
first complementation assays (section 11.2), leading to a loss of infectivity on both
K-12 (TOPIO) and B (BLR(DE3)) strains.

11.10 T7 chimeric fibre
The generation of phages with chimeric fibres with altered host range or for example,
conjugated to antibodies to use the phage as a vector or a detection system, is a
promising technique. However, it has some drawbacks. In the case of T7, the fibres
are trimeric, and they need their C-termini to trimerize and to be soluble and stable,
while the C-terminal ends are relatively inaccessible for modification. The change of
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the C-terminal host-recognition tip domain by the C-terminal domain from other tail
fibre may be successful and induce trimerization or not, resulting in an insoluble fibre.
Substituting the C-terminal tip domain by monomeric proteins or nanobodies would
probably lead to the production of insoluble, improperly folded protein.

As an alternative to this, a T7 fibre chimera was created substituting the tip domain
by the trimerization domain of the T4 fibritin protein (foldon domain. Figure 11.15B).
The foldon corresponds to the 27-amino acid C-terminal domain of T4 fibritin, that
can fold and trimerize autonomously (Frank et ai, 2001). It can also be used to induce
the trimerization of other proteins (Papanikolopoulou et al., 2004). In these cases,
the length of the linker region between the foldon and the rest of the protein is
important. If it is too long, the linker region may be susceptible to proteolysis, be too
flexible, or the trimerization signal might not be transferred to the protein, but, if it
is too short, the protein might fail to fold correctly due to steric effects. The foldon is
a very small domain and its C-terminus is not located in internal regions of the
protein, but on the opposite end of the N-terminus. This property would allow us to
introduce a tip domain or even a monomeric protein just after it, at the C-terminus
of the protein, without affecting the trimerization (Figure 11.15C).

A synthetic gene containing an N-terminal histidine tag, amino acids 371 to 467 from
T7 gpl7 (corresponding to the shaft domain), a short GS linker and T4 fibritine cloned
in pEt30a+, was ordered from Genscript®. The plasmid was expressed in BL21(DE3).
Samples of the pellet and the supernatant before and after heating to 95 °C were
analysed by SDS-PAGE. A super expressed protein band with the size of the monomer
could be observed in the heated fractions, while a protein band corresponding to the
size of the trimer could be observed in the non-heated fractions. These results
indicate thatT7 chimericfibre is trimerizing correctly, forming stable trimers resistant
to the action of SDS and soluble (Figure 11.15D). Different head domains and protein
constructs could be bound to this chimeric structure in the future, to generate phages
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with altered host range or affinity. To design these fibres, the length of the linker
between the foldon and the tip domains will have to be carefully studied.

Sn

Sn

P

Trimer
(60 kDa)

Monomer
(19 kDa)

Figure 11.15: Chimeric gpl7 shaft-foldon fibre design and expression. A) Wild-type gpl7.
B) Gpl7 shaft (371 to 467)-foldon chimera. C) Different designs for future chimeric

proteins, where head domains could be swapped. D) SDS-PAGE showing that the chimeric
fibre is soluble and trimeric.
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12-Discussion
Peptidoglycan cleaving and remodelling enzymes show a high diversity (Alcorlo et oi,
2017). They can be composed of a single catalytic module or be multimodular,
containing several cell wall-binding and catalytic modules. These enzymes differ in
their folds, their target link and their catalytic mechanisms. Different approaches can
be adopted by different enzymes to cleave the same target peptidoglycan links, but
in general, all endolysins are formed by different combinations or shuffling of a
limited number of modules.
The interest in phage-encoded peptidoglycan hydrolases is growing due to their
prospective use as an alternative to antibiotics. A wide variety of endolysin-derived
drugs is necessary for different applications, like antimicrobial agents to treat
resistant infections, bacterial identification, sterilization of surfaces or for
agricultural, livestock and the food industry. Each of these applications requires the
use of endolysins with different characteristics: wide lytic range or high specificity,
high resistance to hot or cold temperatures, or thermal lability, and resistance to a
variety of pH, salinity or humidity.
To obtain these custom-designed endolysins, the known catalytic and cell wall
recognition domains can be combined in different ways to create new proteins with
the selected properties. Some regions can be added to these domains to increase
their solubility or hydrophobicity, as in the case of artilysins, where an outer
membrane permeabilizing region is added to allow them to pass through the
bacterial outer membrane and to be effective even when applied exogenously.
Directed mutagenesis techniques can also be used to modify the characteristics of
these enzymes.
To be able to genetically engineer these enzymes, knowledge is required about their
characteristics, their structure, their catalytic mechanisms, their regulation and the
role their residues play on them. To date, the structure of domains showing each of
the catalytic activities have been determined: muramidases, glucosaminidases,
transglycosilases, amidases and endopeptidases (both metallopeptidases and
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cysteine-histidine dependent aminopeptidases). Regarding the cell wall binding
domain, there are structures available for several SH3 domains, CW_7 family
(showing both 3-helix bundle repeats or a/(3 modules) and CW_1 family (choline
binding). Some full-length endolysins have been crystallized, but only two of them
are composed of more than one peptide, PlyC from streptococcal Cl phage (PDB code
4F88) and CTPlLfrom Clostridium phage phiCTPl (PDB code 5A6S) (Broendum et oi,
2018). Although they share a similar function, bacteriophage-encoded enzymes that
specifically target pathogenic bacteria are highly diverse and their purification
techniques and crystallizability are different. Adequate conditions had to be found
for every protein in order to determine their structure. This fact makes structure
determination and the elucidation of their binding and catalytic mechanisms a
challenging and interesting task.
In this thesis, the structures of two different N-acetyl-muramidases have been solved,
namely those of gp46 from Pseudomonas aeruginosa phage vB_PaeM_KTN6 and of
gpl97 (also called Y3_197) from Erwinia amylovora phage vB_EamM_Y3. Both target
Gram-negative bacteria and they present a single module, divided in two domains.
While gp46 belongs to the glycoside hydrolase family 19, Y3_197 is a member of the
glycosyl hydrolase 108 family. Their catalytic mechanism is similar. Both are inverting
glycoside hydrolases where a nucleophilic water, activated by a general base (Glu60
in gp46 and Asp29 in Y3_197) cleaves the P-(1^4) link of the Cl carbon of the
peptidic MurNAc, while the general acid (GluSl in gp46 and Glul8 in Y3_197) donates
a proton to GInNAc. The general base is assisted by a water-positioning amino acid
(Thrl33 in gp46 and Thr34 in Y3_197).
The main difference between these two enzymes is their groove. In gp46 it is deep
and open, giving the protein its characteristic pac-man shape. In Y3_197 this groove
is small and closed, probably able to alternate between open and closed
conformations thanks to the movement of the loop capping the groove (Figure
12.lA). Y3_197 presents two different domains: an a-domain and a p-domain. To
allow the entry of the substrate, the protein adopts an open conformation. The P-
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domain partially unfolds and moves away from the site where the groove is located.
In this conformation, the catalytic residues are not at distances and geometrical
conformations suitable for catalysis. Once the substrate enters into the cavity, the
protein adopts a closed conformation. The p-domain refolds and moves towards the
groove, causing the reconstitution of the catalytic site, formed by Glul8, Asp29 and
Thr34. Once the peptidoglycan cleavage is produced, the protein returns to the open
conformation. The p-domain unfolds to allow the exit of the cleaved peptidoglycan
and to be ready for the entry of a new substrate (Figure 6.16).
The opening and closing motion had already been observed in muramidases such as
T4 lysozyme. Without peptidolycan substrate, T4 lysozyme remains in its open
conformation. After peptidoglycan is added, the lysozyme transitions to a closed
processive conformation. The change of conformation is caused by an 8 A hinge
motion that brings the two lobes of the enzyme closer (Akhterov et al., 2015). This
movement could explain the differences in thermal agitation observed between the
large and small domains of gp46. The protein might show certain flexibility due to a
hinge or torsion component centred on the catalytic groove. This movement would
generate open and closed conformations, allowing the deep groove to accommodate
and stabilize the peptidoglycan glycan strand, as in the case of T4 lysozyme. In these
two enzymes, the differences between the open and closed conformations are not
as drastic as the observed between the open and closed conformations of Y3_197. In
this protein, the catalytic groove is capped by a p-hairpin in the closed conformation.
This structure would impair the entry of the substrate. To allow access of the
peptidoglycan to the catalytic groove, the p-domain of the protein must suffer a
severe change, partially unfolding away from the groove. Once the substrate has
entered, the P-domain returns to its original position. The motion of the catalytic
base Asp29 from the closed conformation to the predicted open conformation could
vary between 35 A and 45 A.
When the structures of these enzymes are superposed (rmsd 3.5), it can be observed
that they just share the three central a-helices, where the catalytic residues are
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located (Figure 12.1C). The bases of their grooves are perfectly aligned, but they open
in different directions (Figure 12.IB). Their catalytic general acid nucleotide (GluSl in
gp46 and GlulS in Y3_197) is located at the C-terminus of a conserved a-helix, being
placed in the same location in both structures, but the position of the general base
and the water-positioning threonine varies between both proteins (Figure 11.ID).
The structures of these two proteins were sent to the 13th Community Wide
Experiment on the Critical Assessment of Techniques for Protein Structure Prediction
(CASP13, http://predictioncenter.org/caspl3/results.cgi), where several groups tried
to predict their structures using different in silico methods. Gp46 (T0962) was
classified as an easy template-based modelling target, due to the existence of a
template for a high percentage of the protein with high sequence similarity. Almost
half of the groups got close to the overall structure of the protein, but all of them
failed to predict the region from residue 75 to 100, a loop region.
Y3_197 was classified as a hard template-based modelling target (T0951), due to the
absence of a good model that might help to predict the structure. Most of the groups
did a good job at predicting the overall structure of the protein, but all of them failed
at predicting the regions 110-120 and 180-189 corresponding to a loop and a bent ahelix, respectively.
The results are quite satisfactory. Usually, the higher number of proteins with
sequence similarity and the higher the identity with those models, the best result is
obtained for an in silico model of a query protein. Due to this, as long as the number
of endolysin domains determined and deposited on the Protein Data Bank (PDB)
increases, better predictions will be made for unknown structures. By determining
the structure of an endolysin domain, not only that specific protein structure is
determined, but it will also help to predict more accurate models for other related
endolysins.
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rl33

1
Glul8
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Glu60
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Figure 12.1: Comparison between gp46 and Y3_197. A) Overall structure of gp46 (cyan)
and Y3_197 (green). Big differences in the size and shape of their grooves can be
observed. B) Superposition between the surfaces of gp46 (cyan) an Y3_197 (green),
showing that they share their groove position. C) Superposition between gp46 (cyan) an
Y3_197 (green) showing as cartoon the regions they share and as ribbon the regions that
differ. Gp46 catalytic residues are represented in pink, while Y3_197 ones are represented
in yellow. D) Comparison of the catalytic residues of gp46 (pink) and Y3_197 (yellow),
showing that only the position of the catalytic acid (GluSl in gp46 and GlulS in Y3_197)
is conserved. Figure generated with PyMOL (Delano, 2002).
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The structure of gp239 endolysin, a muramidase from Enterobacteria phage
vB_PcaM_CBB could not be determined despite obtaining protein crystals. One
reason for this may be the low quality of the crystals, with far from ideal statistics.
The other reason is the absence of an adequate protein model or new crystals to
perform an experimental phasing. Due to this, I tried to obtain better molecular
replacement models using different in silico methods. However, these models did not
allow to solve the structure of the protein either. The in silico models were highly
similar to each other despite the different computer programs used, suggesting the
predicted structures may be quite accurate. The catalytic mechanism of this protein
is similar to the mechanism of the determined muramidases, being the catalytic
residues in this case Glu20 and Asp42 and, the water positioning residue, Thr48. The
overall shape of the protein is different to the ones of gp46 and Y3_197. In this case
the predicted groove is not as large as the one in gp46 or as closed as the one In
Y3_197 (Figure 12.2A). By doing a structural superposition with these proteins, the
position of the catalytic amino acids coincides perfectly with their positions in one of
the determined structures (Glu20 with GlulS from Y3_197 and GluSl from gp46,
Asp42 with Glu60 from gp46 and Thr48 with Thr34 from Y3_197). The catalytic
grooves are located in the same region (Figure 12.2B). This suggests that the models
are largely correct.
The structure of CHAP domain (CHAPk) of LysK endolysin from staphylococcal phage
K was determined in complex with triglycine. Several structures have been obtained
for CHAP domains: CHAPk (PDB codes 4CSH and 4CT3), the CHAP domain of
staphylococcal phage GH15 (PDB code 40LK), the phage-associated cell wall
hydrolase PlyPy from Streptococcus pyogenes (PDB code 5UDN), the endolysin
Lys7917 from Streptococcus phage phi7917 (PDB code 5D76) or the endolysin PlyC
from Streptococcus phage Cl (PDB code 4F88). In this case, the structure was
obtained in the presence of a substrate analogue (triglycine, as the protein cleaves
between the pentaglycine bridge and the D-alanine of the stem peptide of
peptidoglycan). Surprisingly, the ligand was not found in the catalytic groove of the
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protein, but in a secondary cleft, identifying a putative secondary binding site for the
peptidoglycan.

Thr48
% Gli)
Glu20

V

y

Thr34

|rAsp42

3'
Asp29

GluSl
Thrl33

Figure 12.2: Comparison of CBB_239 structure prediction with gp46 and Y3_197. A)
Overall structure of CBB_239. B) Superposition between the surfaces of gp46 (cyan),
Y3_197 (green) and CBB_239 (yellow), showing that they share their groove position. C)
Comparison of the catalytic residues gp46 (cyan), Y3_197 (green) and CBB_239 (yellow).
Figure generated with PyMOL (DeLano, 2002).

The crystallization of two additional CHAP domains, belonging to the staphylococcal
phage DW2 endolysin (CHAPemss) and tail hydrolase (CHAPthdwz) was attempted. No
protein crystals were obtained, probably due to the presence of flexible or disordered
regions in the sequence. In silico models were generated for these proteins, showing
high resemblance to CHAPk. CHAPemss was structurally aligned to CHAPk (rmsd 0.8)
showing a conserved catalytic triad corresponding to Cys32, His95 and Glulll
residues. The predicted overall structure is identical to that of CHAPk except for the
absence of the N-terminal a-helix and the presence of a loop near the catalytic groove
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that might be regulating the access of the peptidoglycan to the catalytic cleft.
CHAPthdwz

was also aligned to

CHAPk

(rmsd 1.5), the catalytic triad is perfectly

conserved and corresponds with residues Cys38, HislOO and Aspll7. The only
difference between them is the absence of the first a-helix and the presence of an
extra disordered region in the C-terminus of

CHAPthdwz

(Figure 12.3). These are

examples of the importance of the presence of a good model and of how the same
fold can be adapted by different species to incorporate modifications that might vary
the protein function.

Figure 12.3: Superposition of the structure of CHAPk onto models of CHAPthdw2 and
CHAPei -153.

CHAPk (green)

presents

an

extra

N-terminal

a-helix

(red

arrow),

CHAPTHDW2(cyan) shows an extra C-terminal disordered region (blue arrow) and CHAPemss
(magenta) presents an extra loop near the catalytic groove (black arrow). Figure
generated with PyMOL (Delano, 2002).

The endolysin from Listeria monocytogenes phage vB_LmoS_293 was cloned and
purified, although crystallization has not been assayed yet. It contains an amidase
domain, one of the domains with higher potential as wide spectrum antimicrobial
agent, due to its ability to cleave the link between muramic acid and the stem
peptide, present in every bacterium. In addition, it is not as easily modified as the
glycidic part of the peptidoglycan.
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There is a great diversity of peptidoglycan-degrading enzymes that could be used as
a tool for the development of antibacterial agents. To discover a novel endolysin, a
potential candidate gene should be identified bioinformatically, it should be cloned,
expressed, purified and its activity should be evaluated both in vitro and in vivo.

Endolysins are not naturally designed to lyse a cell when applied exogenously. In
nature, they have evolved to act from within and after the holin-mediated collapse
of the membrane potential, that is, after cell death. Although endolysins from phages
infecting Gram-positive bacteria are able to perform "lysis from without" under
certain experimental conditions, it should be checked that they are able to perform
it under physiological conditions and in dividing cells. Naturally, phage endolysins are
not designed to be stable outside the bacterial cell, they are produced and they act
in the intracellular space, so their stability and activity into a complex biological
system such a mammal's body should be tested. To assess the endolysins' potential
for in vivo applications, their performance should be evaluated under different
ranges of pH, temperatures and ionic strengths and also using different environment
conditions and cells in different physiological states mimicking a more likely in vivo
scenario (Oliveira et oi, 2018).

On the other hand, virion associated lysins (VALs), are naturally designed to act "from
without". They need to maintain their stability and activity under different
physiological conditions to allow the phage infection. These characteristics make
them an ideal potential antibacterial agent (Oliveira et al., 2018).

Phage-derived lytic enzymes can be genetically engineered to improve their activity,
their bactericidal spectrum and their properties, and to be used as antibacterial
agents towards Gram-negative bacteria. To be able to design custom-made lytic
enzymes, a deep structural knowledge on these proteins is required.
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The modular character of peptidoglycan hydrolases from Gram-positive systems has
allowed the shuffling and fusion of different catalytic domains or cell wall binding
domains to create chimeric enzymes with modified properties, called chimeolysins.
For instance, a chimeric lysin with the endopeptidase of PlyllS, the endolysin of L
monocytogenes phage A118, and the cell wall binding domain of PlyPSA, the
endolysin from L monocytogenes phage PSA, showed threefold higher activity
against Listeria than the original PlyPSA (Schmelcher et ol., 2011). Other chimeolysins
show a wider lytic spectrum than the native lysin (Schmelcher et ol., 2012; Becker et
al., 2009). VALs catalytic domains have also been used to generate chimeric lytic
enzymes. They present increased thermostability than those of endolysins (Lavigne
et al., 2004; Briers et al.,2008) and they are prepared to act exogenously, but they
lack cell wall binding domains. These binding domains can be added in order to
generate a chimeolysin. An example of this is the increase in staphylolytic activity of
the 5. aureus phage philPLA88 virion lysin HydHS by adding the cell wall binding
domain of lysostaphin (Rodriguez-Rubio et al., 2012).

Apart from domain swapping, other strategies have been used to increase the
features of some endolysins. These strategies include fusion to lytic enzymes
(Donovan et al., 2016), domain deletion (Morgan et al., 2009), domain addition
(Rodriguez-Rubio et ol., 2012), domain duplication (Schmelcher et al., 2011), random
mutagenesis (Heselpoth et ol., 2012), site-directed mutagenesis (Heselpoth et ol.,
2015) or multimerization (Resch et ol., 2011). These strategies have not only been
used to improve the activity and host range of the phage lytic enzymes, but also to
increase their solubility, heterologous production or stability by combining then with
highly soluble domains, elimination of protein segment affecting the stability of the
protein or by codon optimization (Haddad Kashani et ol., 2017)

During this thesis, the CHAP domain of LysK, the endolysin of S. aureus phage K, was
determined in the presence of triglycine. CHAP domains have been widely used for
the generation of chimeolysins. The determination of its structure will allow to
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identify the amino acids and regions important for the stability of the enzyme and for
its specificity, that might be mutated to obtain endolysins with different properties.
Two new CHAP domains, the ones from the endolysin and the virion associated lysin
from 5. aureus phage DW2, have been cloned and expressed successfully. These
proteins could be used for the generation of new chimeolysins. Their structures have
been predicted through computational modelling, showing the differences with
other known CHAP domains that might influence their properties.
Gram-negative bacteria contains an outer membrane that acts as an obstacle for the
access of the endolysin to the peptidoglycan layer when applied exogenously. To
improve endolysin outer membrane penetration they can be fused to domains
targeting some kind of receptors or transport systems in the outer membrane (fusion
of pesticin of Yersinia pestis, that targets the OM transporter FyuA, to the N-terminal
domain of T4 lysozyme, Lukacik et ai, 2012) or to outer membrane destabilizing
peptides, to generate Artilysins (Sao-Jose, 2018).
In this thesis, the structures of two Gram-negative targeting proteins, namely gpl97
from Erwinia amylovora phage vB_EamM_Y3 and gp46 from Pseudomonas
aeruginosa phage vB_PaeM_KTN6, have been elucidated. These atomic resolution
structures could be used to design amino acid modifications or chimeric endolysins
that could be used as a treatment for fire blight disease, that causes important
economic losses in fruit production industry, or for P. aeruginosa infections, an
opportunistic human pathogen, especially affecting immunocompromised patients
and patients suffering cystic fibrosis (Murray et ai, 2007) and for which new
antibacterial agents are urgently needed. These modifications should be specifically
focused on increasing the activity of the protein and stability of the proteins and their
capacity to pass through the outer bacterial membrane of their hosts.

To date, different clinical studies of phase I, I/ll and II have demonstrated the safety
of phages and phage lytic enzymes. Phages can self-replicate and evolve to overcome
bacterial resistance, but this self-replication makes the pharmacokinetics of full
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particles a complex process influenced by both proliferation and decay. On the other
side, lytic enzymes dose can be calculated accurately. Phages have narrow host
ranges and, occasionally, phage cocktails should be used to treat every strain causing
an infection. These cocktails are complex to produce. On the contrary, lysins show a
broader specificity, determined by the chemical composition of the peptidoglycan,
being more flexible for the treatment of certain infections (review from Abdelkader
et oi, 2019).
Phages also produce tail fibre proteins to recognize their host receptors. These
proteins may have some enzymatic activity. Phage fibres fused to surfaces (Singh et
a\., 2009), fluorescent dyes, peroxidase (Denyes et oL, 2017) or beads (Tay et al.,
2012) can be used for the detection or immobilization of pathogenic bacteria
(Shmelcher et al., 2014). They can reduce specific bacterial colonization in \/i\J0
(Waseh et al, 2005). As diagnostics, tail fibres offer several advantages over other
technologies, such as antibodies, including greater stability, ligand specificity, and
affinity even against carbohydrate epitopes which are not typically recognized
effectively by most antibodies (Simpson et al., 2016). Phages with altered hosts
ranges can be obtained by changing their fibres or their C-terminus by other phages'
fibres or antibodies, or mutating some of their residues (Brown et al., 2017).
Producing soluble tail fibre proteins and obtaining well-diffracting crystals for them
is a challenge. They are trimeric and highly intertwined. They may require one or
more chaperones for their folding, and these chaperones may not have been
identified yet. The full-length protein is usually too flexible to be crystallized, but the
design of truncated version of the protein is a delicate process, because if the
truncation is produced at an incorrect location, the trimerization will be impaired and
the protein will aggregate. Their structures are hard to predict, partially because of
their complexity and variability, but also due to the lack of models. Phage
vB_LmoS_293 codes for a tail fibre with potential as antimicrobial. During this work,
a soluble properly folded truncated version of vB_LmoS_293 was purified and
crystallized, but due to the lack of a molecular replacement model, better crystals
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must be grown to obtain data of sufficient quality, plus a suitable heavy atom
derivative, to determine the structure of this protein.
During this work, the sugar moiety of the lipopolysaccharide recognized by T7 tail
fibre (gpl7) was identified as kojibiose, a disaccharide present in E. coli B and K-12
strains. The ligand binding sites of gpl7 were determined by X-ray crystallography,
unveiling a kojibiose binding site in the tip region and another kojibiose binding site
in the shaft, that might be important for the early stages of unspecific adsorption.
Acording to Hu et al., 50% of mature T7 virions observed by cryo electron tomography
had five fibers bound to the capsid while 30% of them had four. These fibres are
facing the phage head, allowing a higher rate of viral difussion. During adsorption,
fibres undergo a large rotation, probably due to the N-terminal domain pivoting on
its connection to the tail to explore a large volume in search of a cell (Hu et al., 2013).
The presence of a receptor binding site in the shaft of the tail fibre, as it was
determined in this work by X-ray crystallography, could be used to recognize the cell
surface while the fibres are folded against the phage capsid, allowing the phage to
attach weakly to their host bacteria while it is in a difussion favorable conformation.
This attachment would give time for the phage fibres to rotate and attach through
their tips to the cell membrane lipopolysaccharide. Through mutational studies, the
effect of 28 amino acids on infectivity to B and K-12 cells was determined. Phages can
change their host range by small point mutations in the C-terminus of their fibres,
amino acids that could lead to a putative host change have been identified by
comparison with the fibres of phages T3 and R. A putative secondary ligand site that
could recognize both KDO or KDO-KDO when they are exposed (Re mutants) and the
last glucose/heptose present in K-12 strains has been identified. This identification
was achieved comparing the results obtained by Quimron et al. (Quimron et al., 2006)
with the results obtained by analysing the infectivity of different T7 phage fibre point
mutants and the information obtained from the crystal structure of gpl7 in complex
with kojibiose.
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It was also determined that, in liquid media, the presence of fibres significantly
increases the infectivity of 17 phage on E. coli B derived cells, but on K-12 derived
cells, it only increases the infectivity at certain MOIs; and that at high MOIs (0.1-1),
tail fibres are not even necessary for the phage to infect B or K-12 cells.
A chimeric fibre with the shaft domain of 17 fibre and a trimerization domain from
14 fibritin has been designed and its trimerization and solubility proved. Different C-

terminal domains could be added to this chimera for different applications.
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13-Conclusions
The

endolysin

(muramidase)

gp46

from

Pseudomonas

aeruginosa

phage

vB_PaeM_KTN6 was crystallized and its structure determined by molecular
replacent. This protein has pacman-like structure with a deep catalytic groove were
the catalytic residues Glu60, GluSl and the water-positioning residue Thrl33 are
located.
The endolysin (muramidase) gpl97 from Erwinia amylovora phage vB_EamM_Y3 was
purified, crystallized and its structure was determined by Hg- experimental phasing.
This protein has a narrow closed groove that is capped by a loop. This loop can
probably move away from the catalytic groove to allow the substrate entry (open
conformation). Then the loop moves back to its original position (closed
conformation), the residues from the catalytic site Asp29, GlulS acquire the proper
distances and geometry for substrate conversion.
The endolysin (muramidase) gp239 from Enterobacteria phage vB_PcaM_CBB, was
purified and crystallized, but no molecular replacement model or new crystals to do
an experimental phasing were obtained. Its structure was predicted in silico, leading
to a hypothesis for its catalytic mechanism.
CHAPK endolysin from staphylococcal phage K was crystallized in presence of a
substrate analogue, triglycine. The substrate was not located inside the catalytic
groove, identifying a putative secondary binding site. The CHAP domains of the tail
hydrolase and endolysin staphylococcal phage DW2 were purified and its
crystallization trials were performed. No crystals were obtained. Nevertheless, in
silico models were generated, and their catalytic residues and particularities
identified.
Several truncated versions of the tail fibre and the endolysin from Listeria
monocytogenes phage vB_LmoS_293 were cloned and expressed. The tail fibre was
crystallized, but the low crystal quality and the absence of an adequate molecular
replacement model has avoided the structure determination.
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Kojibiose was identified as the sugar moiety of the lipopolysaccharide recognized by
the T7 tail fibre. The residues involved in the ligand recognition of the phage T7 fibre
were identified by biochemical and crystallographic methods. It was determined that
in liquid culture, the presence of fibres do not improve T7 infection to E. coli K-12 cell
strains, except at low multiplicities of infection. A soluble chimeric fibre with T7 fibre
shaft domain and foldon C-terminal region was designed.
As a continuation of this work, Y3_197 activity should be tested both in vivo and in
vitro. Both Y3_197 and gp46 should be crystallized in the presence of peptidoglycan
analogues to analyse their interaction with their ligand. Polycationic peptides could
be fused to their N-termini to analyse their stability and their efficiency as
antimicrobials. Their resistance to several pH, temperatures and ionic strengths
should also be tested.
CHAPk should be co-crystallized with pentaglycine, with Gly-L-Ala and with an
analogue of the peptidoglycan stem peptide to check if any of these compounds
binds to the catalytic groove. Once identified, the affinity of this compound could be
tested by surface plasmon resonance or isothermal calorimetry. Site-directed
mutagenesis could be assayed to increase the thermal stability of the enzyme.
CHAPthdwz

and

CHAPemsb

ideal crystallization conditions should be found to obtain

their atomic structure. Once obtained, the accuracy of the in silica modelling could
be evaluated.
CBB_239 crystals should be improved to obtain a good diffraction pattern that could
lead to the determination of the protein structure by molecular replacement or
experimental phasing.
vB_LmoS_293 tail fibre crystals should be improved to obtain diffraction to a good
resolution. Then, they should

be soaked

in

heavy atoms or produce a

selenomethionine derivatized protein to solve the phase problem. vB_LmoS_293
endolysin should be purified at a large scale and crystallization experiments set.

288

Crystallographic structure determination of bacteriophage-encoded enzymes that specifically
target pathogenic bacteria

Gpl7 complementation assays should be performed in tetraplicate to further confirm
the results obtained. More cells strains with different lipopolysaccharide composition
could be tested to increase the knowledge on the infectivity of each mutant. To
confirm the hypothesis that the mutation N501H modifies a secondary ligand binding
site able to recognize both KDO or KDO-KDO when they are exposed (Re mutants)
and the last glucose/heptose present in K-12 strains, an STD-NMR of the N501H
mutant with KDO-KDO and with glucose/heptose and a co-crystallization, in case of
obtaining signal for the ligands, could be performed.
A chimeric tail fibre with an antibody or an actual head domain from other phage tail
fibre attached to the C-terminus of the T7 phage fibre shaft domain/fibritin should
be built and expressed. If it is soluble, a vector containing the full-length chimeric
fibre could be generated and transformed into cells, that could be infected with the
T7 amber mutant unable to produce tail fibres, to obtain T7 phages with the chimeric
fibres instead of the native ones. The host range of these phages should be tested.
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Appendix A: Overview of protein
expression, cell lysis, protein purification
and protein analysis
A.l Protein expression
To obtain enough protein, cell expression is a critical step. A starter culture of the
expression cells carrying the recombinant protein vector was grown in LB medium
supplemented with antibiotics at 37 °C overnight.

Next morning, LB medium supplemented with antibiotics was inoculated with 1:100
of preculture and grown at 37 °C with shaking until the ODeoo reached 0.6. Then it
was induced with 1 mM IPTG and grown for several hours. To check the best
expression time, aliquots must be taken every hour to check when protein levels stop
increasing. If the soluble protein levels are low, the following techniques may be tried
(Lebendiker et al., 2014):
•

To express the protein at lower temperatures during longertimes (30 °C, 16 °C
or 20 °C for 16 hours or even 4 °C for 48 hours). Slower expression may allow
the protein extra time to fold properly.

•

To add some additives to the culture medium such as arginine, sorbitol,
glucose, sucrose or betaine.

•

To use a protease inhibitor cocktail.

•

To decrease the amount of IPTG used for induction.

•

To use cells with strong regulation of the expression such as cells containing
pLys cells or with tuneable expression, such a as Tuner (DE3).

•

To optimize the codons of your insert for the expression cells you are going to
use or to use cell strains with special codons such as Rosetta or Rosettagami.

•

To co-express the protein with chaperones like GroEL/GroES.

•

To change to a cloning vector with lower copy number.

•

To use fusion tags that increase solubility as maltose binding protein (MBP)or
glutation-S-transferase (GST).
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•

To redone a different more stable fragment of the protein.

After expression, cells were harvested by centrifugation (10 minutes 5000 x g),
resuspended in lysis buffer (10 mL per litre of cell culture) and stored at -20 °C. Lysis
buffer composition is important for the yield of protein purification, its pH must be
compatible with the protein to purify and with the first purification technique that
will be used. Lysis buffers in concentrations from 20 to 50 mM can be used. Salts from
50 to 600 mM are usually used to increase the ionic strength and, therefore, protein
solubility. A variable amount of glycerol (from 5 to 20%) can be added to avoid
unspecific protein-protein interactions. Some other solubilizing agents, ligands,
cofactors, detergents, chelators or protease inhibitors can be added to the lysis buffer
to improve the results.

A.2 Cell lysis
Cells were thawed on ice and lysed using several methods. If the cells suspension is
very thick, 10 pg/mL of DNAsel can be added:
•

French press: Good for high volumes. The plunger gets hot after several lysis
cycles and must be cooled down.

•

Sonication: Good for small volumes. The protein can be damaged due to the
high micro-temperatures reached in some parts of the sample. Lysis cycles
must be combined with ice incubation cycles. If foam is generated, protein
can be denatured in the air/liquid interface.

•

Bead beater: Fast method and good protein yields. Protein recovery and bead
regeneration can be time-consuming.

Lysozyme was avoided to help with the lysis, as it crystallizes very easily and even a
small amount maintained during the protein purification can lead to unwanted
lysozyme crystals. Lysed cells were centrifuged at 15,000 x g for 30 min to separate
cell debris (pellet) from soluble proteins (supernatant).
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A.3 Protein purification
To purify a protein, its physical and chemical properties that differ from other
proteins ones must be exploited. Several consecutive purification steps can be
performed. In general, with each step, the protein purity increases, but the protein
yield decreases. The chosen purification protocol depends on what the protein is
going to be used for. After each purification step, the purity and yield of protein must
be checked by SDS-PAGE.
A.3.1 Ammonium sulphate precipitation

At low ammonium sulphate concentrations, the addition of salt increases the
solubility of proteins as ions shield the protein molecules from the charges of other
molecules ("salting-in"). When the ionic strength is too high, the proteins start to
precipitate ("salting-out") because the salt competes with the proteins for the water
molecules, increasing the surface tension of water and causing the protein to fold
tighter. The surface area of the protein decreases and causes less protein-water
interactions, producing more hydrophobic interactions between proteins and
causing aggregation and precipitation (Figure A.l)

Figure A.l: Solubility of carboxyhemoglobin in various electrolyte solutions at 25 °C.

Adapted from Green, 1932.
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The ionic strength at which each protein precipitates is different, and this property
can be used to purify the protein of interest. If the protein of interest precipitates at
a certain percentage of ammonium sulphate, a first step adding a concentration of
salt just below that percentage will precipitate impurities with lower solubility. After
that, a second step adding more salt will precipitate the protein of interest, while
more soluble impurities will stay in solution. As this technique just reduces protein
solubility but does not denature it, the protein can be resuspended in a buffer
without ammonium sulphate. To remove the salt, it can be dialyzed or filtered using
a Centricon device (Millipore).
A.3.2 Affinity chromatography

Affinity chromatography technique is used to separate proteins according to their
affinity to a specific compound bound to a resin. Certain proteins can reversibly
interact with a compound (a ligand, an antibody, a metal or a protein), remaining
bound to the resin while the rest of proteins are not retained by the column. This
technique offers a high selectivity and resolution. To elute the protein of interest the
interaction must be reverted specifically by adding a compound that competes with
the resin or the protein or non-specifically changing the pH, ionic strength or adding
a chelating agent. His-tagged proteins interact specifically with Ni-NTA resins. The
nickel ion interacts with the imidazole group of the histidine, being the protein
retained by the column. This kind of affinity chromatography is known as IMAC
(Immobilized Metal Affinity Chromatography). The protein can be eluted with a 0-1 M
imidazole gradient, that will compete with the protein for the nickel.
A.3.3 Size exclusion chromatography

Size exclusion chromatography separates proteins based on their size. The column is
filled with spherical particles formed by polymer chains linked among them. The
molecules will diffuse through that network according to their size, being the bigger
ones eluted first as they do not interact as much with the pores of the spheres as the
smaller proteins. In general, the larger a protein or complex, the shorter its retention
time within the column. This is not always true, as protein shape can influence its
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retention time. For this kind of chromatography, proteins should not interact with
the resin, which is why some salt (100 mM sodium chloride or more) is usually added
in the running buffer. The fractionation range for every column depends on the size
of its pores. Each column is identified by two numbers, representing the maximum
and minimum molecular weight they can resolve.
A.3.4 Ion exchange chromatORraphy

Ion exchange chromatography separates proteins based on the charge differences on
their surface. Ionic interactions are formed between the charged polar groups on the
protein surface and the resin. If the local protein charge at the pH used is opposite to
the one in the column, it will be retained. The proteins with the same charge as the
column will not interact with it and will be eluted. To elute the proteins bound to the
column, a sodium chloride gradient can be used. The ions will bind to the column,
displacing the protein. For anionic exchange chromatography, the protein must be
negatively-charged or have a strong local negative charge, so it is usually performed
at a relatively high pH. For cationic exchange chromatography, the protein must be
positively-charged or have a strong local positive charge, so the pH of the buffer
should be relatively low.
For anionic exchange, a prepacked column containing a polystyrene/divinylbenzene
matrix substituted with quaternary ammonium (Q), a strong anion exchanger, was
used. For cationic exchange, the column matrix is substituted with sulfoethyl (S), a
strong cation exchanger.
For this thesis, anionic exchange chromatography was performed using a Resource
Q-6 (GE Healthcare) column and an AKTA purifier (GE Healthcare) system. Cationic
exchange chromatography was performed using a Resource S-6 (GE Healthcare)
column in the same system.
A.3.5 Hydrophobic interaction chromatoRraphy

Hydrophobic interaction chromatography separates proteins according to their
hydrophobicity. Proteins in a high ionic force buffer interact hydrophobically with the
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resin and are retained. They are eluted with a decreasing gradient of salt. As salt
concentration decreases, hydrophobic interactions become less favourable and
proteins dissociate from the column resin. In this work, an FF phenyl sepharose
column has been used.

Appendix B: Overview of protein
crystallization, X-ray diffraction and
structure determination
B.l Protein crystallization
One of the most common and powerful techniques to determine the threedimensional structure of a macromolecule at atomic level is X-ray crystallography.
This technique requires a number of complex steps, which are summarized in the
following sections. The first step is obtaining well-diffracting crystals.
B.1.1 Crystal growth
After purification, the protein solution is stable. As long as its concentration stays
below its saturation point, the protein will remain soluble. But in a supersaturated
solution, protein molecules will tend to aggregate and, most likely, precipitate.
However, if the kinetics of a supersaturated solution are controlled, the protein may
aggregate in an ordered fashion, leading to the growth of crystals. The phase diagram
of the crystallization process can help to understand the different stages that the
solution is experiencing (Figure B.l).
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Stable

metastable

unstable

Figure B.l: Protein crystallization phase diagram. At the beginning of the crystallization
experiment the protein is soluble. As the protein sample begins to lose water, both
protein and precipitant concentrations increase, and the sample reaches the metastable
aggregation zone. If the sample continues to lose water, the protein will reach the
nucleation zone, were the first crystal nuclei or clusters show up. New protein molecules
associate with these nuclei, making the crystal grow but decreasing the free protein
concentration in the sample. At some point, the protein concentration reaches the
solubility line and the crystal stops growing. If the protein and precipitant concentrations
are too high, the sample reaches the precipitation zone and amorphous precipitates are
formed. Adapted from Rupp, 2009.

Below the solubility curve, the solution is not saturated. However, if the solution is at
the solubility curve, an equilibrium is reached, leading to supersaturation and
precipitation once this curve is overtaken. If the degree of supersaturation is high,
the protein will precipitate fast and will be lost, but if the supersaturation is reached
slowly, precipitation will be delayed and protein molecules will have time to
accommodate into crystals.
The process by which the process of crystallization starts is called "nucleation", since
the first molecules of protein aggregating will form the so called "nuclei" or
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"clusters", initially composed of a small number of proteins packed in a lattice. Once
stable clusters are formed, crystal growth may begin, because creating new clusters
requires more energy than adding molecules to the existing ones. In this stage, the
remaining molecules of protein will get closer to the nuclei and will be inserted into
their layers and edges, contributing to the growth in size of these structures. During
crystal formation, the concentration of soluble protein decreases, leading the system
to return to the solubility curve. There, the system will reach equilibrium and the
growth of crystals will end.
The whole process of crystallization can be controlled by several factors, being tuned
in different conditions depending on the type of protein and thermodynamic
behaviour. The most common variables to consider in crystallization experiments
with proteins are (Mcpherson et ai, 2014; Kirkwood et a!., 2015):
•

Protein concentration; Statistically, many proteins have crystallized between
5 and 25 mg/mL, therefore this is a usual starting point. However, every
protein is unique, and its solubility can vary a lot. Some basic tests can be
performed to analyze the solubility of the protein sample before running
crystallization experiments.

•

Precipitants: The crystallization of a protein is performed in presence of
different elements, conforming the so called "crystallization condition".
Among these elements, precipitants are quite commonly used. Due to their
nature, and in a range of concentrations, they can promote the aggregation
of the protein while the supersaturation is being reached, assisting on the
nucleation and crystal growth. This kind of compounds acts by sequestering
water molecules, increasing the effective protein concentration. One of the
most common precipitants is poly-ethyleneglycol (PEG) at a variable range of
molecular weights.

•

Salts: Certain salts, at low concentration, help to stabilize the protein by
neutralizing local charges, preventing a massive precipitation soon after
supersaturation is reached.
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•

Additives: Additives include low molecular weight molecules that might bind
to unstable or flexible regions of the protein, stabilizing them and favouring
the packing and crystal growth.

•

pH: The solubility of a protein depends on its pi and the pH at which it is
solubilized. Therefore, different ranges of pH used to be screened to find the
best pH in every particular case.

•

Temperature: Low temperatures generally reduce thermal agitation and
ensure the stability of the protein. Hence, by controlling the temperature we
can reduce the flexibility of some regions, promoting an optimal packing
leading to crystals.

To understand some biological problems, the crystallization in presence of ligands
(analogues of substrates or products, inhibitors) might be required. Two different
methods are generally applied (Hassell et al. 2007):
•

Co-crystallization: The protein is incubated with the ligand for a certain time
and crystallization experiments are set up with this incubated solution.

•

Soaking: Once crystals of the protein have been obtained, they are soaked
into a solution containing the ligand, expecting that it will be absorbed by the
crystal, through the solvent internal channels, reaching their binding site.

Each of these techniques have some advantages and drawbacks. Soaking requires
less amounts of ligand, but the ligand binding site can be obscured by the crystal
contacts, and in some cases, the soaking with a ligand may distort the crystallographic
packing, decreasing or avoiding the diffraction. Co-crystallization requires higher
amounts of protein. The addition of a ligand can change the crystallization conditions,
may impair crystallization or, on the contrary, stabilize a certain conformation of the
protein, promoting crystallization.
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B.1.2 Crystallization setup

Ihere are several different methods that can be used to crystallize proteins
accounting for the previously described variables (Rupp, 2009). The ones used in this
thesis are described below (Figure B.2).

w
Sitting-drop
vapor diffusion
Figure B.2: Protein crystallization setups.

Micro-batch
under oil

Adapted from Rupp, 2009.

B.1.2 .1 Sitting drop vapour diffusion

This setup consists on a drop containing the protein and the crystallization condition,
sitting on a pedestal, next to a well containing a larger volume of crystallization
condition. This system is isolated by covering it with a non-permeable film. The sitting
drop is made up of a drop of protein and a drop of crystallization condition, mixed
together. Therefore, the crystallization condition in the drop will be diluted compared
with the crystallization condition in the well. Due to the difference in concentration
between drop and well, there will be a net transfer of solute from the crystallization
drop to the reservoir, reducing the size of the drop and slowly concentrating the
protein. Since the system is isolated, the equilibrium will be reached after certain
time, moment at which the experiment is finished. During this process, if the
conditions are optimal, supersaturation will be reached and controlled aggregation
and nucleation will occur, potentially leading to crystals.
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B.1.2 .1 Micro-batch under oil

This method is aiso based on concentration by evaporation but, in this case, a single
well is filled with a small volume of protein and crystallization condition, covered by
a layer of oil. The oil allows water evaporation into the environment but at a slow
rate. With this method the equilibrium is never reached, allowing to search for
crystals in those areas of the phase diagram that would not be reached if the
evaporation stops at a certain time. The rate of evaporation can be controlled by
using different oils or mixtures of oils. Here, mineral oil was used.
B.1.3 Search for optimal crystallization conditions

Since every protein behaves differently in a supersaturating environment, nucleating
and packing in different ways, the crystallization condition used to get crystals is
specific for every case. However, the components included in these conditions and
their range of concentrations and pH is usually similar for most of the proteins
crystallized to date. This means that the probability of obtaining crystals of a new
protein in previously known crystallization conditions is high. Therefore, many
companies distribute crystallization screens containing hundreds of conditions
chosen among the most successful experiments in past crystallization experiments.
There are screens of general use suitable for a large range of proteins, and screens
designed for specific cases, like membrane protein, protein complexes, etc. The
screens that have been used during this project are listed in Table B.l. Generally,
high-throughput techniques are used to test these initial screens, since hundreds of
conditions are tested at different protein concentrations and temperatures. In our
case, a Genesis RSP 150 workstation (Tecan Trading AG) nano-dispenser robot has
been used, setting up drops ranging in size from 0.3 to 1.2 pL, in Swissci MRC 2 and
Swissci MRC Maxi crystallization plates (Figure B.3).
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Figure B.3: Different kinds of crystallization plates. A) Terasaki plate used for microbatch
crystallization (Greiner Bio-One). B) Swissci MRC 2 crystallization plate used for sittingdrop vapour-diffusion technique. C) Swissci MRC 2 crystallization plate used for sittingdrop vapour-difusion technique. Images obtained from www.hamptonresearch.com.

Table B.l: Crystal screens used
Screen

Manufacturer

JBScreen Classic 1-10

Jena Biosciences

Pi-Minimal screen

Jena Biosciences

JBScreen PEG/Salt l-ll

Jena Biosciences

JBS screen basic HTS

Jena Biosciences

Crystallization cryo kit

Sigma Aldrich

Crystallization extension kit

Sigma Aldrich

Crystallization Kit for Protein-Protein Complexes

Sigma Aldrich

Wizard l-ll

Emerald BioSystems

Morpheus

Molecular Dimensions

Since these conditions are of general use, the obtained crystals could be small,
twinned or damaged. Sometimes a slight or even a crystalline precipitant is observed,
indicating that a condition similar to the one tested may allow the nucleation and
crystal growth. In those cases, the crystallization condition is optimized by trying
many conditions near the original hit (modifying the protein and/or precipitant
concentration, the pH, the temperature or adding detergents, salts or other kinds of
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additives) and the drops are scaled up, increasing the chances of growing better and
larger crystals, more suitable for X-ray data collection. Another method to improve
the crystallization in a given condition is to alter the proteimcondition ratio in the
crystallization drop, trying not only 1:1 ratio but also 1:2, 2:1, 3:1, etc. This way the
evaporation rate is changed, which may lead to better crystallization conditions.
A technique that can improve crystal quality is seeding (Bergfors, 2003). Once crystals
are obtained, they are broken up, generating microcrystals that can be used as seeds
to re-grow a crystal by adding new protein. To perform this experiment, a cat whisker
or fibre designed to catch these microcrystals is soaked into the solution containing
the smashed crystals. The microcrystals will stick to it and will be transported to a
new drop containing soluble protein and crystallization condition. Therefore, a new
vapour diffusion crystallization experiment is started but, in this case, containing
seeds for more controlled nucleation and crystal growth.

B.2 X-ray diffraction and structure determination
Once a crystal of good quality is obtained, the three-dimensional structure of the
protein can be determined from it. This is achieved by analysing the diffraction
pattern generated from an X-ray beam focused on the crystal. The following sections
contain a summary of the different steps that need to be followed along the process
(Figure B.4).
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Figure B.4: Simplified diagram of a crystallization experiment. An X-ray beam hits the

crystal and produces a diffraction pattern collected by a detector. By informatic tools, the
electron density of the protein can be obtained from this pattern. Finally, a protein
structure fitting this density is built. Adapted from Rupp, 2009.
B.2.1 Diffraction experiment
X-rays are electromagnetic radiation with wavelengths ranging between 0.1 and
100 A (123.9 to 0.124 KeV). Diffraction occurs if the wavelength of the radiation is
similar to the spacing between the atoms of the lattice. Therefore, in protein
crystallography, the wavelengths most commonly used range from 0.6

A (20 keV) to

2.5 A (5 keV) (Figure B.5), similar to the length of the chemical bonds in these
molecules (Als-Nielsen et ai, 2001).
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Figure B.5: X-rays in the electromagnetic radiation spectrum.
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For many years, rotating anodes have been used in many laboratories to generate
fixed-wavelength X-rays suitable for crystallographic studies.

However, their

limitations in brilliance and lack of wavelength flexibility have been largely overcome
by synchrotron radiation sources. These facilities consist of a linear accelerator,
where electron bunches are injected and accelerated, an acceleration ring where the
electrons can reach up to 6 GeV, followed by a storage ring able to keep these high
energy bunches travelling for hours. Tangential to the storage ring, optical hutches
are built. These hutches collect the X-rays generated every time the electron bunches
change their trajectory inside the ring and direct them towards the experimental
hutch, were a detector is installed (Figure B.6). The X-ray beam is tuned to the
appropriate wavelength and attenuated before reaching the crystal, moment at
which the diffraction phenomenon is produced. The diffracted beams are then
collected by the detector.

Figure B.6: Schematic view of a synchrotron. The electrons are injected and accelerated
in the linear accelerator (LINAC). An inner ring accelerates the electrons up to 6 GeV. The
outer storage ring keeps electrons traveling. Experimental lines are located tangential to
the storage ring, collecting the X-rays generated when the electrons change their
direction.
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Different beamlines are suitable for different types of X-ray diffraction experiments.
Particularly, the beamlines used during this project are listed in Table B.2.

Table B.2: Beamlines used during this work

Beamline

Synchrotron

Location

ID30A-1 (Massif-1)

ESRF

Grenoble, France

ID23-1

ESRF

Grenoble, France

ID23-2

ESFR

Grenoble, France

BM30

ESRF

Grenoble, France

BL13 (XALOC)

ALBA

Cerdenyola del Valles, Spain

The crystals need to be transported from the crystallization plates in the laboratory
to the beamline in the synchrotron facility. For that purpose, every single crystal is
harvested ("fished") from the crystallization drop in a loop and, if necessary,
cryoprotected by soaking it into a solution containing the crystallization condition
plus a cryoprotectant agent (usually glycerol, MPD or paratone). Then, the crystal is
picked up again with the loop, flash-cooled into liquid nitrogen and stored in vials for
transportation at low temperature. Once the crystals arrive to the beamline, they are
mounted, one by one, into a goniometric head designed to hold and rotate it during
X-ray data collection. With this rotation we are able to collect diffraction data at
different angles, allowing a complete mapping of the lattice and its content. Since the
X-rays will cause damage to the crystals, the crystal is kept in a stream of cold
nitrogen. Keeping the crystal at low temperatures (usually at 100 K) reduces the
radiation damage accumulated during data collection. Still, an efficient data
collection strategy has to be calculated to allow to obtain of a complete dataset
before significant radiation damage has accrued.

11

Crystallographic structure determination of bacteriophage-encoded enzymes that specifically
target pathogenic bacteria

Figure B.7: Crystals at the synchrotron. A) Frozen crystal placed in a loop and frozen at

the synchrotron just before measurement. B) Crystal mounted on the goniometer at the
synchrotron.

The improvement of the detectors during the last decades has allowed to
dramatically reduce the exposure time, thus the radiation damage, and to increase
the resolution at which the structures can be determined. Currently, the most
sensitive detectors are HPAD (Hybrid Pixel Array Detectors), detecting individual
photons of the diffracted beams and reducing the background noise to the minimum.
In addition to this, their point spread function is very accurate, allowing the precise
determination of the shape of every reflexion
B.2.2 The diffraction pattern
The diffraction phenomenon can be understood as the interference originated after
the cooperative scattering of light by point sources or scatterers ordered in space. In
our particular case, these scatterers are the atoms forming the proteins inside the
crystal, that are organized in an ordered structure in space. Every atom will scatter
an amount of light depending on its atomic scattering factor, which depends on the
density and the shape of its electron cloud, crucial for the calculation of the protein
electron density function. This factor is also of special interest in case of anomalous
scattering techniques, that will be described later.
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Since proteins in a crystal are ordered periodically in space, it is possible to describe
a minimal volume, repeated by translation, that leads to the formation of the crystal.
This volume is called "unit cell" and can be described by the length of its edges (a, b,
c) and their angles (a, P, y). The unit cell may contain several asymmetric units,
related to each other by diverse symmetry operators, including rotation axes and
screw axes. Therefore, there is a minimal amount of information inside the unit cell
that, after applying the symmetry operations on it, returns the content of the whole
unit cell. The volume containing this minimal structure is called "asymmetric unit".
Each asymmetric unit may contain one or more protein molecules. If more than one
identical protein molecule is contained in the asymmetric unit, this is called noncrystallographic symmetry. The electron density map of each asymmetric unit is
determined, followed by the model of our protein. By knowing the content of the
asymmetric unit and applying the symmetry operations we obtain the unit cell, and
by applying translations we obtain the structure of the whole crystal and the packing
interactions. In the case of proteins, 65 different crystal symmetry arrangements are
geometrically allowed (Figure B.8).

Figure B.8: Crystal composition. A) Each of the molecules represented (in this case the
asymmetric unit contains one protein molecule) can be obtained by applying a symmetry
operator to another one, in this case a P2 axis, where each asymmetric unit is obtained
applying a 180° rotation. The ensemble of all symmetrically related molecules is known
as a unit cell. B) Each unit cell can be obtained after applying a translation operation on
another one, in this case along the b axis. Figure adapted from Rupp, 2009.
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The position of every atom in the unit cell can be determined by a vector. Therefore,
the crystal can be mathematically treated as a vector space called "real space". The
reflections scattered during the diffraction experiment, collected in the detector,
define a new lattice and a new vector space, called "reciprocal space". Since the
reciprocal space (diffraction pattern) is generated from a real space (crystal), they are
closely related. More importantly, due to this relationship, a mathematical
transformation should allow us to describe the unknown real space from the known
reciprocal space, determining the position of every atom inside the crystal. This
mathematical operation is the Fourier transform.
Analyzing the diffraction pattern as the result of wave interferences is a tedious task.
Therefore, the geometric model used to establish a relation between the diffraction
pattern and the inner structure of the crystal is based on the Bragg's Law (Bragg,
1913), assuming that once the main X-ray beam reaches the crystal, its inner planes
(known as "Miller planes") will act as mirrors, reflecting the beam towards different
directions (Figure B.9). A theoretical construction called Ewald's sphere (Ewald, 1969)
restricts the reflections that are actually scattered and detected to those following a
particular angle and direction given a specific wavelength.

Figure B.9: Bragg's law. For simplification, it is assumed that sets of planes (Miller's
planes) can be defined inside the crystal, reflecting the X-ray beam. The distance between
planes can be determined by Bragg's law nA = 2d sin (0), with X the incident wavelength
and n an integer.
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Every diffracted reflection generates a spot on the diffraction pattern, acting as a
node of the reciprocal space. The information we can extract from these spots is their
position (h, k, I coordinates, or Miller indices) and their intensity. During data
collection, the crystal is rotated, allowing for the detection, in different consecutive
images, of those reflections scattered at any angle, increasing the completeness of
the dataset and minimizing potential errors in the measurements (Figure B.IO).
Depending on the symmetry of the crystal, internal defects, resistance to radiation
damage, etcetera, there are different strategies that must be followed during data
collection, to optimize the quality of the diffraction pattern obtained (Dauter, 2005;
Bourenkov et oi, 2006). In addition to this, visual inspection of the pattern can help
with determining potential issues as well as the resolution that is expected to be
reached during data processing.
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Figure B.IO: Lysozyme diffraction pattern. Diffraction spots can be observed to a
resolution of 1.7

A. From each spot, its position (h, k, I) and its intensity can be obtained.

Figure from www.rigaku.com.

To start off a diffraction experiment, a few images are collected (for example at 0 and
905) and used to determine the unit cell parameters, the estimated mosaicity (see
below) and the likely symmetry operators present in the crystal. This process is called
indexing. Based on this information, a suitable data collection strategy is determined.
A computer program can be used to estimate the expected completeness and
multiplicity (see below) of a certain rotation range, given the previously determined
parameters. The exact strategy depends on the experiment to be performed. For
example, for structure determination using the anomalous signal, a higher
multiplicity may be necessary to determine the intensities of both members of Friedel
pairs (Fhki and F-h-k-i) accurately and some resolution may need to be sacrificed, while
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for a complete native dataset usually a resolution as high as possible is sought,
sacrificing multiplicity.
An important parameter that can be calculated at this stage is the volume of the unit
cell. Since the molecular weight of the protein is also known, its volume can be
estimated. Therefore, the number of protein molecules per asymmetric unit, the
solvent content and the number of

per Dalton (the so called "Matthews

coefficient", Matthews, 1968) can be estimated.
B.2.3 Diffract ion data a no lysis
Once a complete diffraction dataset is collected (tens, to a few thousand images),
several steps must be followed to process the data and to extract all the information
useful to get the final structure of our molecule. First, a few images are used for
indexing (see above). After indexing, cell parameters are usually refined using a few
tens of images. An accurate value for the mosaicity, a measure of the spread of
different planes in the crystal, is also determined at this stage (Figure B.ll). After
indexing and cell parameter refinement, an integration step is performed (Leslie,
2006). This integration extracts all reflections from all images, accounting for their
position and determining their intensity. Nowadays, due to the high sensitivity of the
detectors, it is quite common to find a single reflection divided into slices, spread
over a few images. There are called "partial reflections" and the integration process
will detect them, calculating their position in space, their shape and summing their
intensities from the adjacent images.
The next step after the integration is a scaling and data reduction stage, in which the
images are compensated based on several parameters. Beam intensity variations,
intensity variations due to different irradiated crystal volumes during data collection,
intensity decay due to radiation damage are all considered (Evans, 2006). Due to
symmetry, a so-called crystallographic symmetry-related reflection may be collected
in different images of the pattern, after the crystal has been rotated a certain angle.
This reflection should have the same intensity as the first. This information is used in
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scaling to compare each collected image to all the others. Data reduction averages
all the reflection measures multiple times and stores each value with an estimated
error.
Highly mosaic crystal

Less mosaic crystal

Figure B.ll: Representation of crystals showing different grades of mosaicity. Figure

from Huang et oL, 2016.
Once the indexing, integration and scaling are performed, the dataset is ready to be
used for further calculations. However, some statistics must be analyzed at this
checkpoint, to ensure the good quality of the data (Kabsch, 2010a; Karplus et al.,
2012; Evans et ai, 2013):
•

Multiplicity: The number of times a reflection (including its symmetry-related
relatives) has been collected is called multiplicity. The higher the multiplicity,
the lower the error in determining the intensity.

•

Completeness: It accounts for the percentage of reflections that have been
collected between all possible reflections generated by the crystal. A high
completeness (close to 100%) means that most of the different reflections
generated by the crystal have been detected (regardless of how often they
have been detected, given by the multiplicity). A low completeness indicates
that crucial information has not been collected, therefore the final maps will
not be as accurate as they should. High completeness is important for all
reflections. For low-resolution reflections a high completeness is important
for structure determination by molecular replacement or anomalous
diffraction methods and to get an accurate solvent boundary. High
completeness is important in high resolution reflections, since these are going
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to provide detailed information about side chains and interactions between
atoms.
•

Mn(l/al): As the resolution increases, the intensity of the reflections
decreases, reaching the background of the detector after the weakest
reflections. Therefore, it is important to set a "border" between what it is
considered background noise and what it is considered actual signal from a
reflection. A Mn(l/ol) value a bit lower than 2.0 (2 times more intense than
the background) is acceptable for current modern detectors.

•

Rpim (Precision-indicating merging R-value): This is a disagreement factor
between the different measurements performed on every specific reflection,
due to symmetry, accounting for the multiplicity of the dataset (Diederichs et
oi, 1997). Values lower than 0.500 (50%) for high resolution reflections are
acceptable, and the overall value should ideally be 0.1 or lower.

•

CCi/2'. This correlation coefficient is calculated after dividing the dataset into
two random subsets of reflections, assuming that the errors obtained in any
new subset will also be stochastic and of similar magnitude (Karplus et al.,
2012). Correlation will be lower for high resolution reflections, since the error
is usually larger. A CC1/2 value higher than 30% for high resolution reflections
may be acceptable, although ideally it should be higher.

Additional parameters accounting for anisotropy, crystal defects or twinning can
be also determined at this stage. The programs used in this project to perform
the data reduction and statistical analysis are XSCALE (Kabsch, 2010b) and
Aimless (Evans et al., 2013), from the CCP4 suite (Winn et al., 2011).
B.2.4 The phase problem

At this stage, the so called "structure factors" (Fhki) need to be calculated. In short,
the structure factor is a mathematical description of how a crystal scatters the
incident X-ray beam, accounting for the amplitude and phase of every diffracted
beam. Therefore, every reflection has its own structure factor associated also related
to the atomic scattering factor. The structure factor is divided into modulus (|F^/(f|)
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and phase (4)hki). The modulus is related to the amplitude of the wave, that can be
calculated directly from the intensity (Ihid) detected in the diffraction pattern, using
this formula:
IF'hkll —

^iV ^hkl\

Where C is a constant dependent on several factors,such as the crystal size, the beam
intensity, the diffraction geometry and the wavelength.
However, the phase of the structure factor depends on the phase of the wave, which
is not measured in the diffraction experiment. Therefore, the phase of the structure
factor cannot be calculated directly from the diffraction experiment.
The final objective of crystallography is to determine the electron density of the
protein (p(x,y,z)), a three-dimensional function describing the electron envelope
produced by the electrons surrounding every atom of the protein. It is described by
this formula;
h
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As observed from the equation, both the structure factor moduli (in green) and
phases (in red) are necessary to calculate the electron density map of the protein,
and as we stated before, the phase is unknown. This is known as "the phase problem"
(Rupp, 2009; Giacovazzo, 2013).
The calculation of these phases is a delicate process, since the addition of wrong
phases could bias the final structure. There are different methods to determine the
phases of a crystal. In the following sections I will describe the methods followed in
this project.
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B.2.4.1 Molecular replacement

This technique consists of taking the phases calculated from a similar protein,
previously determined, assuming that they will be similar to ours (Rossmann et ai,
1962). In order to do this, the known protein needs to be rotated and translated until
fitting the experimental data of the protein in study. Then the phases are extracted
and used as initial phases for our model. This method is useful when the structural
similarity of our protein with the known structure is high. Because, in general,
structural similarity is correlated with sequence similarity, searches for suitable
molecular replacement models are usually done by looking for proteins of known
structure and with a sequence identity of greater than 30%. However, for a successful
molecular replacement experiment the real requirement is a similar structure, which
sometimes exists even if the sequence identity is lower. Molecular replacement
experiments sometimes fail even with a sequence identity of greater than 30%, for
example if the target protein is divided in domains and the relative orientation of the
domains is very different than in the known structure. If a protein is divided into welldefined domains, partial solutions may be found by performing molecular
replacement of different known structures in each of those domains.
The main drawback of the molecular replacement method is the requirement of a
previously determined similar structure which is not always available. Another
disadvantage is the potential insertion of bias in those cases in which the diffraction
data is not especially strong. However, with the number of known structures
increasing steadily, the availability of structures that can be used as molecular
replacement models is in constant growth. The programs used during this project to
perform molecular replacement were Molrep (Vagin et al., 2010) and Phaser (McCoy
et al. 2007).
B.2.4.2 Experimental phasing

If no suitable molecular replacement model is available, an oft-used alternative
approach to solve the phase problem is to insert a limited number of heavy atoms
into the crystal. The substructure of these heavy atoms can be calculated, leading
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later to the determination of the protein structure. There are different variants of the
method that make use of this phenomenon: single or multiple isomorphous
replacement (SIR/MIR), single or multiple anomalous dispersion (SAD/MAD) or
combinations of the two (SIRAS/MIRAS). In the first case, heavy atoms are inserted
into a crystal and, by comparing the diffraction patterns with and without these
elements, the differences can be used to build the initial substructure (Green et al.
1954). Although this method is powerful, all crystals need to be isomorphous, which
is not always achieved.
Nowadays, the most common technique used is the anomalous dispersion, in which
the heavy atoms inserted into the crystal suffer from resonance when irradiated at a
specific wavelength, scattering the light at a different intensity and phase (Karle et
oL, 1981; Hendrickson, 1991). In this kind of experiment, the atomic dispersion factor
(f) has two different components, a regular one (fo, atomic dispersion factor in
absence of anomalous dispersion) and an anomalous one, due to the resonance of
the atom at a certain wavelength (f and f'). The anomalous component can be
represented as a complex number, with real and imaginary part, being the atomic
dispersion factor represented as;

fie,X) = f„{e) + rw + if"{X)
In the absence of anomalous signal, the two members of a Bijvoet or Friedel pair of
reflections, Fhki and F-h-k-i, should have the same intensity, according to Friedel's law
(Friedel, 1913). However, in case of anomalous scattering, these reflections have
slightly different intensities (thus different structure factors). Careful measurement
and calculations using this information allows one to estimate the phases of the
structure factors (Dauter et al., 2002; Dodson, 2003). Since these phases are obtained
from the diffraction data and not from an external model, the method is considered
"experimental phasing". The requirements are the presence of heavy atoms inside
the crystal and the use of an appropriate wavelength to maximize the resonance on
those heavy atoms.
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To introduce heavy atoms inside the crystal, different approaches can be used
(Carman etal., 2003). One of the most common methods is based on the substitution
of methionine by seleno-methionine, that is, methionines in which the sulphur atom
has been substituted by selenium. The number of heavy atoms in the crystallographic
asymmetric unit is important, too many makes it difficult to calculate the heavy atom
substructure, while too few lead to insufficient and unmeasurable anomalous signal.
In addition, these heavy atoms must be located in ordered regions of the protein,
since those located in flexible loops or non-stable regions will not contribute to
diffraction.
The second method requires incubating the crystal in a solution containing heavy
atoms that will be absorbed into the crystal through the solvent channels. These
heavy atoms will interact with exposed residues and may remain attached to the
protein. If this happens in all or most of the protein molecules, the heavy atoms will
contribute to the diffraction event, generating anomalous scattering at their specific
wavelength. The selection of the heavy atom to be inserted in the crystal will depend
on the sequence of the protein, the existence of potential binding sites for them and
their strength as anomalous scatterers. Often, several different heavy atom
compounds are tried, with mercury compounds a favourite because mercury can
form covalent bonds with exposed cysteine side-chains.
As mentioned, the substitution of Met by Se-Met is a common approach, but if the
abundance of this residues in the protein is low, or if the selenomethioninesubstituted protein does not express well, is insoluble or refuses to crystallize,
soaking in salts containing mercury, gold, gadolinium, iodine or other compounds
may be an alternative. The drawback of the presence of a heavy atom in the crystals
is the increased radiation damage suffered at wavelengths optimal for anomalous
scattering. However, if in addition to the heavy atom derivative crystal a native crystal
is available, often a higher resolution dataset can be collected from this for
refinement of the structures solved by SAD or MAD.
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The wavelength at which X-ray data is collected depends strongly on the element
inserted into the crystal, aiming for a wavelength close to the absorption edge of the
element, or "peak'' (Figure B.12). The closer it is, the higher the resonance will be,
therefore higher differences in the structure factors of symmetry related reflections
will be expected. If only one dataset is collected at this wavelength, then the single
wavelength anomalous dispersion method (SAD) is used. However, in those cases in
which the anomalous signal at the peak is not strong, more datasets can be collected
at different wavelengths strategically located along the absorption profile of the
atom, like at the inflection point of the curve or in remote regions (Figure B.12). In
this case, the technique is known as multi-wavelength anomalous dispersion (M.AD).
I p

R1

R2

Figure B.12: Experimental fluorescence spectrum of a protein. In a MAD experiment,
data are collected for the peak (P) and the inflexion point (I), where f" and f are
maximized, respectively, meaning that the anomalous dispersion factor is higher. Data
are also collected in two remote points (R1 and R2). In SAD experiments, a single dataset
is collected at the peak.

Once the diffraction data is collected at the selected wavelength(s), these datasets
are processed as described before until the determination of the unit cell and a
substructure, this is, a preliminary structure including the heavy atoms. As in nonanomalous cases, there are some statistics that account for the quality of the
anomalous signal of these datasets:
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Ranom: A disagreement factor of the measurements of every reflection and their
symmetrycally-related reflections. If Rpim is 1.5 times lower than Ranom, the probability
of determining the structure by anomalous dispersion is high.
Mn(d'7a): Accounts for the anomalous signal-to-noise ratio. A value higher than 1.3
involves the existence of significant anomalous signal. However, the higher this value,
the higher the differences between symmetry-related reflections, hence higher
probability of determining solid experimental phases.
CCanom: Similar to the CC1/2, this correlation coefficient allows to determine the
resolution at which the anomalous signal is significant. Usually, the acceptable limit
is established at a value of 30%.
Here, the programs used to account for the anomalous data in the diffraction
patterns and to calculate the substructure, followed by an initial structure, were
SHELX C/D/E (Sheldrick, 2008). In SHELX, the search of the substructure begins by
placing the expected number of heavy atoms randomly in the asymmetric unit,
calculating the

correlation

coefficient

between

this

substructure

and

the

experimental data. After many iterations, the placing of the atoms is improved,
improving the correlation coefficient. Two correlation coefficients are calculated for
all reflections and for the weak ones
than 30% for

CCaii

and 15% for

(CCaii

CCweak

and

CCweak

respectively), with values higher

usually indicated successful substructure

solution. Once the substructure is obtained, a correlation coefficient of the map
(CCmap)

is calculated to discriminate between the substructure and its enantiomorph.

Both options are known as direct and reverse, being the right one the substructure
showing higher CCmap.

B.3.5 Electron density and refinement
With all the parameters calculated at this point, the electron density function of the
protein can be calculated, which is:
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The electron density map gives valuable information to build the model of the
protein, a process that can be performed automatically for high quality data, or
manually, for those cases that need user management. Different kinds of maps may
be calculated, but the most commonly used are the Fobs-Fcai map, known as
"difference map" and used to find the regions that might contain atoms or not, and
2Fobs-Fcab amplifying the observed data and allowing for a better building of the
overall model. In most cases, several rounds of model building are required, generally
performed in Coot (Emsiey et al. 2010).
As the model is being built, several refinement cycles must be performed in order to
control that the model is fitting the electron density and to get rid of potential errors
that can show up during the building stage. This refinement involves the sequential
improvement of the phases, with the model being modified (improved) in parallel.
During the refinement, many parameters of the model are modified. Some of these
are:
Atomic coordinates: The individual position of each atom might slightly vary once the
phases are improved.
Atomic displacement factors: Also known as B-factors, they account for atomic
vibrations and torsions due to thermal agitation. Depending on the resolution of the
data, these fluctuations can be described with a single B-factor per atom,
corresponding with the radius of a sphere centred in the atom, or with six B-factors,
corresponding with the parameters of an ellipsoid. The first case of refinement is
called "isotropic refinement" and the second, in which a more realistic ellipsoid is
considered, is called "anisotropic refinement" (Merrit, 2012).
Occupancy: Considering the flexibility of some regions, or the binding affinity in case
of a ligand, some atoms might be present in particular locations only in some proteins
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of the crystal. In these cases, those atoms do not contribute as significantly to the
diffraction as the ones that are stable along all crystal. Therefore, their occupancy will
be lower than 100% (Welsh etai 2013).
Non-crystallographic symmetry: In addition to the symmetry of the crystal,
previously described, there could be additional symmetry operators between
different molecules of the asymmetric unit. This non-crystallographic symmetry
(NCS) introduces restraints that can be used to refine related molecules in an
improved way (Vellieux et al. 1997).
R-factors are used to monitor the refinement process and to help prevent bias in the
structure by over-refinement. These R-factors account for the disagreement between
the model built and the diffraction data. They are a measurement of how the model
that has been built is able to predict the observed data, that we know is reliable. The
achievable value of these R-factors depends on the resolution of the data, since a
higher resolution structure should predict the observed data with higher level of
confidence. As a rule of thumb, R-factors of around ten times the resolution are
observed for well-refined structures (i.e. 15% for a 1.5
around 30% for a 3.0

A resolution structure, or

A resolution structures). However, for very well-ordered

crystals, lower R-factors are often achievable, while for structures with a significant
amount of local protein disorder it may not be possible to reach these values, so they
should not be seen as hard targets or as a sign that further improvement attempts
should be abandoned.
These R-factors are commonly known as Rwork and Rfree. While the Rwork accounts for
the disagreement taking into consideration all reflections, the Rfree is calculated over
a small set of reflections that were randomly picked up and kept out of the
refinement since the beginning. Therefore, if the refinement has been correctly
performed, the
process. If the

Rfree

Rfree

value will be similar to the

is much higher than the

Rwork,

Rwork,

hence acting as a control of the

this may mean that the structure is

over-refined and predicting more information than what it should be capable of. In
those cases, a careful look at the whole refinement process, together with an analysis
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of the fitting between the model and the electron density map is required. The
refinement software used in this project was RefmacS (Murshudov et al. 2011).

B.2.6 Validation
Once the model has been built and the refinement is concluded, the structure is ready
for validation. At this stage, the geometry of the final model is analyzed, to find
potential outliers in the bonds, angles, rotamers and Ramachandran configurations
along the protein that might have been introduced by the building or refinement
process (Kleywegt, 2000). Each of these outliers needs to be inspected to see if it can
be removed by rebuilding and re-refinement. The program used to validate
structures was MolProbity (Chen et al. 2010). If the geometry of the model is largely
correct and the model contains few outliers; and the model to data statistics are
reasonable, the resulting structure, together with the data, is deposited in the Protein
Data Bank (PDB, https://www.ebi.ac.uk/pdbe
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